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Abstract  
 
The modulation of the resolution of inflammation (RoI) process represents a novel 
approach to treating inflammatory pathologies. The development of small molecule 
modulators which are able to promote resolution and the ability of tissues for self-
recovery holds significant promise. 
Formyl peptide receptor 2 (FPR2) is a G-protein coupled receptor and expressed mainly 
by neutrophils. FPR2 is involved in the RoI process with implications in cardiovascular 
inflammation processes. The binding modes and structure-activity relationships of small 
molecule FPR2 agonists were investigated using in silico methods. Based on this a 
binding site with three hydrophobic subpockets and two polar clusters was proposed. The 
knowledge gained from SAR studies was used in finding alternative bioisosteric 
replacements and designing novel agonists. The second approach was screening the 
GPCR-Ligand Association database using our pharmacophore model. A new series of 
agonists was then synthesized and screened. The compounds activated the receptor in the 
nanomolar range, and they displayed promising in vitro ADMET profiles. Finally, using 
neutrophil adhesion assays we have shown that FPR2 agonists can reduce the number of 
adherent neutrophils which indicates their anti-inflammatory and pro-resolving 
properties.  
In the second part of project I focused on xanthine oxidoreductase (XOR) and its potential 
protective role in cardiovascular disease. XOR is a large homodimer enzyme with two 
possible binding sites: Molybdenum and Flavin Adenine Dinucleotide (FAD). The goal 
is to find selective inhibitors of the FAD active site and increase the NO bioavailability 
while lowering the production of superoxide. In the search for novel inhibitors a virtual 
screening approach with human XOR structure with potential FAD binding sites was 
used. The preliminary studies showed promising results. The selected inhibitors were able 
to reduce superoxide generation in the presence of either xanthine or NADH. At the same 
time, NADH driven nitrite-reductase activity of XOR was not affected.  
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TEA - Triethylamine 
TM - Template Model 
TMRM – Tetramethylrhodamine, methyl ester 
T3P- Propylphosphonic Anhydride 
THF - Tetrahydrofuran 
VCAM - Vascular Cell Adhesion Molecule 
XOR - Xanthine Oxidoreductase 
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1. Introduction  
1.1. Inflammation as a protective response  
 
Inflammation is a protective response of the human body against the attack of any 
pathogens or pathological expansion. In many cases the inflammation is a good 
physiological response to infection as it helps with the repair of damaged tissues to favour 
elimination of the source of infection. The positive physiological inflammation is 
contained in time and space. However sometimes the inflammatory response can continue 
without any control, which leads to chronic inflammation.1-2 
 
For centuries, acute inflammation was considered as an illness. In the 18th century, 
English surgeon John Hunter was the first to recognize the acute inflammation as a 
reaction to injury that was overall helpful to the human body: “But if inflammation 
develops, regardless of the cause, still it is an effort whose purpose is to restore the parts 
to their natural functions.”3 The acute inflammation is described by five major 
signs: redness (rubor), increased heat (calor), swelling (tumor), pain (dolor), and loss of 
function (functio laesa). Aulus Cornelius Celsus, a Roman encyclopaedist, described first 
four signs of inflammation known as "Celsus tetrad”, the last sign was added by Rudolph 
Virchow in the 19th century.  There are several causes of acute inflammation. The first 
reason is the infective agents for example bacteria, viruses and their toxins. The second 
group which causes the inflammatory response are physical agents like cold, heat, 
radiation and mechanical trauma. The third group are reactions of cell-mediated 
immunity.4 The chemical agents such as organic and inorganic reagents, frostbite, cuts, 
stabbing, inert material and allergens might be also source of inflammation activation. 
Also, the age and genetic factors can amplify the duration and stage of the inflammatory 
response. 5-6 
 
The main parts of inflammation are the vascular changes and a cellular response, 
compared to the normal process, when the organism is healthy, the major differences are 
a vascular dilatation, enhanced permeability of blood vessels, emigration and 
accumulation of leukocyte and increased blood flow.  
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The human organism has well-developed line of defence against any unwanted guest. The 
epithelial barrier guards the entry to the tissue and the innate immune system reacts to 
pathogens in the plasma cascade and phagocytic cells and dendritic cells which work like 
a scanner against the danger-associated molecular patterns (DAMPs). This group includes 
lipopolysaccharides (LPS), lipopeptides, lipoteichoic acid, Gram-positive and Gram-
negative bacteria, allergens, cell death products, toxins, heat shock proteins, fibrinogen, 
adenosine, urate crystals, single stranded RNA and double stranded DNA.6-8 The pattern 
recognition receptors (PRRs) are responsible for distinguishing DAMPs. Their tasks are: 
scavenging of the pathogens (the phagocytic receptors), leading polymorphonuclear 
neutrophils (PMNs) to the infection, recognizing the bacteria products (the nod-like 
receptors) and N-formylated peptide from bacteria (the chemotactic receptors).9 Toll-like 
receptors (TLRs), which are also recognition receptors, identify structurally conserved 
molecules originating from microbes.10 The inflammatory response in cells is obtained 
through mediators and signalling molecules such as growth factors, cytokines and 
chemokines, produced by PRRs. The attraction of platelets, PMNs, basophils and mast 
cells to the site of inflammation is possible because of increasing gradients of pro-
inflammatory cytokines for example interleukins IL-12, IL-8 or IL-1β. 11 The pro-
inflammatory cytokines are supported by some cysteine-cysteine type chemokines to 
recruit leukocytes. The endothelial cells have also their system of defence, they start the 
production of the intercellular adhesion molecules (ICAM-1, ICAM-2), platelet-
endothelial cell adhesion molecules (PECAM-1) vascular cell adhesion molecules 
(VCAM1) and the adhesion proteins (selectins E and P), which will catch the oncoming 
white blood cells. The selectins are creating bonds with the leukocytes, which roll along 
the inner surface of the blood vessels. The adhesion and immobilization of the leukocytes 
are induced by the integrins and chemokines. The white blood cells have the ability to 
penetrate the small holes between the endothelial cells and identify the unwanted guest. 
When the interloper has been recognized, the process of phagocytosis is started. The first 
stage of phagocytosis is the binding of receptors located on the cell membranes of the 
phagocyte to specific molecular patterns on the surfaces of the intruder. This step is 
followed by actin polymerization, which leads to deformation of the plasma membrane. 
Once the intruder has been fully surrounded, its internalization into the phagosome takes 
place. The last step is maturation of the phagosome, and it can fuse with the enzymes, 
proteins and peptides which lead inflammatory response. In the figure below the 
components of acute and chronic inflammatory responses and their principal functions 
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are shown (Figure 1)2, 5 The adhesion molecules, cell trafficking and recruitment will be 
described in greater detail in chapter 6.1. 
 
 
Figure 1 The main components of acute and chronic inflammatory responses and their principal functions.5 
 
Three outcomes of the acute phase of inflammation can be identified: 
• complete resolution, where tissues are regenerated, repaired, and all functions are 
back to normality, with all injurious stimuli and mediators removed. 
• scarring (fibrosis), where significantly destructed tissue has been repaired or when 
inflammation appears in tissues that are not recovered, in which the damaged 
tissue is filled in by connective tissue. 
• development of chronic inflammation, where the injurious stimuli is not removed, 
or this response may occur from the onset of damage. 
If the inflammatory response is not finished, then chronic inflammation can cause the 
development of a diverse range of diseases. The presence of persistent inflammation in 
the human body can lead to chronic autoimmune diseases like Crohn’s disease or bowel 
disease, cardiovascular diseases such as atherosclerosis or calcification, chronic 
obstructive pulmonary disease, cancers, and Alzheimer’s, rheumatoid arthritis and 
obesity. 
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When the inflammation has been prolonged, and its duration lasts several weeks or even 
years then we are talking about chronic inflammation, which comprises of long-lasting 
inflammation, tissue damage, and fibrosis. Chronic inflammation can be described by a 
diverse set of reactions: 
• Tissue damage, mainly caused by the products of the inflammatory cells 
• Infiltration with mononuclear cells, engaging lymphocytes, macrophages, and 
plasma cells 
• Repair, concerning angiogenesis (a proliferation of new vessel) and fibrosis. 
As mentioned above, acute inflammation may develop into chronic inflammation if the 
homeostasis cannot be restored. In the table below the attributes of acute inflammation 
were compared with chronic inflammation (Table 1).5 
 
 Acute Chronic 
Cause Bacterial infections, toxins, 
trauma, infarction 
Viral infections, autoimmune 
diseases, chronic infections, 
persistent injury 
Onset Fast Slow 
Duration It begins within 4-6 hours and 
can last for 3-5 days 
It may last from weeks to years 
Outcomes Complete resolution turns into  
fibrosis, or develops into 
chronic 
Tissue death and the scarring, loss of 
function  
Table 1 Comparison of acute and chronic inflammation 
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1.2. Resolution of inflammation  
 
Homeostasis is the ability to maintain the constant and balanced state in living organisms 
by self-regulation of biological processes.12 Homeostasis is a fundamental term in 
physiology. Claude Bernard, a French physiologist, in 1895 wrote, ‘The stability of the 
internal environment [the milieu intérieur] is the condition for the free and independent 
life’.13-14 It was first time where an idea of body equilibrium was described. In 1932, 
Walter Bradford Cannon, an American physiologist wrote his book The Wisdom of the 
Body, where he used a term homeostasis and characterised the main principles.15 
Maintaining internal body stability requires regulation and control of the most important 
parameters of the internal environment like body temperature, blood pressure, and pH, 
the fluid balance, the correct cations levels e.g. Na+, K+, Ca2+, glucose level, and oxygen. 
On the cellular level, the homeostasis can be described by regulation of the cell volume, 
membrane potential, intracellular ion concertation, pH value, level of proteins, nutrients, 
oxygen, and reactive nitrogen and oxygen species. The signalling proteins are responsible 
to identify any change in numerous basic processes for example levels of reactive oxygen 
species (ROS) and the availability of essential nutrients. In tissue homeostasis, the known 
signalling cells are the immune cells such as mast cells and macrophages.7 
 
As mentioned earlier, the inflammation is a good physiological response to the infections 
by helping with the repair of damaged tissues and eliminating the source of infection 
(Figure 2 option 1-2). The good physiological inflammation is contained in time and 
space. However sometimes the inflammatory response can continue without any control, 
which leads to chronic inflammation (Figure 2 option 4). Resolution-based therapies can 
reduce disadvantageous effects, use the ability of tissues for self-recovery and help to 
return to homeostasis (Figure 2 option 5).1 
 
Figure 2 Graphic overview summarizing the resolution of inflammation process.1 
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The first published scientific report about the resolution of inflammation is from 1907. It 
was demonstrated with the experimental irritant-induced pleurisy that after five days from 
leukocytes formation, the pleural cavity returned to homeostasis with the clearance of the 
leukocytes.16 For many years the process called ‘the resolution of inflammation’ was 
considered as a passive process, mostly associated only with the extraction of 
inflammatory stimuli, termination of chemoattractant formation, or counteracting of 
further leukocyte recruitment.2, 17 The resolution can be described as the period between 
maximal inflammatory cell influx and their clearance from the tissue and re-establishment 
of functional equilibrium. Nowadays it is accepted that the resolution process is active.18 
An important contribution to establishing this principle that resolution was made by 
Serhan’s group from Harvard University. They showed that the active potent mediators 
produced from essential fatty acids can stimulate resolution and the return to homeostasis. 
The main families of molecules that were the subject of their studies were the resolvins, 
protectins, maresins, which can be classified as specialized pro-resolving mediators 
(SPMs).10, 19-21 Proresolving mediators must reduce neutrophil migration, increase the 
recruitment of monocytes, promote the apoptosis of neutrophils, and enhance the 
macrophages to start a process called efferocytosis (during this process, macrophages 
clear all apoptotic or necrotic cells from the site). Finally, it should start a process of a 
regeneration of the tissue. Molecules which we can classify to the family of endogenous 
proresolving mediators are for example: lipoxins e.g. LXA4, proteins and peptides e.g. 
Annexin A1, resolvins e.g. RvD121, gaseous mediators e.g. hydrogen sulphide22, nitric 
oxide23 or a purine (adenosine)17. Pro-resolving AnxA1 decreases neutrophil 
accumulation by several processes for example suppression of transendothelial 
migration24, stimulation of neutrophil apoptosis25, and promotion of removal of dead 
neutrophils.26 Resolvins have similar activities but don’t have any modulatory effect on 
the immune response.27 The next group of pro-resolving mediators is adenosine, apart 
from standard anti-inflammatory activities, adenosine promotes also macrophage 
efferocytosis.28 Among the gaseous mediators, nitric oxide was the first molecule shown 
to have the ability to inhibit the recruitment of neutrophils to postcapillary blood vessels 
by control of guanylate cyclase activity in  endothelial cells.29 Also hydrogen sulphide is 
able to stop neutrophil recruitment, in addition hydrogen sulphide has been described as 
an enhancer of the expression and release of Annexin A1 from intracellular pools.22, 30 
During inflammation, many of the endogenous proresolving mediators work on specific 
cell surface of proresolving receptors such as immunoglobulin-like receptors, G-protein 
coupled receptors (GPCRs), tyrosine kinase receptors and cytosolic receptors. In chapter 
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2 one of the GPCRs, formyl peptide receptor 2 (FPR2/ALX) will be described in detail, 
because of its role in pro-resolving pathways, controlling inflammation and the ability to 
interact with ligands of distinct nature. 
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1.3. Cardiovascular inflammation  
 
Cardiovascular disease (CVD) is a class of diseases that involves the heart or blood 
vessels. CVDs are the number one cause of death globally (WHO, 2013).31 Increasing 
numbers of the population are becoming obese, have uncontrolled blood pressure and 
develop diabetes. In addition, the population is ageing. The percentage of the European 
Union’s population aged over 60 years is expected to nearly double by 2050.32 These four 
conditions are the foundation for the onset of cardiovascular diseases. Within the EU, 
cardiovascular disease accounts for 4 million deaths and costs €192 billion.33 In the 
United Kingdom, the annual healthcare costs associated with cardiovascular diseases 
reached a total of £15.7 billion, creating one-fifth of overall National Health Service 
(NHS) outlays.34 The group of CVD-related healthcare services includes not only primary 
health care, emergency care, hospital days, treatment and drugs but also the rehabilitation 
service, outpatient care, public campaigns to increase cardiovascular health awareness 
and  social services.34-35 According to the WHO, in Europe proportionally 40% of causes 
of death among men and 49% of causes of death among women are the result of CVDs. 
By the year 2020, it is estimated that nearly 40% of all deaths across the world will be 
due to cardiovascular diseases, twice more than the percentage of deaths caused by 
cancer.36 Numbers are expected to rise because of an ageing population, but also because 
of bad nutrition habits and stressful lifestyles. Among the group of cardiovascular 
diseases some of them can be developed because of unresolved chronic inflammation.37 
Inflammation plays a huge role in cardiovascular diseases e.g. ischemia/reperfusion (I/R) 
injury38, coronary heart disease39, stroke40 and atherosclerosis41. A few decades ago, 
atherosclerosis has been taken as a featureless lipid storage disease, it means that the lipid 
layer formed on the surface of vessel and narrowed the arteries and finally blocked the 
blood flow, which could cause further complications such as stroke or myocardial 
infarction (MI). The discovery of adhesion molecules, produced by endothelial cells, 
revealed important insights about atherogenesis.42 Nowadays we know that pro-
inflammatory conditions are the key factors in development of atherosclerosis.43-44 The 
evolution of atherosclerosis can be divided into 5 main stages: 1) leukocytes adhesion and 
increased permeability of the endothelium due to pro-inflammatory conditions in the site; 
2) recruitment of macrophages and accumulation of lipids; 3) formation of the necrotic 
core from dead macrophages and plaque cells. Additionally a fibrous cap forms; 4) 
neovascularization and plaque haemorrhage; 5) plaque rupture and thrombosis.11, 45 The 
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majority of stroke and myocardial infarction events are caused by plaque rupture and 
thrombosis. In both cases an artery can be blocked and cause death of tissue being 
supplied by that vessel.46-47 As mentioned before, type 2 diabetes is one of the diseases 
which greatly increases the risk of cardiovascular diseases. High blood pressure, 
abnormal cholesterol and obesity very often accompany type 2 diabetes. Complications 
of diabetes are divided into two categories: macrovascular (e.g. coronary artery disease, 
stroke) and microvascular (diabetic nephropathy, or retinopathy). 25-40% of diabetic 
patients suffer from diabetic nephropathy which is a risk factor for cardiovascular 
diseases.48 Nowadays within Europe, the United States, China, Russia and Brazil there 
are over 56 million patients with a diagnosis of type 2 diabetes. Many young patients 
before the age of 30 are now being diagnosed, unlike in previous years when type 2 
diabetes usually affected older people.  
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Part One: N-formyl peptide receptor 2 as a key receptor of 
resolution 
  
31 
 
2. Introduction 
 
2.1. G protein–coupled receptors (GPCRs)  
 
Nowadays we can observe the increased interest and exploitation of the resolution of 
inflammation process. It is a novel approach, hence developing modulators as an effector 
of resolution has potential to treat not only the cardiovascular inflammatory pathologies, 
but also for example bowel disease49, rheumatoid arthritis28, Alzheimer’s Disease50 and 
allergies.51  
As mentioned in the previous chapter there are several pro-resolving receptors such as 
immunoglobulin-like receptors, G-protein coupled receptors (GPCRs), tyrosine kinase 
receptors and cytosolic receptors.1, 52 
Although GPCRs are one of the most widely investigated groups of pro-resolving 
receptors, it was only around forty years ago that the existence of G-protein coupled 
receptors was confirmed. Beforehand, the idea of membrane receptors was radical and 
controversial. The British pharmacologist, J.N. Langley was one of the first who 
suggested the existence of receptors. In 1905 he wrote this statement: ‘So we may suppose 
that in all cells two constituents at least are to be distinguished. The chief substance which 
is concerned with the chief function of the cell as contraction and secretion and receptive 
substances which are acted upon by chemical bodies and in certain cases by nervous 
stimuli. The receptive substance affects or is capable of affecting the metabolism of the 
chief substance.’53 
G protein–coupled receptors (GPCRs) are a large family of transmembrane receptors that 
are activated or blocked by active molecules outside the cell. An activated GPCR binds 
to G protein, which is a molecular switch inside cells, and is involved in the transfer the 
information to the cellular interior. The GPCR family has several alternative names such 
as 7TM receptors, seven-(pass)-transmembrane domain receptors, or heptahelical 
receptors. 7TM receptors are activated by a wide range of stimuli such as photons, ions, 
small organic molecules, lipids, peptides and proteins. 54 
The GPCR family is built from around 800 genes in the human genome. They are 
involved in regulation of signalling pathways and play important roles in for example 
immune response, blood pressure regulation, behaviour, taste and mood.55 Numerous 
GPCRs are key therapeutic targets for many diseases, including cancer, cardiovascular 
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disorders, central nervous system disease, metabolic and inflammatory disorders.56 
Indeed, almost 30-40% of all currently available drugs on the market target this receptor 
family.57 
 
The GPCR kingdom is classified into six major subfamilies based on sequence homology: 
• Class A (Rhodopsin-like) 
• Class B (Secretin receptor family) 
• Class C (Metabotropic glutamate/pheromone) 
• Class D (Fungal mating pheromone receptors) 
• Class E (Cyclic AMP receptors) 
• Class F (Frizzled/Smoothened) 
The class A (Rhodopsin-like) includes the largest number of members.58 
 
There is also a second GPCR classification based on phylogenetic origin (GRAFS 
system), where we can distinguish five subfamilies: 
• Glutamate (22 members) 
• Rhodopsin (701 members) 
• Adhesion (33 members) 
• Frizzled/Taste 2 (11 members) 
• Secretin (15 members) 
 
The GPCR family has two numbering schemes. The first one is well known and based on 
the amino sequence and the second one, which is unique for this group of proteins is the 
Ballesteros–Weinstein numbering scheme. This scheme is based on the presence of 
highly conserved residues in each of the seven transmembrane helices. It is built using 
two numbers where the first represents the one of the seven helices, and the second the 
residue position relative to the most conserved residue, which is represented by number 
50. For example, 4.39 represents a residue located in transmembrane helix 4, eleven 
residues before the most conserved residue, Trp4.50.59 
All GPCRs have some similarities in architecture and structural features. They all have a 
seven transmembrane α-helical bundle characteristic, which are joined by three 
extracellular loops (ECL1, 2 and 3) and three intracellular loops (ICL1, 2 and 3) with an 
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extracellular N-terminus and an intracellular C-terminus. The key structural similarities 
are shown in Figure 3, which depicts the A(2A) adenosine receptor crystal structure 
(PDB ID: 4EIY) bound to ligand ZM241385 (antagonist for the adenosine A2A receptor). 
The receptor structure is coloured by the sequence conservation level for rhodopsin-like 
class of G-protein coupled receptors. The transmembrane part is found as the most 
conserved module of GPCRs with representative hydrophobic patterns and some 
functionally potent and highly conserved sequence motifs, for example the CWxP motif 
in helix 6, the NPxxY motif in helix 7 and the D(E)RY motif in helix 3. Two highly 
conserved cysteine residues which are found in the extracellular loop create disulphide 
bonds which help to stabilize the receptor structure.54, 60-61 
 
 
Figure 3 General architecture and structural similarities of GPCRs on an example of the A(2A) adenosine receptor 
crystal structure bound to ligand ZM241385 (green).  
The structure of the receptor has been coloured by sequence conservation; the dark red colour represents the highly 
conserved regions. The most frequently observed conserved motifs are marked in blue.54 
 
In 2012 Brian K. Kobilka and Robert J. Lefkowitz were awarded the Nobel Prize for their 
work and important discoveries in the field of GPCRs.62 The GPCR of their interest has 
been the beta-adrenergic receptor (βAR) which binds to adrenaline and brings about the 
"fight-or-flight” response, the body’s answer to perceived danger. Kobilka and Lefkowitz 
explained how X-ray crystal structures of the receptors have revealed the nature of the 
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intramolecular constraints. One of the first important breakthroughs in GPCR structure 
determination was the sequencing of rhodopsin and cloning of the β2AR and other 
receptors from this family in the 1980s. These discoveries led to confirmation of the 
sequence similarity with rhodopsin and that the seven transmembrane topology is a 
characteristic feature of this superfamily.63-65 In 1988 Kobilka identified areas in the 
sequence involved in ligand binding based on his chimeric studies of sequence of the 
beta-adrenergic receptors.66 At this time studying transmembrane proteins was extremely 
challenging because of the limitation in the identification structure based on only 
mutagenesis studies, problematic expression and purification of the transmembrane 
proteins. In 1993 the first application of fluorescence spectroscopy and circular dichroism 
gave additional information about the biochemistry of transmembrane proteins and the 
stabilizing effect of ligands.67 These studies revealed the activation of the receptor and 
the mechanism of agonist binding. GPCRs were not anymore considered as proteins 
which are present only in two conformational states: an inactive state in equilibrium with 
an active state. By measurements of changes of the fluorescence intensity as a function 
of time, they discovered that at least one conformational intermediate exists and an 
agonist on its own cannot stabilize a constant active conformation, which was later 
confirmed in more recent studies using NMR spectroscopy.68  
In the figure below, we can see how flexible the unliganded protein structure is and only 
the complex with G protein can entirely stabilize the active state (Figure 4). 
 
 
Figure 4 The dynamic character of GPCRs on the example of the β2AR.69  
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The determination of the crystal structure of the protein is a crucial step to visualize the 
3-D architecture and enhances our knowledge of protein function, binding modes and 
possible conformation changes. The excellent quality crystal of the protein is crucial for 
X-ray crystallography. However, despite the great achievements in the pharmacology and 
molecular biology of G-protein coupled receptors, the process of crystallizing membrane 
proteins is enormously challenging. Structural studies of GPCRs encounters the obstacles 
such as the lack of a naturally abundant source of protein, the flexibility, and their partially 
hydrophobic surfaces which cause the problems for creating crystal lattice contacts.60 In 
1997 Schertler’s research group obtained first two-dimensional crystal of rhodopsin.70 
This discovery brought to light the general seven-transmembrane structure of GPCRs and 
was used as the template for homology modelling until 2000 when the first high-
resolution three-dimensional crystal structure of bovine rhodopsin in complex with 11-
cis-retinal by Palczewski’s group was solved.71  
In 2004 Kobilka’s group obtained a low-resolution structure of β2AR (20Å) due to very 
small sizes of crystals (<50 microns). 65 To generate better quality crystals of β2AR, 
researchers from Stanford University decided to use a selective monoclonal antibody 
fragment or T4 lysozyme which can bind to the cytoplasmic ends of helices 5 and 6 which 
are the most flexible. T4 lysozyme is one of most often used fusion proteins. These small 
and well-crystallisable protein domains help to stabilize the highly flexible sections of the 
receptor and improve the size of polar surface area. The first obtained crystal structures 
of β2AR using this method were β2AR-Fab (a monoclonal antibody)
72 and β2AR-T4L
73 
in 2007. The combination protein strategy applied for β2AR has since been applied to a 
growing number GPCRs for example M2 and M3 muscarinic receptors, δ and μ-opioid 
receptors.  
The next step was to obtain a crystal structure in a stable active conformation of agonist-
bound GPCRs, Kobilka’s lab have applied recombinant camelid single-domain antibody 
fragments. The first structure of active β2AR was solved in 2011 using nanobody Nb80 
and a potent agonist BI167107. This achievement exposed new signatures of GPCR 
activation.64 Since this first usage of a nanobody to stabilize the receptor in the active 
state, numerous nanobodies have been synthesized and novel structures of several GPCRs 
in active states have been obtained. In each case, stabilizing camelid-derived nanobodies 
bind to the intracellular portion of helices 5 and 6 of the receptor like the G protein α 
subunit and β-arrestin.65 
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Scientists have made extraordinary improvements in GPCR structural biology during the 
last ten years, with a total of 127 GPCR structures described for more than 30 unique 
receptors from the GPCR superfamily. The majority of GPCR structures which are 
reported until now have depended on slowly dissociating antagonists with high-affinity, 
or creation of defined mutations to minimize this conformational flexibility. The progress 
in structural studies delivers understanding of the ligand binding modes, allosteric 
mechanism, GPCR activation and function but also allows acceptable quality 
homologous models for other GPCRs to be built. Homology modelling is a useful tool to 
predict GPCR structure when the crystal structure is unavailable.54  
 
GPCR activation is initiated by binding of the ligand from the extracellular side. Upon 
the activation, TM helices 5, 6 and 7 undergo the rearrangement to prepare the receptor 
to bind with G protein. TM helix 6 rotates and moves almost 12-14 Å from its primary 
position and lead to the small movements of helix 5 and 7. Conformational changes in the 
structure of helix 7 cause activation of G protein. The receptor couples with G proteins 
such as Gαs, Gαi/o, Gαq/11 by the production of second messenger.61, 74 The coupling 
with Gαs leads to the stimulation of adenylyl cyclase and an increase in the generation of 
cAMP. However, when the receptor is connected with Gαi/o, it produces the reverse 
effect and we can observe the inhibition of adenylyl cyclase and the activation of mitogen-
activated protein kinase. Finally, if the receptor couples with Gαq/11, it initiates the 
activation of phospholipase C enzymes, which activates the release of second messengers 
by hydrolysis of the phospholipid membrane. For the group of second messengers, we 
can include inositol 1,4,5-triphosphate and diacylglycerols. These events increase levels 
of the intracellular Ca2+ and boost protein kinase C (PKC) and protein kinase D1. 
Additionally, the activation of G-protein Gαq/11 might cause the increase of formation 
phosphoinositide 3-kinase. The G receptor kinases (GRKs) regulate the activity of 
GPCRs and start the recruitment of β-arrestins, which drive to the desensitisation of the 
phosphorylated receptor. In parallel, β-arrestin proteins might cause endocytosis, which 
initiates GPCR internalisation and promotes G-protein independent signals cascade. The 
activation of G-protein coupled receptors depends on the nature of the ligand like 
agonists, antagonists and inverse agonists. The mechanism of activation of G-protein 
receptors by agonists is shown below (Figure 5). 
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Figure 5 The activation process of G-protein coupled receptors upon agonist binding. 
Figure was created using the medical images provided by Servier Medical Art (http://www.servier.com) 
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2.2. Characterization of N-formyl peptide receptor 2 (FPR2)  
 
N-formyl peptide receptor 2 (FPR2) is a G-protein coupled receptor situated on the 
surface of many cell types e.g.: neutrophils, monocytes or T-cells. FPR2 is part of the 
formyl peptide receptors group, which belongs to G protein-coupled chemoattractant 
receptors. According to recent nomenclature, the name of the FPRs are defined as FPR1, 
FPR2/ALX, and FPR3.75 FPR2 is commonly named the ALX/FPR2 because of its 
activation upon binding with lipid agonist lipoxin A4 or just ALX receptor. Their name 
comes from the agonists, which are the formylated methionine peptides. In 1970s a series 
of N-Formylmethionine-containing oligopeptides were tested and showed the ability of 
stimulation human neutrophils to migrate in a directional pattern in traditional assays of 
chemotaxis. One of the most potent and studied oligopeptides is N-formyl-methionyl-
leucyl-phenyalanine (fMLF), which is a prototype for microbe-derived formylated 
peptides.76 The first FPR was cloned in 1990, and the studies revealed its ability to bind 
and become activated by the oligopeptides.77 Another two receptors were shortly 
discovered and named FPR1 and FPR2 based on the homology of their amino sequences 
to the FPR.78  Thereafter the three formyl receptors have been renamed as FPR1, FPR2 
(69% identity with FPR1), and FPR3 (56% identity with FPR1).79-80 The sequence 
alignment of the three formyl receptors is showed in the picture below. The residues have 
been coloured by their similarity; the dark red colour represents the highly conserved 
amino residues. On the right hand side the percentage of identity is shown81 (Figure 6).  
 
 
Figure 6 Sequence alignment of the three human formyl peptide receptors. 
The sequence alignment was performed using the Multiple Sequence Viewer (Schrodinger Maestro software). 
 
The formyl peptide receptor 1 shows high affinity to the N-formyl-Met-Leu-Phe (fMLF) 
peptide with a Kd value ~1 nM. Activation of FPR1 leads to cell migration, cytoskeleton 
rearrangement and release of protein degradation enzymes and oxygen radicals via 
activation of the phosphatidylinositol 3-kinase, GTPases and mitogen-activated protein 
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kinases. FPR2 and FPR3, unlike FPR1, do not bind with a high affinity to fMLF. 
Additionally, the overall function of FPR3 is still unclear. FPR2 has been reported to 
interact with the endogenous and exogenous lipid and protein ligands and also with small 
synthetic molecules, and depending on the type of molecule, the receptor has a dual effect 
on the inflammatory response.80 The formyl peptide receptor 2 (FPR2/ALXR) is a 
receptor which is involved in cardiovascular inflammation process. FPR2 can be 
modulated by agonists like annexin A1 or LXA4 to promote the process of resolution. 
The agonists of the formyl peptide receptor 2 promote apoptosis of neutrophils, 
macrophage-mediated phagocytosis and inhibition of epithelial activation as a 
mechanism of resolving acute inflammatory responses. Its activation leads to Ca2+ fluxes, 
inhibition of cAMP, and p-ERK. On the other hand the FPR2 receptor can be modulated 
by pro-inflammatory molecules like SAA, LL-37 and mitochondrial hexapeptides and 
cause the transmigration and survival of neutrophils, monocytes recruitment and 
epithelial activation (Figure 7).82 
 
 
Figure 7 FPR2 and the examples of its dual effect on the inflammatory response82 
 
FPR2 agonists are potential therapeutic agents in diabetic nephropathy and renal fibrosis.  
25-40% of diabetic patients suffer because of a diabetic nephropathy which is a risk factor 
for cardiovascular diseases. 83 FPR2 has been reported to have interactions with a series 
of pro- and anti-inflammatory ligands associated not only with CVDs but also HIV, 
chronic obstructive pulmonary disease or inflammatory bowel disease. Because of the 
wide spectrum of agonists and responses of this receptor, FPR2 might be an excellent 
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target for therapeutic approaches. The FPR2 agonists can be divided into three main 
groups: natural molecules, synthetic peptides and small molecule agonists.84 In this 
project, I am interested in the development of small molecule agonists and in the next 
chapter the FPR2 agonists will be described. 
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2.3. FPR2 agonists and the resolution of inflammation  
 
The dose response curve is the relationship between an effect of a drug and the amount 
of the drug. There are three main characteristic components: potency (position of curve 
along the dose axis), maximal efficacy (the greatest possible response) and slope (change 
in the response per unit dose).85 As mentioned earlier, GPCRs can be in an active or 
inactive state, the activation of receptor depending on the type of the ligand. Ligands can 
be divided into four efficacy classes (Figure 8): 
  
• full agonists can stimulate the receptor to its maximal level. 
• partial agonists cannot fully activate even with high concentration of agonist. 
• neutral antagonists do not show any effect on signalling activity, nevertheless it 
might prevent other ligands from binding to the receptor. 
• inverse agonists bring a reverse response to agonists, decrease the basal level.86 
 
 
 
Figure 8 Dose response curves of a full agonist, partial agonist, neutral antagonist, and inverse agonist87 
 
In GPCR pharmacology we can distinguish one more type of agonist. A “biased agonist” is a 
ligand which stabilizes an active conformation of a receptor thus promoting some signalling 
cascades but not others. Seven transmembrane receptor ligands, for example, can be biased to a 
G protein or β-arrestin and activate one of the signalling pathways. This innovative approach is 
already investigated for some GPCRs like FPR288-89 or the μ-opioid receptor.63-64 . Over the 
past 20 years, it has been shown that the GPCRs display a dynamic character and can 
42 
 
adopt different conformations depending on the nature of ligand. Therefore GPCR 
signalling pathways and the ability to activate only the selected signalling pathways with 
desirable therapeutic effects are being extensively explored.90 It has been shown that 
biased signalling can be linked to good physiological responses but can also cause side 
effects.91 The µ-opioid receptor signalling is a good example of biased signalling resulting 
in the desirable therapeutic response. The activation of the µ-opioid receptor through the G 
protein leads to analgesia, where activation of the β-arrestin pathway contributes to negative 
outcomes such as respiratory depression and constipation.63 
 
In this chapter the FPR2 agonists of diverse origins will be described to illustrate the complex 
nature of this receptor and wide range of functionality. 
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2.3.1. Natural pro-resolving agonists and their derivatives  
 
Natural pro-resolving agonists contributed to the discovery formyl peptide receptor 2 and 
form a good base to propose novel agents. Members of this group include lipoxins, 
annexins and resolvins. 
2.3.1.1. Lipoxins 
 
In 1984 Serhan and colleagues described the isolation of the natural eicosanoids generated 
from arachidonic acid. They isolated these 5-lipoxygenase from human leukocytes and 
called the isomers LXA4 and LXB4.
92
 Serhan, Hamberg and Samuelsson reported that 
these lipoxins inhibited polymorphonuclear neutrophils infiltration and stimulated non-
phlogistic recruitment of macrophages. In 1990 the innovative idea of a role for G-
proteins in the effect of lipoxins on polymorphonuclear neutrophils was proposed. Two 
years later the studies showed a specific recognition site for LXA4 on PMNs.
93 Lipoxins 
are produced locally at the sites of inflammation. There are three biosynthetic routes for 
the generation of lipoxins: the 15-lipoxygenase (15-LO), the 5-Lipoxygenase (5-LO) 
pathway and the aspirin-triggered lipid pathway (Figure 9). 
 
 
Figure 9 Three possible pathways of lipoxins generation from arachidonic acid  
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The 15-lipoxygenase and the 5-lipoxygenase enzymes are classified as non-heme iron-
containing enzymes and are present in various cell types e.g.: epithelial or endothelial 
cells. These enzymes are involved in diverse physiological processes such as inhibition 
of leukocyte trafficking, production of anti-inflammatory cytokines or macrophage 
phagocytosis.94 The first source of lipoxins is the 15-LO pathway. In monocytes or 
epithelial cells, 15-lipoxygenase converts arachidonic acid into 15 S-HETE which can be 
used later as a substrate for leukocytes. 5-Lipoxygenase produces 5,6-epoxytetraene 
which undergoes hydrolysis to form the LXA4 and LXB4.  
The 5-LO pathway involves firstly oxygenation of arachidonic acid by 5-lipoxygenase 
and formation of LTA4. The final products are formed by conversion of the substrate by 
platelet 12-LO.The last route is the aspirin-triggered lipid pathway. Aspirin, by 
acetylation of cyclooxygenase-2 (COX2), blocks formation of prostaglandin. As a result, 
modified COX2 transforms AA to 15R-HETE, which when released from endothelial and 
epithelial cells is converted by polymorphonuclear neutrophils’ 5-LO to produce 15-epi-
LXA4 or 15-epi-LXB4.
95  
 
The main cellular functions of LipoxinA4 are: reduction of leukocytes rolling and vascular 
leakage, modulation of protein-1 and chemotaxis levels, inhibition of neutrophils 
recruitment,96-97 activation of FPR2 receptor and phagocytosis,98 inhibition of T-cells 
adhesion to vascular and salivary epithelium, reduction of NF-κB gene expression.99 
 
Native LXA4 is unstable and is easily metabolized by prostaglandin dehydrogenase. The 
epi-LXA4 generated in aspirin-triggered lipid pathway is more stable compared to LXA4 
however both lipoxins have shown overlapping biological actions.84 Therefore, numerous 
synthetic LXA4 analogues have been performed to improve the stability of the molecule. 
The researchers from UCD School of Chemistry and Chemical Biology in the 
collaboration with Prof Godson’s research group are currently working on heteroaromatic 
synthetic LXA4 derivatives. One of the fragile portions in the native lipoxin’s structure 
which is susceptible for enzymatic decomposition is the triene unit. By replacing this core 
with a more stable mimic group, they increased the stability of the molecules. Synthesis 
of heterocyclic lipoxin analogues improved the bioactivity and bioavailability in 
comparison to the native LX (Figure 10).100-101 
45 
 
 
Figure 10 Replacement of the triene unit with more chemically stable moieties.100 
 
In early 2018 the same group published a patent covering heterocyclic lipoxin derivatives 
with further exploration of replacement of the triene unit with different heterocyclic 
scaffolds for example: quinolone, quinoxaline, isoquinoline, oxazole or imidazole.102 
  
2.3.1.2. Annexin A1 
 
Annexin A1 (AnxA1) formerly known as lipocortin 1 is a glucocorticoid-regulated 
protein. In 1993, Huber and co-workers published the structure of human annexin A1 
lacking the first 32 amino acid residues (PDB code: 1AIN). Ten years later, the full-length 
structure of annexin A1 with the N-terminal domain in the presence of calcium ions (PDB 
code: 1MCX) was published (Figure 11).103 Annexins share common architecture, the 
core domain with four to eight repeats, each part contains a 70-75 amino sequence, and a 
unique N-terminus for each family member. The first insight into mechanistic and 
molecular basis of AnxA1 was done by Gerke et al. in 1999. They proved that FPR 
antagonists [butyloxycarbonyl (Boc) derivatives] diminished the antimigratory and anti-
inflammatory properties of AnxA1, and peptide Ac2-26, in PMN migration assay. It has 
been shown that the unique N-terminus sequence of AnxA1 interacts with the formyl 
peptide receptors.104-105 Upon calcium binding, a resulting conformational change is 
observed exposing the unique N-terminal domain, which can interact with FPR2. 
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Figure 11 Molecular structure of annexin A1103  
 
At the start of inflammation, the presence of Annexin A1 is crucial to reducing 
inflammation by decreasing the activity of some proinflammatory mediators such as 
chemokines, prostaglandins, cytokines, and adhesion molecules, reducing leukocyte 
penetration into tissue. It has been proved that in the absence of Annexin A1, in different 
models of inflammatory diseases, chronic inflammation is more likely to develop.106 
 
Studies showed that AnnexinA1 is associated with some human diseases such as: 
 
• Alzheimer’s disease – by decreasing the expression of peripheral leukocytes.107 
• Coronary artery disease – by increasing levels in circulating neutrophils.108 
• Ulcerative colitis – by preventing intestinal mucosal injury and boosting wound 
healing.109 
• Crohn’s Disease – the low level of ANXA1 expression might serve as a biomarker 
of disease development 110 
• Cystic fibrosis – by higher proteolysis in bronchoalveolar lavage (BAL) and non-
appearance in epithelial cells.111 
• Diabetes type 2 - by protecting peripheral organs against the injury and 
dysfunction.108, 112  
 
2.3.1.3. Resolvin D1 
 
Resolvins are by-products of omega-3 fatty acids. Resolvin D1 (RvD1) is a lipid 
biosynthesized from docosahexaenoic acid that promotes the resolution of inflammation. 
The biosynthesis of Resolvin D1 is shown in Figure 12. 15-LO converts docosahexaenoic 
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acid (DHA) into 17-S-H(p)DHA. The 17-hydro(peroxy) product of DHA is at that point 
transformed by 5-LO into the epoxide, which is hydrolysed to the final product RvD1.113 
The main cellular functions of ResolvinD1 are slightly different to those described for 
LipoxinA4. The ResolvinD1 activates FPR2, inhibits neutrophil recruitment, stimulates 
M2 macrophages phagocytosis, reduces insulin sensitivity and it shortens resolution 
interval. Moreover, the aspirin-triggered epimer of RvD1 shows also potent anti-
inflammatory properties.84 
 
 
Figure 12 Biosynthesis of Resolvin D1113 
 
2.3.2. Synthetic peptide agonists 
 
The first synthetic peptide with specific FPR-family binding properties was identified by 
a high-throughput peptide library study for stimulation of the formation of inositol 
phosphate. The haxapeptide Trp-Lys-Tyr-Met-Val-D-Met, also known as W-peptide or 
WKYMVm has been found to activate both FPR1 and FPR2 with high potency. (Figure 
13). W-peptide is used in several FPR2 activity cells assays including β-arrestin 
recruitment assay114 and calcium mobilization assay115 as a control. Data are normalised 
to the maximum response of WKYMVm.  The EC50 value for W-peptide in a calcium 
mobilization assay for FPR2-HL-60 cells line is 2 nM.  
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Figure 13 Structure of the peptide WKYMVm (16) 
 
Another synthetic peptide is the 21 amino acid derivative 
TIPMFVPESTSKLQKFTSWFM-amide known as CGEN-855A which was designed by 
Compugen Ltd. through an in silico approach. In 2011 Compugen Ltd. in collaboration 
with Merck Serono, reported CGEN-855A to be in preclinical development.84 In vivo, the 
peptide showed cardioprotection in animal models of I/R-induced myocardial 
infarction.116 
 
2.3.3.  Small molecule agonists  
 
The analogues of the native lipoxinA4 compound have a short half-life, whereas the small 
synthetic molecules are more stable. So far, no synthetic FPR2 agonist molecules have 
reached the market as approved drugs. Currently, several companies are interested in the 
development of FPR2 agonists including Actelion Pharmaceuticals Ltd., Allergan, 
Bristol-Myers Squibb and Kyorin Pharmaceuticals. The therapeutic potential of formyl 
peptide receptor agonists has not passed unobserved for pharmaceutical industry and 
academia. For past 15 years an increasing number of synthetic small molecules agonists 
have been developed and these are discussed below. All EC50 values presented in this 
chapter are from calcium mobilization assays.  
 
2.3.3.1. Phenylurea derivatives 
 
The one of the largest groups of potent FPR2 agonists are substituted urea amino acid 
derivatives. This family of the compounds has been developed by Allergan, focusing 
mainly on treatment of an eye inflammation and dry eye syndrome, currently one of their 
FPR2 agonists is in clinical trials. Carboxylic acid compounds (18) were well tolerated 
and more potent compared to their ester analogues (17). Additionally, the stereochemistry 
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plays a key role. According to the patents (S) enantiomers are more potent than (R), for 
example the compound 18 is reported at 0.88 nM, whereas the (R) enantiomer is reported 
at 1229 nM (Table 2).117 
 
 
ID R1 FPR2 EC50 literature [nM] 
17 -OtBu 140 
18 -OH 0.88 
19 -NH2 1.05 
20 -CH3 4.70 
21 
 
2.30 
Table 2 Selected examples from the Allergan patent and literature EC50 values  
 
Modifications of the acid moiety which retain high potency include carboxamide (19), 
methyl ketone (20) and also the tetrazole moiety as a carboxylic acid bioisostere (21)118. 
In addition, the preferred substituted aniline is the para position, preferably with a 
lipophilic and electronegative moiety.  
In 2017 Allergan published novel substituted urea amino acid derivatives as N-formyl 
peptide receptor modulators. They replaced L-leucine with 2- (1-aminoethyl) -4-methyl-
pentanoic acid, which allowed an extra carbon to be introduced between the urea and acid 
moiety. The mixture of diastereoisomers were purified by Supercritical Fluid 
Chromatography (SFC) to obtain compound 22 (earlier eluting enantiomer) and 23 (later 
eluting enantiomer). The biological activity of the compounds was determined in a 
calcium mobilization assay, and the agonists were tested against two targets FPR1 and 
FPR2. The studies showed that both the compounds are potent full FPR2 agonists, with 
high value of efficacy, 1.03 and 0.91 respectively (Table 3).119   
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ID Enantiomer 
FPR1 
EC50 
(Emax) 
FPR2 
EC50 
(Emax) 
Ratio 
FPR1:FPR2 
EC50 
22 
Enantiomer I 
>99% ee, [α]D=-30.6 
(c=1.0 MeOH) 
3239 nM 
(0.56) 
13 nM 
(1.03) 
249 
23 
Enantiomer II 
>99% ee, [α]D=+31.7  
(c=1.0 MeOH) 
855 nM 
(0.89) 
51 nM 
(0.94) 
17 
Table 3 Novel substituted urea amino acid derivatives as N-formyl peptide receptor modulators 
 
2.3.3.2. Bridged spiro[2.4]heptane derivatives 
 
The next family of compounds which are under investigation is bridge compounds 
derivatives from Allergan and Actelion.  In 2010 Allergan published the first patent 
covering the derivatives of cycloalkyl- and cycloalkenyl-1,2-dicarboxylic acid as novel 
FPR2 modulators.120 They showed that the chirality of the molecules is also important. 
The (+)-enantiomer 24 is over 100-fold more active than the (-)-enantiomer 24 (Figure 
14). The methylation of the NH moiety of the compound (+)-24 showed the important 
role of this group in activity. In addition, the preferred substituted position for the aniline 
is the para position, preferably with a halogen atom. 
 
Figure 14 Enantiomerically pure cycloalkenyl derivatives show the crucial role of chirality 
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In the same year Actelion published a patent covering bridged bicyclic compounds. These 
compounds are very similar to the molecules proposed by Allergan. The only difference 
is in the conformation of substituents.  Actelion designed compounds with trans 
configuration, whereas Allergan proposed the cis arrangement of substituents. 
 
 
Figure 15 Derivatives of the most potent compounds from Actelion patents 
 
In the patent covering nonaromatic amine agonists, compound 26 where the aniline has 
been replaced by 3-amino-5-bromopyridine shows good activity in calcium mobilization 
with an EC50= 12.6 nM. Compound 27 is the most active compound covered by a patent 
on ester derivatives of bridge compounds121 (Figure 15). A patent covering a single 
compound 28 is a 1-(p-tolyl)-cyclopropyl-substituted122 example from the optimization 
of compounds from the 2010 patent123 (Figure 16). 
 
Figure 16 1-(p-tolyl)-cyclopropyl-substituted bridge compound 
 
The derivatives of cycloalkyl- and cycloalkenyl-1,2-dicarboxylic acid from Allergan and 
later the bridged spiro[2.4]heptane derivatives were the first group of the FPR2 
modulators with such three-dimensionality in the structure. The results from cellular 
assays and SAR studies confirmed the importance of NH moiety and the preferred 
halogen substitution is at the para position. 
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2.3.3.3. Aminotriazoles derivatives 
 
The third family of compounds which is currently under the investigation is 
aminotriazoles series from Actelion. This series does not contain the typical aniline 
portion but instead a novel aminopyrazole and aminotriazole core. It is a clear signal that 
FPR2 as the potential therapeutic target is still not fully explored. The replacement of the 
pyrazole core (144)124 by triazole (25)125 improved the potency by more than 10-fold 
(Figure 17).  
 
Figure 17 Nonaniline-containing aminopyrazole and aminotriazole FPR2 agonists 
 
 
One of the compounds from the oxazole family was tested in Phase 1 clinical studies. 
ACT389949 has shown agonistic properties and it is safe and well tolerated (Figure 
18).126 The biomarker analysis showed that the response is pro-inflammatory rather than 
anti-inflammatory. Additionally, this compound is reported to have improved covalent 
binding.127 
 
Figure 18 Structure of ACT389949 from the Actelion patent  
 
Additional SAR studies were focused on the improvement of the plasma stability in 
comparison with the keto-analogues (Figure 19). Replacement of the ketone moiety by a 
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methyl ether derivative 30 or hydroxylated derivative 31 enhanced the plasma stability 
(t1/2 >24h).
128-129 
 
Figure 19 Replacement of ketone group allowed improvement of the plasma stability  
where x=N 
 
2.3.3.4. Quinazoline derivatives 
 
In 2004 the University of Illinois and the Shanghai Institute of Materia Medica screened 
a library of over 16 000 compounds, including synthetic and natural molecules.130  
Quin-C1 was the most promising compound from the screen and was tested in calcium 
mobilization assay and neutrophil functional assays. It was shown that compound 32 was 
able to induce the neutrophils degranulation and chemotaxis. The additional SAR studies 
revealed the importance of para methoxy substituent for the activity. The removal of this 
group resulted in loss of the activity and also replacement of the methoxy group by a 
hydroxyl moiety caused loss of activity (Figure 20). 131  
 
 
Figure 20 The structure of Quin-C1 
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2.3.3.5. Pyrazolone derivatives 
 
In 2006, Amgen published a novel scaffold of FPR2 agonists which were identified by 
high-throughput screening of their compound library. Structure-activity relationship 
studies showed that the bulky and electron withdrawing para-substituent R2 had a key 
influence on activity. A drastic loss of potency was observed when the substituent was 
moved from para- (R2) to ortho-position (R1). Over 33-fold decrease of potency was 
observed in the calcium mobilization assay for compound 34 compared to 33 (Figure 
21). Additional modification of phenyl group by replacing it by other heterocyclic rings 
resulted in loss of potency.132 
 
Figure 21 Pyrazolone FPR2 agonists 
 
Following additional SAR studies potent compound 35, often called Compound 43132 
from the original numbering in the publication, has been identified. Compound 43 is a 
selective FPR2 agonist and is often used as a tool compound in several cellular assays 
(Figure 22).  
 
Figure 22 Structure of compound 43 
 
In 2017 a Bristol Myers Squibb patent was published targeting FPR2 for treatment of 
heart disease using compound 43. The patent covers the methods of treating acute and 
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chronic heart failure, myocardial infraction, acute coronary disease and cardiac iatrogenic 
damage.133  
 
2.3.3.6. Pyridazinone derivatives 
 
Pyridazinone derivatives are analogues of Amgen compound 43 (35) developed using a 
ligand-based drug design approach. From the series of compounds, compound 36 was 
identified to be a selective FPR2 agonist, with a Ca2+ EC50 value of 2400 nM.
134 Further 
modifications of the structure led to dual FPR1-FPR2 agonists. Compound 37 is over 2-
fold more active than 36, but it is not selective.135 For this group of analogues, in common 
with previous presented agonists, the authors underlined that a bulky and/or 
electronegative moiety in the para position to the phenyl ring plays a key role for activity 
(Figure 23). 
 
Figure 23 The selective FPR2 and dual FPR1-FPR2 pyridazinone agonists 
 
2.3.3.7. Benzimidazole derivatives 
 
Schepetkin’s research group at Montana University is one of the most active groups 
working in the field of FPR2 ligands. In 2010 they screened a 6000-compound library. 
As a result, twelve FPR agonists with low micromolar activity were identified. One of the 
hit compounds was the benzimidazole derivative 38. An additional 26 benzimidazole 
derivatives were analysed in calcium mobilization and chemotaxis assays. Six of these 
were FPR1-specific agonists (e.g. 38) and six were dual FPR1/FPR2 agonists (e.g. 39) 
(Figure 24). The benzimidazole derivatives are an example of the mixed FPR1/FPR2 
agonists with moderate activity.136 All active agonists contained a para methoxy or 
ethoxy phenyl moiety which is a crucial element for activity. 
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Figure 24 Benzimidazole derivatives 
 
2.3.3.8. Ureidopropanamide derivatives 
 
In 2017 Schepetkin’s research group published novel ureidopropanamide mixed 
FPR1/FPR2 agonists. This group of compounds was proposed based on the tryptophan 
series of dual FPR1/FPR2 agonists.135 Only one analogue showed selectivity towards 
FPR2 (40). Replacement of the nitro group with a methoxy moiety resulted in an increase 
in potency of the agonists but did not improve selectivity (Figure 25). The structural 
modification was motivated by previous SAR studies for benzimidazole derivatives, 
where the introduction of a methoxy group in the para position led to an increase in 
potency. 
 
Figure 25 Ureidopropanamide dual FPR1/FPR2 agonists 
 
2.3.3.9. Piperidinone derivatives 
 
The latest patent from Bristol-Myers Squibb covers piperidinone FPR agonists.  The 
patent provides also the methods of using the compounds for the treatment of heart failure, 
atherosclerosis and chronic pulmonary disease.137 As distinct from other research groups, 
for testing the activity of the compounds they used a cAMP assay (Table 4). Replacement 
of pyridazinones with a more flexible piperidinone core has added the three 
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dimensionality and potentially improved the solubility. Some of the compounds such as 
compound 42 and 43 also have pyridine in the structure. Modelling studies on the 
tryptophan series performed by Schepetkin’s group showed an important role of the polar 
pyridine in the binding mode.135  Based on results from cellular assays the compounds 
(42 and 43) with a bulky and/or electronegative moiety in the para position of the phenyl 
ring are active. Modification of the phenyl group by replacing it by other heterocyclic 
rings resulted in loss of potency in hFPR1 cell line (44). 
 
 Structure 
cAMP EC50 [μM] 
hFPR1 hFPR2 
42 
 
0.0084 0.2 
43 
 
0.0093 0.39 
44 
 
0.38 0.21 
Table 4 Examples of piperidinone FPR agonists 
 
2.3.3.10. Kyorin urea derivatives 
 
In 2015, Kyorin Pharmaceutical announced a license agreement with Bristol-Myers 
Squibb for development of novel FPR2 agonists. As found in the majority of the FPR2 
agonists, Kyorin’s compounds share similar structural features such as an aniline 
substituted with halogen in the para position, a urea moiety and the presence of methoxy 
group. The originality of these derivatives results from a  novel scaffold with high three 
dimensionality, which might help to fit into the binding pocket and increase the solubility 
of the compounds (Figure 26).138  
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Figure 26 Urea derivatives proposed by Kyorin 
 
In 2017/2018 in collaboration with Bristol-Myers Squibb they initiated a Phase I clinical 
trial. The structure of the clinical candidate has been revealed this year, BMS-986235139 
(47) is a selective FPR2 agonist containing a 4-phenylpyrrolidinone motif (Figure 27).  
 
Figure 27 Chemical structure of BMS-986235 (47) 
 
2.3.3.11. Non-natural amino acids series 
 
In 2018 Grünenthal GMBH presented the invention of new modulators of FPR2 which 
can be used in the treatment and/or prophylaxis of disorders which are at least partially 
mediated by FPR2. The claim of the patent is broad and does not reveal the area of 
treatment. The generic structure is similar to the Kyorin analogues, with the phenyl ring 
attached to a urea moiety, a difluoro-substituted phenyl ring and the scaffold with high 
three dimensionality. The 6-membered ring lactam is also similar to the Kyorin and 
Bristol-Myers Squibb cores. Each of the compounds has been synthesized as a racemic 
mixture and compounds shown in Figure 28 were identified to be potent FPR2 agonists, 
with Ca2+ EC50 values of < 1 nM, whereas the values of FPR1 Ca
2+ EC50 were in the range 
1-1000 nM. Unfortunately, Grünenthal GMBH did not disclose precise values for EC50. 
The racemic mixtures were subjected to chiral separation by chiral HPLC. In the example 
of compound 47, the first trans-enantiomer retained the higher potency against FPR2, 
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while the second eluted trans-enantiomer lost its selectivity and Ca2+ EC50 values
 were in 
the range 1-1000nM for FPR1 and FPR2. Due to lack of the exact values of EC50 it is 
hard to confirm the FPR1/FPR2 EC50 ratio and how selective the compounds are (Figure 
28).140 
 
Figure 28 6-membered cyclic amines or lactam derivatives 
 
This review of known FPR2 agonists has shown that Formyl peptide receptor can be activated 
by agonists of diverse origins. In the last 10 years several synthetic small molecules have been 
submitted for Phase I clinical trials, but none of them has yet become the first-in-class anti-
inflammatory drug. Nevertheless, each synthesized small molecule agonist has made its 
contribution to the progress in pharmacology and molecular biology of FPR2. 
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3.  Aims and objectives 
 
The aim of this major section of the thesis is to design and develop new probe compounds 
to support target validation associated with vascular inflammation such as atherosclerosis 
or myocardial infarction. The discovery of natural proresolving lipid mediators and 
corresponding receptors, such as formyl peptide receptor 2 (FPR2) has unlocked new 
opportunities for the proresolving approach of treating chronic inflammation. Very often 
the first stage of the evolution of the inflammatory process is leukocyte adhesion and 
increased permeability of the endothelium due to pro-inflammatory conditions in the site. 
The FPR2 agonists such as LXA4 reduces the level of IL-8 in human neutrophils in 
vitro141 and their synthetic analogues can also block adhesion of neutrophils142. Our 
knowledge of the mechanisms behind the resolution of inflammation process has been 
significantly broadened in the XXI century,143 resulting in innovative and pioneering 
approaches to help in controlling pathologies with underlying unresolved inflammation.. 
Several companies are interested in the development of FPR2 agonists including Bristol 
Myers Squibb which has an FPR2 small molecule agonist in phase 1 clinical trials. An 
example of an FPR2 small molecule agonist which could be used as a good tool 
compound to support target validation associated with vascular inflammation is 
Compound 43. Bristol-Myers Squib, in collaboration with research groups from 
University of California San Diego and University of Montreal, published their work on 
the beneficial effect of long-term oral treatment with Compound 43 on myocardial 
infarction. They proved FPR2 agonism has a positive impact on protection of post-
infarction cardiac structure and function.144 These results correlate to current studies 
performed by Vasundhara K et al. which showed that FPR2 inactivation by the antagonist 
WRW4 led to non-resolving inflammation events in acute heart failure.145 These results 
increased the confidence in the link between FPR2 and the resolution of vascular 
inflammation and further exploration of new agonists regulating the receptor have the 
potential to provide additional insights. 
Existing FPR2 agonists can be divided into three main groups: natural molecules, 
synthetic peptides and synthetic small molecule agonists. In this project I have focused 
on the synthetic small molecule agonists which are more stable compared to the analogues 
of the native LXA4. In addition, they are more synthetically accessible than peptides and 
lipid molecules. So far, there are no synthetic FPR2 agonist molecules which are marketed 
drugs.  
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The goal is to design and synthesise novel probe compounds which will have sub-
micromolar or ideally nanomolar activity and acceptable ADME properties. The selected 
compounds should have at least moderate kinetic solubility (Ks > 10 µM) to avoid 
solubility issues during in vitro and in vivo studies. The logD value should be in the range 
of 1-3. In order to prevent undesired rapid clearance in in vivo studies, the molecules 
should also show good microsomal stability (Intrinsic Clearance < 47 µL/min/mg 
protein). As part of the target product profile, the aim is a compound which is suitable for 
oral in vivo administration, although intravenous (IV) or intraperitoneal (IP) dosing may 
be used for validation studies . Finally, the small molecules agonists cannot show any 
cytotoxic effect.  
It is envisaged that the probe compounds will be useful for studying the role of FPR2 
receptor signalling and can also act as starting points for further lead compound 
optimization. 
 
In the search for novel agonists, the project objectives are: 
 
▪ Synthesis of selected existing FPR2 agonists based on literature reviews to use as 
reference compounds to establish biological assays (Calcium mobilization and β-
arrestin recruitment assays using CHO FPR2 cell line) and to act as benchmarks 
for comparison against novel compounds (chapter 5.1). 
 
▪ Development of novel FPR2 agonists based on ligand-based virtual screening 
using Cresset software. In the absence of crystal structure of target protein this 
approach facilitates the exploration of novel active molecules using the SAR of a 
series of existing agonists (Pyridinone and pyrimidin-2-one series, chapter 5.2).  
 
▪ Development of protein model structures and application of in silico screening to 
the project target. Homology modelling is a useful tool to predict GPCR structure 
when the crystal structure is unavailable and enables rational design of novel 
ligands (chapter 4). 
 
▪ Development of novel agonists of FPR2 based on knowledge gained from 
homology modelling using two approaches: 
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o Alternative bioisosteric replacements of the L-Leucine moiety and 
preserving key structural features such as para-bromoaniline and urea 
moiety which are key to maintain the biological activity. This approach 
facilitates the development a new series of compounds with the desired 
biological activity and physicochemical properties based on the structures 
of existing agonists (Non-natural amino acids series, chapter 5.3). 
o Screening the GLASS (GPCR-Ligand Association) database using our 
pharmacophore model (Phase Ligand Screening). This approach enables 
the ligand-based virtual screening of the compounds which are part of a 
repository for experimentally validated GPCR-ligand interactions 
(Pyrrolidinone series chapter 5.4).  
 
▪ Examination of possible anti-inflammatory and pro-resolving properties of FPR2 
agonists using in vitro assays of human neutrophils adhesion and in vivo assays of 
neutrophil trafficking to the site of inflammation (chapter 6). 
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4. Investigating the binding modes and structure-activity 
relationships of small molecule FPR2 agonists using in 
silico methods 
 
4.1. Homology model 
 
Structural studies of GPCRs remain challenging due to the lack of a naturally abundant 
sources of protein, the flexibility, and their partially hydrophobic surfaces which cause 
the problems for creating crystal lattice contacts. Formyl peptide receptor 2 is one of many 
GPCRs which is lacking a crystal structure. In addition, there is relatively little 
information about the possible mode of interaction of ligands with a binding site. Most of 
the site-directed mutagenesis studies focused on peptide binding. The mutation of Asp-
281 to Gly (D2817.32G) showed the importance of asparagine to maintaining the 
interaction of receptor with a positively charged C-terminal residue containing formyl 
peptides. Understanding the protein structure and interactions of active molecules with 
the target are fundamental for drug design. Therefore, homology modelling is useful in 
allowing a model of the desired target to be developed, which can then be used to develop 
a hypothesis for the binding sites of the ligands. It is worth mentioning that there is 
minimum identity level required to call the homology model trustworthy. Homology 
models with the sequence identity greater than 50% are having only minor chain packing 
errors. At the 30–50% identity level, the quality of the homology model is lower with 
more frequent errors which are usually situated in the loops. Below 30% identity, 
significant errors can be observed due to low accuracy. 
The development of protein model structures and work with homology models of FPR2 
was part of my secondment in Maastricht during the second year of the PhD programme. 
In these studies, two ‘ready-to-use’ homology models were adopted, an agonist bound μ-
opioid based structure (5C1M)146 and a dual template model based on the antagonist-
bound μ-opioid receptor and antagonist-bound chemokine receptor crystal structure.147 
Both models were validated using template model (TM) score, Protein Model Check 
(WHAT IF portal), Multiple Sequence Viewer Maestro and VMD Structure Alignment 
with MultiSeq.  
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A dual template model based on the antagonist-bound μ-opioid receptor and antagonist-
bound chemokine receptor crystal structure was provided by Prof Filipek from Warsaw 
University.147 Their model was built using GPCRM pipeline (Figure 29). 148 
 
 
Figure 29 The GPCRM modelling pipeline148 
The homology model is built from several templates. The most promising alignment is chosen for further 
optimization using Modeller and Rosetta. The final homology model can be applied directly in molecular docking 
studies. 
 
In the first step of model validation, the dual template model was aligned with both 
templates µ-opioid receptor (4DKL) and chemokine receptor CXCR4 (3ODU) using 
VMD Structure Alignment with MultiSeq and analysed TM score (Figure 30). The TM-
align algorithm was used to compare the sequence independent protein structure. The 
TM-score scales the structural similarity. TM-score has the value in the range 0-1, where 
1 indicates a perfect match between two structures. The scores greater than 0.5 assume is 
about the same fold in SCOP (Structural Classification of Proteins database) and CATH 
(Class Architecture Topology Homologous superfamily database). TM-align algorithm 
was run for two protein structures pairs: FPR2 homology model versus µ-opioid receptor 
(4DKL) and FPR2 homology versus chemokine receptor CXCR4 (3ODU). In both cases 
the TM-score was greater than 0.5 which indicates that they are about the same fold 
(Figure 30). Protein Model Check (WHAT IF portal) showed the absence of the alternate 
atoms and duplicates. All residues have a complete backbone and any missing atoms were 
not detected in residues. No steric clashes were reported in protein preparation wizard. 
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Figure 30 Dual template VMD Structure Alignment with MultiSeq and TM alignment analysis. 
 
In the Ramachandran plot the residues represented by black points are located within 
allowed (yellow), preferred (red), or disallowed (white) regions of φ/φ space. The 
residues placed in white regions are the warning signs and revealed the information about 
bad torsion angles.  
 
The Ramachandran plot was generated in Maestro Schrodinger software using the protein 
preparation wizard to verify structural accuracy (Figure 31 A). The plot has shown four 
amino acid residues presented in the disallowed regions. The outlier residues were 
presented as sticks in the structure of the receptor: Ser-182 (ECL2), Lys-231 (TM5), Met-
87 and Gly-88, both located in TM2 helix (Figure 31 B). 
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Figure 31 A) Ramachandran plot of the FPR2 homology model built on dual template. B) The outlier residues are 
represented as sticks and highlighted in red 
 
The second model of interest is a FPR2 homology model in an active configuration from 
GPCRdb. They used a strategy called ‘Less model-more Xtal’, which means the model is 
built based on experimental data from the main template and alternative local templates 
for missing or distorted segments. The final model was built using Modeller software.149 
The workflow is divided into 9 steps starting with sequence alignment followed up by 
selection of main template based on: class, state (active or inactive), sequence similarity, 
structure coverage and resolution of crystal structure. The full GPCRdb homology 
pipeline is presented in Figure 32.146  
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Figure 32 The GPCRdb homology model pipeline 
 
To build this homology model 5 backbone (5C1M, 4N1J, 3ODU, 4XES and 5LWE) and 
13 rotamer templates were used. A crystal structure of active µ-opioid receptor bound to 
the agonist BU72 (5C1M) is the main template (Table 5). The X-ray crystal structure 
with a resolution 2.1 Å and stabilized by Nb39 (a G protein mimetic camelid antibody 
fragment) was solved by the research group of Prof Kobilka and published in 2015.64 The 
full protein sequence alignment can be found in Appendix 1. 
 
Templates 
Main 
template 
Additional 
templates 
Freely 
modelled 
Backbones 76.9% 12.2% 10% 
Side chains 27.1% 47.5% 25.4% 
Table 5 Backbones and side chains templates used to build FPR2 homology model 
 
Using the Multisequence Alignment tool in Schrodinger Maestro, the sequence alignment 
between FPR2 and main template (µ-opioid receptor) was performed. In the table below 
the percentage of identity, similarity and homology are shown (Table 6). A criterium of 
a minimum 30% sequence identity was met for this homology model.  
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FPR2 vs 5C1M sequence 
Identity 30% 
Similarity 47% 
Homology 49% 
Table 6 Sequence alignment of FPR2 homology model with µ-opioid receptor structure 
 
In figure 33 full alignment of both sequences is shown and coloured based on similarity 
of the residues.  
 
 
Figure 33 Sequence Alignment coloured by the residue similarity (Schrodinger Maestro) 
 
The high value of the template model score (TM-score=0.89) proved high degree of 
similarity between FPR2 homology structure with agonist bound μ-opioid (5C1M) 
tertiary structure. The RMSD value calculated for the structures alignments was 1.65 Å 
(Figure 34).  In this case Protein Model Check (WHAT IF portal) also proved the absence 
of the alternate atoms and duplicates. All residues have a complete backbone and any 
missing atoms were not detected in residues. 
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Figure 34 A protein structure alignment of active u-opioid and FPR2 homology model 
 
For further assessment of the homology model quality, the Protein Report from Protein 
preparation wizard was used to examine its quality and fix any problems, such as steric 
clashes, prior to using the model for tasks such as virtual screening. Steric Clashes are 
observed between Ile-282 and Pro-286: the measured distance was 2.67 Å, where the 
minimum allowed is 3.2 Å (Figure 35).  
 
 
Figure 35 Steric clashes between Ile-282 (green) and Pro-286 (orange) in FPR2 homology model built on active µ-
opioid receptor 
 
In the Ramachandran plot, there are nine outlier residues: Trp-267 (TM6), Cys-176 
(ECL2), Gly-232 (ICL3), Pro-159 (TM4), Gln-307 (H8), Lys-90 (ECL1), Asn-179 
(ECL2), Gly-184 (ECL2), Gly-185 (ECL2) of which more than half are located in the 
intra- or extracellular loops, which is not surprising because the loops are the most flexible 
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regions of the receptor (Figure 36). Additional molecular dynamics simulation could help 
to loosen up modelled loops, however it can lead to the quality loss of modelled helix.  
 
Figure 36  A) Ramachandran plot of the FPR2 homology model built on µ-opioid structure 5CM1 B) The outlier 
residues are represented as sticks and highlighted in red 
Finally, Protein Surface Analyzer was run for GPCRdb FPR2 homology model. In the 
figure below the general protein properties and protein surface are presented. The main 
cavity is characterised mainly by hydrophobic features (Figure 37). 
 
Figure 37 Protein Surface Analyzer 
Positive: blue; negative: red; hydrophobic: green 
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4.2. Molecular docking studies 
 
The docking studies were performed for both models. However, further studies were 
focused on an agonist bound μ-opioid based structure which is in the active conformation 
and has not been described in the literature. 
Protein-Ligand docking was performed using the Glide SP-protocol. All ligands were 
treated as flexible molecules. The binding site was identified using Sitemap (Schrödinger 
Release 2018-2: Schrödinger, LLC, New York, 2018.) Ligands were prepared and 
visualized using Maestro 11.5. To generate decoys for active agonists the DUDE database 
was used. Decoy molecules are computed based on analogous physical properties but 
different chemical structures.150 In 2012 Perretti et al. generated FPR1/FPR2 chimera 
proteins to identify the distinct domains which are crucial for FPR2 receptor activation 
using Anx A1, SAA and Compound 43.151 The studies showed that extracellular loop I, 
transmembrane region III and intracellular loop II contain the binding site for small 
molecule agonist Compound 43. From mutagenesis studies and later docking studies, the 
four amino acid residues are suggested to take part in binding of peptide agonists: Arg-
26, Asp-106, Arg-205 and Asp-281.79, 147 However, the receptor grid generation built on 
these four residues did not give consistent results. The final receptor grid generation was 
performed using the results from SiteMap using Glide SP-protocol with outer box 
20x20x20 Å. 
SiteMap is a helpful tool in the identification and assessment of probable protein binding 
sites. Proposed binding regions are characterised by group of site points at or close to the 
receptor surface.  A lattice of points is used to identify feasible hydrophobic and 
hydrophilic areas. The potential binding sites on the surface of the protein are ranked and 
returned as the top-ranking sites.  The proposed binding sites can be ranked based on 
volume, size, Sitescore and Dscore. 
Site Score is calculated based on the number of site points (n), the enclosure score (e), 
and the hydrophilic score (p). The highest possible Site Score value is 1 (Equation 1). A 
SiteScore with the value greater than 0.80 correctly differentiates between drug-binding 
and non-drug-binding sites. 
SiteScore = 0.0733√n + 06688 e − 0.2p (1) 
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Druggability Score (Dscore) is calculated using the same parameters like in the case of 
SiteScore, however the hydrophilic score is not capped and Dscore value can be higher 
than 1.0 (Equation 2). 
Dscore = 0.094√n + 0.6e − 0.324p  (2) 
The detection of binding site using SiteMap was firstly performed for HM dual template. 
Five possible binding sites were ranked. The site number 3 with the best SiteScore is 
allocated between TM1, TM7 and H8 in the intracellular region, forming an allosteric 
binding pocket. Site 1 was selected for protein-ligand docking. It forms the orthosteric 
binding site with a large hydrophobic cavity with the upper part of the pocket being 
exposed to extracellular space These results overlap with the FPR1/FPR2 chimera protein 
studies mentioned at the beginning of this chapter. The hydrophobic regions are marked 
in yellow, hydrophilic are represented in green. The hydrogen bond donor regions are 
marked in purple, or blue if they overlapped with hydrophilic. The hydrogen bond 
acceptors are shown in red/brown colour (Figure 38). 
 
 
Figure 38 Identified binding site of FPR2 receptor using SiteMap algorithm (HM dual template) 
Binding Site 1 was identified as the orthosteric binding site and marked in the figure. hydrophobic map—yellow; 
hydrophilic map—green; hydrogen-bond donor map—blue; hydrogen-bond acceptor map—red; metal-binding 
map—pink 
 
In the table below examples of chemical structures of selected FPR2 agonists used in 
virtual screening were presented. Six main families were chosen to explore possible 
binding modes. All literature or experimental EC50 values presented in this chapter are 
from the calcium mobilization assays.  
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# Chemical structure 
EC50 
[nM] 
# Chemical structure 
EC50 
[nM] 
Pyrazolone132 Allergan117-118, 152 
50 
 
980 18 
 
140 
51 
 
90 19 
 
1.05 
52 
 
490 21 
 
48 
53 
 
2730 77 
 
1.4 
54 
 
170 82 
 
11 
Oxazole124 Kyorin153 
14
2 
 
260 
(N) 
157 
 
0.25 
14
3 
 
170 
(N) 
158 
 
2 
(N) 
Table 7 Chemical Structures of representative FPR2 agonists taken for virtual docking studies 
(N-new compound, not described, I-intermediate, not lit. EC50) 
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Table 7 (continued) 
# Chemical structure 
EC50 
[nM] 
# Chemical structure 
EC50 
[nM] 
Bridged spiro[2.4] heptane 121-123 Pyridazinone135 
109 
 
2.9 35 
 
3800 
111 
 
23 
(N) 
55 
 
6800 
112 
 
1 56 
 
8200 
98 
 
I    
 
The outcomes were examined manually, and the protein-ligand docking showed three 
different binding modes in orthosteric pocket. Compound 50 (Figure 39, green) 
represents first binding mode, where we can observe H bonds with Gly-264, possible 
edge stacking with Phe-257 and with phenyl ring. An aromatic H-bond formed between 
Asn-284, Phe-180. In this group we can include: pyrazolone, pyridazinone, Kyorin and 
some of the bridge compounds. The second binding mode is made by the Allergan urea 
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derivatives. Compound 19 interacts with binding site through several hydrogen bonds. 
The carbonyl group of the primary amide acts as hydrogen bond acceptor and interacts 
with the amino groups of Arg-26. The carbonyl group of aspartic acid (Asp-281) plays 
the role of hydrogen bond acceptor and forms hydrogen bonds with the urea moiety of 
the compound. Formation of the aromatic H-bond between the aryl halide and Tyr-22 was 
observed. The bulky L-leucine moiety fits into the cavity formed by Tyr-277, Leu-272, 
Ile-280, Thr-7 (Figure 39, purple). Interestingly, compound 77 which has a dimethylated 
amide group can no longer act as a hydrogen bond donor and we can observe loss of 
contact with Arg-26 however it interacts through its carbonyl group forming an additional 
H-bond with Asp-281. The third binding mode has only one representative, compound 
143 from oxazole family. The terminal oxazole ring forms aromatic H-bonds with Arg-
205. Possible aromatic π-π stacking interactions are detected with His-102 and Phe-257 
(Figure 39, orange).  
 
 
Figure 39 Proposed three binding modes based on results from ligand-protein docking using HM Dual template 
compound 19 – purple, compound 77 – green, compound 143 – orange 
 
In the dual template three main binding modes have been reported. Amino residues such 
as Arg-26, Arg-205, Asp-281, Phe-257 and His-102 play crucial roles here. However 
radically different regions of the receptor are occupied by diverse small molecule 
agonists. In order to check the quality of the receptor grid, the trial virtual screening of 
actives and decoys was performed. The enrichment factor was calculated and value of 
receiver operating characteristic (ROC) was only 50% with the active molecules spread 
among all screened compounds (Figure 40). 
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Figure 40 The enrichment factor calculated for homology model built on a dual template using Schrodinger Maestro 
software 
 
Unfortunately, these results did not give the confidence to distinguish actives from 
inactives using the dual template homology model. The additional constraints in virtual 
screening could be applied; however, the lack of enough information from mutagenesis 
studies made it difficult to decide which binding mode is the best and choose one 
particular binding site for screening the novel compounds. 
As a further step it was decided to perform virtual screening using the second template 
obtained from GPCRdb. The final receptor grid generation was performed using the 
results from SiteMap using Glide SP-protocol with outer box 20x20x20 Å as in the case 
of the dual template homology model. In the figure below, the predicted binding site is 
shown with the results. For this receptor structure, two results from the SiteMap algorithm 
were merged and highlighted in figure 41. Both are located next to each other and together 
create the large orthosteric binding pocket with a total volume of 641.5Å3. Two active 
sites ranked in the second and third position are the allosteric binding sites (Figure 41). 
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Figure 41 Identified binding site of FPR2 receptor using SiteMap algorithm (GPCRdb  FPR2 homology model) 
Binding Site 2 and 4 were identified as orthosteric binding sites and marked in the figure. hydrophobic map—yellow; 
hydrophilic map—green; hydrogen-bond donor map—blue; hydrogen-bond acceptor map—red; metal-binding 
map—pink 
 
The first series which was investigated was the pyrazolone derivatives identified by 
Amgen. This family has two possible binding modes. In both cases the phenyl ring linked 
directly to the pyrazolone core is placed in the deepest pocket I, formed with hydrophobic 
amino residues such as Phe-292, Phe-257. The aromatic π-stacking interaction is 
observed between the core pyrazolone ring and His-102. The analogues which contain 
the para halogen moiety interact with the residue in the loop, Cys-176, which acts as 
hydrogen bond acceptor and forms hydrogen bonds with the nitrogen from the urea 
moiety. The para halide substituted ring fits in to subpocket III: Tyr-175, Tyr-174, Phe-
163. For analogues with a para-methoxy substituent, we might observe a flick into the 
subpocket II which contains the amino acid residues: Ser-84, Val-284 and Tyr-175 
(Figure 42). 
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Figure 42 Proposed binding modes for pyrazolone series 
Compound: 50 (blue), 51 (dark green), 52 (pink), 53 (purple), 54 (yellow) 
 
The pyridazinone family (compounds 55 and 56) has a different binding mode compared 
to the pyrazolone. The pyridazinone core fits into the pocket I, through possible π-
stacking of the core with Phe-257, Phe-292, Phe-74. The meta-methoxy aryl fits in the 
lower part of subpocket II, interacts through the aromatic hydrogen interactions with 
residues Thr-77, Phe-292, Phe-80 and His-102. The para-substituted phenyl rings 
occupied the third subpocket, with possible edge π-π stacking interactions with Phe-163. 
The carbonyl group of the amide moiety acts as a hydrogen bond acceptor and interacts 
with amino groups of Arg-205 (Figure 43). 
 
Figure 43 Proposed binding modes for pyridazinone series 
Compound: 35 (orange), 55 (blue), 56 (green) 
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The compounds 142 and 143 represent the oxazole family. The oxazole core with its 
phenyl substituent is buried deep in the receptor. The phenyl ring is surrounded by Phe-
257, Phe-292 and Ser-288. The carbonyl group of the amide moiety acts as a hydrogen 
bond acceptor and interacts with amino groups of Arg-205. The pyrazole ring interacts 
with Phe-163 via π-stacking. The oxazole ring with the methyl ether moiety is moved 
towards the polar cluster. The oxygen atom of the methyl ketone acts as a hydrogen bond 
acceptor and interacts with amino groups of Arg-205 (Figure 44). 
 
 
Figure 44 Proposed binding modes for oxazole series 
Compound: 142 (blue), 143 (orange) 
 
The bridged spiro[2.4]heptane derivatives have a less rigid structure compared to other 
small molecule FPR2 agonists. The bridged spiro[2.4]heptane core occupies the 
subpocket, where we can observe hydrophobic interactions between the core and amino 
acids such as Phe-257 and Phe-292. The aryl halide moiety fits into subpocket II, with 
possible halogen bonding with Ser-284 (109, purple). The piperidine moiety is allocated 
in the subpocket III. The nitrogen atom from the piperidine moiety forms the hydrogen 
bonds (111, pink). The Arg-205 acts here as a hydrogen bond donor and forms hydrogen 
bonds with the carbonyl group of amide moiety (98, 109, 111, 112) (Figure 45).  
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Figure 45 Proposed binding modes for bridge compounds 
compound 109 – purple, compound 111 – pink, compound 112 - green 
 
The largest family of FPR2 agonists is represented by Allergan urea derivatives with L-
leucine as a core. Subpocket I pocket is occupied by the para-substituted aniline. There 
is a π-stacking interaction between the aniline ring and amino residues such as Phe-257 
and Phe-292. In addition, Ser-288 forms an aromatic H-bond with the aniline ring.  A 
possible halogen bond could be formed between the para-bromoaniline and Gln-258. The 
L-leucine alkyl chain is located in the cavity formed with Met-85, Ser-84, Leu-81 and 
His-102 which forms a hydrophilic cluster which can interact with the amino group of the 
urea moiety. The terminal carboxylic moiety of molecules 18 (purple), and terminal 
amide of 19 (green) binds to Arg-205 forming hydrogen and ionic bonds. The 
dimethylated amide analogue 77 (blue) is not a good hydrogen bond acceptor and cannot 
interact with Arg-205. The tetrazole ring of 21 (orange) is involved in a π-π interaction 
with Tyr-175. The alcohol group of the follow-up 82 (yellow) is oriented toward the 
extracellular loop region.  
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Figure 46 Proposed binding modes for Allergan urea 
Compound: 18 (purple), 19 (green), 21 (orange), 77 (blue), 82 (yellow) 
 
The last group of investigated small molecule agonists is the tetrahydrofuran series 
invented by Japanese company Kyorin. Both compounds 157 and 158 present a consistent 
binding mode. The tetrahydrofuran core occupies the subpocket, where we can observe 
π-stacking between the core and Phe-257. The Ser-288, which belongs to the polar cluster, 
acts here as hydrogen bond donor and interacts through hydrogen bonding with urea. The 
His-102 forms an edge-π stacking interaction with the methoxy substituted phenyl rings 
of both compounds (Figure 47).   
 
Figure 47 Proposed binding modes for Kyorin series 
Compound: 158 (purple), 157 (black) 
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In order to check the quality of the receptor grid, test virtual screening of actives and 
decoys was performed. The enrichment factor was calculated and value of receiver 
operating characteristic (ROC) was 0.70 with all active molecules placed in the first 35% 
of screened compounds (Figure 48).  
 
Figure 48 The enrichment factor calculated for GPCRdb FPR2 homology model using Schrodinger Maestro software 
 
These results gave us confidence that we can distinguish actives from inactive 
compounds. Our model emphasized the concept of three hydrophobic subpockets with 
two polar clusters. FPR2 agonists do not need to occupy all three proposed subpockets 
(Figure 49). The five main binding modes can be distinguished, in the same region of the 
binding pocket. These results are different compare to dual template. This concept 
corresponds partially with binding modes suggested by research groups from Montana 
University and Warsaw University.80, 136, 147 
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Figure 49 Model of the compounds (Allergan urea and pyrazolone) docked to FPR2 and proposed three hydrophobic 
subpockets model with two polar clusters. 
 
Analysis of the binding modes showed that for each molecule important aromatic stacking 
with at least one of the amino residues: Phe-257, Phe-292, Phe-163, Tyr-175 and His-102 
was observed. The advantage of the μ-opioid based structure is that the FPR receptor and 
opioid families have a conserved T2.56xP2.58 (Thr-77 and Pro-79 motif in TM 2, which 
plays a key role in many G-protein coupled receptors activation. Moreover, a common 
conserved DRY motif (Asp-122, Arg-123 and Tyr-221) can be observed. 
The docking studies were performed for both models. However, further studies were 
focused on an agonist bound μ-opioid based structure which is in the active conformation 
and has not been described in the literature. Due to the small number of antagonists it is 
still hard to describe the difference in binding mode for antagonist and agonist. 
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4.3. Pharmacophore model 
 
“A pharmacophore is the ensemble of steric and electronic features that is necessary to 
ensure the optimal supramolecular interactions with a specific biological target and to 
trigger (or block) its biological response.”  C.-G. Wermuth et al., Pure Appl. Chem. 1998, 
70: 1129-1143 
A pharmacophore model was the next in silico method used for investigating the binding 
modes and structure-activity relationships of small molecule FPR2 agonists. The 
pharmacophore model gives a reflection of the active site geometry. In these 
pharmacophore studies the ligand-based design approach was applied.  
Development of a pharmacophore hypothesis was performed using the Phase tool from 
the Schrodinger Maestro software. The set of active compounds used for prediction of 
binding modes and their predicted 3D conformations were applied at this stage. Because 
of the diverse origins of investigated structures, the pharmacophore model was created 
using an option ‘multiple ligands’ with the method ‘best alignment and common features. 
The 32 pharmacophore hypotheses were manually checked. Four main factors were taken 
into consideration. The first main factor was the PhaseHypoScore which helps to order 
the hypothesis according to their possible performance in virtual screening and the quality 
of ligand alignment. The enrichment factor (EF) showing the enrichment of actives in top 
1%. The last two criteria were ROC and BEDROC values (Figure 50). 
 
 
Figure 50 Selected pharmacophore hypotheses 
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In the next step ligands and hypotheses were grouped into binding modes using a 
clustering algorithm from the Phase tool. The ligands which matched a hypothesis are 
shown as the blue cells in the table, otherwise red cells represent compounds which do 
not fit. The modes proposed by the algorithm are divided with a black line. The software 
proposed eight binding modes (Figure 51 A). Pyrazolone, bridge spiro [2.4] and Kyorin 
compounds form the first binding mode (Figure 51 B and C). The Allergan urea 
derivatives belong to a second binding mode, a small cluster of unsubstituted bridge 
spiro[2.4] compounds 98 and 112 form the third binding mode. The oxazole compounds 
142 and 143 represents another binding mode. The final binding mode is represented by 
pyridazinone derivatives. The detection binding mode option did not allow the binding 
modes to be clearly distinguished however gave some insight (Figure 51). 
 
Figure 51 Detection binding modes based on pharmacophore hypotheses 
A) The detection of binding modes was performed in Phase (Schrodinger Maestro). The ligands which matched a 
hypothesis are shown in blue, otherwise molecules which do not fit the algorithm are in red. The modes proposed by 
the algorithm are divided with a black line. Two hypotheses highlighted in the yellow are shown on the left-hand side 
in the 3D conformations. B) Pharmacophore hypothesis ADHR_1 and C) Pharmacophore hypothesis ADHHR_7; 
The letter system describing the pharmacophore features: A-acceptor, D-donor; H-hydrophobic; R-ring 
 
The five-point pharmacophore hypothesis ADHHR_7 has been chosen among 32 
hypotheses with PhaseHypoScore equals 1.17 and ROC value 0.9. The ADHR_1 had 
slight greater value of ROC and PhaseHypoScore. The four-point ADHR_1 hypothesis 
covers all screened compounds; however, the ADHHR_7 hypothesis emphasises an 
additional hydrophobic feature, which is a common structural part of the FPR2 agonists 
and covers better the wide range of these modulators. The total number of actives used in 
this virtual screening was 34. Overall, 1034 ligands (actives + decoys) were screened. 
The decoys were part of Phase Decoy library. In the end 31 actives were ranked.  
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Our pharmacophore model emphasized a substituted ring at the para position, preferably 
with a lipophilic and electronegative moiety, for example halogens. The results from the 
pharmacophore studies confirmed the importance of the NH moiety and the oxygen atom 
from the carbonyl group. The hydrophobic feature (H8) covers alkyl chains and three-
dimensional cores of the bridged spiro[2.4]heptane derivatives and Kyorin compounds 
(Table 8). 
 
 
 
 
 
 
 
 
Table 8 Key pharmacophore features 
 
The obtained pharmacophore model was employed to screen the GLASS database using 
Phase Ligand Screening (Schrodinger software) [Chapter 5.4].  
  
Pharmacophore feature Atoms/Groups involved 
Acceptor (A3) oxygen atom from carbonyl group 
Donor (D4) -NH group from amide/urea moiety 
Hydrophobic (H6) para halogen/methoxy substitution 
Hydrophobic (H8) bulky alkyl chain or saturated ring 
Ring (R9) phenyl or aniline ring 
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4.4. Structure-activity relationships of small molecule FPR2 agonists 
 
The design and structure-activity relationship (SAR) study of the existing series of urea-
based FPR2 agonists were performed based on the results from docking and 
pharmacophore studies. The scope was to identify interactions which take place and 
essential groups. 
 
SAR studies on the phenyl-urea moiety established the importance of a para-substituent 
on the aniline ring. The analogues with ortho- or meta-substituted aniline rings showed a 
drastic loss of potency. Small lipophilic and electronegative substituents are favourable. 
The amide and urea moieties are crucial for stabilization of the molecule in the binding 
pocket and the molecule can interact with the receptor though hydrogen bonds. The R1 
position is usually occupied by a bulky chain or cyclic feature. In the case of the Allergan 
analogues, the L-leucine alkyl chain occupied the hydrophobic cavity and this improves 
the fit in the binding pocket. The core of the bridged spiro[2.4]heptane derivatives is 
another example, which in this case of spiro moiety in R1 position. Moving to right hand 
side with mono-substituent amide. The nitrogen of amide moiety as hydrogen bond donor 
is not so crucial in the structure, the pyrazolone series where this nitrogen atom forms 5-
membered ring is showing good activity. In addition, 77 is the example showing that 
methylated analogues of 19 does not implicate in losing the activity. However not only 
aromatic rings are required to maintain the activity, alkyl chains with functional groups 
such as alcohol, ether, amide or carboxylic acids help in forming additional hydrogen 
bonds, Allergan analogues are good examples of that (Figure 52).  
 
Figure 52 Structure-activity relationship of small molecule FPR2 agonists from homology modelling studies 
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4.5. Summary 
 
Comparison of docking binding poses based on two different homology models assisted 
the rationalization of the structure-activity relationships. Using homology modelling, 
molecular docking and a pharmacophore hypothesis, the binding site with three 
hydrophobic subpockets and possible binding modes for small molecule agonists of 
diverse origins were proposed. The results from cellular assays showed that replacement 
of the lipophilic and electronegative moiety from the molecule (pharmacophore feature 
H6) decreases activity. It might be caused by the loss of the possible halogen interactions 
with residues such as phenylalanine, serine or tryptophan. The H-bonds formed between 
the -NH groups of the amide and urea moieties and one of the amino residues such as 
Arg-205, Cys-176 or His-102 helps to stabilize the structure in the pocket. The molecular 
docking studies and ligand-based pharmacophore modelling are in good agreement with 
each other. The pharmacophore hypothesis was then deployed in parallel with the 
homology model to design novel ligand structures and also in virtual screening.  
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5. Design and synthesis of novel small molecule agonists 
of FPR2 receptor  
 
5.1. The identification and evaluation of existing tool compounds from 
literature 
 
The identification of existing tool compounds was performed based on literature review 
and these were analysed through calculation of the properties such as distribution 
coefficient (logD), partition coefficient (logP), polar surface area and numbers of 
hydrogen bond acceptors and donors. For prediction of those values the ACD Percepta 
software was used.154 Based on this analysis I selected four diverse groups of compounds 
for synthesis (the urea derivatives from Allergan patents117, the bridge compounds121-123 
and the oxazole compounds both based on Actelion patents124 and the urea compounds 
with a more 3-dimensional scaffold from Kyorin patent138, 153. Usually authors of patents 
do not provide all the essential information about the compounds, for example solubility 
and stability. Therefore, all synthesised compounds were submitted for absorption, 
distribution, metabolism and excretion (ADME) assays such as kinetic solubility, 
microsomal stability, permeability (PAMPA). The answers to four basic questions can be 
found by testing compounds in these in vitro ADME assays: if the compound gets in, 
where it goes, if it remains intact and if it stays in. The kinetic solubility assay is a quick 
test for solubility at physiological pH 7.4. There are three categories: low solubility (<10 
µM), moderate solubility (10-60 µM), and high solubility (>60 µM). The logD 
measurements give us a measure of the lipophilicity of the compound, where the ideal 
value should be in the range of 1-3. The right balance between lipophilicity and polarity 
should be maintained, the lipophilic character of molecule helps it cross the fatty 
membranes, while the polarity increases solubility and also makes the molecule less likely 
to cross the blood-brain barrier. The human liver is an important site of drug metabolism; 
using a microsomal stability assay, the metabolism of the compounds can be investigated. 
Molecules with high clearance values are undesired since the compound could be rapidly 
cleared in in vivo studies. The intrinsic clearance classification band clusters compounds 
into three groups: low, medium and high, the range depends also on the species (Table 
9). 
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Category 
Intrinsic Clearance 
[µL/min/mg protein] 
Human Mouse 
low <8.6 <8.8 
high >47 >48 
Table 9 The intrinsic clearance classification band system 
 
The last ADME assay is the Parallel Artificial Membrane Permeability (PAMPA) assay. 
The compounds with moderate and good solubility are tested in order to answer the 
question if new oral compound might be absorbed across the gastrointestinal tract.  
In every drug development project, the assessment of - the biological activity is a key step 
in order to deliver active small molecules. It is important to have one experimental 
system, in which we test the molecules, to be able to compare results of known agonist 
with novel molecules. In this project two cellular assays were adopted: β-arrestin 
recruitment and calcium mobilization. FPR2 activation is initiated by binding of the 
ligand from the extracellular side. The activated receptor might trigger the G-protein 
and/or β-arrestin signalling cascade. Both assays are high-throughput using 384-well 
plates and the PathHunter™ Chinese hamster ovary (CHO)–FPR2 cells (DISCOVERx). 
The CHO-FPR2 cells expressing complementing fragments of the β-galactosidase 
enzyme. In order to check if compounds can induce the β-arrestin signalling cascade, the 
PathHunter™ GPCR β-Arrestin assay was used. The inactive β-galactosidase is fused to 
the C-terminus of human β-Arrestin and the ProLink peptide tag is attached to the C-
terminus of FPR2. An active β-galactosidase enzyme is formed upon the GPCR 
activation. Using chemiluminescent PathHunter Detection Reagents we can measure the 
enzyme activity and thereby β-Arrestin recruitment. In the second cellular assay the 
ability of the compounds to activate a G-protein-dependent calcium flux was examined. 
In the calcium mobilization assay FLIPR calcium 6 dye (Molecular Devices) was used. 
The increase in cytosolic Ca2+ was measured by the FLIPR® Tetra® High-Throughput 
Cellular Screening System.  Ten mM stock solutions of compounds were serially diluted 
in assay buffer using a half log dilution protocol on a Biomek instrument. In both assays 
W-peptide was used as a control compound (100 nM). 
One of the largest groups of potent FPR2 agonists are the substituted urea amino acid 
derivatives. This family of compounds has been developed by Allergan, focusing mainly 
on treatment of an eye inflammation and dry eye syndrome, and one of their FPR2 
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agonists was in phase 1 of clinical trials. A general synthetic route is shown below 
(Scheme 1). Starting with commercially available 4-Bromophenyl isocyanate 57 or 4-
trifluoromethylphenyl isocyanate 58 reaction to give the urea or carbamate products 63-
65 proceeded in good yield (70-80%). Cleavage of tert-butyl ester group with formic acid 
at room temperature generated an acid 66-68 in quantitative yield. The final amide 
coupling was performed in the presence of triethylamine and T3P as a coupling agent 
(Y=20-80%). Compounds with ester moiety were transformed into their acids 18 and 73-
76 by hydrolysis. 
 
 
Scheme 1 Synthesis of urea derivative from Allergan patents 
Conditions: A) RNH2 1 eq., TEA 1.5eq, DCM, RT, 4h; B) formic acid, RT, 4h; C) and D) T3P 1.5eq, RNH2 
1.1eq, ethyl acetate, RT, overnight; or  RNH2 1.5eq,  EDCI 1.5eq,  HOBT 1.5eq, N-methylmorpholine 2eq, 
DCM, RT overnight; E) formic acid, RT, 2-4h 
 
The amino acids used in synthesis of the urea derivatives were commercially available, 
except alcohol 62, for which the synthetic route is showed in the scheme below (Scheme 
2). After a few attempts at forming 59, the α-hydroxy acid was purchased, and the 
synthesis was carried out from this stage. The intermediate 64 was used to form carbamate 
65. Carbamates are commonly employed to mimic a peptide bond. They are characterized 
by good chemical stability and cell membrane permeability.  
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Scheme 2 Synthesis of alcohol 62 
Conditions: A) Acetyl chloride, RT, 1h; B)  2.1 eq. t-butyl alcohol, 0.33 eq. DMAP, 1.33 eq. DCC, DCM, 0⁰C to RT 
12h;  C) Na2CO3, water/MeOH, RT, on 
 
The stereochemistry plays a key role here. According to the patents (S) enantiomers are 
more potent than (R), e.g. compound 18 is reported at 0.88 nM, whereas the (R) 
enantiomer is reported at 1229 nM (calcium mobilization assay).117 The preferred 
substitution position for the aniline is the para position.  I decided to synthesize the 
existing and hybrid compounds with a bromine and trifluoromethyl group in the 4-
position, as the most potent from the patents, additionally the –CF3 group is very 
commonly used in medicinal chemistry to increase lipophilicity and bioavailability. 
According to the results from the ADME assays (Table 10), all ester derivatives show 
low kinetic solubility, whereas their equivalent carboxylic acids have good values of 
LogD and they are soluble. The dimethylcarboxamide analogues 77 and 80 of amides 19 
and 74 respectively show the same activity range in both assays, which could indicate 
that the -NH is not involved in binding into the pocket. Their solubility is lower but still 
these compounds fit in the moderate solubility range.  A suitable modification of the acid 
moiety without losing good ADME properties is dimethylcarboxamide 77 (-Br) or methyl 
ketone 20 (-Br) and 81 (-CF3). The acid bioisostere with tetrazole moiety 83 shows also 
suitable properties and activity. The tetrazole ring contain an acidic proton, their structure 
is also planar. In addition, the tetrazole anion is ten times more lipophilic compared to 
carboxylic anion itself which can be an advantage when we are trying to increase the logD 
value.86 Compound 83 has a higher logD value of 1.7 compared to 1.4 for compound 17. 
From literature it has been shown that methylation of either of the urea nitrogen atoms 
caused loss of activity. If we compare two tetrazole compounds 83 and 21 where one of 
the urea nitrogen atoms was replaced with oxygen, we can see a small decrease in the 
EC50 value (185 nM and 83 nM respectively). Compounds 74 and 75 are two examples 
showing that methylation of the amide does not result in losing the activity. In the table 
below a summary of the results from ADME and biological assays performed in our 
laboratory on the synthesised compounds is shown (Table 10). The substituted urea 
amino acid derivatives show good ADME profiles with the ability to fully activate the 
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FPR2 receptor in nanomolar potency range. The synthetic pathway is robust and allows 
the synthesis of a vast number of the compounds in reasonable yields.  
 
 
 R1 R2 
KS 
[μM] 
LogD 
Microsomal stability Ca2+ 
EC50 
[µM] 
(Emax) 
β 
EC50 
[µM] 
(Emax) 
T1/2 
[min] 
CLint 
(µL/min/mg) 
HLM MLM HLM MLM 
19 -Br 
 
218 2.9 >400 - < 2 <2 
0.19 
(72) 
0.07 
(98) 
79 -CF3 208 3.3 >400 378 0.6 4.1 
0.06 
(68) 
0.15 
(96) 
77 -Br 
 
82 3.1 >400 243 <2 6 -* 
0.059 
(100) 
80 -CF3 35 3.5 383 - 4.0 <2 
0.15 
(68) 
0.13 
(98) 
18 -Br 
 
200 1.3 >400 >400 <2 <2 
0.19 
(90) 
0.56 
(98) 
73 -CF3 217 1.4 >400 238 <2 7 
0.02 
(68)* 
0.17 
(97) 
17 -Br 
 
2 >4 66 51 23 30 
0.04 
(53) 
0.183 
(94) 
69 -CF3 0 >4 28 58.7 55 26 
0.33 
(47) 
0.90 
(89) 
74 -Br 
 
206 0.78 - 429 < 3 4 
0.02 
(98) 
0.086 
(96) 
75 -CF3 289 1.1 - >400 < 3 <3 -* 
0.051 
(100) 
70 -Br 
 
13 4 44 30 35 50 0.11 
0.045 
(98) 
71 -CF3 8 >4 36 45 46 34 
0.16 
(38) 
0.5 
(100) 
 
Table 10 Selected ADME properties and biological activity of Allergan compounds series.  
NA - very low response (Emax <30% of max response) or weak activation EC50> 10 µM; *broad curve 
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Table 10 (continued) 
 R1 R2 
KS 
[μM] 
LogD 
Microsomal stability 
Ca2+ 
EC50 
[µM] 
(Emax) 
β 
EC50 
[µM] 
(Emax) 
T1/2 
[min] 
CLint 
(µL/min/mg) 
HLM MLM HLM MLM 
20 -Br 
 
188 >4 406 210 4 7 
0.07 
(91) 
NA 
81 -CF3 141 >4 - 181 <2 9 
0.55 
(41) 
0.44 
(100) 
72 -Br 
 
13 >4 8 7 197 208 
0.59 
(115) 
0.114 
(101) 
76 -Br 
 
200 1.8 >400 >400 <2 <2 
0.46 
(55) 
0.079 
(102) 
78 -Br 
 
207 3.3 >400 - <2 <2 
0.61 
(109) 
0.26 
(91) 
82 -CF3 200 >4 603  3   
1.8 
(100) 
21 -Br 
 
200 1.7 - - <2 <2  
0.083 
(103) 
83 
 
200  
no 
data 
    
0.185 
(100) 
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The next family of compounds which was investigated was the bridge compound 
derivatives from Actelion (Scheme 3). The synthesis started with cracking of 
dicyclopentadiene 84 to obtain freshly distilled cyclopentadiene 85 which was used 
directly in the formation of spiro[2.4]hepta-4,6-diene 86 in good yield (Y=70%). The next 
step is a Diels-Alder reaction and synthesis of the core, 4,7-ethylene-spiro[2.4]heptane 
87. A single Diels-Alder product was formed as a diastereomer. This uncatalyzed Diels-
Alder reaction has been reported by Helmen et al. and it is highly diastereoselective and 
can be switched by adding TiCl4.
155 Saponification of the intermediate with lithium 
hydroxide generated an acid 88 in quantitative yield. Iodolactonization with iodine and 
potassium iodide provided the iodolactone 89, which was later used in the esterification 
using TMSCH2N2 at room temperature. According to Becker et al. iodolactone 89 has 
very high enantiomeric excess (e.e.).156 For retro-iodolactonization zinc powder in acetic 
acid at 65 degrees for 4 hours was used (91, Y=80%). Reduction of the double bond was 
performed using Pd/C as a catalyst in an H-cube (Continuous-flow Hydrogenation 
Reactor) with a quantitative yield of 92. The amide coupling of the intermediate with an 
amine, in the presence of triethylamine and T3P as a coupling agent was performed at 
room temperature (93-96). Treatment with aqueous base furnished the carboxylic acids 
97-100. This intermediate was not purified and used directly in the last step. Amide 
coupling with a commercially available amine, employing classic conditions with HOBT 
and EDCI, gave the final compounds 101-113 and 27 (Y=30-60%). 
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Scheme 3 Synthetic pathway for compounds from Actelion bridge compounds series 
Conditions: A) Cracking, 160⁰C; B) 0.045eq benzyl triethylammonium chloride, 0.92eq, DCE; 50% aq.NaOH, 45-
50⁰C;  C) bis[(1S)-2-ethoxy-1-methyl-2-oxo-ethyl] (E)-but-2-enedioate, hexane, RT, on; D) 6eq. LiOH, THF/water 
24h; E) 1.2 eq. I2, 3.7 eq. KI, DCM, RT, 3h; F) 5 eq.TMSCH2N2, MeOH, RT; G) Acetic acid, 15 eq. Zn powder, 
65⁰C, 4h; H) H-cube, Pd/C,  H2, THF, RT 10mg/1mL; I) 1-1.5 eq.R1NH2, 1.5 eq T3P, 2 eq. TEA, EtOAc, RT, 
overnight; J) 2M NaOH, THF; K) 1.5 eq. R2NH2, 1.5 eq.HOBT, 1.5 eq. EDCI, 1.5 equiv. DIPEA, DCM and later 
deprotection with TFA at room temperature if needed. 
 
In our in-house assays intermediates 97, 98, 100 and 115, show weak agonistic effects 
which indicates the importance of a cyclic substituent in this position. In addition, we 
were unable to get methods on the MS for compounds 98, 100 and 115 for microsomal 
stability. Compound 27 is the most active covered by a patent on ester derivatives of 
bridge compounds, where the aniline has also been replaced by 3-amino-5-
bromopyridine. 103 is a 1-(p-tolyl)cyclopropyl-substituted example from optimization of 
compounds from the patent from 2010.123 Each example from this family is showing very 
good solubility.  The most stable compound from this list is 27, the rest of the molecules 
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show short half-life. To improve the ADME properties of the compound 27, I have 
synthesized hybrid molecules by replacing the ester group with an amide, keeping the 
piperidine moiety 111 or introducing methylated piperidine 113. In addition to this 
modification I decided to exchange piperidine with methylpiperazine 102, which 
decreases the basicity of the molecule. Compound 111 showed an improvement in 
microsomal stability, replacement of an ester group with an amide resulted in moderate 
intrinsic clearance in HLM and a low value in MLM without losing the activity. Changing 
the ester group to a more stable amide group can reduce hydrolysis. However, the LogD 
value is low at 0.26, so the compound needs more optimization. The analogues 113 with 
methylated piperidine at nitrogen position demonstrated higher values for intrinsic 
clearance, but keeping values in moderate band, which means that metabolically labile 
methyl might be a reason for shortening the half-life of the molecule. Through introducing 
-CH3 group we increased the logD value up to 1.4, but at the same time the activity in 
calcium mobilization assay dropped by around 10-fold which corresponds to the idea that 
-NH is involved in an important interaction. The same trend can be observed when we 
compared follow ups 107 with 109 and 108 with 110. By eliminating an alkyl linker 
between the core and piperidine ring compound 107 is nearly twice as stable compared 
to 111 but the activity in both assays drops by around 20-fold. Compound 107 is still 
showed good activity in the nanomolar range and the efficacy is higher than 100% (Table 
11). The bridge compound series is a very potent group of the FPR2 agonists, however 
the ADME profile is not ideal. Most of the compounds are showing moderate or high 
intrinsic clearance and low values of LogD which can be expected to cause later problems 
in in vivo studies.  
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Compound 
KS
 
[μM] 
LogD 
Microsomal stability 
Ca2+ 
EC
50
 
[μM] 
(Emax) 
β-
arrestin 
EC50 
[μM] 
(Emax) 
T1/2[min] 
Clint 
[µL/min/mg] 
HLM MLM HLM MLM 
 
115 
200 0.9 - - - - NA 
4.81 
(113) 
 
97 
200 1.4 82  19  NA 
3.83 
(115) 
 
112 
200 3.9 9 14 172 112 NA 
0.067 
(85) 
 
98 
200 - - - - - NA NA 
 
100 
200 - - - - - NA NA 
 
116 
197 1.8 10 20 163 76 0.011 <0.001 
Table 11 Selected ADME properties and biological activity of bridge compounds series.  
NA - very low response (Emax <30% of max response) or weak activation EC50>10 µM 
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Table 11 (continued) 
Compound 
KS
 
[μM] 
LogD 
Microsomal stability 
Ca2+ 
EC
50
 
[μM] 
(Emax) 
β- 
arrestin 
EC50 
[μM] 
(Emax) 
T1/2[min] 
Clint 
[µL/min/mg] 
HLM MLM HLM MLM 
 
27 
200 0.7 82 120 19 13 0.185 
0.002 
(100) 
 
102 
200 1.6 10 38 148 40 
0.220 
(115) 
0.030 
(107) 
 
103 
200 1.8 9 11 171 139 
0.420 
(110) 
0.033 
(70) 
 
109 
193 0.5 216 361 7 4 
0.48 
(143) 
0.025 
(105) 
 
107 
200 1.7 148 >400 10 <2 
5.66 
(151) 
0.85 
(83) 
 
110 
200 0.8 37 44 42 35 
0.730 
(160) 
0.014 
(106) 
100 
 
 
Table 11 (continued) 
Compound 
KS
 
[μM] 
LogD 
Microsomal stability 
Ca2+ 
EC
50
 
[μM] 
(Emax) 
β-
arrestin 
EC50 
[μM] 
(Emax) 
T1/2[min] 
Clint 
[µL/min/mg] 
HLM MLM HLM MLM 
 
108 
200 1.9 89  17 <3 NA 
1.38 
(107) 
 
 
111 
200 0.26 124 >200 12 5 
0.023 
(200) 
<0.001 
 
113 
200 1.4 57 83 27 19 
0.132 
(192) 
0.003 
(102) 
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The third family of compounds which was investigated was an oxazole series from 
Actelion. One of the compounds from the oxazole family was tested in Phase 1 of clinical 
studies. ACT-389949 which is (2-methyl-5-m-tolyl-oxazole-4-carboxylic acid (2-[4-
(1,1-difluoro-ethyl)-oxazol-2-ylmethyl]-2H-[1,2,3]triazol-4-yl)-amide) (29, Figure 19) 
has shown agonistic properties and it is safe and well tolerated.126 Unfortunately, the 
biological evaluation of ACT-389949 exposed some pro-inflammatory features e.g. the 
activation of the NADPH-oxidase.157 
 
The 1,3-oxazoles are very stable compounds. Assembly of the ring from an isocyanide 
was used as a way to access intermediate 120. The anion derived from ethyl cyanoacetate 
118 was acylated with benzoyl chloride 117, the intermediate then spontaneously closed 
to give the 1,3-oxazole 119 (Scheme 4). 
 
 
Scheme 4 Preparation of 1,3-oxazoles - pathway 1 
1.5eq Benzoyl chloride, 1.15eq NaH 60%, toluene, RT, on; B) 2eq. LiOH, MeOH/water 5/1 60deg, on 
 
In the next step the substituted 1,3-oxazole was synthesised. The carboxylic moiety of 
glycine 121 was protected with benzyl alcohol. Intermediate 122 was treated with 4M 
HCl in dioxane to obtain free amine 123. Then benzophenone imine was used to give the 
doubly protected glycine 124. Condensation of 124 with methylbenzoyl chloride using 
NaHMDS as a base, followed by imine hydrolysis and final acylation with acyl chloride 
yielded α-amido-β-ketoester 125. Then intermediate 125 was treated with 
triphenylphosphine in the presence of iodine and triethylamine in DCM to give the 2,5-
disubstituted oxazole 126. Finally, the removal of ester was performed using Pd/C as a 
catalyst in an H-cube (Continuous-flow Hydrogenation Reactor) with a quantitative yield 
to give 127 (Scheme 5).158 
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Scheme 5 Preparation of 1,3-oxazoles - pathway 2 
Conditions: A) 1 eq. BnOH, 0.1 eq. DMAP, 1 eq. 1M DCC, DCM, RT, on; B) 4M HCl in dioxane, DCM, RT, 4h; 
C) 1 eq.Ph2C=NH, DCM; RT,8h; D) 1) 1 eq. NaHMDS, 1 eq.CH3PhC(O)Cl, THF, -78⁰C→RT, 2h; 2) 2 eq. 4M HCl 
in dioxane ; 3) 1.5 eq. NMM, THF, 1 eq.CH3C(O)Cl; E) 2eq. Ph3P/I2, 1 eq. TEA, DCM; F) H-cube full H2 mode, 
10% Pd/C CatCart, 40 degree, 10 mg/ 1 mL, 1mL/min 
 
Compounds from the oxazole family contain two oxazole moieties in their structure. The 
right hand side of the molecules is a 2-[(pyrazol-1-yl)methyl]oxazole with variety of 
functional group in position 4 such as ketones or ethers. The synthesis starts with the 
formation of oxazoline 130 which was performed with sodium methoxide in methanol. A 
crude product was used in the next step to obtain oxazole 131 with a good yield (87%). 
Reduction of the ester group to the primary alcohol 132 was performed using DIBAL-H 
in THF (Y=20-35%). O-Methylation of the intermediate using silver (I) oxide and 
iodomethane at 40⁰C gave compound 133. The synthesis of ketone 136 starts with 
formation aldehyde 134 using Dess-Martin reagent. The secondary alcohol 135 was 
obtained in the reaction of aldehyde 135 with trimethylaluminum. Finally, the Dess-
Martin reagent was used in the oxidation of the secondary alcohol to yield the desired 
ketone 136 (Scheme 6). 
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Scheme 6 Synthetic pathway for the preparation of compounds from Actelion oxazole series 
Conditions: A) NaOMe (10mol%), MeOH, -10 to 0oC, serine methyl ester hydrochloride, MeOH 0oC to RT 
overnight; B) TEA, 50oC, overnight; C) 1) 3.4eq DIBAL-H, THF  1h, 0oC to RT 2) Rochelle salt solution, EtOAc 
1.5h RT; D) 1.2 eq. MeI, 1.5 eq. silver (I) oxide, DCM, on 40oC, protected from light; E) 1.6 eq. Dess-Martin, DCM, 
RT, overnight; F) 5 eq. Trimethylaluminum (2 mol/L) in heptane, DCM,  0oC to RT, 1h; G) 1.6 eq. Dess-Martin, 
DCM, RT, overnight;   
 
Thermal amination gave the intermediate 138-139, followed by reduction of the nitro 
group using Pd/C as a catalyst in an H-cube (Continuous-flow Hydrogenation Reactor) 
which gave amines 140-141 with a quantitative yield. A general synthetic route is shown 
below (Scheme 7). 
 
 
Scheme 7 Synthetic pathway for the preparation of compounds from Actelion oxazole series 
Conditions: A) 3 eq. DIPEA, DMF, 30min RT, on 50oC; B) H-cube 20 bar, 50⁰C; C) 1 eq. Acid 120 or 127, 2 
eq.TEA, 1.5eq. T3P, ethyl acetate, RT, on. 
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A compound which I selected to synthesize is a hybrid 142 (Figure 53 D) of the 
compounds covered by an Actelion patent on oxazolyl-methyl ether derivatives of 
aminotriazoles (Figure 53 B) and nonaniline-containing aminopyrazoles (Figure 53 
C).124 The oxazolylmethyl ether derivatives were reported to have an improved plasma 
stability over that of the ketone analogues. Compound 142 was tested in in-house ADME 
assays to examine its physical and metabolic properties. This compound was active in the 
β-arrestin assay (EC50=278 nM, efficacy 78%), and in calcium mobilization the EC50 
value is 256 nM, however the efficacy is only 50%. 142 has shown good solubility (170 
µM) and stability in HLM (T1/2=300 min). Indeed, the oxazolylmethyl ether 143 has 
shown better microsomal stability in both species compared to ketone analogue 144. 
 
 
Figure 53 Nonaniline-containing aminopyrazoles  
A) Agonist tested in Phase I clinical studies B) Nonaniline-containing aminopyrazole C) Oxazolyl-methyl ether and 
ketone derivatives of aminotriazoles D) Hybrid compound synthesized based on Actelion patents 
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Selected ADME properties and biological activity of oxazole compounds series are 
shown in the table below. 
 
 
ID R1 R2 R3 
KS 
[μM] 
LogD 
Microsomal stability Ca2+ 
EC50 
[μM] 
(Emax) 
β-arrestin 
EC50 
[μM] 
(Emax) 
T1/2 
[min] 
Clint 
[µL/min/mg] 
HLM MLM HLM MLM 
142 H H  170 1.3 293 199 5.2 7.7 
0.26 
(56) 
0.28 
(78) 
143 Me Me  49 3.2 619 237 2.5 6.5 0.17 NA 
144 Me Me 
 
36 3.3 77 37 20 41 
0.02 
(50) 
0.01 
Table 12 ADME properties and EC50 values for Actelion oxazole series 
NA - very low response (Emax <30% of max response) or weak activation EC50>10 µM 
 
The last family of FPR2 agonists is another group of urea derivatives but with novel furan 
scaffolds (Scheme 8)138. The synthesis of ethyl 4-hydroxy-2,5-dihydrofuran-3-
carboxylate 149 was initiated from ethyl glycolate 147 and ethyl acrylate 148 under basic 
conditions. Then 149 was converted to the triflate 150, subsequent coupling with the 
appropriate boronic ester produced compounds 151 and 152. The acid 153 was obtained 
from hydrolysis of the ethyl ester then reduction of the double bond was performed using 
the H-cube. In the case of ester intermediate 152 the reduction of double bond was 
performed following with the cleavage ester group was performed to give intermediate 
156. The Curtius rearrangement of the intermediates 155-156 allowed in situ production 
of the isocyanate which was then reacted with para-chloroaniline to give the final urea 
compounds 157-158. 
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Scheme 8 Synthetic pathway for the preparation of compounds from Kyorin nonpeptidic series 
Conditions: A) 1) 1.2 eq. NaH, Et2O, 1eq. 147 45min, 0°C to RT 2) 1 eq. 148, DMSO, 0 °C to RT, 1h ; B) 2eq. 
DIPEA, 1.2 eq. trifluoromethanesulfonic anhydride, DCM, 0°C to RT, 1.5 h ; C); 1.8eq. boronic acid, 3eq. TEA, 0.1 
eq. tetrakis(triphenylphosphine)palladium(0), DMF, 100 degree for 3h D); 2M KOH in water/ methanol 1:1, 50°C, 
4h; E) H-cube: 10% Pd/C CatCart at 1mL/min, 35°C, 20bar;;  F) 1) 2.4 eq. TEA, 1.2 eq. Diphenyl phosphoryl Azide, 
toluene, room temperature for 2h and then at 100°C for 30 minutes; 2) 1.0 eq. p-chloro-aniline, reflux, 1h 
 
 
ID R1 R2 
KS 
[μM] 
LogD 
Microsomal stability Ca2+ 
EC50 
[μM] 
(Emax) 
β-arrestin 
EC50 
[μM] 
(Emax) 
T1/2[min] 
Clint 
(mL/min/mg) 
HLM MLM HLM MLM 
157 H H 90 3 17 13 89 114 
0.003 
(108) 
0.011 
 
158 F F 10 >4 71 45 22 34 
0.002 
(107) 
0.086 
(120) 
Table 13 ADME properties and EC50 values for Kyorin nonpeptidic series 
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Both compounds 157 and 158 showed nanomolar activity in both cellular assays.  157 
showed good solubility (Ks=90 µM), however low stability in HLM (T1/2=17 min), 
whereas addition of two fluorine atoms to the phenyl ring in compound 158 decreased the 
solubility  (Ks=10 µM) but an increase in the microsomal stability was observed (T1/2=71 
min and 45 min in HLM and MLM respectively). 
At this stage of the project I had a good range of diverse compounds in hand to use as a 
tool compounds to establish biological assays and to act as benchmarks for comparison 
against novel compounds. 
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5.2. Pyridinone and pyrimidin-2-one series 
 
Based on the results from the synthesis and testing of known FPR2 agonists, I wanted to 
identify novel FPR2 agonists and find new scaffolds while keeping specific groups which 
are responsible for the biological activity. In the absence of a crystal structure of the 
receptor, in silico ligand-based design such as pharmacophore methods can be used. It is 
a helpful tool to find biologically active molecules using the structure activity 
relationships of a series of already synthesized molecules. For the pharmacophore studies 
I started by choosing a molecule which is quite rigid, potent (EC50=23 nM) and for which 
we have some information about the predicted docking poses from the homology 
modelling studies. I chose the well-known Amgen Compound 43 (35) and its other 
pyrazolone derivatives,132 using Cresset software I proposed some new cores e.g. 
pyridinone, or pyrimidin-2-one. An exploration was started with the replacements for the 
pyrazolone core of the molecule. The Cresset software has three main computational 
chemistry tools: Forge, Torch and Spark. In these studies, Spark was used for scaffold 
hopping. Once the fragment of the compound is selected, it can be screened against 
several databases available in Spark e.g.: ZINC drug-like, ChEMBL or VEHICLe. The 
novel compounds were created in situ. The results are scored and theoretical values of 
SlogP, TPSA and molecular weight are provided. The scoring compares new molecules 
with starting compound using electrostatic similarity and 3D shape. In the final selection, 
compounds with the correct alignments, the highest score and low 2D similarity value 
were chosen (Figure 54).   
 
Figure 54 Examples of pyrazolone core replacement 
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As the next step analogues of 159 were synthesized. In order to decrease lipophilic 
character of the molecule the methyl and trifluoromethyl groups were removed. The 
synthesis starts with a Chan-Lam reaction followed by a nitro reduction using the H-cube 
and the final step is the urea formation. The synthetic pathway is shown in Scheme 9. 
 
 
 
Scheme 9 Synthetic pathway for pyridinone series 
Conditions: A) 1.7 eq. phenylboronic acid; 2eq. pyridine; 2eq. TEA; 0.4 eq. copper (II) acetate; THF; RT, overnight; 
B) H-cube, Conditions: 10% Pd/C CatCart at 1mL/min, full mode, room temperature; C) 1.2 eq. isocyanate, 1.5eq. 
TEA, DCM, RT 
 
 
Unfortunately, the pyridinone series were inactive in both cellular assays. Each 
representative of this family showed poor solubility and has a high value of LogD. Based 
on these results the series was discontinued (Table 14). The lack of activity can be caused 
by their insolubility and highly rigid structure. In order to increase the flexibility of the 
structure the pyridinone scaffold could be replaced by piperidinone. This modification 
could provide a sp3-rich core. However it was decided not to  explored this series further 
because in 2017 Bristol-Myers Squibb published a patent covering piperidinone FPR1 
and FPR2 agonists with submicromolar and nanomolar activity in cAMP assay.137 
  
110 
 
 
 
ID R1 R2 
KS 
[μM] 
LogD 
Microsomal stability 
Ca2+ 
EC50 
[μM] 
(Emax) 
β-
arrestin 
EC50 
[μM] 
(Emax) 
T1/2[min] 
Clint 
(mL/min/mg) 
HLM MLM HLM MLM 
171 Cl H 0 >4 114 240 13.5 6.4 NA NA 
172 Br H 1 >4 372 209 4.1 7.3 NA NA 
173 OMe H 2  611 151 2.5 10.2 NA NA 
174 Br OMe 0 4 249 445 6.2 3.5 NA NA 
175 OMe OMe 0 3.4 636 262 2.4 5.9 NA NA 
Table 14 ADME properties and EC50 values for pyridinone series 
NA - very low response (Emax <30% of max response) or weak activation EC50>10 µM 
 
The same strategy was applied to the other families of compounds, which I had 
synthesized from the patents. Structures from the Kyorin patents seem to be well covered 
because I was not able to find any new interesting replacements for their core. For the 
bridge compounds the variability in predicted docking poses and high flexibility of the 
molecule make the calculation less reliable. In the case of the urea derivatives from the 
Allergan patents and oxazole compounds we can suggest some modifications.   
Spark as a bioisosteric replacement tool is useful to generate novel potential agonists with 
new intellectual property. However, it is important to use the molecule in its active 
conformation to increase the probability of selecting the correct bioisosters which lead to 
new active compounds.  
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5.3. Non-natural amino acids series 
 
In the first round of exploration I looked to replace the L-Leucine moiety at the R1 
position (189) with alternative, non-natural amino acids (Figure 55). For this purpose, 
the commercially available unnatural amino acids were chosen. A series of urea 
compounds was designed and synthesized via introducing an alkyl or cyclic moiety into 
the R1 position and most of these compounds exhibited equivalent or enhanced agonistic 
activity. Compounds were tested in the two cellular assays: β-arrestin recruitment and 
calcium mobilization. Each compound was tested in in-house ADME assays to examine 
the physical properties and metabolism of the molecules. In scheme 1, two possible 
synthetic pathways are shown. 
 
 
Pathway 1 can be used when we start with the alpha amino acid ester and commercially 
available 4-bromophenyl isocyanate 57 to obtain urea derivatives 65, 178-182 with good 
yield. Cleavage of ester group with formic acid or 2M aqueous solution of sodium 
hydroxide at room temperature generated an acid 68, 183-187 in quantitative yield. Final 
amide coupling was performed in the presence of triethylamine and T3P as a coupling 
agent 188-230. When the alpha amino acid ester is not available pathway 2 was used, the 
first step is amide coupling with the BOC-protected amino acid 232-233 in the presence 
of triethylamine and T3P as a coupling agent. Then deprotection of BOC protected amine 
is performed using 4M HCl in dioxane in quantitative yield. Finally, the urea derivative 
246-250 is obtained in the coupling with 4-bromophenyl isocyanate 57 (Scheme 10).   
Figure 55 Chemical structure of compound 189 and structural evaluation 
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Scheme 10 Two possible synthetic pathways for non-natural amino acids series 
Conditions: Pathway 1: A) 1 eq. amino acid., 1.5 eq. TEA, DCM, RT, 4h; B) formic acid, RT, 4h; C) 1.5 eq 
T3P, 1.1 eq. amine, ethyl acetate, RT, overnight; D) 4M HCl in dioxane, DCM, RT, 2-4h; Pathway 2: A) 1.5 eq 
T3P, 1.1 eq. amine, ethyl acetate, RT, overnight; B) 4M HCl in dioxane, DCM, 0⁰C to RT, 2-4h or overnight; C) 
1 eq. amino acid., 1.5 eq. TEA, DCM, RT, 4h 
 
Functional assays showed that presence of a bulky substituent in the position R1 is crucial 
to maintain the activity. 188 is inactive in the β-arrestin assay, and in calcium mobilization 
the EC50 value is 1.8 µM, however the efficacy is below 50%. In the calcium mobilization 
assay only compounds 190, 246 and 247 show full agonistic activity. Various non-natural 
amino acid cores are well tolerated in microsomal stability assays, showing good stability 
in human liver microsomes (HLM). By introducing a tetrahydropyran core 191 the 
activity is maintained in the nanomolar range, yet the efficacy drops down up to 70%. 
The introduction of 2-amino-3-cyclohexyl-propanoic acid 192 led to a decrease in agonist 
potency in calcium mobilization. Moreover, this structural modification had a negative 
effect on metabolic stability and kinetic solubility (Table 15). 
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ID R1 
KS
 
[μM] 
LogD 
Microsomal stability 
Ca2+ 
EC50 
[μM] 
(Emax) 
β-arrestin  
EC50 [μM] 
(Emax) 
 
T1/2[min] 
CLint 
[µL/min/mg] 
HLM MLM HLM MLM 
188 -H 27 3.6 112 22 14 71 
0.73 
(49) 
NA 
189 
(S) 
34 4.2 95 65 16 24 
0.03 
(38) 
4.26 
(82) 
190 
 
17 > 4 83 33 19 47 
0.02 
(137) 
0.74 
(98) 
191 
 
32 4.7 188 90 8 17 
0.072 
(77) 
4.17 
(93) 
192 
 
0 > 4 61 11 25 142 
1.3 
(150) 
215 
(77) 
246 
(S) 
11 > 4 91 44 17 35 
0.068 
(90) 
1.35 
247 
 
41 > 4 80 41 19 38 
0.097 
(100) 
7.8 
(92.6) 
Table 15 ADME properties and EC50 values for urea derivatives. 
NA - very low response (Emax <30% of max response) or weak activation  EC50>10 µM 
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Additional follow up molecules have been proposed and synthesised (Table 16). Amongst 
the L-leucine analogues the most active was compound 201 with an azetidine substituent. 
It showed a good ADME profile with high kinetic solubility and LogD of 1.3. The 
intrinsic clearance is in the medium range. The EC50 value for 201 in the β-arrestin assay 
is 28 nM, where in the calcium mobilization assay it showed submicromolar activity. 
Both 197 and 198 have a pyridine substituent in the R2 position. The intrinsic clearance 
value goes up in both cases suggesting that the 2- and 4-pyridine are not favourable. These 
follow-ups are weak agonists with similar potency like 189 but less metabolically stable. 
Compounds 246 and 247 with cyclopropanepropanoic and cyclopropaneacetic cores 
respectively showed promising results, however the exchange of the 3-pyridine 
substituent to other aromatic rings 248-250 led to a decrease in metabolic stability and 
efficacy. Moreover, the three membered cyclic moieties are very strained and could open 
under mild conditions. The tetrahydropyran analogue 199 shows moderate stability 
however it is only partial agonist for FPR2 receptor. Compounds 203-208 with six-
membered cyclic amino acids as the core showed micromolar activity in the calcium assay 
with the maximal efficacy. All compounds demonstrated high solubility, only 207 which 
has tetrahydropyran in position R2 has moderate solubility. The compounds 206 and 208 
proved that 2-amino-3-cyclohexyl-propanoic acid core affected the metabolic stability. 
The exploration of the R1 position demonstrated the importance of a bulky substituent 
and medium size of the moiety. The glycine series 193-196 confirmed that lack of any 
substituent leads to reduced activity relative to leucine. The compounds with larger 
substituents than cyclopentane had excellent efficacy, but lower potency. The 
investigation of alternative L-leucine core replacements showed that non-natural amino 
acids can be successfully applied in scaffold exploration. They helped in the improvement 
of biological activity and gave better understanding of SAR (Table 16).  
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ID R1 R2 
KS 
[μM] 
LogD 
Microsomal stability Ca2+ 
EC50 
[μM] 
(Emax) 
β 
EC50 
[μM] 
(Emax) 
T1/2 
[min] 
Clint 
[µL/min/mg] 
HLM MLM HLM MLM 
193 
-H 
 
200 2.8 >400 >400 2 2 NA NA 
194 
 
18 3.9 91 9 17 173 
1.6 
(48) 
NA 
196 
 
210 0 285 329 5 5 
0.25 
(98) 
1.93 
197 
(S)
 
 
13 
no 
data 
50 23 31 68 
0.02 
(39) 
1.4 
198 
 
75 3.9 18 14 86 109 NA 4.67 
199 
 
5 > 4 121 101 13 15 
0.04 
(66) 
0.4 
201 
 
158 1.3 123 69 13 22 
0.75 
(120) 
0.028 
248 
 
 
8 > 4 27 21 58 72 9 4 
249 
 
0 > 4 65.4 71 24 22 
0.2 
(77) 
0.028 
Table 16 ADME properties and EC50 values for additional urea derivatives. 
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Table 16 (continued) 
 
ID R1 R2 
KS 
[μM] 
LogD 
Microsomal stability Ca2+ 
EC50 
[μM] 
(Emax) 
β 
EC50 
[μM] 
(Emax) 
T1/2 
[min] 
Clint 
[µL/min/mg] 
HLM MLM HLM MLM 
250 
 
 
 5.6 44 245 35 6 
0.37 
(52) 
0.81 
(101) 
203 
  
188 2 96 29.1 16 53 
1.5 
(99) 
4.4 
(97) 
205 
  
222 0.3 - - <2 <2 NA NA 
206 
 
 
17 > 4 38 26 41 59 
1.6 
(150) 
2.15 
(92) 
208 
 
137 2.4 98 32 16 48 
1.0 
(92) 
1.56 
(94) 
 
Based on these data and results from human neutrophil adhesion assay [chapter 5.2 and 
5.3] 190 was chosen for further modification. The main issue which needs to be improved 
with these compounds is their kinetic solubility (Ks). In order to address this, a new series 
of agonists was designed and synthesised by replacement of the aromatic ring with more 
hydrophilic moieties (Table 17). Indeed, compounds 212 and 213 have improved kinetic 
solubility and LogD values, however at the same time a drop-off in the potency was noted. 
The compounds 214-216 showed submicromolar activity. The 3-pyridine was replaced 
with cyclic ethers: oxetane, tetrahydropyran and 2-methyltetrahydrofuran. The oxygen in 
the cyclic ethers can act as a hydrogen bond acceptor. For further investigation the oxygen 
could be replaced with methylene to see if it affects the binding affinity. The cyclic ether 
analogues showed good microsomal stability, except 216 which is highly unstable. The 
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stark difference in metabolic stability with 216 suggests that either a CH2 in the 
tetrahydrofuran ring or the -CH2 linker can act as a metabolic soft-spot in this example.  
 
 
ID R1 
Ks 
[μM] 
LogD 
Microsomal stability Ca2+ 
EC50 
[μM] 
(Emax) 
β-arrestin 
recruitment 
EC50 [μM] 
(Emax) 
T1/2 [min] 
Clint 
(µL/min/mg) 
HLM MLM HLM MLM 
190 
 
17 > 4 83 33 19 47 
0.02 
(100) 
0.74 
(98) 
210 
 
47 4 184 92 8 17 
0.8 
(120) 
6.33 
(100) 
212 
 
178 1.6 121 65 13 24 3.85 
0.50 
(97) 
213 
 
200 2.5 110 477 14 3 
3.67 
(130) 
NA 
214 
 
26 4.3 >400 >400 <3 <3 
0.62 
(95) 
NA 
215 
 
1 > 4 207 104 7 14 
0.6 
(132) 
 
216 
 
22 4.7 13 25 121 62 
0.540 
(96) 
0.94 
(101) 
Table 17 Summary showing ADME properties and EC50 values of selected compounds from cyclopentyl-acetamide 
series 
NA - very low response (Emax <30% of max response) or weak activation EC50>10 µM 
 
The next step in the optimization process was removal of one carbon atom from the 
carbon skeleton of a linker between the cyclopentane moiety and the scaffold. The 
cyclopentane ring is fused to the alpha-C atom of the amino acid. The 
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cyclopentanecarboxamide series showed significantly improved solubility and the 
potency was maintained in the nanomolar range (Table 18). The novel series showed 
good metabolic stability in vitro.  
 
 
ID R1 
Ks 
[μM] 
LogD 
Microsomal stability 
Ca2+ 
EC50 [μM] 
(Emax) 
β-arrestin 
recruitment 
EC50 [μM] 
(Emax) 
T1/2 [min 
Clint 
(µL/min/mg) 
HLM MLM HLM MLM 
218 
 
103 4.1 108 79 14 19 
0.250 
(110) 
1.3 
(99) 
219 
 
214 3.7 110 104 14 15 
0.366 
(90) 
7.27 
(92) 
Table 18 Summary showing ADME properties and EC50 values of selected compounds from 
cyclopentanecarboxamide series 
NA - very low response (Emax <30% of max response) or weak activation  EC50>10 µM 
 
At this stage, four promising compounds were selected for the cell health assay to 
determine whether any cytotoxic effects are seen from the compounds in HepG2 cells, a 
human hepatocyte carcinoma line. A range of parameters which may have effect on the 
cell viability, cell death, cytotoxicity and cell proliferation was tested. Among tested 
compounds, none of them appear to show any signs of toxicity at any of the parameters 
tested up to 30 μM (Figure 56). 
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Figure 56 Cytotoxic effects from the non-natural amino acids series (compound: 190, 210, 218 and 219) in HepG2 
cells, a human hepatocyte carcinoma cell line. 
Seven cell parameters are normalised as a percentage against low control (medium with 0.5% DMSO). HepG2 cells 
were treated +/- with compounds for 72h. Four fluorescent dyes were used for imaging: (Hoechst 33342, TMRM, 
TOTO-3 Iodide; Fluo-4 AM). Any cell measurement that deviates  from baseline (dashed lines) shows a switch in 
cell phenotype and cytotoxicity. Each cell measurement is represented as mean ± SEM (n=3). Ionomycin and 
Amiodarone which lead to hepatotoxicity were used as high controls. Results were visualised in IN Cell and analysed 
in IN Cell Workstation and Genedata Screener analysis software. 
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The additional exploration of this series was pursued. The SAR studies were focused on 
the replacement of pyridine ring (Table 19). For the pyridine replacement heterocyclic 
rings such as: pyrazoles, tetrazoles were proposed. Furthermore, I have designed and 
synthesized a number of analogues by decorating the pyridine ring with small substituents 
(such as: -CH3, -Cl) that could increase agonistic activity without drastically changing the 
solubility. Finally, the compounds containing 1-methylpiperidyl moiety was synthesized 
to assess the importance of aromatic ring in the compound activity. The introduction of a 
dimethyl pyrazole moiety increased kinetic solubility and boosted the activity in the 
calcium mobilization assay. Compound 220 has a low clearance amongst both species 
and LogD is slightly above 3. Another compound with encouraging profile is 221 with a 
tetrazole as substituent. 221 demonstrates high metabolic stability and solubility. 
However, the acidic proton in the tetrazole ring affected the activity compared to 220, 
which is 4-fold weaker (272 nM) and inactive in the β-arrestin assay. In order to increase 
lipophilic character of the molecule it would be worth synthesizing the follow-up with 
methylated tetrazole. The higher logD value could help to gain double-digit nanomolar 
EC50. The poorer performance of the 1-isopropyl-1H-pyrazole 223 in the biological 
assays could be explained by lower solubility compared to 220 and 221. The isopropyl 
moiety could also cause some clashes in the binding pocket which affect the binding 
affinity. Compound 224, with 2-pyridine showed more than 10-fold shorter half-life, 
highlighting the 3-pyridine’s stability. The compound 222 containing 1-methylpiperidyl 
moiety was synthesized to examine if non-aromatic rings affect the biological activity. 
222 showed moderate micromolar activity and was able to fully activate the receptor 
which correlates with the results for cyclopentyl-acetamide series, where replacement of 
the aromatic ring caused the drop of activity. Further follow-ups with other cycloalkenes 
and cyclic amines are required.  
Compounds 225-227 display promising stability in HLM which unfortunately is not 
translated to MLM. Introduction of a methyl group adjacent to the pyridine nitrogen (225) 
reduced solubility and stability in MLM, but still maintained activity in the nanomolar 
range. By contrast a methyl group at the pyridine 3-position (226) led to a significant 
drop-off in activity in the calcium mobilization assay. Methyl replacement with a chlorine 
227 did not improve metabolic stability. By increasing the lipophilic character of the 
molecule, we have gained the activity in calcium mobilization assay (EC50 = 107 nM). 
The efficacy of this compound might be affected by its very low solubility.  
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 R1 
Ks 
[μM] 
LogD 
Microsomal stability Ca2+ 
EC50 
[μM] 
(Emax) 
β-arrestin 
EC50 
 [μM] 
(Emax) 
T1/2 [min] 
CLint 
[µL/min/mg] 
HLM MLM HLM MLM 
220 
 
225 3.1 156 227 10 7 
0.089 
(86) 
1.85 
(89) 
221 
 
223 1.1 520 419 3 4 
0.272 
(88) 
NA 
222 
 
226 1.2 157 194 10 7.9 
1.6 
(95) 
NA 
223 
 
33 4.2 130 90 12 17 
1.1 
(96) 
4.15 
(51) 
224 
 
43 4.3 8 9 186 180 
6.07 
(49) 
NA 
225 
 
31 3.9 100 36 16 42 
0.60 
(68) 
9.9 
(60) 
226 
 
30 3.7 86 39 18 39 
1.75 
(79) 
9.8 
(60) 
227 
 
0 4.4 52 32 30 47 
0.11 
(60) 
2.58 
(71) 
Table 19 The pyridine replacement for cyclopentanecarboxamide series with ADME properties and EC50 values 
NA - very low response (Emax <30% of max response) or weak activation  EC50>10 µM 
 
122 
 
Three compounds containing a pyrazole or tetrazole ring were tested finding that they did 
not shown any signification effect on the parameters tested up to 30 μM (Figure 57). 
 
 
Figure 57 Cytotoxic effects from the cyclopentanecarboxamide series with 5-membered rings in the position R2 
(HepG2 cells, a human hepatocyte carcinoma cell line) 
Seven cell parameters are normalised as a percentage against low control (medium with 0.5% DMSO). HepG2 cells 
were treated +/- with compounds for 72h. Four fluorescent dyes were used for imaging: (Hoechst 33342, TMRM, 
TOTO-3 Iodide; Fluo-4 AM). Any cell measurement that differentiate from baseline (dashed lines) shows a switch in 
cell phenotype and cytotoxicity. Each cell measurement is represented as mean ± SEM (n=3). Ionomycin and 
Amiodarone which lead to hepatotoxicity were used as high controls. Results were visualised in IN Cell and analysed 
in IN Cell Workstation and Genedata Screener analysis software. 
 
Based on the observed SAR, it was decided to synthetize three additional analogues of 
191 with pyridine replacement. This included pyrazole variants, which were expected to 
represent a good compromise for the overall molecular properties. It also allows 
comparison of both series and demonstration of the advantages that the spiro-cyclopentyl 
group brings in improving microsomal stability and solubility of FPR2 modulators. The 
dimethylpyrazole analogue 228 showed moderate microsomal stability which is 2-fold 
lower compared to 220. In addition, the kinetic solubility dropped from 225 µM to 0 µM, 
and LogD value increased by more than 1 unit. 220 showed nanomolar activity in calcium 
mobilization assay, but we observe decrease in potency by around 5-fold. The 1-
isopropyl-1H-pyrazole has a negative influence on the potency among both series. 
However, 229 presented decrease in kinetic solubility and microsomal stability compared 
to 223. The pyridazine 230 was the most active amongst these three variants however it 
suffers from low metabolic stability (Table 20). 
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R1 
Ks 
[μM] 
LogD 
Microsomal stability Ca2+ 
EC50 
[μM] 
(Emax) 
β-
arrestin 
EC50 
[μM] 
(Emax) 
T1/2 [min] 
Clint 
[µL/min/mg] 
HLM MLM HLM MLM 
228 
 
0 >4 72 83 22 19 0.481 
1.9 
(86) 
229 
 
0 >4 55 12 28 126 1.33 
7.45 
(43) 
230 
 
59 >4 16 11 99 133 0.117 
1.41 
(84) 
Table 20 Additional heterocyclic analogues from cyclopentanecarboxamide series 
NA - very low response (Emax <30% of max response) or weak activation  EC50>10 µM 
 
 
The SAR established the importance of more rigid cyclic amino acids, where the cyclic 
ring is spiro to alpha carbon (R1). This may allow better capture of the active 
conformation compared to analogues with methyl or ethyl linkers. The 
cyclopentanecarboxamide series introduced the improvement of kinetic solubility and the 
activity was sustained in the nanomolar range. The non-natural amino acid series have 
fewer metabolic labile spots compared to bridge compounds.  For future work it would 
be worth synthesizing analogues with other spiro cyclic rings at the alpha carbon and 
small natural amino acids such as alanine, valine or isoleucine. Through establishing the 
structure-activity relationship (SAR), we discovered importance of aromatic ring at 
position R2 such as: 3-pyridine, pyrimidine, pyrazoles. It is worth noting that not all 
heterocyclic rings are well tolerated. Introduction of the 2- and 4-pyridine and pyridazine 
rings decreased the stability of the compounds in in vitro microsomal stability studies, 
which might point out the metabolic hot spots. The five membered rings such as pyrazoles 
and tetrazoles showed the most promising ADME and activity profiles in 
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cyclopentanecarboxamide series. The replacement of the aromatic ring at the R2 position 
caused the drop of activity amongst each family. However, additional follow-ups with 
other cycloalkenes and cyclic amines for the lead series are required. In the end, the 
previous SAR studies on the phenyl-urea moiety established the importance of para-
substituent aniline ring. For future work it would be worth investigating the left-hand side 
of the molecule and propose a possible replacement of bromine atom (Figure 58). 
 
 
 
Figure 58 Summary of SAR studies for non-natural amino acids series 
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5.4. Pyrrolidinone series 
 
Following the development of both the homology and pharmacophore models, they were 
then deployed in the search for novel ligands. To find novel structures of the FPR2 
agonists we decided to use the GLASS (GPCR-Ligand Association) database (234,229 
compounds). This selection of the compounds is part of a repository for experimentally 
validated GPCR-ligand interactions. As a first step the collection of compounds was 
implemented in Pipeline Pilot to eliminate possible duplicates and compounds which 
don’t meet the Lipinski rule of 5. This prepared dataset was used to generate 3D 
conformations using a Ligprep tool in Schrodinger software. To this end, the GLASS 
database was screened using ADHHR_7 using Phase Ligand Screening (Schrodinger 
software). The group of 330 compounds was selected based on the results of 
pharmacophore screening. These molecules were then docked using the FPR2 receptor 
homology model in order to examine their possible binding modes (Scheme 11). The 
docked molecules where manually examined for their interactions with key residues such 
as His-102, Arg-205, Cys-176. The aromatic stacking with at least one of the amino 
residues: Phe-257, Phe-292, Phe-163, Tyr-175 was required as well. In this approach we 
linked together our pharmacophore model with docking using receptor homology model. 
This workflow can be applied with any other available database.  
 
Scheme 11 Selection of the compounds using Phase Ligand screening 
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The results were analysed, and 13 novel ligand structures were chosen and then tested in 
the cellular assays and in vitro ADME assays (Table 21). Nine out of 11 ligands have the 
urea moiety in their structure. Compounds 251-257 and 262-263 were commercially 
available. Compounds 258-261 were synthesised. Each compound except 255 and 257 
contains the halogen atom in its structure. The urea moiety is a structural motif which is 
present in the majority of the selected compounds. These results fit well in the SAR 
observed through examining the binding modes of the FPR2 agonists in the homology 
model studies. Two compounds are covered by patent. The compound 258 is a modulator 
for GPCRs and antagonists of gonadotropin-releasing hormone. The molecule 257 is 
known as PF-04449913, the smoothened (SMO) receptor inhibitor.159  
 
Compound 
KS 
[μM] 
LogD 
Microsomal stability 
Ca2+ 
EC50 
[μM] 
(Emax) 
β-
arrestin 
EC50 
[μM] 
(Emax) 
T1/2[min] 
Clint 
[µL/min/mg] 
HLM MLM HLM MLM 
251 
2 3.7 149 79 10 19 NA NA 
 
252 
65 > 4 81 4 19 401 NA NA 
 
253 
10 > 4 41 24 37 64 NA NA 
254 
0 3.8 42 25 37 62 NA NA 
Table 21 The compounds selected based on results from virtual screening of GLASS collection 
NA - very low response (Emax <30% of max response) or weak activation  EC50>10 µM 
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Table 21 (continued) 
Compound 
KS 
[μM] 
LogD 
Microsomal stability 
Ca2+ 
EC50 
[μM] 
(Emax) 
β-
arrestin 
EC50 
[μM] 
(Emax) 
T1/2[min] 
Clint 
[µL/min/mg] 
HLM MLM HLM MLM 
255 
10 3.92 46 91 34 17 NA NA 
256 
0 3.97 21 97 71 16 NA 9 
257 
200 3.96 76 61 20 25 NA NA 
258 
2 > 4 84 130 18 12 NA 8.3 
259 
120 2.3 132 142 11 11.7 1.63 NA 
260 
0 >4 38 49 41 31 NA 1.8 
261 
200 1.64 165 209 9 7 NA NA 
262 
15 >4 >400 >400 2 2 
0.43 
(73) 
0.302 
263 
0 >4 >400 33 3 46 
1.97 
(82) 
0.51 
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Amongst these selected ligands, two pyrrolidinone compounds turned out to be the most 
active.  In both assays 262 showed the ability to activate the FPR2 receptor in the 
nanomolar range (β-arrestin EC50 = 302 nM, Calcium mobilization EC50 = 431 nM). 263, 
the 4-fluoro analogue of 262 showed slight drop-off in the β-arrestin recruitment assay 
(EC50 = 500 nM), but larger drop-off in potency in calcium mobilization (Table 21). 2-
Pyrrolidone is 5-membered lactam which is presented in various drugs available on the 
market such as cotinine, doxopram, povidone, piracetam and ethosuximide.  
Based on the results from the cellular assays and in-house in vitro ADME tests 262 was 
selected for further optimization. The stability of the compound was determined in human 
liver microsomes, where it was very stable (half-life >400 min). In addition, the lead 
compounds did not show a cytotoxic effect in the cell health assay (Figure 60). The low 
kinetic solubility and high logD of 262 are two properties which we would like to improve 
while maintaining or improving the agonist activity (Table 21).  
In order to look for improved compounds and further optimise the profile, 2000 virtual 
compounds with replacement of the phenyl ring attached to pyrrolidinone core were 
proposed and screened using the homology model. The results of the virtual screening 
suggested that molecules like 262 are more likely occupy subpockets I and II, whereas 
compounds 316 (purple) and 315 (green) with an additional linker group in their 
structures can potentially bind into subpockets III and I with formation of hydrogen bonds 
with Cys-176 and His-102 (Figure 59). 
 
Figure 59 Binding poses of pyrrolidinone agonists 
Compound 262 (blue) occupies subpockets I and II where compounds 316 (purple) and 315 (green) occupy 
subpockets I and III. 
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The introduction of different linker moieties offered the opportunity to improve the fit 
into the binding pocket and add more three-dimensionality into the molecules. For the 
linker moieties we proposed alkyl moieties and rings such as: piperidine, pyrrolidine, 
azetidine, and heterocyclic aromatic rings such as pyrazoles, oxadiazoles. The first step 
in the synthesis of these was N-acylation of the desired amine with 264 resulting in 
formation of N-substituted 2,4-dibromo-butanamide intermediate. The crude product was 
used directly in the cyclization (265-280). Overall yield after two steps was in the range 
30-60%. The introduction of amine group is performed by stirring the substrate in the 
mixture ACN/aqueous ammonia 1/1 at 40oC overnight to give products 281-296 in good 
yield. The urea derivative was obtained by reacting intermediates with 4-bromophenyl 
isocyanate at room temperature overnight (297-310). Cleavage of the BOC protecting 
group was performed with 4M HCl in dioxane at room temperature and obtain as free 
base in quantitative yield using SPE cartridges (311-314). N-alkylation, employing 
classic conditions with DIPEA and benzyl bromide, gave the final compounds 315-318 
(Scheme 12). The cyclization step and later the introduction of amine group were limiting 
steps for linkers 5-phenyl-1,3,4-oxadiazol and 5-phenyloxazol due to degradation of the 
products. 
 
 
Scheme 12 Synthetic pathway for pyrrolidinone series 
Conditions: A) 1) 2 eq. TEA, 1 eq. amine, Et2O or THF, 0⁰C to RT, overnight; 2) 1.5 eq. sodium hydride (60 mass%) 
in mineral oil, THF, 0⁰C to RT, 2-6h; B) 35% aq. Ammonia/ acetonitrile 1/1, 40⁰C, overnight; C) 1.1 equiv. 
isocyanate, DCM/DMF 9/1, RT, overnight D) 4M HCl in dioxane, DCM,  0⁰C to RT; 2-4h; E) 2.5 eq. DIPEA, 1.1eq. 
benzyl bromide, DMF, RT, overnight 
 
The first structural modification on our hit compound 262 was made by removal of the 
phenyl group and its replacement with benzyl substituent. Surprisingly, 297 was inactive 
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in the both cellular assays. Nevertheless, the ADME profile of 297 is promising with good 
stability across two species and high kinetic solubility. A number of the analogues with 
the linker moieties were synthesized and tested in the calcium mobilization assay. In table 
22, ADME properties and EC50 values are summarized for pyrrolidinone derivatives with 
the linkers: piperidines, pyrrolidine, azetidine, and pyrazoles. Each linker contains at least 
one nitrogen atom to increase polarity and water solubility of molecules. Each compound 
from this family shows good activity in the nanomolar range. However, the agonistic 
profile is quite flat. The size of the linker had little impact on its potency. It is worth 
noting that agonists which have an aromatic ring attached to the linker demonstrate better 
efficacy compared to those with only a linker moiety. The novel series showed good 
metabolic stability in vitro. Despite promising results in the cellular assay, compounds 
with pyrrolidine and 3-aminopiperidine as a linker were not chosen for further 
optimization due to problems with separations of the diastereomers. Based on these data 
three compounds were chosen for further modification: 315, 316 and 305. Compound 315 
and 316 have in their structure the piperidine moiety as a linker. The piperidine ring can 
be found in many natural alkaloids and synthetic small molecules and the ring nitrogen 
atom can be readily functionalised to allow rapid exploration of the SAR. By introducing 
the benzyl moiety in the molecule 316 we were able to retain the basic nitrogen of 
piperidine, which led to moderate kinetic solubility (Ks= 31 µM), but still LogD value is 
above 3.  Introducing an additional -CH2 between the pyrrolidinone core and piperidine 
linker, in the compound 315, higher flexibility might lead to improvement of kinetic 
solubility value and microsomal stability for about 2-fold in HLM and 50% in MLM. In 
addition, the LogD value drop down about one unit. Replacement of the piperidine linker 
with pyrrolidine ring caused creation of another stereo centre in the molecule which 
resulted in two diastereoisomers 317 and 318, their HLM/MLM stabilities are lower 
compared to parent compounds 315 and 316. The same trend is observed in the case of 
compounds 301 and 302 where 3-piperidine was introduced as a linker and yielded a 
drastic drop in stability. Compound 305 with a 3,5-dimethyl-pyrazole linker shows good 
stability in HLM, however stability did not translate to MLM. This molecule shows 
moderate solubility and high LogD value. 305 demonstrated full activation in the calcium 
mobilization assay in nanomolar range with a promising ADME profile, where LogD 
value needs to be optimized and if it possible the MLM stability improved.   
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ID R1 
KS 
[μM] 
LogD 
Microsomal stability Ca2+ 
EC50 
[μM] 
(Emax) 
β 
EC50 
[μM] 
(Emax) 
T ½  
[min] 
CLint 
(µL/min/mg) 
HLM MLM HLM MLM 
297 
 
75 4.4 168 127 9 12 NA NA 
298 
 
61 4.6 250 31.3 6 49 
0.73 
(42) 
6.3 
(93) 
299 
 
43 >4 19 19 80 80 
0.40 
(86) 
2.16 
(92) 
311  227 0.8 381 140 4 11 
0.27 
(84) 
3.29 
(102) 
312 
 
234 0.3 - - <2 <2 
0.23 
(68) 
1.03 
(100) 
300 
 
222 >4 113 112 14 14 
0.41 
(67) 
2.35 
(103) 
315 
 
192 2.5 227 121 7 12 
0.25 
(99) 
2.25 
(93) 
316 
 
152 3.5 112 70 13 21 
0.35 
(76) 
2.87 
(96) 
317 
diastereomer I 
210 3.3 78 35 20 44 
2.7 
(128) 
1.365 
(100) 
318 
diastereomer II 
207 3.0 56 36 28 43 
0.37 
(84) 
0.697 
(99) 
301  
diastereomer I 
71 >4 35 19 44 80 
0.13 
(71) 
1.384 
(89) 
302 
 
 
diastereomer II  
54 4.1 71 30 22 50 
0.06 
(73) 
0.55 
(86) 
305 
 
57 4.6 189 38 8 40 
0.28 
(150) 
0.395 
(95) 
Table 22 ADME properties and EC50 values for pyrrolidinone derivatives. 
NA - very low response (Emax <20% of max response) or weak activation  EC50>10 µM 
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Eight compounds were selected for the cell health assay to determine whether any 
cytotoxic effects are seen from the compounds in HepG2 cells, a human hepatocyte 
carcinoma cell line.  Four compounds appear to show no signs of toxicity at any of the 
parameters tested up to 30 μM, two compounds showed an effect on mitochondrial area 
and cell count, one compound, 299, shows weak effects on mitochondrial area and 
cellular calcium and affects cell count with an EC50 of 20.5 μM, 315 weakly affects dead 
nuclei and affects cell count with an IC50 of 28.6 μM (Figure 60). 
 
 
Figure 60 Cytotoxic effects from the pyrrolidinone compounds (312, 315, 316 and 305) in HepG2 cells, a human 
hepatocyte carcinoma cell line. 
Seven cell parameters are normalised as a percentage against low control (medium with 0.5% DMSO). HepG2 cells 
were treated +/- with compounds for 72h. Four fluorescent dyes were used for imaging: (Hoechst 33342, TMRM, 
TOTO-3 Iodide; Fluo-4 AM). Any cell measurement that differentiate from  baseline (dashed lines) shows a switch in 
cell phenotype and cytotoxicity. Each cell measurement is represented as mean ± SEM (n=3). Ionomycin and 
Amiodarone which lead to hepatotoxicity were used as high controls. Results were visualised in IN Cell and analysed 
in IN Cell Workstation and Genedata Screener analysis software. 
 
Another structural modification on the hit compound 262 was made by removal of the 
para-bromo substituent from the phenylureidic group or its replacement with -CN, -Et, -
OCH3 or 3,5-difluoro substituents.  The proposed changes were driven by the SAR 
studies, which showed the importance of the small lipophilic and/or electronegative 
substituent at the para position. We proposed also three replacements with more basic 
133 
 
centres such as imidazole (319) and two 4-pyridine containing analogues (320 and 324). 
In figure 61 two proposed binding modes for four analogues are shown. For first two 
compounds 325 (grey) and 320 (pink), phenyl ring linked directly to pyrrolidinone core 
is placed in the deepest pocket I, formed with hydrophobic amino residues such as Phe-
292, Phe-257. The aromatic π-stacking interaction is observed between a heterocyclic 
ring attached to urea moiety and Tyr-175. The NH groups of the urea moiety act as 
hydrogen bond donors and interact with Cys-176 and His-102.  The imidazole nitrogen 
atoms in histidine side chain can fulfil an acceptor or a donor function, which is 
conditioned on their protonation state. The second binding mode is represented by the 
analogues with imidazole directly linked to the core, compounds 322 (orange) and 321 
(blue). In this case we might observe a flick into the subpocket II which is built with 
amino residues: Ser 84, Val 284, Tyr 175. More interestingly, the imidazole moiety is not 
buried in the subpocket I but occupies the subpocket II, creating a π-π interaction with the 
phenyl ring of Tyr 175 sidechain. The NH groups of the urea moiety act as hydrogen bond 
donors and interact with hydroxy groups of Ser-288 located in second polar cluster.  
Those two binding modes are in good correlation with the binding poses of pyrrolidinone 
agonists presented in Figure 61. 
 
 
Figure 61 Proposed binding modes for non-para-bromo-phenylureidic pyrrolidinone analogues: 322 (orange) and 
321 (blue). 
 
However, only 325 was able to induce calcium mobilization, even though with low 
potency. It might be explained by the fact that 325 is the only molecule where the phenyl 
ring is attached directly to the urea group. This makes the molecule more rigid and 
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perhaps it is responsible for better fitting in the binding pocket. The lack of the activity 
could be triggered also by poor solubility of the molecules. Due to the high insolubility 
of these compounds the robot protocol crashed as the dilution series in 20% DMSO PBS 
contained large amounts of precipitate. No kinetic solubility results could be reported for 
these compounds. The logD and microsomal stability values for compounds 319-325 are 
in a good range (Table 23). Despite their poor performance in the cellular assays it is 
worth applying similar replacements of para-bromo substituent from the phenylureidic 
group in other series of FPR2 small molecule agonists to see if the activity could be 
retained.  
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Compound 
KS 
[μM] 
LogD 
Microsomal stability Ca2+ 
EC50 
[μM] 
 
β  
EC50 
[μM] 
 
T1/2[min] Clint 
(mL/min/mg) 
HLM MLM HLM MLM 
 
319 
- 1.0 - - <2 <2 NA NA 
 
320 
- 2.0 410  3.8 <2 NA NA 
 
321 
- 2.1 584  2.6 <2 NA NA 
 
322 
- 
not 
tested 
    NA NA 
 
323 
 
- 
2.8 329 357 4.7 4.3 NA NA 
 
324 
- 1.99 505 151 3.0 10.2 NA NA 
 
325 
- 2.7 85 172 
17.9
4 
8.9 
15 
(123) 
NA 
Table 23 The replacement of phenylureidic group in pyrrolidinone series. 
NA - very low response (Emax <30% of max response) or weak activation  EC50>10 µM 
 
Investigation of the receptor-ligand complex shows that an additional linker helps the 
compound fit better into the sub-pockets I of the FPR2 binding site. Based on the 
knowledge gained from ADME and cellular assays, three compounds were chosen for 
further modification: 315, 316 and 305. In order to explore better the pyrrolidinone series 
five analogues were synthesized and tested (Table 24). Compounds 306-309 are 
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analogues of 305 with 3,5-dimethyl-pyrazol linker. Compounds 308-309 lack activity in 
the calcium mobilization assay. This could be caused by lack of solubility but also by the 
absence of methyl group in pyrazole linker which can introduce rigidity by 
conformational blocking. In the case of compound 306, I decided to maintain two methyl 
groups and remove a phenyl ring. It led to better microsomal stability among both species, 
good LogD value (2.6) and unfortunately low solubility (9 µM). By this modification the 
analogues gained activity in the calcium mobilization assay. Ring replacement by 
isopropyl (307) improved the microsomal stability and lowered the LogD value, however 
the agonist is less active in the calcium mobilization assay compared to lead compound 
305 which can be caused again by absence of methyl group and its insolubility. Molecule 
310 is a follow-up on 316. The benzyl replacement by pyrimidine boosted the activity, 
which could be explained with a higher degree of rigidity compared to 316. At the same 
time, the logD value increased by around a half log unit and the solubility was lost.  The 
introduction of pyrimidine didn’t improve the microsomal stability values, moreover it 
made it less stable, which might suggest that the second and sixth position in the 
heterocyclic ring could be a metabolic hotspot.  
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ID R1 
Ks 
[μM] 
LogD 
 
Microsomal stability 
Ca2+ 
EC50 
[μM] 
(Emax) 
β-arrestin 
EC50 
[μM] 
(Emax) 
T1/2 [min] 
Clint 
(mL/min/mg) 
HLM MLM HLM MLM 
306 
 
9 2.6 183 172 8 9 0.142 
0.74 
(98) 
307 
 
1 3.7 322 159.3 526 10 0.884 NA 
308 
 
3 4.3 658  2  NA 
3.76 
(103) 
309 
 
0 >4 209 107 7 14 NA NA 
310 
 
0 3.9 57 44 27 35 0.0078 
0.385 
(96) 
Table 24 The additional analogues of pyrrolidinone series 
NA - very low response (Emax <30% of max response) or weak activation  EC50>10 µM 
 
 
During the evaluation of the pyrrolidinone follow-ups we observed a problem with 
cyclization, which happened to be a limitation step in the broader SAR exploration 
(Figure 62). The formation of pyrrolidinone core with substituent of interest is divided 
into two steps. The first step involved N-acylation of the desired amine to obtain N-
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substituted 2,4-dibromo-butanamide intermediate. This step is usually carried out in low 
boiling solvent e.g. diethyl ether or THF to avoid an aqueous work up. After filtration and 
evaporation of solvent, the crude product is used directly in the cyclization. However, the 
substituted piperidines seems to have low solubility in those solvents and DMF needs to 
be used in order to improve solubility. After removal of DMF, the crude product goes 
into the cyclization step. In the case of the compounds 329-334, the mixture of THF/DMF 
5/1 was used to allow the substrate to fully dissolve. Unfortunately, the process of 
degradation goes in parallel to cyclization. In two cases 330 and 331 it was possible to 
isolate small amount of desired product, though it wasn’t sufficient to carry out the 
following steps. 
 
 
Figure 62 Additional piperidyl amines used for pyrrolidinone core synthesis 
 
An alternative route which could be applied involves formation of tert-butyl N-[(3S)-2-
oxopyrrolidin-3-yl]carbamate 336 and as second step introduction of desired substituted 
linker, depending on the chemical character of the substrate we can use palladium 
catalysed reaction, reductive amination or N-alkylation where we can use broader 
spectrum of solvents (Scheme 13). The disadvantage of this route is that racemic 337 is 
expensive whereas the (S)-enantiomer is reasonably priced. Nevertheless, this route 
seems to be a good alternative for problematic amines.  
 
 
Scheme 13 Alternative route to pyrrolidinone core 
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The SAR studies around the phenyl-urea moiety established the importance of a para-
substituted aniline ring. Introduction of short alkyl linker between the aryl and urea 
moiety was not tolerated and led to the solubility deterioration and lack of activity in both 
biological assays. Para-substitution at position R1 was crucial for pyrrolidinone series. 
Based on results from the in silico studies, the introduction of different linker moieties 
such as alkyl and heterocycle moieties offered the chance to improve the fit into the 
binding pocket and add more flexibility into the structure. Dimethylpyrazole and 
symmetric linkers such as piperidine and azetidine exhibit promising ADME profile and 
keep biological activity in nanomolar range. From the first round the agonistic profile is 
quite flat and the size of the linker had little impact on its potency. However, it had impact 
on ADME properties: asymmetric linkers such as pyrrolidine and 3-piperidine have 
negative influence on microsomal stability, caused by high values of intrinsic clearance. 
Further investigation showed that aromatic rings directly attached to the pyrrolidinone 
core give rise to good stability and cellular activity but exhibit poor solubility. The linker 
moiety helps to maintain the agonistic effect and improves solubility, in the end heteroaryl 
group attached to the linker leads to increase of efficacy (Figure 63). 
 
 
Figure 63 Structure activity relationship (SAR) study of pyrrolidinone series 
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6. FPR2 agonists and their potential application in the 
treatment of cardiovascular inflammation 
6.1. Neutrophils in cardiovascular disease 
 
Good physiological inflammation is contained in time and space. However, sometimes 
the inflammatory response can continue without any control, which leads to chronic 
inflammation. Very often the first stage of the evolution of the inflammatory process is 
leukocytes adhesion and increased permeability of the endothelium due to pro-
inflammatory conditions in the site.43-44  
 
Adhesion molecules such as E-selectins, P-selectins, ICAMs and VCAMs are surface 
bound glycoprotein molecules expressed on leukocytes and/or endothelial cells. They are 
transmembrane proteins with the ability to undergo out/in signalling and control the status 
of the cytoskeleton.160 161 The molecular mechanism of leukocyte adhesion and later 
extravasation can be divided into 3 main stages: 1) capturing and rolling of leukocytes; 
2) activation of integrins; 3) adhesion and transmigration.  
In the first stage, selectins are creating bonds between the leukocytes and endothelium 
cells. The Sialyl Lewis carbohydrate presented on the surface of the leukocytes are 
ligands for the selectins. These interactions are reversible and the white blood cell (e.g. 
the neutrophil) can be detached. While rolling, though, leukocytes can receive a second 
stimulus leading to firm adhesion. Thus, the second step involves activation of integrins 
and binding of chemotactic cytokines expressed on the surface of endothelium to their 
transmembrane receptors.162. The chemoattractant signal causes re-arrangement of the 
integrin structure leading to binding to its endothelial counterpart. On the surface of 
endothelium cells there are two types of cell adhesion molecules ICAM-1 and VCAM-1 
and can be stimulated by the proinflammatory cytokines TNFα, IFN-γ, IL-1and LPS. 
ICAM-1 is an endothelial ligand for integrin LFA-1 and the VCAM-1 is a ligand for 
another integrin VLA-4. At this stage the neutrophils are firmly attached to the 
endothelium. Finally, through the out/in signalling provoked by the integrins on one side, 
and the CAMs on the endothelial side, the cytoskeletons of the leukocytes are modified 
and the transmigration process happens. This is sustained by PECAM-PECAM 
homophilic interactions, and the neutrophil penetrates small holes between the 
endothelial cells, to then migrate towards the site of tissue damage or infection. The 
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leukocyte adhesion cascade is shown below (Figure 64). 
 
 
Figure 64 The leukocyte adhesion cascade. 
Figure was created using the medical images provided by Servier Medical Art (http://www.servier.com) 
 
In the cardiovascular system, Formyl peptide receptor 2 (FPR2) oversees atherogenic-
plaque stabilization and healing. Activation of this receptor, in pre-clinical settings, seems 
to promote an anti-fibrotic wound healing to favour the return of the inflamed tissues to 
homeostasis.133 In this chapter two examples of small FPR2 non-peptide agonists for 
treating inflammatory diseases. First is a family of urea derivatives invented by Allergan 
company. One of these compounds was in phase 1 of clinical trials for dry eye syndrome. 
The compounds disclosed in patent application US20170320897 are represented by 
general formula showed in Figure 65.152 
 
 
Figure 65 General formula of Allergan urea derivatives 
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Dry eye syndrome is a disorder where the eyes do not produce enough tears. This can 
lead to the eyes drying out and becoming inflamed.  In these studies, the compounds show 
the good anti-inflammatory properties. Small molecule agonists can significantly reduce 
the infiltration of neutrophils. Moreover, ligands improve the process of healing and re-
epithelialization in mouse models of corneal wound. As it is shown in figure 66 there is 
significant reduction of neutrophils. 
 
Figure 66 Allergan FPR2 Agonists series of compounds- cell count in AqH152 
The second interesting compound is l-(4-chlorophenyl)-3-(5-isopropyl-l -methyl-3-oxo-
2-phenyl-2,3-dihydro-lH-pyrazol-4-yl) urea also known as Compound 43, developed by 
Amgen, which shows anti-inflammatory properties. This agonist is reported to enhance 
wound healing and empower the resolution of inflammation in the same way as natural 
SPMs. Compound 43 (35) is often used as a tool compound in a range of cellular assays 
(Figure 67). 
 
Figure 67 Chemical structure of Compound 43 
In 2017 a Bristol Myers Squibb patent was published targeting FPR2 for treatment of 
heart disease using compound 43. The patent covers the methods of treating acute and 
chronic heart failure, myocardial infraction, acute coronary disease and cardiac iatrogenic 
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damage133, 163 Ostrowski et al. performed the chemotaxis assay using a human HL60 cell 
line. Compound 43 stimulated chemotaxis, by itself, in the nanomolar range (78 nM) but 
on the other hand it also antagonized chemotaxis induced by SAA with a potency of 189 
nM. It was also shown that this small molecule agonist is able to promote phagocytosis 
of the fluorescently labelled zymosan in mouse bio-gel elicited peritoneal macrophages. 
Dufton et al. and Sogava et al. demonstrated that Compound 43 can inhibit dose-
dependently neutrophil migration in vivo.111, 164 Based on these results, Compound 43 acts 
as a functional antagonist for numerous chemoattracting receptors through the induction 
of cross-desensitization of the receptors. (Figure 68). 
 
Figure 68 Cpd43 inhibits neutrophil migration into the airways in lipopolysaccharide (LPS)-exposed mice 
 
During my secondment at LMU (Munich) I wanted to investigate if my FPR2 small 
molecule agonists could reduce the neutrophil adhesion.  In order to test the hypothesis, 
I optimized and performed the static adhesion assay and flow chamber adhesion assay. 
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6.2. Static adhesion assay 
 
The static adhesion assay was performed with the aim of examining the small molecule 
agonists and their anti-inflammatory and proresolving properties. It was decided to 
simplify the environment and instead of using HUVEC cell line to coat the assay plates, 
I used two types of leukocyte-endothelial cell adhesion molecule: P-selectin and ICAM-
1. P-Selectin plays a role in the primary contact of circulating white blood cells with 
endothelium which imply the capture of neutrophils and a ‘rolling' of the leukocytes on 
the endothelium can be observed. Later ICAM-1 and VCAM-1 are responsible for 
stronger interactions. 
 
 
Blood was collected from healthy donors in accordance with a protocol approved by the 
Ludwig Maximilian University of Munich. Neutrophils were isolated from the blood 
using Polymorphprep protocol [12.3.4]. Isolated neutrophils were washed and 
resuspended in HBSS buffer (0.5x106 cells/mL) and used on the day of the experiment. 
96-well flat-bottomed plates were coated with cell adhesion molecules:  P-selectin and 
ICAM-1 (1 μg/mL). The human neutrophils were labelled with CellTracker™ Red 
CMTPX. The agonists were added into assay plate, following by addition of neutrophils 
per well. The adhesion was allowed for 20 min at. 37°C. Non-adherent neutrophils were 
removed and the fixations step was performed with PFA 4%. Pictures were taken with 
Leica inverted microscope type DMI8, and cell count was performed with Fiji software. 
Results were shown as a percentage of adherent cell numbers for the control. However, 
no trend was observed (Figure 69, plate 1), therefore a pre-incubation step was introduced 
in order to encourage the FPR2 receptor activation. The pre-incubation step involves 
incubating the cells with agonists for 30 min at 37°C with gentle continuous mixing to 
prevent neutrophils sedimentation. After this time the reaction mixture from each well is 
transferred into the assay plate, the next part of the assay is continued according to the 
protocol described previously. By introducing the additional step, the dose dependent 
inhibition of neutrophils adhesion to the cell adhesion molecules was observed (Figure 
69, plate 2). 
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Figure 69 Optimization of static adhesion assay with compound 17 
Data are mean ± SEM, 3 technical replicates; The difference between control group, and treatment groups was 
evaluated via one-way Anova followed by Dunnett’s multiple comparison test, and the difference was considered 
significant for a P value <0.05, *** P < 0.001; ** P< 0.01; * P < 0.05 
 
Unfortunately, during preincubation of neutrophils with agonists bleaching of the dye was 
observed and the pictures taken by fluorescence microscope, using the adaptive focus 
control (AFC) option, were not always sharp enough to perform the cell counting. To 
reduce this time-consuming step of manually taking the pictures the CellTracker™ Red 
CMTPX was replaced with DAPI. 4′,6-diamidino-2-phenylindole (DAPI) is a blue 
fluorescent stain which can be used to stain fixed cells. This improved the quality of the 
pictures and helped in the process of quantification. The final scheme and plate layout are 
shown in Figure 70. Measurement of triplicate samples for each concentration was 
performed in each independent experiment. The full final protocol can be found in chapter 
12.3.5. 
 
 
Figure 70 Scheme of static adhesion assay setup and plate layout 
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The last step in the protocol optimization was examination of the plates to determine if 
neutrophils are not adhered when added in a concentration-dependent manner to the non-
coated plastic surface during pre-incubation step. To exclude this possibility, when the 
reaction mixture from each well was transferred into the assay plate, the fixation step was 
performed with PFA 4%. The results of this experiment are shown in the figure 71. In the 
graphs A-C three treatments are presented independently, and it can be seen that the 
neutrophil count did not increase compared to the control. Only in the case of treatment 
3, we could observe some small fluctuation in the numbers of cells across the whole plate, 
nevertheless if we present data from three treatments as mean and percentage of the 
control, the cell count for each concentration is at the same level. The agonists do not 
promote the adhesion during pre-incubation stage. The number of the cells transferred 
from pre-incubation plate into the assay plate is mostly even (Figure 71 D). 
 
 
Figure 71 Preincubation plate cell count 
A-C: Data are mean ± SEM, 3 technical replicates for each treatment; D: Data are mean ± SEM, average of 
3 independent treatments. The difference between control group, and treatment groups was evaluated via 
one-way Anova followed by Dunnett’s multiple comparison test, and the difference was considered 
significant for a P value <0.05, *** P < 0.001; ** P< 0.01; * P < 0.05, ns – nonsignificant 
 
A selection of 50 active agonists was based on their biological activity in in vitro cell 
based assays (EC50< 1 μM). This group of molecules was tested at least with one blood 
donor (3 technical replicates).  After the first round of testing, FPR2 agonists could be 
divided into 3 groups based on the outcome (Figure 72):  
a) inhibition of neutrophils adhesion. 
b) number of neutrophils corresponds with a control. 
c) small increase of adherent neutrophils. 
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Figure 72 Preliminary results from static adhesion assay depending on the outcome. 
Data are mean ± SEM, 3 technical replicates, The difference between control group, and treatment groups 
was evaluated via one-way Anova followed by Dunnett’s multiple comparison test, and the difference was 
considered significant for a P value <0.05: * P < 0.05, ** P< 0.01, *** P < 0.001; ns – not significant. 
 
 
Compound 18 showed good inhibition of neutrophil adhesion (Figure 72 A). 17 is one of 
the small molecule agonists described in patent application US20170320897 covering 
treatment of ocular inflammation.152 Compound 27 is a representative of the series of the 
compounds which are not affecting the number of adherent neutrophils. Only compound 
110 from this family shows 10-15% reduction however this value is constant, it can be 
caused by desensitization of the receptor.  Many of the compounds causing a small 
increase in the number of neutrophils are urea derivatives with a para-trifluoromethyl 
group such as compound 71 (Figure 72 C). 
 
In addition to the small molecule agonists, the selective FPR2 antagonist WRW4 peptide 
was tested. The results showed that the number of neutrophils is in the same range 
compare to the control, which indicates that blockade of FPR2 per se does not affect the 
neutrophil adhesion process (Figure 73).  
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Figure 73 Results for WRW4 in static adhesion assay 
Data are mean ± SEM, 3 technical replicates The difference between control group, and treatment groups was 
evaluated via one-way Anova followed by Dunnett’s multiple comparison test, and the difference was considered 
significant for a P value<0.05: * P < 0.05, ** P< 0.01, *** P < 0.001; ns – not significant. 
 
Based on the preliminary data, the number of agonists was narrowed to 23 compounds 
which show the inhibitory effect on adhesion process. They were tested in three 
independent experiments (three independent healthy donors).  
 
The β-arrestin and calcium mobilisation assays revealed that in the non-natural amino 
acid series, the presence of a bulky substituent in the position R1 is crucial to maintain 
the activity. In Figure 74 four compounds from this series are presented. These 
compounds were tested in primary cell assays and this has shown that majority of them 
can reduce number of adherent neutrophils which indicates their anti-inflammatory 
properties. The L-leucine compound 189 showed minimal reduction of adherent 
neutrophils.  Replacement of the L-leucine moiety with the cyclopropane core 247 did 
not improve anti-inflammatory properties of the molecule. The number of neutrophils 
corresponds with a control. Compound 246, with the cyclopropylmethyl core, shows 40-
50% reduction and this value is constant across whole concentration range; this could be 
caused by desensitization of the receptor. The cyclopentane analogue 190 reduces the 
number of adherent cells in concentration dependent manner (Figure 74). The analogues 
with larger cyclic substituents show better anti-inflammatory properties compared to 
alkyl 189 and cyclopropane 247 analogues.  
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Figure 74 Anti-adhesive properties of non-natural amino acids series 
Data are mean, 3-4 independent experiments with 3 technical replicates The difference between control group, and 
treatment groups was evaluated via one-way Anova followed by Dunnett’s multiple comparison test, and the 
difference was considered significant for a P value<0.05: * P < 0.05, ** P< 0.01, *** P < 0.001; ns – not significant. 
 
Anti-adhesive properties were observed also for urea derivatives with novel furan 
scaffolds.  The compounds 157 and 158 were developed in a collaboration between 
Bristol Myers Squibb and Kyorin for treatment of cardiovascular diseases.138  The 
reduction of adherent neutrophils is moderate across the whole concentration range; it can 
be caused by desensitization of the receptor. Introduction of fluorine atoms caused a small 
loss in the inhibition; the activity could be affected by low solubility of the compound 
158 (Figure 75 B). 
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Figure 75 Anti-adhesive properties of urea derivatives with furan scaffold 
Data are mean ± SEM, 3 independent experiments: 3 technical replicates The difference between control group, and 
treatment groups was evaluated via one-way Anova followed by Dunnett’s multiple comparison test, and the 
difference was considered significant for a P value<0.05:* P < 0.05, ** P< 0.01, *** P < 0.001; ns – not significant. 
 
 
Reduction of neutrophil adhesion to P-selectin and ICAM‐1‐coated wells was also 
observed in the case of oxazole derivatives. Both compounds reduced the number of cells 
in the dose dependent manner (Figure 76). Compounds 143 and 144 are pyrazole 
analogues of ACT-389949 which was tested in Phase 1 trials in healthy subjects. 
However, results of Phase I studies showed that ACT-389949 shows some pro-
inflammatory effects.157 
 
 
Figure 76 Anti-adhesive properties of oxazole series 
Data are mean ± SEM, 3 independent experiments: 3 technical replicates The difference between control group, and 
treatment groups was evaluated via one-way Anova followed by Dunnett’s multiple comparison test, and the 
difference was considered significant for a P value<0.05; * P < 0.05, ** P< 0.01, *** P < 0.001; ns – not significant. 
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Figure 77 shows representative compounds with anti-adhesive properties which were 
chosen for the subsequent flow chamber assay. These small molecule agonists exhibit 
anti-inflammatory action in a dose-dependent manner.  
 
 
Figure 77 Static adhesion assay and selected compounds. 
Data are mean ± SEM, 3-4 independent experiments The difference between control group, and treatment groups was 
evaluated via one-way Anova followed by Dunnett’s multiple comparison test, and the difference was considered 
significant for a P value<0.05: * P < 0.05, ** P< 0.01, *** P < 0.001; ns – not significant. 
 
In the static adhesion assay it was apparent that the number of adherent neutrophils was 
decreased. The continuing activation of FPR2 receptor by agonist administration could 
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desensitize the receptor and down-regulate receptor protein, which is why we might 
observe a similar percentage of inhibition between different doses of agonists. 
Nevertheless, the binding of anti-inflammatory agonists might prevent binding of the 
other pro-inflammatory ligands like SAA, or control release of pro-inflammatory 
cytokines.  
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6.3. Flow chamber adhesion assay 
 
Under the inflammation conditions circulating neutrophils which flow with the 
bloodstream can be trapped by selectins and roll over the surface of endothelial cells. At 
this stage some of them might be detached from the endothelium and join the blood 
stream, before they can be arrested by ICAM and VCAM.  In this assay, the idea was to 
add one more factor to the system in order to mimic a natural blood flow.  
 
The pre-incubation step is the same as in the case of the static adhesion assay. After pre-
incubation time the reaction mixture was transferred into the flow chamber slide. Each 
treatment group (duplicates) had its own reservoir. The leukocyte samples were perfused 
through the channels. Non-adherent neutrophils were removed, and the fixation step was 
performed with PFA 4%. The pictures were taken manually with Leica inverted 
microscope type DMI8 in the bright field (4 pictures per chamber). Raw data was entered 
into the GraphPad Prism 7.01 analysis software for data processing and visualisation. The 
full final protocol can be found in chapter 12.3.6. In Figure 78 the slide layout is shown. 
In every slide 6 chambers are available. For the final flow chamber adhesion assay 5 
compounds were tested, two literature compounds: 18 and 35, one hybrid compound 144 
and two novel compounds: 262 and 190. In our experiment each slide represents one 
concentration. Each compound is tested at three different concentrations: 100 nM, 1 μM 
and 10 μM in duplicates. 
 
 
Figure 78 A 6 channel slide layout for flow experiments. 
 
On the example of compound 18 we can observe decrease of adherent neutrophils to 
ICAM-1/P-Selectin coated chambers at different agonist concentrations (1: control, no 
agonist, 2: 10 μM, 3: 1 μM, and 4: 100 nM). The concentration of ICAM-1 and P-Selectin 
is 5 µg/mL. Neutrophil flow speed is 5 µL/min (Figure 79).  
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Figure 79 Compound 18 causes a decrease in the number of the adherent neutrophils and possibly their detachment. 
 
It is worth noting that Formyl peptide receptor 2 appears as the receptor which might be 
mostly responsible for the “detachment” phase165, which may explain why in the flow 
chamber adhesion assay a better dose-dependent trend in reduction of adherent 
neutrophils was observed. Compound 190 which is a representative of the non-natural 
amino acid series with a cyclopentane core exhibits anti-inflammatory action in the dose 
dependent manner, using a 1 µM dosage of 190 the cell count was reduced up to 40% 
(Figure 80 A). The compound 262 with novel pyrrolidine core decreased the neutrophil 
adhesion by 35-40% with 1 µM and 10 µM dosage. Compound 35 inhibited dose-
dependently neutrophil adhesion, with results comparable with 190. Only compound 144 
displayed constant 40-50% reduction regardless of compound concentration. However, 
only compound 18 has been tested in two independent assays, which showed good 
replicability of the results (Figure 80 B). The adhesion of neutrophils under the 
stimulation for 30 minutes with 100 nM concentration of 18 was decreased by 30-35%, 
which is promising.  
 
Figure 80 Results of flow chamber assay 
A) Data are mean ± SEM, 2 technical replicates B) data collected for compound 18 from 2 independent experiments. 
The statistics test was performed for Compound 18. The difference between control group, and treatment groups was 
evaluated via one-way Anova followed by Dunnett’s multiple comparison test, and the difference was considered 
significant for a P value<0.05: * P < 0.05, ** P< 0.01, *** P < 0.001; ns – not significant. 
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The neutrophil flow chamber adhesion assay has been optimized and two novel 
compounds 190 and 262 showed positive results in the preliminary experiments. In the 
future, the remaining four compounds need to be retested to confirm their anti-
inflammatory properties.   
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6.4. Discussion  
 
In each adhesion assays it was apparent that the number of adherent neutrophils was 
decreased upon activation of FPR2. There could be a degree of desensitization and 
receptor down-regulation upon continued continuing activation of the FPR2 receptor, 
which could explain why we might observe similar percentage of inhibition between 
different doses of agonists. Nevertheless, the binding of anti-inflammatory agonists might 
prevent binding of the other pro-inflammatory ligands like SAA, or control release of pro-
inflammatory cytokines. 
As the next step it would interesting to test the most promising compounds in the adhesion 
assays using the plates and chambers coated with monolayer of the HUVEC cell line. It 
would add another factor to our system and better mimic the physiological environment. 
In the absence of pre-treatment, endothelial cells will show a small ability to adhere 
neutrophil. That is why HUVECs cells need prior stimulation to upregulate adhesion 
molecule expression. It is proven that numerous inflammatory agents stimulate 
endothelial cells to synthesize E-selectin and P-selectin. The anti-adhesive action of small 
molecule agonists should be tested using HUVECs cell line with pro-inflammatory agents 
e.g. fMLP-induced endothelial cells activation. Finally, it is worth to examine their 
antimigratory properties in the chemotaxis assay. 
The small molecule FPR2 agonists presented here might be valuable tools to study the 
molecular mechanisms, for example atherosclerosis or ischemia reperfusion. 
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7. FPR2 agonists: General discussion and future work  
 
During this project, my work has been focused on the development of Formyl peptide 
receptor 2 (FPR2) small molecule agonists and their application in treatment of 
cardiovascular inflammation. FPR2 is as an important receptor involved in the process 
called ‘resolution of inflammation’. The activation of the receptor by proresolving 
molecule triggers the resolution phase, promotes the tissue self-recovery and stops the 
development of chronic inflammation. In the last 10 years several synthetic small 
molecules have been submitted for Phase I clinical trials, but none of them has yet become 
the first-in-class anti-inflammatory drug. Currently small molecule agonist BMS-
9862235 is in Phase I clinical trials, this compound belongs to the 4-phenylpyrrolidinone 
series and is a candidate for the prevention of heart failure. 
In this project, homology modelling, molecular docking and pharmacophore studies have 
initially assisted the rationalization of the structure-activity relationships of known FPR2 
agonists. Based on these results we proposed the binding site with three hydrophobic 
subpockets and two polar clusters. For each molecule we observed important aromatic 
stacking with at least one of the amino residues: Phe-257, Phe-292, Phe-163, Tyr-175 and 
His-102. The H-bonds formed between -NH group from amide/urea moieties and one of 
the amino residues such as Arg-205, Cys-176 or His-102 helps to stabilize the structure 
in the pocket.  The developed pharmacophore hypothesis has then been used in parallel 
with the homology model for the design of novel ligand structures and in virtual 
screening. In additional to the virtual screening approaches, SAR-driven design 
employing bioisosteric replacement and synthesis, supported with ADME properties, is a 
rational option for the development of novel molecules. In total from the different 
approaches, over 130 compounds have been synthesized and tested in the β-arrestin and 
calcium mobilisation assays. These assays revealed that the presence of bulky substituent 
in the position R1 is crucial to maintain the activity. During my secondment at LMU 
(Munich, Germany), I screened over 50 of these compounds in primary cell assays and 
this has shown that FPR2 agonists can reduce number of adherent neutrophils which 
indicates their anti-inflammatory properties. Based on the results from the primary cell 
assays and in-house in vitro tests we have chosen two compounds for further 
optimization: 262 and 190. Both lead compounds showed no cytotoxicity in the cell health 
assay. The main issue which we had to improved was kinetic solubility. The optimization 
of cyclopentyl-acetamide series was approached by exploration of possible replacement 
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of 3-pyridine moiety in lead compound 190. The functional assays showed the importance 
of aromatic rings to maintain activity, while the improvement of kinetic solubility was 
achieved with non-aromatic amines such as azetidine or piperidine. Further investigation 
led to more rigid cyclic amino acids, where the cyclic ring is spiro to the alpha carbon 
(R1). The cyclopentanecarboxamide series introduced the improvement of kinetic 
solubility and the activity was sustained in the nanomolar range. In addition, the 
compounds from this series showed no cytotoxicity in the cell health assay. 
In parallel to further development of compound 190, the pyrrolidinone compound 262 
was optimized as well. The 262 was selected for cellular assays based on screening the 
GLASS database using our pharmacophore model. Additional analogues of 262 
containing the linker moieties were synthesized and tested in the functional assay. 
Amongst proposed linkers the dimethylpyrazole and symmetric linkers such as piperidine 
and azetidine display promising ADME profile and keep activates the receptor in 
nanomolar range. The compounds from this series showed no cytotoxicity in the cell 
health assay. For future work, it will be important to perform chiral separation of the 
selected compounds and test the enantiomers in in vitro assays. The results would help to 
answer if there is any preference in the chirality of the molecules from the activation 
mechanism point of view and ADME properties as well.  
In GPCR pharmacology there is currently increased interest in the developing biased 
agonists. Over the past 20 years, we have deepened our knowledge about GPCR 
signalling pathways and ability to activate only the selected signalling pathways with 
desirable therapeutic effects. That is why I have attempted to calculate bias factor 
∆log (
𝐸𝑚𝑎𝑥
𝐸𝐶50
).166 The potency of the modulators for FPRs depends on the cell type, where 
the receptors are expressed, in both our cellular assays we have used the same cell type, 
however the hill coefficient was not always equal one or Emax values were not always 
similar for all compounds. Therefore, the data were not included in this thesis. The 
bioluminescence resonance energy transfer (BRET) would be a good technique to use to 
estimate the degree of recruitment β-arrestin vs. G-protein mobilization. In the pursuit of 
novel biased agonist, we would need a better understanding which signalling pathways 
have a translation to the clinical effects. 
In this study the main focus was put on the development of novel agonists for the FPR2 
receptor. However, it would be interesting to test the compounds which showed a lack of 
agonistic activity in the additional cellular assays using antagonist mode. The 
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identification of antagonists would be useful to further explore the structure-activity 
relationship for both series of agonists. Moreover, it could bring new insight into possible 
different binding modes of FPR2 modulators. . 
 
In addition to our in-house functional assay, the six leading compounds (190, 218, 220, 
228, 262 and 306) are currently being tested in the ERK Phosphorylation Assay (FPR1 
and FPR2 HEK cell lines), which takes place at the William Harvey Research Institute (, 
QMUL, London). The activation of ERK signalling in cardiomyocytes promotes 
beneficial and prosurvival effects.88-89, 167 We would like to examine these compounds 
and check if they are selective FPR2 agonists or rather FPR1/FPR2 dual agonists to clarify 
whether the pro-resolving strategy will contribute to healing human inflammatory 
diseases and their complications. The normal mock-transfected HEK cell line will be used 
as control in order to examine any possible off-target effects of the compounds.   
 
Finally, two compounds 190 and 262 will be tested in vivo (Figure 81). To investigate 
further the results of in vitro static and flow chamber adhesion assays, the inhibition of 
leukocyte recruitment will be examined in mice peritonitis model. These studies will take 
place in Prof. Oliver Söhnlein’s research group (LMU, Munich, Germany). 
  
Figure 81  FPR2 agonists - in vivo candidates 
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Part two: Role for xanthine oxidoreductase in 
cardiovascular diseases 
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8. Introduction 
 
8.1. Structure of Xanthine oxidoreductase  
 
The first recognition of the transformation of xanthine to uric acid in the presence of tissue 
brei and oxygen was made by Spitzer in 1899. At the beginning of the last century, 
Austrian biochemist Franz Schardinger discovered xanthine oxidase. He observed the 
reduction of methylene blue in fresh milk after the addition of formaldehyde. The enzyme 
which oxidized the aldehyde was initially called Schardinger’s enzyme.168 At the time 
scientists assumed that Schardinger’s enzyme and xanthine oxidase were two different 
enzymes. In the 1920s new discoveries brought additional information about the enzyme. 
Morgans et al. found that hypoxanthine is the reducing substance and milk has a high 
level of xanthine oxidase. Later Dixon proved that these enzymes are identical.169 In 1938 
Booth compared both enzymes in several experiments e.g. oxidation of different types of 
purines, and showed that Schardinger’s enzyme was xanthine oxidase.170 
 
Xanthine oxidoreductase (XOR) is part of the group of molybdenum-containing enzymes. 
Five main families can be marked out based on their mechanism of catalysis and structure 
of the molybdenum centre:  
 
• Xanthine oxidase family (Xanthine oxidase/dehydrogenase and Aldehyde 
oxidoreductase). 
• Sulphite oxidase family (Sulphite oxidase and Nitrate reductase) 
• DMSO oxidase family (DMSO reductase, Nitrate reductase (dissimilatory), 
Formate dehydrogenase and Pyrogallol-phloroglucinol transhydroxylase) 
• Aldehyde ferredoxin oxidoreductase family (Aldehyde ferredoxin 
oxidoreductase, Formaldehyde ferredoxin oxidoreductase, Glyceraldehyde-3-
phosphate, Carboxylic acid reductase and Aldehyde dehydrogenase)  
• Unclassified enzymes (Acetylene hydratase).171 
 
In the figure below a comparison of the secondary structure of xanthine oxidoreductase 
(XOR), aldehyde oxidase (AO), and sulphite oxidase (SO) is presented (Figure 82).172-
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173 Aldehyde Oxidase is closest to human XOR with identity 50% and similarity 67% 
(alignment has been performed with Multiple Sequence Viewer Maestro).81 
 
 
Figure 82 The secondary structure of selected the molybdenum-containing enzymes.172 
 
XOR is a large homodimer enzyme with a molecular weight of 270 kDa, each subunit 
contains one Molybdenum cofactor (Mo-co), two iron-sulphur clusters and one Flavin 
adenine dinucleotide (FAD) cofactor. The active sites of the enzyme are the 
molybdopterin cofactors and FAD cofactor. The [2Fe-2S] ferredoxin iron-sulphur 
clusters take part in electron transfer reactions. In the human body, xanthine 
oxidoreductase is present in many tissues such as the lung, kidney, and in the splanchnic 
system.174-175 The enzyme controls the production of uric acid and generation of two 
reactive species: superoxide anion and hydrogen peroxide but also XOR is a nitrite 
reductase so a source of nitric oxide.172 In the figure below, we can see the crystal 
structure of human XOR (PDB: 2E1Q, 2.6 Å, mutant, Glu803Val). The protein subunit 
domains are presented in the table and coloured as follows: ferredoxin iron-sulphur 
clusters in pink, FAD cofactors in green, and molybdopterin domains in purple. The 
interdomain loop is highlighted in red. The C-terminal domain is coloured blue (Figure 
83).176  
 
Figure 83 Structure of human XOR with marked protein subunit domains.176 
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In 2000 the first crystal structures of bovine XOR (XDH at 2.1 Å resolution and XO at 
2.5 Å resolution) were determined by two research groups, led by Nishino and Pai.177 
This discovery helped to define the main changes that occur during the transformation of 
XDH to the XO form. 
 
The degradation of purine takes place at molybdenum cofactor (Figure 83)178. At the 
beginning two electrons are shifted from the hypoxanthine to molybdenum of Mo-co, 
reducing Mo (VI) to Mo (IV) and forming xanthine. In the first step H+ + 2e- is formed, 
as hydride is moved to a sulphur ligand of Mo-co179(Equation 3). 
 
𝑀𝑜(𝑉𝐼) = 𝑆 → 𝑀𝑜(𝐼𝑉) − 𝑆𝐻   (3) 
 
Electrons are shifted to the flavin adenine dinucleotide cofactor through the iron-sulphur 
clusters. Finally, oxidized nicotinamide adenine dinucleotide (NAD+) or an O2 molecule 
accepts an electron from FAD to give reduced nicotinamide adenine dinucleotide 
(NADH) or hydrogen peroxide and superoxide. The cycle starts once again to 
hydroxylated xanthine to uric acid. The xanthine dehydrogenase (XDH) uses NAD+ as an 
electron acceptor, whereas the oxidase form (XO) utilises O2 as an electron acceptor.
177 
The conversion includes post-translational adaptation like disulphide formation.180 The 
electron flow pathway during catalysis is as follows (Equation 4): 181 
 
𝑀𝑜 → 𝐹𝑒 𝑆𝐼⁄ → 𝐹𝑒 𝑆𝐼𝐼⁄ → 𝐹𝐴𝐷  (4) 
 
The second important role for Mo-co is the reduction of nitrite to nitric oxide.175 For many 
years, xanthine oxidase activity during ischemia-reperfusion injury was associated mainly 
with production of reactive oxygen species. Nevertheless, the studies from the last 20 
years showed that XOR is able to reduce nitrates to nitric oxide under pathological 
hypoxic conditions.182-183 In 1998, Blake et al. determined the nitric oxide production by 
using an ozone chemiluminescence assay in a continuous flow apparatus. They noticed 
that indeed, under hypoxic conditions and acidic pH, xanthine oxidase reveals a nitrite 
reductase activity. XO catalyses the process of reduction of nitrates to nitric oxide in the 
presence of the reducing substrate, NADH.182 The important role of nitric oxide in 
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cardiovascular events such as myocardial ischemia/reperfusion will be described in the 
section 7.2 and 7.4.  
 
In order to explain the mechanisms of hydroxylation at the Mo-co, the electron flow 
pathway and the reduction at the FAD, numerous mutation studies and chemical 
modification have been done since 1989. Figure 84 shows possible binding modes of 
hypoxanthine and xanthine. Glu-803 and Arg-881 are responsible for purine binding, 
where hydrogen bonds between them and the substrate facilitate nucleophilic reaction. In 
the mutation studies Glu-803 was replaced with valine (E803V) and Arg-881 with 
methionine (R881M), the mutant showed lower activity of enzyme in hydroxylation of 
purine substrates.184 Further mutagenesis studies revealed the importance of Glu-1262 
which forms a hydrogen bond with N-1 of the substrate. When Glu-1262 was replaced 
with alanine, the enzyme was entirely deactivated176, 185 (Figure 84 right hand side). 
 
 
Figure 84 Mechanism of purine degradation176, 186 
 
Xanthine oxidoreductase contains also two iron-sulphur clusters. This domain is 
important for the electron flow pathway and acts as an electron sink to provide electrons 
for the Flavin adenine dinucleotide cofactor. Once MoVI is reduced to MoIV, electrons 
from the molybdenum cofactor are transferred to the iron-sulphur clusters. Later each 
electron is transferred ~12.5 Å from Fe/SI to Fe/SII (Figure 85).181  Both centres Fe/SI 
and Fe/SII have different electron paramagnetic resonance (EPR) properties and redox 
potentials. The EPR signal for Fe/SI  shows g-values of g = 2.02, 1.93, 1.90, with the 
properties representative for a [2Fe-2S] ferredoxins, whereas Fe/S II has g-values of g = 
2.10, 1.98, 1.91 which is unusual, but specific for some Mo-containing hydroxylases, 
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when the temperature is below 22 K.181 Site-directed mutagenesis experiments revealed 
that Cys-43, Cys-51 and Cys-116 are important components of Fe/SI and II ligands. It 
was determined that the mutation at cysteine Cys-43 to serine or cysteine Cys-51 to 
alanine, caused the presence of insoluble/monomeric proteins. These studies proved that 
the Fe/S I cluster plays an important role in protein conformation and folding (Figure 
85).178, 187 The Fe/SI domain is linked to the second FAD domain by a long fragment that 
is partly disordered, amino residues 166 to 225. The second domain binds the FAD by 
the fragment residues 226 to 531. [The 2Fe-2S] cluster are located ~7.8 Å away from the 
FAD site. 
 
 
Figure 85 Schematic diagram of FeS I, FeS II and FAD cofactors arrangement181 
 
At the FAD-containing domain the oxidation of NADH and ROS generation take place. 
The flavin adenine dinucleotide is firstly reduced to the semiquinone (FADH·), and later 
hydroquinone (FADH2) form, then FAD is able to reduce a final electron acceptor by 
transferring electrons out of the enzyme site.171, 181 In order to explain the mechanisms of 
the electron transfer out of the enzyme and the reduction of FAD, directed mutagenesis 
experiments have been performed. The studies revealed the importance of Arg-427, Arg-
335, Trp-336, Phe-337, Tyr-339, Aspr-429, Cys-536 and Lys-552.178 During the 
conversion XDH/XO we can observe the dislocation of the atoms situated in the active-
site loop (Gln-423–Lys-433). As a consequence, the electrostatic environment in the FAD 
site is changed and blocks the access of the NAD substrate to the FAD cofactor in the XO 
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form.  Thirty years ago Nishino’s group showed  the crucial role of tyrosine Tyr-393 in 
NAD+ binding.188 In 2003, Nishino et al. performed site-directed mutagenesis 
experiments and revealed that Phe-549, Arg-335, Trp-336, and Arg-427 are the members 
of the cluster XDH/XO conversion which is linked to the proteolytic cleavage to the 
active-site loop (Gln-423 – Lys-433).189 The most recent studies show that two amino 
residues Phe-337 and Asp-429 also play an important role for the redox potential of 
FAD.178 In the figure below FAD is shown in yellow. The key amino acid from the 
directed mutagenesis experiments has been marked in green (Figure 86).178, 190 
 
 
 
  
Figure 86 Structure of the active site cavity of FAD in human xanthine oxidoreductase (PDB: 2E1Q)  
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8.2. Nitric oxide as a cardiovascular protector  
 
Nitric oxide is a small soluble colourless gas which can diffuse through a water and lipid 
phases and shows anti-inflammatory properties. In 1772 nitric oxide was identified as a 
gas by Joseph Priestley.191 In the last century, three remarkable scientists Robert F. 
Furchgott, Ferid Murad and Louis Ignarro contributed to the discovery of NO as a 
cardiovascular signalling molecule. Ferid Murad revealed that nitroglycerin releases NO 
and in the result causes the relaxation of smooth muscle cells. Robert Francis Furchgott 
and Louis Ignarro identified nitric oxide as endothelium-derived relaxing factor (EDRF). 
It was the first time in history that such a small molecule was shown to have a key role in 
the regulation of biological processes. In 1992, NO was titled "the molecule of the 
year".192 In 1998 Robert F. Furchgott, Ferid Murad and Louis Ignarro were awarded the 
Nobel Prize in Physiology or Medicine for discovering nitric oxide's role as a 
cardiovascular signalling molecule.193 
 
A low level of NO production is related with almost all known cardiovascular diseases. 
It inhibits the aggregation of platelets194, prevents smooth muscle cell proliferation195, 
reduces the adherence of leukocytes to the surface of blood vessels17, decreases the blood 
pressure and causes vasodilation. When NO binds to guanylyl cyclase it causes its 
activation. This enzyme catalyses the production of cGMP which leads to smooth muscle 
relaxation. An increased level of cGMP also has a significant anti-platelet result. 194  NO 
is helpful in treating myocardial ischemia reperfusion injury. Administration of NO or 
NO donors prior to ischemia attenuates the consequences of myocardial 
ischemia/reperfusion; i.e. reduces infarct size and endothelial dysfunction.196 The role of 
nitric oxide in the myocardial ischemia during hypoxic conditions has turned into an 
important topic of interest in the heart disease research field. So far, the majority of studies 
have revealed that NO has a beneficial role. Myocardial ischemia reperfusion injury will 
be described in section 8.4. 
 
Nitric oxide is produced through the acidification from nitrite or via reaction with a 
number of mammalian nitrite reductase (the globins: Hb, Mb, Ngb, xanthine 
oxidoreductase, mitochondrial cytochrome bc1complex, eNOS, cytochrome P450s, 
aldehyde oxidase).197 The NOS synthetic pathway is the best known pathway of nitric 
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oxide synthesis. L-Arginine in this reaction is the precursor of NO. Later nitric oxide can 
be oxidized to nitrate/nitrite. Under acidic/hypoxic conditions, nitrite can be recycled in 
vivo to form nitric oxide, demonstrating an alternative source of NO (Figure 87).198-199 
 
Figure 87 NOS synthetic pathway 
 
Nitric oxide can be generated from nitrite and dietary nitrate through nitrate reductase, 
using an endogenous nitrate-nitrite-nitric oxide pathway, which is an independent route. 
Good examples of dietary sources of nitrate are green leafy vegetables (e.g.: spinach, 
rocket and lettuce) and beetroot.200 This dietary nitrate can be used in the NO generation 
catalysed by xanthine oxidoreductase, described in the previous section. Ahluwalia et al. 
showed that nitrite has blood pressure-lowering effects, in an experimental model of 
hypertension. Nitrite brought potent dose-dependent reduction of blood pressure in 
spontaneous hypotensive rats (SHR), but not Wistar Kyoto (WKY) rats (Figure 88).201  
 
Figure 88 Changes in mean arterial blood pressure (MAP) in response to concentration of nitrate 201 
where  WKY – Wistar Kyoto, SHR – spontaneous hypotensive rats 
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NO plays an important role in protection of cardiovascular health, although it should not 
be forgotten that a high level of its production is toxic to cells, and it can lead to cell death. 
Reactive oxygen species are the main cause of oxidative stress, which is unwanted, and 
they increase inflammation. The reaction of superoxide and nitric oxide leads to the 
generation of the strong oxidant peroxynitrite (ONOO−)202 which is why maintenance of 
the internal stability between all biological processes and parameters such as body 
temperature, blood pressure and pH is crucial. 
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8.3. Inhibitors of Xanthine oxidoreductase  
 
Xanthine oxidoreductase takes part in purine metabolism and its activity is one of the 
sources of uric acid. An abnormally high level of uric acid in the blood is the main 
symptom of hyperuricemia. It can be caused by decreased excretion, high purine food and 
drinks and increased purine metabolism. The first inhibitors of xanthine oxidoreductase 
that were developed block production of uric acid and are still used for treatment of 
hyperuricemia and gout. The XOR inhibitor drugs available on the market, e.g. 
Allopurinol and Febuxostat, bind tightly to the molybdenum active site.186 During the last 
decade relevant clinical research has concentrated on the usage of the allopurinol and 
febuxostat in the prevention of CVD. This therapy might play a significant role in the 
treatment of hyperuricemia-related cardiovascular events such as acute stroke, coronary 
disease or hypertension.203  
 
8.3.1. Allopurinol 
In 1940s American scientists and the Nobel Prize laureates, George Hitchings and 
Gertrude Elion discovered the first inhibitor of xanthine oxidoreductase.204 Allopurinol is 
a hypoxanthine analogue. XOR hydrolyses the drug to Oxypurinol which binds tightly to 
the reduced molybdenum ion (MoIV) (Figure 89).186 In 1966, Allopurinol was approved 
by the FDA (US Food and Drug Administration) as a drug for the treatment of urate 
nephropathy, uric acid kidney stones, acute gouty arthritis and hyperuricemia.186, 205 
 
 
Figure 89 Hydrolysis of Allopurinol and formation of Oxypurinol 
 
Allopurinol has a good oral bioavailability of ~79% and an elimination half-life of 1.2 ± 
0.3 hours. Its active metabolite, Oxypurinol has a long half-life in tissues and it is cleared 
renally.206 Allopurinol is the most frequently prescribed drug for treatment of gout and 
171 
 
hyperuricemia. Moreover allopurinol may reduce the risk of myocardial infarction and 
decrease mortality caused by cardiovascular events in high-risk patients.207 In general, 
Allopurinol is well-tolerated, however 2-5% of patients experience adverse effects. The 
side-effects of usage of Allopurinol are life-threatening hypersensitivity reactions, toxic 
epidermal necrolysis, Stevens-Johnson syndrome, and drug rash.208 Although the 
mechanism of allopurinol toxicity is not completely known, there is the theory of 
metabolite accumulation.209  
 
8.3.2. Febuxostat 
 
In response to the side effects of allopurinol, Febuxostat was developed and it is used by 
patients with low tolerance to treatment with allopurinol. Febuxostat was developed by 
Japanese scientists and approved by the European Medicines Agency in 2008 and a year 
later by FDA.210 Febuxostat is a non-purine drug which can inhibit both the oxidised (Mo 
(VI)) and reduced (Mo (IV)) form of the enzyme and is more effective in reducing uric 
acid and ROS production (Figure 90). In clinical trials Febuxostat is less toxic than 
Allopurinol, however some of the studies showed that Febuxostat can lead to skin 
reactions and in some cases to hepatotoxicity.211 The latest results from Phase 3B of 
clinical trials where clinicians evaluated the cardiovascular safety of both inhibitors in 
group of patients with gout and coexisting cardiovascular events showed that the 
cardiovascular mortality and the all-cause mortality were greater with febuxostat than 
with allopurinol.212 
 
 
Figure 90 Structure of Febuxostat 
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8.3.3. DPI 
 
Diphenyleneiodonium (DPI) is an irreversible inhibitor of iNOS (IC50= 50 nM) and eNOS 
(IC50= 0.3 µM) (Figure 91).
213 DPI is not a selective inhibitor and interacts with other 
flavin-containing enzymes, including our enzyme of interest, xanthine oxidoreductase. In 
1997, Harrison et al. showed that 1 μM DPI can inhibit almost completely the XO activity 
(90.4%).214   
 
Figure 91 Structure of Diphenyleneiodium chloride (DPI) 
 
Although DPI is a non-selective inhibitor, it showed that the activity of XOR can be 
controlled not only by inhibition of Molybdenum active site but also at the FAD site. It 
may therefore be possible to design and develop more selective inhibitors which target 
the FAD active site. 
 
There is no available inhibitor drug currently on the market which can selectively bind to 
the FAD cofactor site and at the same time inhibit the process of production of ROS and 
increase the production of NO. In this project, the design of novel compounds that could 
selectively target the FAD area was investigated. A new generation of XOR inhibitors 
which selectively reduce the formation of the reactive oxygen species and helps to 
improve the production of nitric oxide, our cardiovascular protector, could be promising 
agents in CVD treatment. Nitric oxide is beneficial in treating myocardial ischemia-
reperfusion injuries. Therefore, the development of novel XOR inhibitors could improve 
treatment and decrease mortality. The next chapter focuses on one of the cardiovascular 
events where levels of ROS and nitric oxide play important roles. 
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8.4. Myocardial ischemia reperfusion injury  
 
Inflammation plays a huge role in cardiovascular diseases for example in 
ischemia/reperfusion (I/R) injury. Myocardial ischemia reperfusion injury contributes to 
cardiovascular outcomes after myocardial ischemia. Myocardial ischemia happens when 
blood flow is decreased or blocked and blood cannot arrive to a portion of the heart, 
bringing injury to the heart muscle. One of the causes of the blocked blood flow might be 
the lipid layer formed on the surface of vessel which is the complications of 
atherosclerosis.44-45 According to the British Journal of Anaesthesia 8% of patients, who 
are above the age of 45 suffered myocardial injury, based on a troponin assay, after non-
cardiac surgery, of which 84.2% were asymptomatic. This discovery was important 
because from this group of patients, 1 in 10 died within 30 days.215 216 This is one of the 
major causes of death and disability worldwide. Moreover, patients with diabetes are not 
responding to the treatments such as ischaemic pre-conditioning or post-conditioning. 
 
During acute myocardial ischemia, the cells change metabolism from aerobic to anaerobic 
respiration. It causes oxidative stress and the level of intracellular pH decreased. Based 
on these findings, antioxidant therapy was taken under consideration as a possible 
treatment route. Unfortunately, it gave mixed results. One of the reasons for the moderate 
success of this therapy might be the low permeability of tested antioxidants.217  Under 
anaerobic conditions the intracellular concentrations of Na+ and Ca2+ are increased. The 
workflow of the Na/K pumps is deregulated and high level of Ca2+ causes the increase of 
wall stress.218 The mitochondrial permeability transition pore (MPTP) cannot be opened 
under hypoxic conditions which results in cardiomyocyte hypercontracture. It only opens 
in the reperfusion phase in the response to pH correction, high level of mitochondrial Ca2+ 
and phosphate. The immunosuppressant cyclosporine A is a well-known inhibitor of 
MPTP and is administrated during the reperfusion phase to prevent activation of MPTP 
and reduced complications related to MI.219 During the reperfusion phase the 
physiological pH is renewed by wash-out of lactic acid, the electron transport is restarted 
and the process of ROS production. ROS plays role as a neutrophil chemoattractant and 
opens the MPTP (Figure 92). 
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Figure 92 The main proponents of acute myocardial IR 
ROS – reactive oxygen species; MTP - mitochondrial permeability transition pore; SR - sarcoplasmic reticulum 
Figure was created using the medical images provided by Servier Medical Art (http://www.servier.com) 
 
Concentration of nitric oxide increases during hypoxic conditions (Figure 93). Hypoxic 
conditions activate PKA, PKB, PKC, PI3K, and LDH which leads to generation of nitric 
oxide.  The NO level can be also increased by tissue acidosis, which occurs during the 
ischemic conditions.220 The increased lactate dehydrogenase (LDH) activity causes 
increased production of NADH, which is one of the reducing substrate for xanthine 
oxidoreductase. XOR can catalyse the generation of nitric oxide from nitrates and nitrites 
even at normal pH, xanthine oxidase in the presence of low partial pressure of oxygen 
(pO2) and high NADH level can generate nitric oxide.
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Figure 93 Impact of acute hypoxia and ischemia for NO production196 
 
For patients with ST-segment elevation (STEMI) the most effective way to reduce acute 
myocardial ischemia is thrombolytic therapy or primary percutaneous coronary 
intervention (PPCI).  
Current therapeutic treatments for reducing myocardial reperfusion injury can be divided 
into three groups: 
• Ischemic postconditioning (IPost)221 
• Remote ischemic conditioning222 
• Therapeutic hyperoxemia and hypothermia.223  
 
Exploiting the ability of XOR to generate nitric oxide from nitrates and nitrites under 
hypoxic conditions offers the opportunity to develop novel treatments for cardiovascular 
diseases. Selective inhibitors of the FAD active site which inhibit the process of 
production of ROS and increase the production of NO might be a breakthrough for the 
treatment of the myocardial-ischemia reperfusion injury. 
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9. Aims and objectives 
 
The aim of this project is to exploit the ability of XOR to generate nitric oxide from 
nitrates and nitrites under hypoxic conditions as a novel opportunity for the treatment of 
cardiovascular diseases. The existing XOR inhibitors e.g. Allopurinol and Febuxostat, 
bind tightly to the molybdenum active site and block the nitrate and nitrite reductase 
functions. Currently there are no available selective inhibitors of  XOR which are able to 
increase NO bioavailability while lowering the production of superoxide. There is a great 
need to develop novel small molecules targeting XOR but in a different way compared to 
its classical inhibitors and embrace the nitrite reductase activity of XOR. This innovative 
approach can be the foundation of a novel treatment for myocardial ischemia reperfusion 
injury. In hypoxic settings, XOR is a key vascular nitrite reductase and has protective 
properties in cardiomyocytes. 
 
In the search for novel inhibitors, the project objectives are: 
▪ a virtual screening approach with human and bovine XOR crystal structures with 
potential FAD binding sites. This approach was chosen as it  allows the 
identification of  a range of potential inhibitors from a large set of compounds and 
reduces the number of expensive and time-consuming laboratory experiments.  
▪ the selection of the best inhibitor candidates based on predicted interactions of 
small molecules with the FAD active site. 
▪ SAR-driven design and selection of further analogues supported with ADME 
properties as a rational option for development of novel molecules. 
 
The principal aim of this research is to identify a range of novel potential inhibitors which 
will have sub-micromolar activity and acceptable ADME properties to enable study of 
the mechanism of action, with a focus on applying this treatment for myocardial ischemia 
reperfusion injury. Assessments of the physicochemical properties of hit compounds are 
critical to their preliminary selection. Therefore, the carefully chosen candidates should 
have at least moderate kinetic solubility (Ks > 10 µM) to avoid solubility issues during in 
vitro and in vivo studies. Moreover, the small molecules agonists cannot show any 
cytotoxic effect. Ideally, the best inhibitor candidate should be orally bioavailable, 
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therefore maintaining suitable physicochemical and ADME properties such as kinetic 
solubility, microsomal stability and permeability are key factors. 
 
In collaboration with Prof. Amrita Ahluwalia’s research group the selected compounds 
will be tested in order to prove the mechanism of action. Two in vitro assays are being 
performed: 
 
• Reactive oxygen species (ROS) quantification via Lucigenin enhanced 
chemiluminescence reaction (LECL). 
• Nitric oxide quantification via GAS-phase chemiluminescence to better 
understand the electron “shuttling” process between the Mo-Pt and the FAD site, 
and the potential role of our drugs in increasing their availability at the Mo-Pt site. 
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10. Investigating the XOR potential flavin adenine 
dinucleotide (FAD) binding site using in silico methods 
 
10.1. Molecular docking studies 
 
In the preliminary exploration of crystal structures of Xanthine oxidoreductase, possible 
binding sites in the Xanthine Dehydrogenase (XDH) and Xanthine Oxidase (XO) forms 
were investigated. Using SiteMap, the ligandability of the bovine XDH form was 
assessed. In Figure 94 A the binding pocket of bovine XDH with various disjointed 
subpockets can be seen – largely open and polar but with some hydrophobic nooks. These 
hydrophobic cavities are worth focusing on because they are located close to functional 
parts - FAD/NAD/A-loop. Even with NAD bound there is some nearby potential (ternary 
complex). It is worth highlighting that this position is partially occupied by C-terminal 
Trp in the human crystal (Figure 94 B). In figure 94 C another pocket on reverse side is 
shown. This pocket is contacting the 422-432 loop. The surface loop is restricting entry; 
however, it is still a narrow pocket which could be explored via fragment-based screening 
(Figure 94 C). 
 
Figure 94 SiteMap – assessing ligandability of bovine XDH form (PDB: 1FO4, 2.1 Å) 
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Using SiteMap, the ligandability of the bovine XO form (PDB: 1FIQ; 2.5 Å) was assessed 
as well (Figure 95). Movement of the 422-432 loop changes the nature of the pocket 
though it is difficult to conclude if this makes it significantly better or worse. The pocket 
on the reverse side also changed significantly: it is much larger and more open, partly due 
to movement of the 422-432 loop into the FAD site, but also because the surface loop is 
missing. A large loop A (422-432) movement blocks NAD binding and changes the 
electrostatic environment around the FAD to favour use of oxygen to generate superoxide 
and H2O2. 
 
Figure 95 SiteMap – assessing ligandability of bovine XO form (PDB: 1FIQ; 2.5Å) 
 
Finally, the ligandability of the human XDH form (PDB: 2E1Q, 2.6 Å) was examined. In 
the literature no crystal structures of the enzyme with an inhibitor bound at the FAD site 
exist, so there was no precedent for docking patterns for the FAD area. The identification 
and assessment of probable protein binding sites was performed once again using 
SiteMap algorithm. The FAD-binding site of human XOR (XDH form) is shown in Figure 
96. The view is into the si-site of the flavin ring (Figure 96 A). Two out of five detected 
binding sites are shown, the first binding site contains the 422-432 loop (dark green) but 
is located on the opposite side of protein to NAD site. The second rather extended site 
includes the FAD (green, drawn in ball-and-stick mode) and NAD site. The amino acid 
residues surrounding the FAD have mostly hydrophobic character or are negatively 
charged. Phe-337 interacts via π-stacking interaction with flavin ring on the re-side. The 
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side chains of Asp-429 and Asp-430 are only ~4Å from flavin. The main chain of amino 
acids Gly-47, Gly-46 and Glu-45 are close to the methyl groups of the flavin ring. The 
hydrogen binding interactions were shown on the diagram (Figure 96 B). 
 
Figure 96 A) SiteMap – assessing ligandability of human XDH form (PDB:2E1Q, 2.6Å); B) FAD ligand interactions 
 
In the search for novel XOR inhibitors a virtual screening approach with two different 
protein structures was explored: bovine XOR (PDB: 3NVW, XDH form, 1.6 Å) with two 
potential binding sites (si-side and re-side) and human XOR structure (PDB: 2E1Q, 2.6 
Å). Structures of bovine and human XOR were obtained from the Protein Data Bank. 
Bovine XOR has a narrow pocket, it is occupied by Arg-426 which is quite close to the 
FAD cofactor, and so the final selection of compounds for the biological tests was 
performed with a human XOR structure (Figure 97).  
 
Figure 97  Human XOR binding site (PDB: 2E1Q, 2.6Å) 
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The preparation of protein and ligands, virtual screening and post-processing steps were 
performed with Schrödinger GLIDE.81 For the visualization of results Schrödinger 
Maestro was used. XOR is a large homodimer therefore only one chain was chosen for 
the in silico studies. At this stage, the results from SiteMap were not used to build a 
docking grid because the binding site was rather extended including a flavin ring and an 
adenosine monophosphate region. The final receptor grid generation was performed using 
the Glide SP-protocol. The active site for grid generation was defined with outer box 
14x16x14 Å and by choosing 5 residues: Lys-271, Arg-335 (disrupted during conversion 
from XDH to XO), Asp-430 (loop A), Ile-431 (loop A) and Ser-1226. The size of the 
outer box and amino acids residues were chosen to keep the flavin ring in the middle of 
the proposed active site and include the amino residues from the loop A. The LifeArc 
collection of compounds (145 000 molecules) was screened. All ligands were treated as 
flexible molecules. Analysis of receptor-ligand complex models and selection of the most 
promising ligands were based on the parameters such as: the π stacking interactions with 
flavin ring and the hydrogen bond interactions with amino residues in the pocket. On the 
last stage of selection, the docking scores were used to classify which ligands are most 
likely to interact favourably to the receptor (Figure 98).  
 
 
Figure 98 Stages of virtual screening 
 
Based on the docking scores 11 compounds were selected for the first biological 
investigations, which were tested at the William Harvey Research Institute. All 
compounds are commercially available and are not protected by any patent. For prediction 
of physicochemical properties such as LogD, LogP and TPSA values the ACD Percepta 
software154 was used. The kinetic solubility (Ks) was measured experimentally to confirm 
that the compounds were soluble enough to warrant testing in the biological assays (Table 
25).  
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Structure ID 
Docking 
score 
Key 
residues 
ACD 
prediction 
Ks 
[µM] 
 
342 -7.06 
π stacking, 
Arg-394, 
Glu-263, 
Glu-45 
LogD= 2.66 
LogP=2.55 
H-donors: 3 
H-acceptors:7 
TPSA: 116 
156 
 
343 -7.16 
π stacking, 
Asp-831, 
Lys -271, 
Arg -1223, 
Arg-394, 
Glu-45 
LogD= 2.88 
LogP=3.03 
H-donors:3 
H-acceptors:5 
TPSA: 104 
13 
 
344 -7.82 
π stacking, 
Arg-394, 
Glu-263, 
Glu-45, 
Lys-271 
LogD=1.19 
LogP=1.48 
H-donors:3 
H-acceptors:6 
TPSA: 117 
238 
 
345 -6.69 
π stacking,  
Arg-394, 
Glu-263, 
Lys-271 
LogD= 2.41 
LogP=  3.12 
H-donors: 1 
H-acceptors:6 
TPSA: 88 
5 
 
346 -7.64 
π stacking, 
Arg-394 
 
LogD= 3.44 
LogP= 4.15 
H-donors: 0 
Hacceptors:10 
TPSA: 124 
 
20 
Table 25  Predicted interactions of small molecules with FAD active site 
Ks – Kinetic solubility; NT – not tested 
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Table 25 (continued) 
Structure ID 
Docking 
score 
Key 
residues 
ACD 
prediction 
Ks 
[µM] 
 
347 -7.67 
π stacking, 
Arg-394 
LogD= 3.95 
LogP=4.94 
H-donors:3 
H-acceptors:8 
TPSA: 134 
0 
 
348 -7.17 
π stacking, 
Arg-394, 
Glu-263, 
Ser-365 
LogD= 2.46  
LogP= 3.26 
H-donors:2 
H-acceptors: 6 
TPSA: 79 
45 
 
349 -6.71 
π stacking, 
Thr-1227, 
Lys -271, 
Arg -1223 
LogD= 1.55 
LogP= 0.37 
H-donors: 3 
H-acceptors: 7 
TPSA: 90 
214 
 
350 -7.05 
π stacking, 
Arg-394, 
Glu-263 
LogD= 0.79 
LogP=  0.72 
H-donors: 3 
H-acceptors: 8 
TPSA:112 
124 
 
351 -6.93 
π stacking, 
Glu-45, 
Lys-271 
LogD= 1.31 
LogP=1.0 
H-donors: 1 
H-acceptors: 8 
TPSA: 83 
239 
 
352 -7.59 
π stacking, 
Arg-394 
LogD= 1.24 
LogP=0.73 
H-donors: 0 
H-acceptors: 6 
TPSA: 58 
NT 
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10.2. Preliminary biological results  
 
Selected compounds were firstly examined to see if they could inhibit the O2
- production 
in the presence of Xanthine, NADH, or NADPH as a reductive reagent. Lucigenin is 
broadly used for the chemiluminescence detection of the superoxide ion (O2
∙−)  from e.g. 
XDH/XO, NADPH oxidoreductases, neutrophils, endothelial cells, I–R injury perfusate, 
and vascular tissue. The mechanism of lucigenin chemiluminescence is shown in Figure 
97. The superoxide ion (O2
∙−) reacts with the lucigenin radical cation to form the dioxetane 
and through internal rearrangement, the lucigenin dioxetane is converted into the N-
methylacridium excited state. During relaxation, light emission is observed. Emitting 
light is registered at 470 nm using a luminometer (Figure 99). 
 
 
 
Figure 99 Mechanism of lucigenin chemiluminescence.224 
 
Briefly, in the lucigenin assays, a hXDH HEK-293 stable cell line was used. Cells were 
collected and lysate extracted. 100 𝜇g of protein was added per well into 96-well plates. 
Protein was pre-incubated for 30 minutes at 37oC with DMSO or screening compound 
(10 nM, 100 nM, 1 μM, 10 μM, 100 μM). After this step 100 μM of reducing agent 
(xanthine or NADH) was added. The 100 μM concentration of Xanthine was chosen 
because it replicates the levels encountered in vivo under ischemic/hypoxic conditions in 
which ATP degradation triggers the rise of hypoxanthine/xanthine levels.225 Superoxide 
anion production was recorded for up to 24 minutes. From the first series of the 
experiments three of the 11 molecules showed a reduction of the superoxide ion 
production (342, 346 and 348) (Figure 100). 
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Figure 100 Structures of potential XOR inhibitors. 
 
The compound 342 is able to reduce the superoxide ion production in the presence of 
either reducing agent (Figure 101 A, B), where compound 2-[4-(2,5-difluorophenyl)-4-
methyl-2,5-dioxo-imidazolidin-1-yl]-N-(3-fluoro-4-methyl-phenyl) acetamide (348) 
showed minor effect (Figure 101 F, G). Inhibition of xanthine induced superoxide ion 
production was observed with all three hit compounds. An upward trend in the oxygen 
reduction in the presence of NADH was observed when protein was treated with 346 
(Figure 101 E). The effect of the hit compounds on ROS formation in the presence of 
xanthine (Figure 101 A, D and F), and NADH (Figure 101 B, E and G) as reducing 
agent are shown below. Compound 346 showed a lack of ability to inhibit NADH-driven 
ROS formation (Figure 101 E). Compound 348 did not inhibit O2
∙− production driven by 
NADPH, demonstrating selectivity of any effects at the FAD site of the compounds for 
XOR (Figure 101 H). Results in the figure below show total counts over the first three 
minutes calculated from the area under the curve (AUC). 
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Figure 101 Changes in ROS production in response to concentration of compounds depending on reducing agent. 
Effect of the hit compounds on ROS production in the presence of xanthine [A, D and F], NADH [B, E and G], and 
NADPH [C and H] as reducing agent. All data are presented as mean ± SEM (N=7). The difference between control 
group, and treatment groups was evaluated via one-way Anova followed by Dunnett’s multiple comparison test, and 
the difference was considered significant for a P value,  <0.05. *P-value < 0.05, **P-value < 0.01, ***P-value < 
0.001 
 
  
187 
 
10.3. Structure-activity relationship (SAR) study 
 
Based on the initial results, the SAR was explored further through the selection of 14 
analogues (3-5 analogues for each hit compound). We docked over 1000 commercially 
available lead-like compounds against the FAD binding pocket. These compounds are 
currently being tested in Prof. Amrita Ahluwalia’s research group.  
 
2-[4-(2,5-Difluorophenyl)-4-methyl-2,5-dioxo-imidazolidin-1-yl]-N-(3-fluoro-4-
methyl-phenyl)acetamide (348) is a representative compound from the first group. In 
Figure 102 the predicted binding mode is presented. According to molecular docking the 
2,5-difluorophenyl moiety can form a π-stacking interaction with the flavin hydroquinone 
part. In addition, there are several hydrogen bonds formed between the dioxo-
imidazolidin-1-yl core and amino acids residues including Arg-394, Glu-263, and amide 
moiety with Ser-356. The 3-fluoro-4-methyl-phenyl sits on the edge of the binding pocket 
(Figure 102). 
 
 
Figure 102 Predicted binding mode for compound 348 
 
Compound 348 comes from the Enamine HTS collection; therefore, a large number of 
analogues were available commercially. Based on further virtual screening five 
compounds were chosen. With the first three compounds: 353-355 we have proposed a 
modification in the 3-fluoro-4-methyl-phenyl part of molecule, which is located at the 
edge of the binding pocket. Each of these compounds is predicted to maintain the same 
interactions with the binding site.  In addition, the cyano group in molecule 354 is 
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modelled to hydrogen bond with Arg-508. For last two analogues, I sought a replacement 
of the 2,5-difluorophenyl ring by two different moieties: 4-chlorophenyl (356) and phenyl 
(357). By replacing this moiety, we have maintained the potential π-stacking interactions 
with the flavin hydroquinone part (Table 26).  
 
Structure ID 
Docking 
score 
Key 
residues 
Ks 
[µM] 
 
348 -7.17 
π stacking 
Arg-394, 
Glu-263, 
Ser-356 
45 
 
353 -7.16 
Ser-356, 
Arg-394, 
Glu-263, 
π stacking 
134 
 
354 -7.31 
Arg-508, 
Arg-394, 
Glu-263, 
π stacking 
170 
 
355 -7.13 
Ser-356, 
Arg-394, 
Glu-263, 
π stacking 
25 
 
356 -6.61 
Ser-356, 
Arg-394, 
Glu-263, 
π stacking 
13 
 
357 -6.08 
Ser-356, 
Arg-394, 
Glu-263, 
π stacking 
36 
Table 26 Compound 348 and its analogues 
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The second compound which was selected for optimization is 2-[4-chloro-5-[(4-
methoxyphenyl)sulfamoyl]-2-methyl-phenoxy]acetamide (342).  The 4-methoxyphenyl 
ring forms a π-stacking interaction with FAD, the sulphonamide moiety interacts with 
Arg-394 and Glu-263. A halogen bond is observed between Arg-394 and the chlorine 
atom. Finally, a hydrogen bond is predicted between the acetamide group and Glu-45 
(Figure 103).  
 
 
Figure 103 Predicted binding mode for compound 342 
 
For this family of compounds, I decided to make the modifications on the 4-
methoxyphenyl ring moiety. In most of the examples, the changes were very small, and 
the lipophilic character was retained. The binding mode is not affected when the methoxy 
groups is replaced with e.g.: -I, -F or methyl ketone. The only exception is compound 361 
where para-methoxyphenyl was replaced with propanoic acid, which completely changed 
the binding mode. The hydrogen bonds between the sulphonamide moiety and Glu-263 
remained, however a new a hydrogen bond was observed between acetamide and Ser-
1226. The 2-chloro-4-methyl-phenyl core interacts by edge π-stacking interaction with 
the FAD cofactor (Table 27). 
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Structure ID Docking score Key residues  
Ks 
[µM] 
 
342 -7.06 
π stacking, 
Arg-394, 
Glu-263, 
Glu-45 
156 
 
358 -5.80 
2xArg-394, Glu-263, 
Glu-45, 
π stacking 
8 
 
359 -6.29 
2xArg-394, 
Glu-263, 
π stacking 
160 
 
360 -6.35 
Arg-394, 
Lys-271, 
Glu45, 
edge π stacking 
231 
 
361 -6.12 
Ser-1226, 
Glu-263, 
edge π stacking 
200 
 
362 -6.11 
Arg-394, 
Lys-271, 
Glu-45, 
edge π stacking 
200 
 
363 -5.11 
Arg-394, 
Glu-263, 
π stacking 
6 
Table 27 Compound 342 and its analogues 
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The [(2S)-1,4-bis(benzenesulfonyl)piperazin-2-yl]-[4-(2-methoxyphenyl) piperazin-1-
yl] methanone (346) is the third compound which showed promising results in the 
Lucigenin assay.  This compound is predicted to interact via one of the oxygen atoms of 
its sulfonyl group with Arg-394. One of the benzene rings of the 1,4-
bis(benzenesulfonyl)piperazine core forms a key π-stacking interaction with the flavin 
hydroquinone part. In designing the analogues, the 1,4-bis(benzenesulfonyl)piperazine 
core was fully maintained and the modifications were introduced though different amide 
substituents (Figure 104).  
 
 
Figure 104 Predicted binding mode for compound 346 
 
The docked molecules were manually examined for their interactions with key residue 
Arg-394 and π-stacking. Three novel compounds were proposed based on 346. The key 
interactions were maintained; however, the structures have slightly different binding 
modes and the docking scores are lower (Table 28). 
  
192 
 
 
Structure ID 
Docking 
score 
Key 
residues 
Ks 
[µM] 
 
346 -7.64 
π stacking, 
Arg-394, 
Lys-433 over pocket 
20 
 
364 -4.77 
Ser-1226, 
Lys-271, 
Glu-263, 
π stacking 
0 
 
365 -5.40 
Ser-1226, 
Arg-394, 
 Lys-271, 
π stacking 
129 
 
366 -5.00 
Arg-394,  
Cys-271, 
Ser-1226, 
edge π stacking 
35 
Table 28 Compound 346 and its analogues 
  
193 
 
Preliminary experiments showed that 342 and its analogues (358, 359 and 360) were able 
to reduce O2
∙− production in the presence of reducing agents such as xanthine, NADH. 
Compounds 358 with a para-iodine aniline moiety significantly reduced production of 
ROS in the presence NADH even at the lower concentrations. Using NADPH as reducing 
agent the production of  O2
∙−  was not affected (Figure 105). 
  
 
Figure 105 Changes in ROS production in response to concentration of compound 358 depending on reducing agent 
Data are mean ± SEM. *P-value < 0.05, **P-value < 0.01, ***P-value < 0.001 
N=7 (Repeated 1-Way ANOVA, Dunnett’s multiple comparison)  
 
 
Compound 359 demonstrated the ability to reduce O2
∙−  production driven by xanthine and 
NADH (Figure 106). 
 
 
Figure 106 Changes in ROS production in response to concentration of compound 359 depending on reducing agent. 
All data are presented as mean ± SEM (N=7).  The difference between control group, and treatment groups was 
evaluated via one-way Anova followed by Dunnett’s multiple comparison test, and the difference was considered 
significant for a P value,  <0.05. *P-value < 0.05, **P-value < 0.01, ***P-value < 0.001 
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Compound 360, another analogue of 342 was able to reduce O2
∙− production in the 
presence of Xanthine and NADH as reducing agents, however to a lesser extent than 358 
(Figure 107).  
 
 
Figure 107 Changes in ROS production in response to concentration of compound 360 depending on reducing agent. 
All data are presented as mean ± SEM (N=7).  The difference between control group, and treatment groups was 
evaluated via one-way Anova followed by Dunnett’s multiple comparison test, and the difference was considered 
significant for a P value,  <0.05. *P-value < 0.05, **P-value < 0.01, ***P-value < 0.001 
 
Compounds 358 and 360 did not show major effect on the O2
∙− production driven by 
NADPH, demonstrating selectivity of any effects at the FAD site of the compounds for 
XOR. The differences were not considered as significant because of low P values. 
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Compound 362 with a para-fluorine aniline moiety showed a small reduction in the 
production of ROS in the presence NADH and Xanthine. Using NADPH as reducing 
agent the production of O2
∙− was not affected (Figure 108). Compound 362 is less 
effective compared to the para-iodine aniline analogue 358. For additional SAR studies 
it would be worth testing derivatives containing the para-chloro and para-bromo anilines. 
 
 
Figure 108 Changes in ROS production in response to concentration of compound 362 depending on reducing agent. 
All data are presented as mean ± SEM. The difference between control group, Xanthine NADH, or NADPH 100μM 
alone, and treatment groups was evaluated via one-way Anova, and the difference was considered significant for a P 
value <0.05. n=7 for Xanthine and NADH, n=5 for NADPH (*P-value < 0.05, **P-value < 0.01, ***P-value < 0.001) 
(Dunnett’s multiple comparison) 
 
One of the tested analogues, 363, was not able to reduce O2
∙− production in the presence 
of either reducing agent (Figure 109). The lack of the activity could be caused by 
replacement of the acetamide group by an ethoxy moiety which caused loss of interaction 
with Glu45. 
 
Figure 109 Effect of compound 363 in ROS production in the presence of xanthine and NADH 
All data are presented as mean ± SEM (N=4)  The difference between control group, and treatment groups was 
evaluated via one-way Anova followed by Dunnett’s multiple comparison test, and the difference was considered 
significant for a P value,  <0.05. *P-value < 0.05, **P-value < 0.01, ***P-value < 0.001 
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In the second part of the project the most promising compounds were tested in the nitrite 
reductase activity assay using the Gas-Phase chemiluminescence assay. These results 
would give better insight into the electrons “shuttling” process between the molybdenum 
cofactor and the FAD site. 
 
Briefly, in the chemiluminescence assays, a hXDH HEK-293 stable cell line was used. 
Nitric oxide measurement by chemiluminescence detection helps to measure NO levels 
in tissue samples as well as to evaluate the NO generating capacity from nitrite. In this 
technique a gas phase chemiluminescent reaction between NO and the ozone is used.  
 
𝑁𝑂 +  𝑂3  →  𝑁𝑂2
∗  +  𝑂2 
𝑁𝑂2
∗  →  𝑁𝑂2  +  ℎ𝑣 
 
The chemiluminescent species NO2
∗  releases energy when it returns from the excited state 
to the ground state.  The photon emission is linearly correlated to the nitric oxide content 
in the biological sample. In this assay, a sealed 10 mL glass reaction chamber containing 
citric acid-Na2HPO4 buffer at pH 6.8 and 1% DMSO are used to perform the experiments. 
The solution is flushed with nitrogen gas and with the addition of sodium nitrite (10-1000 
μM) in 1 mL. The nitric oxide content is measured by Sievers 280A nitric oxide analyser. 
In this experiment designed by Prof. Amrita Ahluwalia’s research group, five different 
conditions were proposed: 
 
• Control (untreated): cell lysate was pre-incubated for 30 min with 1% DMSO  
• 20 µM Xanthine or 100 µM NADH as reducing reagent: Cell lysate was pre-
incubated for first 25 minutes with 1% DMSO and final 5 minutes with the 
reducing agent. 
• 10 µM Febuxostat: Cell lysate was incubated for 30 min with Febuxostat. 
• Test compound: Cell lysate was incubated for 30 min with 100 µM compound. 
• Test compound and Xanthine/NADH: Cell lysate was incubated for 25 min with 
the test compound in the highest concentration (100 µM) and final 5 minutes with 
Xanthine (20 µM) or NADH (100 µM). 
 
Millar et al. showed that nitric oxide production can be inhibited at higher concentrations 
of Xanthine182. Therefore, the dosage of Xanthine was reduced from 100 to 20 µM to 
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perform the nitrite-reductase assay.  Under hypoxic conditions xanthine and NADH 
trigger nitrate reduction to nitrite and NO, where febuxostat which can inhibit both the 
oxidised (Mo (VI)) and reduced (Mo (IV)) form of the enzyme reduces the uric acid and 
NO production.  
 
The compound 358 does not inhibit either xanthine or NADH driven nitrite-reductase 
activity of XOR (n=4) even in the highest concentration (Figure 110). At the same time, 
it reduces O2
∙− generation in the presence of either xanthine or NADH but does not affect 
NADPH-driven O2
∙− generation (Figure 105). From the results shown in the graph below 
we can observe that compound 358 (purple) stimulates generation of NO from nitrite and 
the level of nitric oxide is higher compared to untreated sample (red). The increased NO 
level could be explained by decreased level of O2
∙− which is a nitric oxide scavenger and 
can interfere with the NO bioavailability.  
 
Figure 110 The results of compound 358 in the nitrite-reductase assay 
Data are expressed as mean ± SEM with n=7. Statistical significance between curves determined using 2-way 
ANOVA followed by Tukey post tests and shown as **P<0.005. Statistic was reported on single comparison graph 
for more convenience but done considering all the curves 
 
The second compound tested in the nitrite-reductase assay was compound 359. This 
analogue does not affect nitric oxide production. However, further assays where cell 
lysate is incubated with the test compound and later with one of two reducing agents 
(Xanthine or NADH) need to be performed in order to see if it disturbs xanthine or NADH 
driven nitrite-reductase activity of XOR (Figure 111). 
 
 
198 
 
 
Figure 111 The results of compound 359 in the nitrite-reductase assay 
Data are expressed as mean ± SEM with n=6. Statistical significance between curves determined using 2-way 
ANOVA followed by Tukey post tests and shown as #P<0.05, ##P<0.005, ****P<0.0001. # Refers to the comparison 
between Xanthine 20μM vs Untreated with * referring to Untreated vs Febuxostat 10μM 
 
Compound 360 also does not interfere with the xanthine or NADH driven nitrite-
reductase activity of XOR (Figure 112). Simultaneously, it reduces O2
∙− production in the 
presence of Xanthine and NADH as reducing agents (Figure 106). 
 
 
Figure 112 The results of compound 360 in the nitrite-reductase assay 
Data are expressed as mean ± SEM with n=4. Statistical significance between curves determined using 2-way 
ANOVA followed by Tukey post tests and shown as *P<0.05 for NADH 100 µM. Statistic was reported on single 
comparison graph for more convenience but done considering all the curves 
 
The additional analogues of compounds 342, 348, and 346 are currently being tested in a 
nitrite reductase activity assay in order to assess whether the nitrite reductase ability of 
XOR remains intact.   
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The compounds 358-359 were tested in in-house ADME assays to examine the physical 
properties and metabolism of the molecules. Compound 358 contains a para-iodo aniline 
moiety which leads to a decrease in kinetic solubility compared to parent compound 342. 
Introduction of an ortho methyl group to the aniline ring (359) increased solubility but 
decreased stability in MLM. Compound 360 has an electron-withdrawing methyl ketone 
group at the para- position which improves its stability in MLM although unfortunately 
this is not translated to HLM (Table 29). Compounds 359 and 360 show very good kinetic 
solubility and LogD values, however the microsomal stability needs to be improved. 
 
 
 
Compound 
ID 
Ks 
[μM] 
LogD 
 
Microsomal stability 
T1/2 
[min] 
CLint 
[µL/min/mg] 
HLM MLM HLM MLM 
358 8 4.1 72 38 21 41 
359 160 3 55 22 28 72 
360 231 2.1 15.5 576 99 3 
Table 29 ADME properties of compounds 358-360 
  
Finally, three promising compounds were selected for the cell health assay. Full 10-point 
dose-response curves to determine whether any cytotoxic effects are seen from the 
compounds were generated in HepG2 cells, with a top concentration of 30 μM. From the 
three compounds tested, two appear to show no signs of toxicity at any of the parameters 
tested up to 30 μM and one compound, 358, shows effects on multiple parameters tested. 
Compound 358 contains a para-iodine aniline moiety, the iodine is a  potential structural 
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alert and confers a higher lipophilicity to the whole compound which could cause 
cytotoxic effects for concentrations higher than 10-12 μM (Figure 113).  
 
 
Figure 113 Cytotoxic effects from the analogues of 342 (HepG2 cells, a human hepatocyte carcinoma cell line) 
Seven cell parameters are normalised as a percentage against low control (medium with 0.5% DMSO). HepG2 cells 
were treated +/- with compounds for 72h. Four fluorescent dyes were used for imaging: (Hoechst 33342, TMRM, 
TOTO-3 Iodide; Fluo-4 AM). Any cell measurement that differentiate from 100% baseline (dashed lines) shows a 
switch in cell phenotype and cytotoxicity. Each cell measurement is represented as mean ± SEM (n=3). Ionomycin 
and Amiodarone which lead to hepatotoxicity were used as high controls. Results were visualised in IN Cell and 
analysed in IN Cell Workstation and Genedata Screener analysis software. 
 
At this stage, further SAR exploration is required. The additional investigation of this 
series could be started with the replacement of the aniline ring. We have proposed the 
heterocyclic rings such as: pyridines, thiadiazol, pyrazole or oxazole. The decoration of 
the aniline ring with other small substituents could be pursued as well. Preliminary results 
have showed importance of acetamide group. Compound 363 was not able to reduce O2
− 
generation in the presence of either xanthine or NADH. The lack of the activity could be 
caused by replacement of the acetamide group by an ethoxy moiety which caused loss of 
interaction with Glu45. Therefore, another modification which may be tolerated would 
be replacement of the linker oxygen atom with methylene or amine, which could improve 
the microsomal stability. Moving to the 2-chloro-4-methylbenzenesulfonamide core, the 
chlorine atom could be replaced with other halides or potentially removed, and the 4-
methyl group could be extended into a longer alkyl chain (Figure 114).  
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Figure 114 Proposed additional modifications of sulphonamide series 
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11. XOR inhibitors: General conclusions and future 
work  
 
In this part of the project I designed inhibitors targeting the FAD active site of XOR, with 
the aim of inhibiting the process of the production of reactive oxygen species and 
increasing the production of NO, which has the potential to form the basis of  a novel 
treatment of myocardial ischemia reperfusion injury. By decreasing the production of 
ROS, we could increase nitric oxide bioavailability and for example reduce the overt 
cell/tissue damage. Currently the only XOR inhibitors available on the market are 
Allopurinol and Febuxostat which inhibit the activity of the Molybdenum cofactor. These 
drugs reduce uric acid levels and ROS production, but simultaneously lower the 
production of nitric oxide. Moreover, long-term treatment with Allopurinol has a negative 
effect on the cardiovascular system.226 DPI, which can block the FAD site, is not a 
selective XOR inhibitor and interacts with other FAD containing enzymes. 
The design process for novel XOR inhibitors started with an investigation of the potential 
flavin adenine dinucleotide (FAD) binding site using in silico methods. From this, eleven 
hit compounds were selected and screened in the lucigenin assay to examine their ability 
to reduce the superoxide ion production. From the first series of the experiments three 
molecules were selected for further investigation. Compounds 342, 348, and 346 showed 
promise in reducing ROS production. Inhibition of xanthine induced superoxide ion 
production was observed with all three hit compounds. Compounds 342 and 348 did not 
inhibit O2
−  production driven by NADPH, demonstrating selectivity of any effects at the 
FAD site of the compounds for XOR. The additional analogues of these 3 hit compounds 
were selected by docking over 1000 commercially available lead-like compounds against 
the FAD binding pocket. The analogues of 342 have been tested already in the lucigenin 
assay and the gas-phase chemiluminescence assay.   
The analogues of 342 (358, 359 and 360) do not inhibit xanthine or NADH driven nitrite-
reductase activity of XOR even in the highest concentration. At the same time, they 
reduce ROS generation in the presence of either xanthine or NADH, but not do not affect 
NADPH-driven ROS generation (Figure 115). The additional analogues of compounds 
342, 348, and 346 are currently being tested in a nitrite reductase activity assay in order 
to assess whether the nitrite reductase ability of XOR remains intact. 
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 The next step would be a larger structure-activity relationship (SAR) study in order to 
further investigate the potential of the compound series and improve microsomal stability. 
19 novel structures were proposed by replacing the aniline moiety and will be tested in 
cellular assays.  If a crystal structure of the small molecule-protein complex could be 
obtained, it would be helpful for further compound optimization. For future work, it will 
be important to confirm target engagement and the inhibitory mechanism. In addition, it 
is worth performing additional assays for nonspecific and off-target effects.  
  
Figure 115 Novel potential XOR inhibitors as the therapeutic agents 
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12. Experimental part 
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12.1. In silico studies 
 
FPR2 homology models: An agonist bound μ-opioid based structure receptor was 
acquired from GPCRDB [http://gpcrdb.org/protein/fpr2_human/]. A dual template model 
based on the antagonist-bound μ-opioid receptor and antagonist-bound chemokine 
receptor crystal structure was provided by Prof Filipek from Warsaw University.147 
XOR crystal structures: the bovine XO form (PDB: 1FIQ; 2.5 Å), the bovine XDH form 
(PDB: 1FO4, 2.1 Å) and the human XDH form (PDB:2E1Q, 2.6Å) were obtained from 
the Protein Data Bank. 
Docking Studies: Docking studies were performed using the Schrödinger software. The 
small molecules were prepared using the LigPrep module to generate a low energy 
conformation. The protein structures were prepared using the Protein Preparation Wizard 
with default parameters. Protein-Ligand docking was carried out using the Glide SP-
protocol. All ligands were treated as flexible molecules. Binding sites were identified 
using Sitemap (Schrödinger Release 2018-2: Schrödinger, LLC, New York, 2018.) 
Ligands were prepared and visualized using Maestro 11.5. To generate decoys for active 
agonists the DUDE database (http://dude.docking.org/) was used.  
 
Pharmacophore Studies: The pharmacophore hypothesis was obtained from multiple 
active ligands using Phase (Schrödinger Release 2018-2: Schrödinger, LLC, New York, 
2018)  
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12.2. General synthetic procedures 
12.2.1. Analysis techniques 
 
Analytical LCMS Methods: 
 
LC-MS was carried out on an Agilent 6120 quadrupole LC-MS with an Xbridge C18 
column (3.5 μm particle and 4.6 x 30 mm dimension) and a diode array UV detector.  
 
Method A: AN_MECN_pH1-10-100_3_POS.M 
HPLC column: 4.6x30mm (3.5µm) C-18 Xbridge; flow rate: 3ml/min; Run time: 3.2 min:  
Solvent A: 0.1% Trifluoro Acetic acid in water, Solvent B: Acetonitrile; Gradient - 10-
100%B; Gradient time: 2.35 min. 
 
Method B: AN_MECN_pH10-10-100_3_POS.M 
HPLC column: 4.6x30mm (3.5µm) C-18 Xbridge; flow rate: 3ml/min; Run time: 3.2 min:  
Solvent A: 0.1% Ammonium Hydroxide in water, Solvent B: Acetonitrile; Gradient - 10-
100%B; Gradient time: 2.35min. 
 
Method C: AN_MEOH_pH1-10-100_3_POS.M 
HPLC column: 4.6x30mm (3.5µm) C-18 Xbridge; flow rate: 3ml/min; Run time: 3.2 min:  
Solvent A: 0.1% Trifluoro Acetic acid in water, Solvent B: Methanol; Gradient - 10-
100%B; Gradient time: 2.35min. 
 
Method D: AN_MEOH_pH10-10-100_3_POS.M 
HPLC column: 4.6x30mm (3.5µm) C-18 Xbridge; flow rate: 3ml/min; Run time: 3.2 min:  
Solvent A: 00.1% Ammonium Hydroxide in water, Solvent B: Methanol; Gradient - 10-
100%B; Gradient time: 2.35min. 
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NMR Analysis: 
 
NMR solvents were obtained from Cambridge Isotope Labs. All 1H NMR (500 MHz) and 
13C NMR (126 MHz) spectra were recorded on a JEOL ECA-500 spectrometer at 21 °C. 
Chemical shifts (δ) are in ppm and are relative to residual undeuterated NMR solvent.  
Spectra are referenced to a singlet at 7.27 ppm (CDCl3), the centerline of quintet at 2.50 
ppm ((CD3)2SO), quintet at 3.31 ppm (CD3OD) for 
1H NMR and to the centerline of a 
triplet at 77.23 ppm (CDCl3), septet at 39.7 ppm ((CD3)2SO), septet at 49.15 ppm 
(CD3OD) for 
13C NMR. The abbreviations: s, singlet; d, doublet; dd, doublet of doublets; 
ddd, doublet of doublets of doublets; dt, doublet of triplets; dq, doublet of quartets; t, 
triplet; td, triplet of doublets; tq, triplet of quartets; q, quartet; qt, quartet of triplets; quint, 
quintet; sxt, sextet; sept, septet; m, multiplet; br., broad; appt, apparent triplet; dappt., 
doublet of apparent . All 13C NMR spectra were proton decoupled. 
Structural assignments were denoted as follows: 1HNMR: ArCH - aryl proton, C(CH3)3 
- protons of tertbutyl ester, COOH = H of carboxylic acid, OH =H of alcohol, CH = single 
alkenyl proton, CHO = aldehyde proton, CH2 = methylene protons, COCH3 = a methoxy 
group proton, ; 13CNMR:, OCH3 = C atom of methoxy group, C=O = C atom of carbonyl, 
ArCH = aryl carbon bearing a hydrogen atom, ArC – aryl carbon bearing other atom than 
hydrogen, Cspiro = the alpha-C atom of the amino acid attached directly to cyclopentane,  
Cquat. = quaternary carbon, ArCquat.-  quaternary aromatic carbon, CH - alkenyl carbon, 
CH2 = methylene carbon, CH3 = methyl carbon, COOH = carbon atom of carboxylic acid, 
, C(CH3)3  = carbon atom of tertbutyl group, , C(CH3)3  = tertiary carbon atom of tertbutyl 
group  
 
High Resolution Mass Spectra (HRMS) 
 
HRMS were recorded on a Thermo-Fisher Q-Exactive operating at 70,000 Resolution.   
 
12.2.2. Experimental techniques 
 
All reagents were purchased from Sigma-Aldrich, Enamine, Fluorochem and other major 
suppliers and used without further purification. Solvents were purchased from Fisher 
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Scientific (HPLC grade) or Sigma-Aldrich (anhydrous). 
 
Thin-layer chromatography: 
 
Each reaction was monitored by thin-layer chromatography (TLC) on pre-coated TLC 
plates ADAMANT silica gel 60 visualised by UV absorption or potassium permanganate 
solution and heating. 
 
Flash Column Chromatography Methods: 
 
Flash column chromatography was carried out with Biotage KP-Sil Snap cartridges using 
a Biotage Isolera-One and HPLC grade solvents. 
Reverse phase column chromatography was carried out on a Biotage Isolera with 
prepacked columns of C18 silica and HPLC grade solvents and buffers. 
Buffer A: 0.1% Ammonium Hydroxide in water 
Buffer B: 0.1% Trifluoroacetic acid in water 
 
Preparative HPLC Methods: 
 
Purification of compounds by preparative HPLC was carried out on an Agilent Reverse 
Phase Mass Directed Prep HPLC system by a member of the purification team.  
 
H-cube: 
 
The hydrogenation reactions were carried out on H-Cube Mini Plus™ using in situ 
hydrogen generation and the sealed 10% Pd/C or Raney-type Ni catalyst cartridges 
(CatCart®).  
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12.2.3. Compound characterization 
 
12.2.3.1. The substituted urea L-leucine derivatives 
 
(2S)-2-Acetoxy-4-methyl-pentanoic acid (60) 
 
Prepared according to the literature procedure.227 The α-hydroxy acid 
(520 mg) was dissolved in acetyl chloride (1 mL). Reaction mixture was 
stirred at room temperature overnight. Acetyl chloride was removed 
under reduced pressure. Residue was dissolved in small amount of water 
and extracted with DCM three times. Organic layer was dried, filtered and concentrated 
under reduced pressure. Crude product was used in the next step without further 
purification. Yield: 640 mg, 90%; Appearance: colourless oil; LCMS: UV-inactive; 1H 
NMR (500 MHz, CHLOROFORM-d)  ppm 5.05 (dd, J=14.32, 4.60 Hz, 1 H, CH), 2.15 
(s, 3 H, O=CCH3), 1.76 - 1.87 (m, 3 H, CH2, CH ), 0.99 (m, J=6.30 Hz, 6 H, CH3); Purity 
~75-80%; Data corresponded to that reported in the literature. 
 
tert-Butyl (2S)-2-acetoxy-4-methyl-pentanoate (61) 
 
Prepared according to the literature procedure.227 (2S)-2-acetoxy-4-
methyl-pentanoic acid (60) (1.72 mmol) and t-butyl alcohol (2.1 
equiv., 3.6 mmol) were dissolved in DCM and DMAP (0.33 equiv., 
0.56 mmol) was added. The DCC (1.33 equiv., 2.29 mmol) in dichloromethane was added 
at 0⁰C. The reaction mixture was stirred at room temperature for 12 h. Consumption of a 
starting material was checked by TLC (PE/EtOAc 7/3, SM RF=0.4, DP RF=0.8). After 
the urea was filtered the organic layer was washed with water, dried over MgSO4 and 
evaporated under reduced pressure. The crude residue was purified by flash column 
chromatography (PE/EtOAc 8/2) to obtain clean oil as desired product. Yield: 390 mg, 
97%; Appearance: colourless oil; LCMS: UV-inactive; 1H NMR (500 MHz, 
CHLOROFORM-d)  ppm 4.89 (dd, J=9.45, 4.30 Hz, 1 H, CH), 2.13 (s, 3 H, O=CCH3), 
1.70 - 1.80 (m, 3 H, CH2, CH), 1.47 (s, 9 H, CH3), 0.95 (dd, J=16.61, 6.30 Hz, 6 H, CH3); 
Data corresponded to that reported in the literature. 
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tert-Butyl (2S)-2-hydroxy-4-methyl-pentanoate (62) 
 
 
Prepared according to the literature procedure.227 To the solution of 
Na2CO3 (3 equiv., 4.56 mmol) in methanol: water (2:3) a tert-butyl 
(2S)-2-acetoxy-4-methyl-pentanoate (61) was added. The resulting 
solution was stirred vigorously at room temperature. Methanol was evaporated and aq. 
Residue was extracted with ethyl acetate. Organic layer was dried over Na2SO4, filtered 
and concentrated under reduced pressure. Crude product was purified by flash column 
chromatography using as an eluent PE/EtOAc. The fraction was collected, and solvents 
were evaporated under reduced pressure. Yield: 140 mg, 50%; Appearance: colourless 
oil; LCMS: UV-inactive; 1H NMR (500 MHz, CHLOROFORM-d)  ppm 4.09 - 4.04 (m, 
1 H, CHOH), 1.98 - 1.84 (m, 2 H, CH2), 1.78 - 1.71 (m, 1 H, CH), 1.49 (s, 9 H, CH3), 
0.96 (dd, J=6.87, 2.86 Hz, 6 H, CH3); Data corresponded to that reported in the literature. 
 
General procedure A for urea formation: 
 
Prepared according to the literature procedure.117-118, 228 To a solution of H-Leu-OtBu HCl 
(1.1 equiv.) or tert-butyl (2S)-2-hydroxy-4-methyl-pentanoate (62) (1.1 equiv.)  in 
dichloromethane at room temperature was added the appropriate isocyanate (1 equiv.) 
and triethylamine (1.5 equiv.). The resulting mixture was stirred at room temperature for 
3 hours. RM was concentrated and purified by flash column chromatography using as an 
eluent PE/EtOAc to obtain desired product as white solid. 
 
tert-Butyl (2S)-2-[(4-bromophenyl)carbamoylamino]-4-methyl-pentanoate (63) 
 
Prepared according to procedure A with 4-bromophenyl 
isocyanate (2.7 mmol) and H-Leu-OtBu HCl (1.1 equiv., 3 
mmol); Crude product was dry loaded onto silica and purified 
by flash column chromatography (EA/PE 1:1 gradient) Yield: 
700 mg, 70%; Appearance: white solid; LCMS: 2.00 min, m/z 329.9, 331.9 ((M+H)+ 1:1, 
79/81Br, without tert-butyl group); Purity>95%, Method D; 1H NMR (500 MHz, 
CHLOROFORM-d)  ppm 7.33 - 7.28 (m, 2 H, ArCH), 7.24 - 7.20 (m, 2 H, ArCH), 7.11 
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(s, 1 H, NH), 5.86 (d, J=8.02 Hz, 1 H, NH), 4.43 (ddd, J=9.74, 8.02, 5.16 Hz, 1 H, NCH), 
1.81 - 1.72  (m, 1 H,CH2), 1.67 - 1.59 (m, 1 H, CH2), 1.52 (s, 9 H, CH3), 1.50 - 1.43 (m, 
1 H, CH), 0.97 (dd, J=6.59, 4.87 Hz, 6 H, CH3); 
13C NMR (126 MHz, DMSO-d6)  ppm 
172.53 (1C, C=O), 154.62 (1 C, C=O), 139.57 (1C, ArC.), 131.44 (2C, ArCH), 119.54 
(2C, ArCH), 112.57 (ArCBr), 80.61 (1C, C(CH3)3), 51.39 (CH), 40.85 (1C, CH2), 27.65 
(3C, C(CH3)3), 24.41 (1C, CH), 22.69 (1C, CH3), 21.67 (1C, CH3); Data corresponded to 
that reported in the literature.118 
 
tert-Butyl (2S)-4-methyl-2-[[4(trifluoromethyl)phenyl]carbamoylamino]pentanoate 
(64) 
 
Prepared according to procedure A with 1-isocyanato-4-
(trifluoromethyl)benzene (3 mmol) and  H-Leu-OtBu HCl (1.1 
equiv., 3.3 mmol); Yield: 880 mg, 90%, Appearance: white 
solid; Crude product was purified by flash column 
chromatography (silica gel, PE/EtOAc 1/1, gradient); LCMS: 1.99 min, m/z 319.1 
((M+H)+ without tert-butyl group), Method A; 1H NMR (500 MHz, CHLOROFORM-d) 
 ppm 7.29 - 7.35 (m, 2 H, ArCH), 7.22 - 7.26 (m, 2 H, ArCH), 7.12 (s, 1 H, NH), 5.88 
(d, J=8.02 Hz, 1 H, NH), 4.45 (ddd, J=9.74, 8.02, 5.16 Hz, 1 H, NCH), 1.72 - 1.84 (m, 1 
H, CH2), 1.61 - 1.69 (m, 1 H, CH2), 1.54 (s, 9 H, CH3), 1.44 - 1.52 (m, 1 H, CH), 0.99 
(dd, J=6.59, 4.87 Hz, 6 H, CH3); Data corresponded to that reported in the literature
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tert-butyl (2S)-2-[(4-bromophenyl)carbamoyloxy]-4-methyl-pentanoate (65) 
 
Prepared according to procedure A with tert-butyl (2S)-2-
hydroxy-4-methyl-pentanoate (0.53 mmol) (62). Yield: 100 mg, 
50%, Appearance: white solid; LCMS: 2.49 min, m/z 329.9, 
331.9 ((M+H)+ 1:1, 79/81Br, without tBu group), Purity>90%, 
Method B; 1H NMR (500 MHz, CHLOROFORM-d)  ppm 7.40 - 7.43 (m, 2 H, ArCH), 
7.28 - 7.32 (m, 2 H, ArCH), 4.98 (dd, J=9.45, 4.30 Hz, 1 H, CH), 1.86 - 1.93 (m, 1 H, 
CH2), 1.72 - 1.78 (m, 1 H, CH2), 1.51 - 1.54 (m, 1 H, CH), 1.48 - 1.49 (m, 9 H, C(CH3)3), 
0.94 - 0.98 (m, 6 H, CH3); Data corresponded to that reported in the literature
228 
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General procedure B: Cleavage of ester: 
 
Prepared according to the literature procedure. A solution of ester in formic acid was 
stirred at room temperature for 3 hours. The resulting mixture was quenched with water 
then extracted with ethyl acetate. Crude product was purified by flash column 
chromatography (PE/EtOAc) to obtain desired product as white solid. 
 
(2S)-2-[(4-bromophenyl)carbamoylamino]-4-methyl-pentanoic acid (66) 
 
Prepared according to procedure B with intermediate tert-butyl 
(2S)-2-[(4-bromophenyl)carbamoylamino]-4-methyl-
pentanoate (63) (2 mmol). Crude product was purified by flash 
column chromatography (silica gel, PE/EtOAc 2/8, gradient). Yield: 440 mg, 83% 
Appearance: white solid; LCMS: 0.90 min, m/z 329.0, 331.0 ((M+H)+ 1:1, 79/81Br), 
Purity>95%, Method B; 1H NMR (500 MHz, DMSO-d6)  ppm 12.66 (s, 1 H, COOH), 
8.71 (s, 1 H, NH), 7.32 - 7.43 (m, 4 H, ArCH), 6.45 (d, J=8.59 Hz, 1 H, NH), 4.17 (td, 
J=8.59, 5.73 Hz, 1 H, CH), 1.67 (dquin, J=13.75, 6.73 Hz, 1 H, CH), 1.46 - 1.57 (m, 2 H, 
CH2), 0.90 (dd, J=10.31, 6.30 Hz, 6 H, CH3); Data corresponded to that reported in the 
literature.118 
 
 (2S)-2-[(4-bromophenyl)carbamoyloxy]-4-methyl-pentanoic acid (67) 
 
Prepared according to procedure B with intermediate tert-butyl 
(2S)-2-[(4-bromophenyl)carbamoyloxy]-4-methyl-pentanoate 
(65) (0.3 mmol); Crude product was purified by flash column 
chromatography (silica gel, PE/EtOAc 2/8, gradient). Yield: 45 mg, 75%; Appearance: 
sticky white solid; LCMS: 1.68 min, m/z 330.0, 331.9 ((M+H)+ 1:1, 79/81Br), Purity>90%, 
Method D;  1H NMR (500 MHz, DMSO-d6)  ppm 9.98 (br. s., 1 H, COOH), 7.41 - 7.47 
(m, 4 H, ArCH), 4.83 (dd, J=10.31, 4.01 Hz, 1 H, CH), 1.72 - 1.82 (m, 1 H, CH2), 1.57 - 
1.72 (m, 2 H, CH2, CH ), 0.92 (dd, J=9.16, 6.87 Hz, 6 H, CH3); Data corresponded to that 
reported in the literature.228 
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(2S)-4-methyl-2-[[4-(trifluoromethyl)phenyl]carbamoylamino]pentanoic acid (68) 
 
Prepared according to procedure B with intermediate tert-butyl 
(2S)-4-methyl-2-[[4(trifluoromethyl)phenyl] carbamoylamino] 
pentanoate (64) (2 mmol); Crude product was purified by flash 
column chromatography (silica gel, PE/EtOAc 2/8, gradient). 
Yield: 380 mg, 70%; Appearance: white solid; LCMS: 1.62 min, m/z 319.0 (M+H)+ 
Purity>95%, Method A; 1H NMR (500 MHz, DMSO-d6)  ppm 12.70 (s, 1 H, COOH), 
8.99 (s, 1 H, NH), 7.63 - 7.54 (m, 4 H, ArCH), 6.57 (d, J=8.59 Hz, 1 H, NH), 4.19 (td, 
J=8.45, 5.44 Hz, 1 H, CH), 1.72 - 1.63 (m, 1 H, CH), 1.58 - 1.49 (m, 2 H, CH2), 0.90 (dd, 
J=9.45, 6.59 Hz, 6 H, CH3); Data corresponded to that reported in the literature.
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General procedure C: Amide coupling using HATU: 
 
Prepared according to the literature procedure.117 Acid (0.6 mmol) was dissolved in 
anhydrous DMF (4 mL). HATU (1.5 equiv., 0.92 mmol) was added in one portion. 
Reaction mixture was stirred at room temperature for 10 minutes then glycine t-butyl ester 
(2 equiv., 0.9 mmol) was added, reaction mixture was stirred for 20 minutes before 
DIPEA (3 equiv., 1.84 mmol) was added. A solution was allowed to stir overnight at an 
ambient temperature. RM was quenched with water and extracted with EtOAc, then dried 
over MgSO4, filtered and concentrated under reduced pressure. Crude product was 
purified by FCC using as an eluent PE/EtOAc to obtain desired product as white solid.  
 
tert-butyl 2-[[(2S)-2-[(4-bromophenyl) carbamoylamino]-4-methyl-pentanoyl] 
amino] acetate (17) 
 
Prepared according to procedure C with intermediate 
(2S)-2-[(4-bromophenyl)carbamoylamino]-4-methyl-
pentanoic acid (66)  (0.6 mmol) and glycine t-butyl ester 
(1.5 equiv., 0.92 mmol); Yield: 210 mg, 78% 
Appearance: white solid; LCMS: 1.82 min, m/z 386.0, 388.0 and 442.1, 444.1 ((M+H)+ 
1:1, 79/81Br), Purity>95%, Method A; 1H NMR (500 MHz, DMSO-d6)  ppm 8.72 (s, 1 
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H, NH), 8.47 (t, J=6.01 Hz, 1 H, NH), 7.46 - 7.28 (m, 4 H, ArCH), 6.36 (d, J=8.59 Hz, 1 
H, NH), 4.28 (td, J=8.88, 5.16 Hz, 1 H, CH), 3.71 (qd, J=6.87, 5.73 Hz, 2 H, CH2), 1.70 
- 1.59 (m, 1 H, CH2), 1.52 - 1.40 (m, 2 H, CH , CH2), 1.39 (s, 9 H, C(CH3)3), 0.90 (dd, 
J=6.59, 4.30 Hz, 6 H, CH3); HRMS: Exact Mass: 441.1263; (M+H)
+: 442.1341; Observed 
Mass: 442.1337; 1.00 ppm; Data corresponded to that reported in the literature.117-118  
 
General procedure D: Amide coupling using HOBT and EDCI: 
 
Prepared according to the literature procedure.229 To a solution of SM (1 equiv) in DMF 
(2 mL), HOBT (1.5 equiv.), EDCI·HCl (1.5 equiv.), amine (1.5 equiv.) and N-morpholine 
(2 equiv.), were added. RM was stirred at room temperature overnight. RM was quenched 
with water and extracted with ethyl acetate. Crude product was purified by flash column 
chromatography using as eluent PE/EtOAc to obtain desired product as a white solid. 
 
tert-butyl 2-[[(2S)-4-methyl-2-[[4-(trifluoromethyl)phenyl] carbamoylamino] 
pentanoyl]amino]acetate (69) 
  
Prepared according to procedure D with intermediate 
(2S)-4-methyl-2-[[4-(trifluoromethyl) phenyl] 
carbamoylamino] pentanoic acid (68) (0.25 mmol) and 
glycine t-butyl ester (1.5 equiv., 0.38 mmol); Crude 
product was purified via flash column chromatography 
(silica, EtOAc/PE (1/1)); Yield: 95 mg, 88% Appearance: 
white solid; LCMS: 1.84 min, m/z 376.0 and 432.0 (M+H)+, Purity>90%, Method A;  
1H NMR (500 MHz, DMSO-d6)  ppm 9.01 (s, 1 H, NH), 8.50 (t, J=5.73 Hz, 1 H, NH), 
7.50 - 7.62 (m, 4 H, ArCH), 6.48 (d, J=8.59 Hz, 1 H, NH), 4.31 (td, J=8.88, 5.16 Hz, 1 
H, CH), 3.64 - 3.79 (m, 2 H, CH2), 1.60 - 1.70 (m, 1 H, CH2), 1.40 - 1.54 (m, 2 H, CH 
,CH2), 1.39 (s, 9 H, CH3), 0.91 (dd, J=6.30, 2.86 Hz, 6 H, CH3); HRMS: Exact Mass: 
431.2032; (M+H)+: 432.2110; Observed Mass: 432.2101; 2.12  ppm; Data corresponded 
to that reported in the literature. 
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tert-butyl 2-[[(2S)-2-[(4-bromophenyl)carbamoylamino]-4-methyl-pentanoyl]-
methyl-amino]acetate (70) 
Prepared according to procedure D with intermediate (2S)-2-
[(4-bromophenyl)carbamoylamino]-4-methyl-pentanoic acid 
(66)  (0.33 mmol) and tert-butyl 2-(methylamino)acetate. Crude 
product was purified via flash column chromatography (silica, 
EtOAc/PE (1/1)); Yield: 90 mg, 60% Appearance: white solid; 
LCMS: 2.00 min, m/z 400.0, 402.0 and 456.1, 458.1 ((M+H)+ 1:1, 79/81Br), Purity>90%, 
Method B; 1H NMR (500 MHz, DMSO-d6)  ppm 8.78 (s, 1 H, NH), 7.22 - 7.46 (m, 4 H, 
ArCH), 6.38 - 6.52 (m, 1 H, NCH), 4.75 (td, J=10.31, 5.16 Hz, 1 H, 0.5 NCH), 4.51 (td, 
J=9.45, 4.01 Hz, 1 H, 0.5 NCH), 4.12 (d, J=17.18 Hz, 1 H, 0.5 CH2), 3.83 (d, J=17.18 
Hz, 1 H, 0.5 CH2), 3.09 (s, 2 H, 0.7 NCH3), 2.84 (s, 1 H, 0.3 NCH3), 1.64 - 1.72 (m, 1 H, 
CH2), 1.56 - 1.64 (m, 1 H, CH2), 1.44 - 1.53 (m, 1 H, CH), 1.39 (s, 9 H, C(CH3)3), 0.83 - 
0.97 (m, 6 H, CH3); HRMS: Exact mass: 455.1420; (M+H)
+: 456.1498; Observed mass: 
456.1495; 0.64 ppm; Data corresponded to that reported in the literature229 1HNMR 
spectrum showed the existence of rotamers. 
 
tert-butyl 2-[methyl- [(2S)-4-methyl-2-[[4-(trifluoromethyl) phenyl] 
carbamoylamino] pentanoyl]amino] acetate (71) 
Prepared according to procedure D with intermediate 
(2S)-4-methyl-2-[[4-(trifluoromethyl) phenyl] 
carbamoylamino] pentanoic acid (68) (0.25 mmol) and 
tert-butyl 2-(methylamino)acetate (1.5 equiv. 0.37 
mmol); Crude product was purified via flash column 
chromatography (silica, EtOAc/PE (1/1));  Yield: 90 mg, 
80% Appearance: white solid;  LCMS: 2.00 min, m/z 390.0, 446.2 (M+H)+, Purity>90%, 
Method B; 1H NMR (500 MHz, METHANOL-d4)  ppm 7.50 - 7.56 (m, 4 H, ArCH), 
4.90-4.64 (m, 1H NCH), 4.26 (d, J=17.18 Hz, 1 H, 0.5 NCH2), 3.82 (d, J=17.18 Hz, 1 H, 
0.7 NCH2), 3.22 (s, 2 H, 0.7 NCH3), 2.96 (s, 1 H, 0.3 NCH3), 1.76 - 1.86 (m, 1 H, CH2), 
1.51 - 1.61 (m, 2 H, CH, CH2), 1.45 - 1.50 (m, 9 H, C(CH3)3), 0.94 - 1.06 (m, 6 H, CH3); 
HRMS: Exact Mass: 445.2188; (M+H)+: 446.2267; Observed Mass: 446.2262; 1.04ppm; 
Data corresponded to that reported in the literature229; 1HNMR spectrum showed the 
existence of rotamers. 
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tert-butyl (2S)-2-[[(2S)-2-[(4-bromophenyl)carbamoylamino]-4-methyl-pentanoyl] 
amino]-3-methyl-butanoate (72) 
 
Prepared according to procedure D with intermediate  (2S)-
2-[(4-bromophenyl)carbamoylamino]-4-methyl-pentanoic 
acid (66) (0.30 mmol) and L-Valine tert-butyl ester (1.5 
equiv., 0.45 mmol). Crude product was purified via flash 
column chromatography (silica gel, EtOAc/PE (8/2)); 
Yield: 134 mg, 91.5% Appearance: white solid; LCMS: 
2.03 min, m/z 428.0, 430.0 and 484.0, 486.0 ((M+H)+ 1:1, 79/81Br), Purity>95%, Method 
A; 1H NMR (500 MHz, CHLOROFORM-d)  ppm 7.57 (s, 1 H, NH), 7.26 - 7.21 (m, 2 
H, ArCH), 7.14 - 7.09 (m, 2 H, ArCH), 6.73 (d, J=8.59 Hz, 1 H, NH), 6.56 (d, J=8.02 Hz, 
1 H, NH), 4.47 (td, J=8.59, 6.30 Hz, 1 H, CH), 4.32 (dd, J=8.59, 5.16 Hz, 1 H, CH), 2.13 
(dq, J=12.32, 6.78 Hz, 1 H, CH), 1.78 (dquin, J=13.68, 4x6.61 Hz, 1 H, CH), 1.62 - 1.55 
(m, 2 H, CH2), 1.48 (s, 9 H, CH3), 0.98 (dd, J=6.59, 4.87 Hz, 6 H, C(CH3)2), 0.91 (dd, 
J=6.87, 1.72 Hz, 6 H, C(CH3)2); HRMS: Exact Mass: 483.1733; (M+H)
+: 484.1811; 
Observed Mass: 428.1185 (loss tBu); NA  ppm; Data corresponded to that reported in the 
literature.117 
(2S)-2-[(4-bromophenyl)carbamoylamino]-N-(2-hydroxyethyl)-4-methyl-
pentanamide (78) 
 
Prepared according to procedure D with intermediate (2S)-2-
[(4-bromophenyl)carbamoylamino]-4-methyl-pentanoic acid 
(66) (0.16 mmol) and 2-aminoethanol (1.5 equiv. 0.24 mmol); 
Crude product was purified via flash column chromatography 
(silica gel, EtOAc/PE (8/2)); Yield: 24 mg, 40% Appearance: 
white solid; LCMS: 1.35 min, m/z 372.1, 374.1 ((M+H)+ 1:1, 79/81Br), Purity>95%, 
Method B; 1H NMR (500 MHz, DMSO-d6)  ppm 8.74 (s, 1 H, NH), 8.11 (t, J=5.44 Hz, 
1 H, NH), 7.42 - 7.30 (m, 4 H, ArCH), 6.35 (d, J=8.59 Hz, 1 H, NH), 4.66 (t, J=5.44 Hz, 
1 H, OH), 4.23 (td, J=8.74, 5.44 Hz, 1 H, CH), 3.39 (q, J=6.30 Hz, 2 H, CH2), 3.12 (q, 
J=6.87 Hz, 2 H, CH2), 1.66 - 1.52 (m, 1 H, CH), 1.47 - 1.34 (m, 2 H, CH2), 0.89 (d, J=6.87 
Hz, 6 H, CH3); HRMS: Exact Mass: 371.0844; (M+H)
+: 372.0923; Observed Mass: 
372.0918; 1.29  ppm; Data corresponded to that reported in the literature117 
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 (2S)-N-acetonyl-2-[(4-bromophenyl)carbamoylamino]-4-methyl-pentanamide (20) 
 
Prepared according to procedure D with intermediate 
(2S)-2-[(4-bromophenyl)carbamoylamino]-4-methyl-
pentanoic acid (66) (0.152 mmol) and 1-aminopropan-2-
one (1.5 equiv, 0.22 mmol). Crude product was firstly 
purified by flash column chromatography (silica gel, EtOAc/PE (6/4)) and later by 
preparative HPLC (19x100mm (5µm) C-18 Waters Xbridge, MeOH pH=10); Yield: 15 
mg, 26%; Appearance: white solid; LCMS: 1.48 min, m/z 384.0, 386.0 ((M+H)+ 1:1, 
79/81Br), Purity>90%, Method B; 1H NMR (500 MHz, DMSO-d6)  ppm 8.73 (s, 1 H, 
NH), 8.40 (t, J=5.73 Hz, 1 H, NH), 7.48 - 7.24 (m, 4 H, ArCH), 6.38 (d, J=8.59 Hz, 1 H, 
NH), 4.29 (td, J=8.88, 5.16 Hz, 1 H, NCH), 3.97 - 3.84 (m, 2 H, NCH2), 2.06 (s, 3 H, 
O=CCH3), 1.72 - 1.59 (m, 1 H, CH), 1.53 - 1.37 (m, 2 H, CH2), 0.90 (br. t, J=6.30, 6.30 
Hz, 6 H; CH3); HRMS: Exact Mass: 383.0844; (M+H)
+: 384.0923; Observed Mass: 
384.0916; 1.77  ppm; Data corresponded to that reported in the literature.117 
 
 (2S)- N-acetonyl-4-methyl-2-[ [4-(trifluoromethyl)phenyl] carbamoylamino] 
pentanamide (81) 
 
Prepared according to procedure D with intermediate 
(2S)-2-[(4-trifluoromethylphenyl) carbamoyloxy]-4-
methyl-pentanoic acid (68) (0.25mmol) and 1-
aminopropan-2-one (1.5 equiv., 0.37 mmol). Crude 
product was purified via preparative HPLC (19x100mm 
(5µm) C-18 Waters Xbridge, MeOH, pH=10). Yield: 20 mg, 21%; Appearance: white 
solid; LCMS: 2.12 min, m/z 374.0 (M+H)+, Purity>95%, Method D; 1H NMR (500 MHz, 
DMSO-d6)  ppm 9.03 (s, 1 H, NH), 8.43 (t, J=5.44 Hz, 1 H, NH), 7.63- 7.50 (m, 4 H, 
ArCH), 6.52 (d, J=8.59 Hz, 1 H, NH), 4.31 (td, J=9.02, 5.44 Hz, 1 H, CH), 4.02 – 3.82 
(m, 2 H, CH2), 2.06 (s, 3 H, CH3), 1.70 - 1.61 (m, 1 H, CH), 1.55 - 1.38 (m, 2 H, CH2), 
0.91 (dd, J=6.87, 4.58 Hz, 6 H, C(CH3)2); HRMS: Exact Mass: 373.1613; (M+H)
+: 
374.1692; Observed Mass: 374.1684; 2.01ppm; Analogue of para bromo derivative 
described in the literature.117 
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 (2S)-N-(2-hydroxyethyl)-4-methyl-2-[[4-(trifluoromethyl)phenyl] 
carbamoylamino]pentanamide (82) 
 
Prepared according to procedure D with intermediate (2S)-
4-methyl-2-[[4-(trifluoromethyl) phenyl] carbamoylamino] 
pentanoic acid (68) (0.25 mmol) and 2-aminoethanol (1.5 
equiv. 0.37 mmol). Crude product was purified via flash 
column chromatography (silica gel, EtOAc/PE (7/3)). Yield: 
50 mg, 55%; Appearance: white solid; LCMS: 1.47 min, m/z 362.0 (M+H)+, Purity>90%, 
Method A; 1H NMR (500 MHz, DMSO-d6)  ppm 9.02 (s, 1 H, NH), 8.14 (t, J=5.73 Hz, 
1 H, NH), 7.53 - 7.60 (m, 4 H, ArCH), 6.46 (d, J=8.59 Hz, 1 H, NH), 4.66 (t, J=5.44 Hz, 
1 H, OH), 4.25 (td, J=8.59, 5.73 Hz, 1 H, CH), 3.39 (q, J=5.92 Hz, 2 H, CH2), 3.13 (q, 
J=6.11 Hz, 2 H, CH2 ), 1.53 - 1.66 (m, 1 H, CH), 1.36 - 1.48 (m, 2 H, CH2), 0.89 (d, 
J=6.30 Hz, 6 H, C(CH3)2); HRMS: Exact Mass: 361.1613; (M+H)
+: 362.1692; Observed 
Mass: 362.1683; 2.35 ppm; Analogue of para bromo derivative described in the 
literature.117 
 
 (2S)-N-(2-amino-2-oxo-ethyl)-4-methyl-2- [[4-(trifluoromethyl) phenyl] 
carbamoylamino] pentanamide (79) 
 
Prepared according to procedure D with intermediate 
(2S)-4-methyl-2-[[4-(trifluoromethyl) phenyl] 
carbamoylamino] pentanoic acid (68) (0.25 mmol) and 
glycinamide hydrochloride (1.5 equiv. 0.36 mmol). Crude product was purified via flash 
column chromatography (silica gel, DCM/MeOH 92/8). Yield: 21 mg, 22%; Appearance: 
white solid; LCMS: 1.50  min, m/z 375.1 (M+H)+, Purity=93%, Method A; 1H NMR (500 
MHz, DMSO-d6)  ppm 9.03 (s, 1 H, NH), 8.35 (t, J=5.73 Hz, 1 H, NH), 7.61 - 7.50 (m, 
4 H, ArCH), 7.24 (br. s., 1 H, NH), 7.06 (br. s., 1 H, NH), 6.54 (d, J=8.02 Hz, 1 H, NH), 
4.27 - 4.20 (m, 1 H, CH), 3.63 (qd, J=16.61, 5.73 Hz, 2 H, CH2), 1.71 - 1.58 (m, 1 H, 
CH), 1.55 - 1.38 (m, 2 H, CH2), 0.94 - 0.86 (m, 6 H, C(CH3)2); HRMS: Exact Mass: 
374.1566; (M+H)+: 375.1644; Observed Mass: 375.1637; 1.87 ppm; Analogue of para 
bromo derivative described in the literature.117 
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 (2S)-N-[2-(dimethylamino)-2-oxo-ethyl]-4-methyl-2-[[4-(trifluoromethyl) phenyl] 
carbamoylamino]pentanamide (80) 
 
Prepared according to procedure D with intermediate (2S)-4-
methyl-2-[[4-(trifluoromethyl) phenyl] carbamoylamino] 
pentanoic acid (68) (0.25 mmol) and 2-amino-N,N-
dimethylacetamide (1.5 equiv., 0.37 mmol); Crude product was 
purified via flash column chromatography (silica gel, DCM/MeOH 92/8).Yield: 25 mg, 
25% Appearance: white solid; LCMS: 1.49 min, m/z 403.2 (M+H)+, Purity=94%, Method 
A; 1H NMR (500 MHz, DMSO-d6)  ppm 9.02 (s, 1 H, NH), 8.18 (t, J=5.16 Hz, 1 H, 
NH), 7.50 - 7.64 (m, 4 H, ArCH), 6.50 (d, J=8.59 Hz, 1 H, NH), 4.34 (td, J=8.45, 5.44 
Hz, 1 H, CH), 3.97 - 3.87 (m, 2 H, CH2), 2.94 (s, 3 H, CH3), 2.82 (s, 3 H, CH3), 1.73 - 
1.60 (m, 1 H, CH), 1.55 - 1.36 (m, 2 H, CH2), 0.90 (d, J=6.30 Hz, 6 H, C(CH3)2); HRMS: 
Exact Mass: 402.1879; (M+H)+: 403.1957; Observed Mass: 403.1950; 1.74 ppm; 
Analogue of para bromo derivative described in the literature.117 
 
(2S)-N-(2-amino-2-oxo-ethyl)-2-[(4-bromophenyl)carbamoylamino]-4-methyl-
pentanamide (19) 
 
Prepared according to procedure D with intermediate (2S)-
2-[(4-bromophenyl)carbamoylamino]-4-methyl-pentanoic 
acid (66) (0.24 mmol) and glycinamide hydrochloride (1.5 
equiv. 0.36 mmol). Crude product was purified via flash 
column chromatography (silica gel, DCM/MeOH 92/8). 
Yield: 58 mg, 62%; Appearance: white solid; LCMS: 1.32 min, m/z 385.0, 387.0 ((M+H)+ 
1:1, 79/81Br), Purity>90%, Method A; 1H NMR (500 MHz, DMSO-d6)  ppm 8.75 (s, 1 
H, NH), 8.32 (t, J=5.44 Hz, 1 H), 7.31 - 7.40 (m, 4 H, ArCH), 7.23 (br. s., 1 H, NH), 7.06 
(br. s., 1 H, NH), 6.42 (d, J=7.45 Hz, 1 H, NH), 4.16 - 4.25 (m, 1 H, CH), 3.54 - 3.70 (m, 
2 H, CH2), 1.58 - 1.68 (m, 1 H, CH), 1.35 - 1.51 (m, 2 H, CH2), 0.84 - 0.95 (m, 6 H, 
C(CH3)2); HRMS: Exact Mass: 384.0797; (M+H)
+: 385.0875; Observed Mass: 385.0870; 
1.37 ppm; Data corresponded to that reported in the literature.117 
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(2S)-2-[(4-bromophenyl)carbamoylamino]-N-[2-(dimethylamino)-2-oxo-ethyl]-4-
methyl-pentanamide (77) 
 
Prepared according to procedure D with intermediate (2S)-
2-[(4-bromophenyl)carbamoylamino]-4-methyl-pentanoic 
acid (66) (0.24 mmol) and 2-amino-N,N-dimethylacetamide 
(1.5 equiv., 0.36 mmol). Crude product was purified via flash 
column chromatography (silica gel, DCM/MeOH 95/5).  
Yield: 35 mg, 35%; Appearance: white solid; LCMS: 1.42 min, m/z 413.1, 415.1 ((M+H)+ 
1:1, 79/81Br), Purity>95%, Method A; 1H NMR (500 MHz, DMSO-d6)  ppm 8.74 (s, 1 
H, NH), 8.14 (t, J=5.16 Hz, 1 H, NH), 7.42 - 7.31 (m, 4 H, ArCH), 6.39 (d, J=8.59 Hz, 1 
H, NH), 4.31 (td, J=8.88, 5.16 Hz, 1 H, CH), 3.99 - 3.85 (m, 2 H, CH2), 2.94 (s, 3 H, 
CH3), 2.82 (s, 3 H, CH3), 1.71 - 1.59 (m, 1 H, CH), 1.54 - 1.33 (m, 2 H, CH2), 0.89 (dd, 
J=6.30, 3.44 Hz, 6 H, C(CH3)2); HRMS: Exact Mass: 412.1110; (M+H)
+: 413.1188; 
Observed Mass: 413.1185; 0.79 ppm; Data corresponded to that reported in the 
literature.117 
 
General procedure E for amide coupling using T3P: 
 
SM was dissolved in ethyl acetate, then amine (1equiv), TEA, (1.5 equiv.), and T3P (1.5 
equiv.) were added. Reaction mixture was stirred overnight at room temperature, then 
EtOAc was added and washed with water. An organic layer was dried over Na2SO4, 
filtered and concentrated under reduced pressure. Crude product was purified by reverse 
phase flash column chromatography.  
 
(2S)-2-[(4-bromophenyl)carbamoylamino]-4-methyl-N-(2H-tetrazol-5-ylmethyl) 
pentanamide (21) 
 
Prepared according to procedure E with intermediate (2S)- 
(2S)-2-[(4-bromophenyl)carbamoylamino]-4-methyl-
pentanoic acid (66) (0.15 mmol) and C-(2H-tetrazol-5-yl)-
methylamine (1.5 equiv. 0.23 mmol). Crude product was 
purified by reverse phase flash column chromatography 
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(acetonitrile/water pH=1). Methanol solution of desired product was passed through an 
Isolute NH2 SPE cartridge (500mg) and filtrate was concentrated under reduced pressure 
to get desired product as a free base. Yield: 25 mg, 40%; Appearance: white solid; LCMS: 
1.45 min, m/z 410.0, 412.0 ((M+H)+ 1:1, 79/81Br), Purity>95%, Method A; 1H NMR (500 
MHz, DMSO-d6)  ppm 8.83 (t, J=5.73 Hz, 1 H, NH), 8.71 (s, 1 H, NH), 7.27 - 7.39 (m, 
4 H, ArCH), 6.35 (d, J=8.02 Hz, 1 H, NH), 4.48 - 4.57 (m, 2 H, CH2), 4.25 (td, J=5.16, 
4.01 Hz, 1 H, CH), 1.52 - 1.65 (m, 1 H, CH), 1.34 - 1.49 (m, 2 H, CH2), 0.86 (d, J=6.30 
Hz, 6 H, C(CH3)2); HRMS: Exact Mass: 409.0862; (M+H)
+: 410.0940; Observed Mass: 
410.0936; 1.00 ppm; Data corresponded to that reported in the literature118 
 
[(1S)-3-methyl-1-(2H-tetrazol-5-ylmethylcarbamoyl) butyl] N-(4-bromophenyl) 
carbamate (83) 
 
Prepared according to procedure E with intermediate  
(2S)-2-[(4-bromophenyl)carbamoyloxy]-4-methyl-
pentanoic acid (67) (0.12 mmol) and C-(2H-tetrazol-5-
yl)-methylamine (1.5 equiv. 0.18 mmol). Crude product 
was firstly purified by reverse phase flash column 
chromatography (acetonitrile/water pH=10). The fractions are combined and the product 
redissolved in DMSO and  product was purified via preparative HPLC (19x100mm (5µm) 
C-18 Waters Xbridge, MeOH, pH=10). Yield: 8 mg, 15%; Appearance: white solid; 
LCMS: 1.45 min, m/z 411.0, 413.0 ((M+H)+ 1:1, 79/81Br), Purity=83%, Method D; 1H 
NMR (500 MHz, DMSO-d6)  ppm 9.96 (br. s., 1 H, NH), 8.77 (t, J=5.44 Hz, 1 H, NH), 
7.50 - 7.32 (m, 4 H, ArCH), 4.97 (dd, J=10.02, 3.72 Hz, 1 H, OCH), 4.56 - 4.45 (m, 2 H, 
NCH2), 1.74 - 1.65 (m, 1 H, CH), 1.64 - 1.50 (m, 2 H, CH2), 0.87 (dd, J=6.30, 4.01 Hz, 6 
H, C(CH3)2); HRMS: Exact Mass: 410.0702; (M+H)
+: 411.0780; Observed Mass: 
411.0777; 0.79 ppm; Data corresponded to that reported in the literature.228 
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Compounds prepared according general procedure B: Cleavage of ester: 
   
2-[[(2S)-2-[(4-bromophenyl)carbamoylamino]-4-methyl-pentanoyl]amino]acetic 
acid (18) 
 
Prepared according to procedure B with intermediate tert-
butyl 2-[[(2S)-2-[(4-bromophenyl) carbamoylamino]-4-
methyl-pentanoyl] amino] acetate (17) (0.395 mmol). 
Crude product was purified by flash column 
chromatography (silica gel, DCM/MeOH 95/5); Yield: 152 mg, 82% Appearance: white 
solid; LCMS: 1.41 min, m/z 386.0, 388.0 ((M+H)+ 1:1, 79/81Br), Purity>95%, Method A; 
1H NMR (500 MHz, DMSO-d6)  ppm 8.92 (br. s, 1 H, NH), 8.32 (br. s., 1 H, NH), 7.32 
- 7.41 (m, 4 H, ArCH), 6.60 (br. s, 1 H, NH), 4.28 (td, J=9.16, 5.16 Hz, 1 H, CH), 3.70 
(d, J=5.16 Hz, 2 H, CH2), 1.58 - 1.71 (m, 1 H, CH), 1.36 - 1.52 (m, 2 H, CH2), 0.89 (dd, 
J=6.59, 3.72 Hz, 6 H, C(CH3)2); HRMS: Exact Mass: 385.0637; (M+H)
+: 386.0715; 
Observed Mass: 386.0712; 0.89 ppm; Data corresponded to that reported in the 
literature.117 
 
2-[[(2S)-4-methyl-2-[[4-(trifluoromethyl)phenyl]carbamoylamino] pentanoyl] 
amino]acetic acid (73) 
 
Prepared according to procedure B with intermediate tert-
butyl 2-[[(2S)-4-methyl-2-[[4-(trifluoromethyl)phenyl] 
carbamoylamino] pentanoyl]amino]acetate (69) (0156 
mmol); Crude product was dissolved in 1mL of DMSO, 
and purified by reverse phase column chromatography (acetonitrile/water pH=1) to obtain 
desired product as a white solid. Yield: 32 mg, 54% Appearance: white solid; LCMS: 
1.49 min, m/z 376.1  (M+H)+, Purity>95%, Method A; 1H NMR (500 MHz, DMSO-d6) 
 ppm 9.02 (s, 1 H, NH), 8.49 (t, J=6.01 Hz, 1 H, NH), 7.64 - 7.52 (m, 4 H, ArCH), 6.49 
(d, J=8.59 Hz, 1 H, NH), 4.32 (td, J=9.02, 4.87 Hz, 1 H, CH), 3.84 - 3.68 (m, 2 H, CH2), 
1.72 - 1.59 (m, 1 H, CH), 1.54 - 1.36 (m, 2 H, CH2), 0.90 (dd, J=6.30, 1.72 Hz, 6 H, 
C(CH3)2); HRMS: Exact Mass: 375.1406; MH+: 376.1484; Observed Mass: 376.1477; 
1.90 ppm; Data corresponded to that reported in the literature117 
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2-[[(2S)-2-[(4-bromophenyl)carbamoylamino]-4-methyl-pentanoyl]-methyl-amino] 
acetic acid (74) 
 
Prepared according to procedure B with intermediate  tert-butyl 
2-[[(2S)-2-[(4-bromophenyl)carbamoylamino]-4-methyl-
pentanoyl]-methyl-amino]acetate (70) (0.2 mmol); Crude 
compound was purified by flash column chromatography (silica 
gel, PE/EtOAc 100% next EtOAc/MeOH 95/5); Yield: 80 mg, 60 % Appearance: white 
solid; LCMS: 1.50 min, m/z 400.0, 402.1 ((M+H)+ 1:1, 79/81Br), Purity>88%, Method A; 
1H NMR (500 MHz, DMSO-d6)  ppm 9.07 (br. s., 1 H, NH), 7.36 (m, 4 H, ArCH), 6.40 
- 6.71 (m, 1 H, NH), 4.69 - 4.78 (m, 0.5 H, CH), 4.45 - 4.65 (m, 0.5 H, CH), 3.91 - 4.07 
(m, 1 H, CH2), 3.55 - 3.71 (m, 1 H, CH2), 3.04 (s, 1.5 H, CH3), 2.79 (s, 1.5 H, CH3), 1.55 
- 1.73 (m, 1 H, CH), 1.30 - 1.48 (m, 2 H, CH2), 0.81 - 0.96 (m, 6 H C(CH2)3); HRMS: 
Exact Mass: 399.0794; (M+H)+: 400.0872; Observed Mass: 400.0865; 1.73 ppm; Data 
corresponded to that reported in the literature229; 1HNMR spectrum showed the existence 
of rotamers. 
 
2-[methyl-[(2S)-4-methyl-2-[[4-(trifluoromethyl)phenyl]carbamoylamino] 
pentanoyl]amino]acetic acid (75) 
 
Prepared according to procedure B with the intermediate  
tert-butyl 2-[methyl- [(2S)-4-methyl-2-[[4-
(trifluoromethyl) phenyl] carbamoylamino] 
pentanoyl]amino] acetate (71) (0.11 mmol). Crude 
compound was purified by flash column chromatography (silica gel, DCM/MeOH 9/1); 
Yield: 18 mg, 15% Appearance: white solid; LCMS: 2.145 min, m/z 390.1 (M+H)+, 
Purity>90%, Method C; 1H NMR (500 MHz, DMSO-d6)  ppm 9.27 (br. s., 1 H, NH), 
7.50 - 7.65 (m, 4 H, ArCH), 6.69 (d, J=8.59 Hz, 1 H, NH), 4.77 (td, J=9.16, 4.01 Hz, 0.5 
H, CH), 4.56 (d, J=6.30 Hz, 0.5 H, CH), 4.11 (s, 1 H, 0.5 CH2), 3.75 - 3.98 (m, 1 H, 0.5 
CH2), 3.08 (s, 2 H, 0.7 CH3), 2.83 (s, 1 H, 0.3 CH3), 1.57 - 1.73 (m, 1 H, CH), 1.33 - 1.48 
(m, 2 H, CH2), 0.83 - 0.98 (m, 6 H; C(CH3)2); HRMS: Exact Mass: 375.1406; (M+H)
+: 
390.1641; Observed Mass: 390.1633; 1.96 ppm; Data corresponded to that reported in 
the literature229; 1HNMR spectrum showed the existence of rotamers. 
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(2S)-2-[[(2S)-2-[(4-bromophenyl)carbamoylamino]-4-methyl-pentanoyl]amino]-3-
methyl-butanoic acid (76) 
 
Prepared according to procedure B with the intermediate 
tert-butyl (2S)-2-[[(2S)-2-[(4-bromophenyl) 
carbamoylamino] -4-methyl-pentanoyl] amino]-3-
methyl-butanoate (72) (0.206 mmol). The crude product 
was purified  by flash column chromatography ( silica gel, 
PE/EtOAc 2/8); Yield: 25 mg, 28.4%; Appearance: white solid; LCMS: 1.605 min, m/z 
428.0, 430.0 ((M+H)+ 1:1, 79/81Br), Purity>92%, Method A; 1H NMR (500 MHz, DMSO-
d6)  ppm 12.49 (br. s, 1 H, COOH), 8.74 (br. s., 1 H, NH), 8.12 (d, J=8.02 Hz, 1 H, NH), 
7.43 - 7.22 (m, 4 H, ArCH), 6.35 (d, J=7.45 Hz, 1 H, NH), 4.43 - 4.28 (m, 1 H, CH), 4.08 
(dd, J=7.45, 6.30 Hz, 1 H, CH), 2.01 (dd, J=13.17, 6.30 Hz, 1 H, CH), 1.69 - 1.56 (m, 1 
H, CH), 1.52 - 1.32 (m, 2 H, CH2), 0.92 - 0.80 (m, 12 H C(CH3)2); HRMS: Exact Mass: 
427.1107; (M+H)+: 428.1185; Observed Mass: 428.1179; 1.39ppm; Data corresponded 
to that reported in the literature.117 
  
225 
 
12.2.3.2. Bridge compounds series 
 
Cyclopenta-1,3-diene (85) 
 
The reaction apparatus was assembled by attaching a 
thermometer, Vigreux distilling column and Liebig condenser 
to a two-neck flask. The receiver was cooled. A dicyclopentadiene (20 g, 151.29 mmol) 
was placed in the two-neck flask and heated to about 160oC. Thermal decomposition is 
beginning at around 150⁰C and distilled at 38⁰C. A cyclopenta-1,3-diene was stored in 
the fridge or/and used directly to the next step.; Yield: 14g, 70% Appearance: beige 
liquid; UV-inactive; 1H NMR (500 MHz, CHLOROFORM-d)   ppm 6.59 - 6.57 (m, 2 
H, CH), 6.46 - 6.48 (m, 2 H, CH), 2.99 (m, J=2.90, 1.10 Hz, 2 H, CH2); Data corresponded 
to that reported in the literature.121, 230 
 
Spiro[2.4]hepta-4,6-diene (86) 
 
In a dried round-bottomed flask equipped with a magnetic stir bar and under 
inert atmosphere, a mixture of benzyltriethylammonium chloride (0.045 
equiv.) in 12.5% aqueous solution of sodium hydroxide (12.5 mass%) was 
heated to 45⁰C. A chilled solution of cyclopentadiene (85) in 1,2-dichloroethane (0.92 
equiv.) was added to stirred NaOH solution while keeping the internal temperature below 
50⁰C.  After the addition, the mixture was stirred at 50⁰C for 2h and allowed to cool down 
to rt. The layers were separated, the organic layer washed with 1M NaOH, dried (Na2SO4) 
and filtered. The crude brown liquid was distilled under reduced pressure (85-95 
mbar).Yield: 6g, 31%; Appearance: clear liquid; 1H NMR (500 MHz, CHLOROFORM-
d)  ppm 6.57 - 6.50 (m, 2 H, CH), 6.18 - 6.12 (m, 2 H, CH), 1.67 (br.s, 4 H, CH2); Data 
corresponded to that reported in the literature.121, 230 
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Bis[(1S)-2-ethoxy-1-methyl-2-oxo-ethyl] (1S,2R,3R,4R)-spiro[bicyclo[2.2.1]hept-5-
ene-7,1'-cyclopropane]-2,3-dicarboxylate (87) 
 
In a dried round bottomed flask equipped with a magnetic stir 
bar and under inert atmosphere to a solution of bis[(1S)-2-
ethoxy-1-methyl-2-oxo-ethyl] (E)-but-2-enedioate (2 g, 1.0 
equiv.) in n-hexane (20 mL) was added 86 (1.5 equiv). The 
reaction mixture was stirred at RT overnight. The mixture was 
concentrated under reduced pressure and the crude product was 
purified by flash column chromatography (silica gel, PE/EA 9/1). Yield: 2.33g, 90.2%; 
Appearance: transparent oil; 1H NMR (500 MHz, CHLOROFORM-d)  ppm 6.43 (dd, 
J=5.73, 3.44 Hz, 1 HC=CH), 6.30 (dd, J=5.73, 2.29 Hz, 1 H, HC=CH ), 5.10 (q, J=7.26 
Hz, 1 H, CH3CH), 5.04 (q, J=7.45 Hz, 1 H, CH3CH), 4.16 - 4.23 (m, 4 H, CH3CH2), 3.75 
(appt, J=4.01 Hz, 1 H, CH), 2.90 (d, J=4.58 Hz, 1 H, CH), 2.85 (m, , 1 H, CH), 2.78 - 
2.81 (m, 1 H, CH), 1.50 (t, J=7.45 Hz, 6 H, CH2CH3), 1.28 (td, J=7.16, 2.29 Hz, 6 H, 
OCH2CH3), 0.64 - 0.72 (m, 1 H, CH2), 0.44 - 0.53 (m, 3 H, CH2); Data corresponded to 
that reported in the literature.121, 231 
 
(1S,2R,3R,4R)-spiro[bicyclo[2.2.1]hept-5-ene-7,1'-cyclopropane]-2,3-dicarboxylic 
acid (88) 
To a solution of 87 (2.33 g, 5.71 mmol, 1.00) in tetrahydrofuran (15 
mL)/water (15 mL) was added lithium hydroxide (8 equiv.). The 
reaction mixture was stirred at room temperature overnight. 
Consumption of starting material was checked by TLC plate 
(DCM/MeOH 9/1). The solution of 1N HCl was added in order to 
adjust the pH of the reaction mixture to pH=3, the layers were separated, and the aq. layer 
extracted with ethyl acetate three times. The combined organic extracts were dried over 
MgSO4, filtered and concentrated under reduced pressure. Yield: 0.79, 60%; UV-inactive; 
Appearance: white solid; 1H NMR (500 MHz, CHLOROFORM-d) δ ppm 6.42 (dd, 
J=5.44, 3.72 Hz, 1 H, HC=CH), 6.24 (dd, J=6.30, 2.29 Hz, 1 H, HC=CH), 3.69 (appt, 
J=4.30 Hz, 1 H,), 2.88 (d, J=4.58 Hz, 1 H), 2.77 (d, J=2.29 Hz, 1 H), 2.70 (br s, 1 H),  
0.47 - 0.56 (m, 4 H, CH2); Compound has been reported in the literature.
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6-iodo-2-oxohexahydrospiro[3,5-methanocyclopenta[b]furan-4,1'-cyclopropane]-7-
carboxylic acid (89) 
 
To a solution of 88 (0.78 g, 1.0 equiv.) in dichloromethane (10 ml) 
were added sodium bicarbonate (1.05 equiv.), water (15 ml), 
potassium iodide (3.7 equiv.) and iodine (1.2 equiv.). The reaction 
mixture was stirred at room temperature for 3.5 hours (TLC plate: ethyl acetate 100% 
rf=0.1). The reaction was quenched by the addition of sat. Na2S2O3. The layers were 
separated, and the aq. phase was extracted three times with DCM.  The combined organic 
phases were filtered through a phase separator and solvent was evaporated to give as a 
white foam. Product was used for next reaction without any further purification. Yield: 
0.89g, 80%; Appearance: white foam; 1H NMR (500 MHz, CHLOROFORM-d)  ppm 
5.26 (d, J=5.16 Hz, 1 H, COOCH), 3.98 (s, 1 H, ICH), 3.43 - 3.40 (m, 1 H, CH), 3.00 (d, 
J=2.29 Hz, 1 H, CH), 2.70 (s, 1 H, CH), 2.66 (td, J=4.87, 1.15 Hz, 1 H, CHCOOH), 1.22 
(dappt, J=9.59, 6.09 Hz, 1 H CH2), 0.93 (dappt , J=9.17, 6.30 Hz, 1 H, CH2), 0.59 - 0.51 
(m, 2 H, CH2); Compound has been reported in the literature.
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Methyl 6-iodo-2-oxohexahydrospiro [3,5-methanocyclopenta[b] furan-4,1'-
cyclopropane]-7-carboxylate (90) 
 
In a dried round-bottomed flask equipped with a magnetic stir bar 
and under inert atmosphere, to a solution of 89 (0.68 g, 1.0 equiv.) 
in methanol (10 mL) was added (trimethylsilyl)diazomethane (2 
mol/L) in hexane (5 equiv.). The reaction mixture was stirred at 
room temperature overnight, concentrated under reduced pressure and purified by FC 
(PE/EA 4/1) to give the title compound as a white solid. Yield: Appearance: white solid; 
1H NMR (500 MHz, CHLOROFORM-d)  ppm 5.25 (d, J=5.16 Hz, 1 H, COOCH), 3.96 
(s, 1 H, ICH), 3.75 (s, 3 H, CH3), 3.42 - 3.47 (m, 1 H, CH), 2.93 (d, J=1.72 Hz, 1 H, CH), 
2.65 (s, 1 H, CH ), 2.63 (td, J=4.87, 1.72 Hz, 1 H, CH), 1.18 (dappt, J=9.74, 6.01 Hz, 1 
H, CH2), 0.90 (dappt, J=9.45, 6.16 Hz, 1 H, CH2), 0.51 (dappt, J=9.74, 5.16 Hz, 1 H, 
CH2), 0.42 (dappt, J=9.74, 5.73 Hz, 1 H CH2); Compound has been reported in the 
literature.121 
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(1S,2R,3R,4R)-3-methoxycarbonylspiro[bicyclo[2.2.1]hept-5-ene-7,1'-
cyclopropane]-2-carboxylic acid (91) 
 
In a dried round-bottomed flask equipped with a magnetic stir bar 
and under inert atmosphere, to a solution of 90 (0.5 g, 1 equiv.) in 
acetic acid (8 mL) was added zinc (15 equiv.). The reaction 
mixture was stirred at 65 °C for 4h, cooled to RT, filtered through 
a celite and partitioned between water and ethyl acetate. An aqueous phase was washed 
with ethyl acetate twice. The combined organic layer was dried over MgSO4, filtered and 
concentrated under reduced pressure. The crude product was purified via FCC, PE/EA 
1/1 to give desired product. Yield: 232 mg, 70% Appearance: white solid; 1H NMR (500 
MHz, CHLOROFORM-d)  ppm 6.41 (dd, J=5.73, 4.01 Hz, 1 H, HC=CH), 6.23 (d, 
J=5.39 Hz, 1 H, HC=CH), 3.73 (s, 3 H, CH3), 3.72 - 3.69 (m, 1 H, CH), 2.82 (d, J=4.58 
Hz, 1 H, CH), 2.75 - 2.72 (m, 1 H, CH), 2.71 - 2.69 (m, 1 H, CH), 0.54 - 0.42 (m, 4 H, 
CH2); Compound has been reported in the literature
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(1'S,2'R,3'R,4'R)-3'-methoxycarbonylspiro[cyclopropane-1,7'-norbornane]-2'-
carboxylic acid (92) 
 
A (1S,2R,3R,4R)-3-methoxycarbonylspiro[bicyclo[2.2.1]hept-5-
ene-7,1'-cyclopropane]-2-carboxylic acid  (91) (0.105 g, 1.0 
equiv.) was dissolved in tetrahydrofuran (10mg/1mL). A reduction 
of the double bond of a starting material has been performed using 
the H-Cube. Conditions: 10% Pd/C CatCart at 1mL/min, room temperature, H2 full mode. 
A solvent was evaporated to give a product as a white solid. Yield: 100 mg, 96% 
Appearance: white solid; 1H NMR (500 MHz, CHLOROFORM-d)  ppm 3.70 (s, 3 H, 
CH3), 3.62 - 3.57 (m, 1 H, CH), 2.94 (d, J=5.73 Hz, 1 H, CH), 2.01 (d, J=4.58 Hz, 1 H, 
CH), 1.97 - 1.93 (m, 1 H, CH), 1.92 - 1.83 (m, 1 H, CH2), 1.78 - 1.69 (m, 1 H, CH2), 1.52 
- 1.43 (m, 2 H, CH2), 0.62 - 0.55 (m, 1 H, CH2), 0.51 (ddd, J=16.61, 9.45, 4.30 Hz, 2 H, 
CH2), 0.47 - 0.41 (m, 1 H, CH2)  Compound has been reported in the literature.
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Compounds prepared according general procedure E for amide coupling using T3P: 
 
methyl (1'R,2'R,3'R,4'S)-3'-[(4-bromophenyl)carbamoyl]spiro[cyclopropane-1,7'-
norbornane]-2'-carboxylate (93) 
 
Prepared according to procedure E with the intermediate 
(1'S,2'R,3'R,4'R)-3'-methoxycarbonylspiro[cyclopropane-1,7'-
norbornane]-2'-carboxylic acid (92) (0.089 mmol) and 4-bromoaniline 
(1.5 equiv., 0.13 mmol); Crude product was purified by flash column 
chromatography (silica gel, PE/EA 1/1) to obtain desired product. Yield: 
25 mg, 75%; Appearance: white foam; LCMS: 2.02 min, m/z 378.1, 
380.0 ((M+H)+ 1:1, 79/81Br), Purity >90%, Method A; 1H NMR (500 MHz, 
CHLOROFORM-d)  ppm 7.82 (s, 1 H, NH), 7.45 - 7.40 (m, 4 H, ArCH), 3.73 (s, 3 H, 
CH3), 3.47 - 3.42 (m, 1 H, CH), 3.01 (br.d, J=5.73 Hz, 1 H, CH), 2.05 (br.d, , 1 H, CH), 
1.90 - 1.82 (m, 2 H, CH2), 1.77 - 1.68 (m, 2 H, CH2), 1.54 - 1.48 (m, 1 H, CH), 0.60 - 
0.40 (m, 4 H, CH2); Compound has been reported in the literature.
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methyl (1'R,2'R,3'R,4'S)-3'-[(6-bromo-3-pyridyl)carbamoyl]spiro[cyclopropane-
1,7'-norbornane]-2'-carboxylate (94) 
 
Prepared according to procedure E with the methyl (1'S,2'R,3'R,4'R)-3'-
methoxycarbonylspiro [cyclopropane-1,7'-norbornane]-2'-carboxylic 
acid  (92) (0.54 mmol) and 6-bromopyridin-3-amine (1.5 equiv., 0.59 
mmol); Crude product was purified by flash column chromatography 
(silica gel, PE/EA 2/1) to obtain desired product. Yield: 112 mg, 55%; 
Appearance: transparent film; LCMS: 1.76 min, m/z 379.0, 381.0121 
((M+H)+ 1:1, 79/81Br), Purity >90%, Method A; 1H NMR (500 MHz, CHLOROFORM-
d)  ppm 8.37 (d, J=2.86 Hz, 1 H, NH), 8.07 (dd, J=9.17, 2.86 Hz, 1 H, ArCH), 8.01 (s, 
1 H, ArCH), 7.43 (d, J=8.59 Hz, 1 H, ArCH), 3.78 - 3.72 (m, 3 H, CH3),  3.44 (appt,, 
J=4.87 Hz, 1 H, CH), 2.95 (d, J=6.30 Hz, 1 H, CH), 2.07 (d, J=4.01 Hz, 1 H, CH), 1.93 - 
1.82 (m, 2 H, CH2), 1.79 - 1.70 (m, 2 H, CH2), 1.52 - 1.45 (m, 1 H, CH), 0.61 - 0.46 (m, 
4 H, CH2), Compound has been reported in the literature.
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methyl (1'R,2'R,3'R,4'S)-3'-[[1-(p-tolyl)cyclopropyl]carbamoyl]spiro 
[cyclopropane-1,7'-norbornane]-2'-carboxylate (95) 
 
Prepared according to procedure E with the intermediate 
(1'S,2'R,3'R,4'R)-3'-methoxycarbonylspiro[cyclopropane-1,7'-
norbornane]-2'-carboxylic acid (92) (0.36 mmol) and 1-(p-
tolyl)cyclopropanamine (1.1 equiv., 0.39 mmol); Crude product 
was purified by flash column chromatography (silica gel, PE/EA 
1/1) to obtain desired product. Yield: 55mg, 44%; Appearance: white solid; LCMS: 1.87 
min, m/z 354.2 (M+H)+, Purity >80%, Method A; 1H NMR (500 MHz, CHLOROFORM-
d)  ppm 7.21 - 7.13 (m, 2 H, ArCH), 7.13 - 7.06 (m, 2 H, ArCH), 6.27 (s, 1 H, NH), 3.68 
(d, J=1.15 Hz, 3 H, CH3), 3.36 - 3.30 (m, 1 H, CH), 3.02 (d, J=5.73 Hz, 1 H, CH), 2.30 
(s, 3 H, CH3), 1.96 (d, J=4.58 Hz, 1 H, CH), 1.73 (appt, J=4.01 Hz, 1 H, CH), 1.58 (d, 
J=1.72 Hz, 2 H, CH2), 1.54 - 1.45 (m, 2 H, CH2), 1.29 - 1.16 (m, 4 H, CH2), 0.50 - 0.55 
(m, 2 H, CH2), 0.40 - 0.48 (m, 2 H, CH2); Compound has been reported in the literature.
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methyl (1'R,2'R,3'R,4'S)-3'-[(4-bromo-2-fluoro-phenyl)methylcarbamoyl]spiro 
[cyclopropane-1,7'-norbornane]-2'-carboxylate (96) 
 
Prepared according to procedure E with the intermediate 
(1'S,2'R,3'R,4'R)-3'-methoxycarbonylspiro[cyclopropane-1,7'-
norbornane]-2'-carboxylic acid (92) (0.9 mmol) and (4-bromo-2-
fluoro-phenyl)methanamine (1.1 equiv., 1 mmol). Crude product 
was purified by flash column chromatography (silica gel, PE/EA 
2/1) to obtain desired product. Yield: 255mg, 70%; Appearance: transparent film; LCMS: 
1.90 min, m/z 410.0, 412.0 ((M+H)+ 1:1, 79/81Br), Purity >90%, method A; 1H NMR (500 
MHz, CHLOROFORM-d)  ppm 7.26 - 7.24 (m, 2 H, ArCH), 7.24 - 7.21 (m, 1 H, ArCH), 
6.07 (t, J=5.73 Hz, 1 H, NH), 4.55 - 4.37(m, 2 H, CH2), 3.68 (s, 3 H, CH3), 3.33 (ddd, 
J=5.87, 4.15, 2.00 Hz, 1 H, CH), 3.00 (d, J=5.73 Hz, 1 H, CH), 1.99 (d, J=4.58 Hz, 1 H, 
CH), 1.88 - 1.76 (m, 1 H, CH2), 1.72 (t, J=3.72 Hz, 1 H, CH), 1.64 (m, 1 H, CH2), 1.56 - 
1.44 (m, 2 H, CH2), 0.56 - 0.49 (m, 2 H, CH2), 0.48 - 0.40 (m, 2 H, CH2); Compound has 
been reported in the literature.121 
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Methyl (1S,2R,3R,4R)-2-[(4-bromophenyl)carbamoyl]spiro[bicyclo[2.2.1]hept-5-
ene-7,1'-cyclopropane]-3-carboxylate (114) 
 
Prepared according to procedure E with the intermediate 
(1S,2R,3R,4R)-3-methoxycarbonylspiro[bicyclo[2.2.1]hept-5-ene-
7,1'-cyclopropane]-2-carboxylic acid (91) (0.4 mmol) and 4-
bromoaniline (1.5 equiv., 0.7 mmol). A crude product was purified by 
flash column chromatography (PE/EA 6/4) to obtain compound 114; 
Yield: 43 mg, 30%, Appearance: white foam; LCMS: 1.86 min, m/z 
376.0, 378.0 ((M+H)+ 1:1, 79/81Br), Purity >90%, method A; 1H NMR (500 MHz, 
CHLOROFORM-d) δ ppm 8.24 (br s, 1 H, NH), 7.40 (m, 4 H, ArCH), 6.42 (dd, J=5.73, 
2.86 Hz, 1 H, HC=CH),  6.33 (dd, J=5.73, 3.44 Hz, 1 H, HC=CH), 3.80 (s, 3 H, CH3), 
3.49 (dd, J=5.73, 3.44 Hz, 1 H, CH), 2.77 (br s, 1 H, CH),  2.69 (d, J=5.73 Hz, 1 H, CH), 
2.59 (br s, 1 H, CH), 0.58 - 0.39 (m, 4 H, CH2); Compound has been reported in the 
literature.123   
 
General procedure F: Ester hydrolysis: 
 
Ester intermediate (93-96 and 114) (1 equiv.) was dissolved in tetrahydrofuran /sodium 
hydroxide (1 mol/L) in water. Reaction mixture was stirred at room temperature 
overnight. The mixture was then washed with Et2O, the aq. layer acidified and extracted 
three times with ethyl acetate. The combined organic extracts were filtered through a 
phase separator and concentrated under reduced pressure to give the title compound as a 
solid. 
 
(1'R,2'R,3'R,4'S)-3'-[(4-Bromophenyl)carbamoyl]spiro[cyclopropane-1,7'-
norbornane]-2'-carboxylic acid (97) 
 
Prepared according to procedure F with the intermediate methyl 
(1'R,2'R,3'R,4'S)-3'-[(4-bromophenyl)carbamoyl]spiro[cyclopropane-
1,7'-norbornane]-2'-carboxylate (93) (0.19 mmol). Compound was used 
for next step without further purification. Yield: 70 mg, 100%; 
Appearance: white solid; LCMS: 1.76 min, m/z 364.0, 366.0 ((M+H)+ 
1:1, 79/81Br), Purity>85%, method A; 1H NMR (500 MHz, 
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CHLOROFORM-d)  ppm 7.55 - 7.50 (m, 1 H, NH), 7.47 - 7.40 (m, 4 H, ArCH), 3.44 
(t, J=4.30 Hz, 1 H, CH), 3.08 (d, J=6.30 Hz, 1 H, CH), 2.11 (d, J=4.58 Hz, 1 H, CH), 
1.92 - 1.85 (m, 2 H, CH2), 1.72 (m, J=8.60, 5.20 Hz, 2 H, CH2), 1.53 (ddd, J=12.17, 8.16, 
4.30 Hz, 1 H, CH), 0.69 (dt, J=9.31, 4.80 Hz, 1 H, CH2), 0.63 - 0.55 (m, 1 H, CH2), 0.49 
- 0.55 (m, 2 H, CH2); HRMS: Exact mass: 363.0470; (M+H)
+: 364.0548; Observed mass: 
364.0543; 1.46 ppm; Compound has been reported in the literature123 
 
(1'R,2'R,3'R,4'S)-3'-[(6-Bromo-3-pyridyl)carbamoyl]spiro[cyclopropane-1,7'-
norbornane]-2'-carboxylic acid (98) 
 
Prepared according to procedure F with the intermediate methyl 
(1'R,2'R,3'R,4'S)-3'-[(6-bromo-3-pyridyl)carbamoyl] spiro 
[cyclopropane-1,7'-norbornane]-2'-carboxylate (94) (0.29 mmol); 
Compound was used for next step without further purification. Yield: 90 
mg, 80%; Appearance: white solid; LCMS: 1.50 min, m/z 365.1, 366.9 
((M+H)+ 1:1, 79/81Br), Purity >90%, method A; 1H NMR (500 MHz, 
CHLOROFORM-d) δ ppm 9.32 (s, 1H, COOH), 8.51 (d, J=2.86 Hz, 1 H, ArCH), 8.41 
(dd, J=8.59, 2.86 Hz, 1 H, ArCH), 7.47 (d, J=8.59 Hz, 1 H, ArCH),  3.40 (ddd, J=7.16, 
3.72, 2.29 Hz, 1 H, CH), 2.84 (d, J=6.87 Hz, 1 H, CH), 2.20 (d, J=4.01 Hz, 1 H, CH), 
1.97 - 1.76 (m, 4 H, CH2), 1.50 - 1.43 (m, 1 H, CH),  0.74 - 0.67 (m, 1 H, CH2), 0.60 - 
0.49 (m, 3 H, CH2); HRMS: Exact mass: 364.0422; (M+H)
+ : 365.0501; Observed mass: 
365.0498; 0.77 ppm; Compound has been reported in the literature.121 
 
(1'R,2'R,3'R,4'S)-3'-[[1-(p-Tolyl)cyclopropyl]carbamoyl]spiro[cyclopropane-1,7'-
norbornane]-2'-carboxylic acid (99) 
 
Prepared according to procedure F with the intermediate methyl 
(1'R,2'R,3'R,4'S)-3'-[[1-(p-tolyl)cyclopropyl] carbamoyl]spiro 
[cyclopropane-1,7'-norbornane]-2'-carboxylate (95) (0.16 
mmol); Compound was used for next step without further 
purification; Yield: 23 mg, 44% Appearance: white solid; 
LCMS: 1.63 min, m/z 340.0 (M+H)+, Purity=75%, Method A (weak UV active); 1H NMR 
(500 MHz, CHLOROFORM-d)  ppm 7.20 - 7.15 (m, 2 H, ArCH), 7.14 - 7.10 (m, 2 H, 
ArCH), 6.31 (s, 1 H, NH), 3.21 (ddd, J=7.02, 3.87, 1.72 Hz, 1 H, CH), 2.82 (d, J=7.45 
Hz, 1 H, CH), 2.32 (s, 3 H, CH3), 2.08 (d, J=4.01 Hz, 1 H, CH), 1.85 (m, , 2 H, CH2), 
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1.49 - 1.56 (m, 2 H, CH2), 1.39 - 1.49 (m, 2 H, CH2), 1.23 - 1.29 (m, 4 H, CH2), 0.44 - 
0.57 (m, 4 H, CH2); Compound has been reported in the literature.
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(1'R,2'R,3'R,4'S)-3'-[(4-Bromo-2-fluoro phenyl)methylcarbamoyl] 
spiro[cyclopropane-1,7'-norbornane]-2'-carboxylic acid (100) 
 
Prepared according to procedure F with the methyl 
(1'R,2'R,3'R,4'S)-3'-[(4-bromo-2-fluoro-phenyl) methylcarbamoyl] 
spiro[cyclopropane-1,7'-norbornane]-2'-carboxylate (96) (0.609 
mmol); Compound was used for next step without further 
purification. Yield: 242 mg, 100%; Appearance: white solid; 
LCMS: 1.62 min, m/z 396.0, 398.0 ((M+H)+ 1:1, 79/81Br), Purity >90%, method A; 1H 
NMR (500 MHz, DMSO-d6)  ppm 12.10 (br. s., 1 H, COOH), 8.40 (t, J=6.01 Hz, 1 H, 
NH), 7.51 (dd, J=9.74, 1.72 Hz, 1 H, ArCH), 7.39 (dd, J=8.31, 2.00 Hz, 1 H, ArCH), 7.23 
(t, J=8.02 Hz, 1 H, ArCH), 4.41 - 4.14 (m, 2 H CH2), 3.32 - 3.28 (m, 1 H, CH), 2.83 (d, 
J=5.73 Hz, 1 H, CH), 1.86 (d, J=4.58 Hz, 1 H, CH), 1.80 (t, J=4.30 Hz, 1 H, CH), 1.73 - 
1.65 (m, 1 H, CH2), 1.52 - 1.43 (m, 1 H, CH2), 1.34 - 1.21 (m, 2 H, CH2), 0.51 - 0.35 (m, 
4 H, CH2); Compound has been reported in the literature.
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(1S,2R,3R,4R)-2-[(4-bromophenyl)carbamoyl]spiro[bicyclo[2.2.1]hept-5-ene-7,1'-
cyclopropane]-3-carboxylic acid (115) 
 
Prepared according to procedure F with the Methyl (1S,2R,3R,4R)-
2-[(4-bromophenyl)carbamoyl]spiro[bicyclo[2.2.1]hept-5-ene-7,1'-
cyclopropane]-3-carboxylate (114) (0.10 mmol); Compound was 
used for next step without further purification. Yield: 38 mg, 99%; 
Appearance: white solid; LCMS: 1.64 min, m/z 362.0, 363.9 ((M+H)+ 
1:1, 79/81Br), Purity >90%, method A;  1H NMR (500 MHz, 
CHLOROFORM-d) δ ppm 7.99 (br s, 1 H, NH), 7.38 (s, 4 H, ArCH), 6.40 - 6.33 (m, 2 
H, HC=CH),  3.51 (dd, J=5.73, 3.44 Hz, 1 H, CH), 2.78 - 2.71 (m, 2 H, CH), 2.58 (br s, 
1 H, CH), 0.65 - 0.39 (m, 4 H, CH2);  HRMS: Exact mass: 361.0313; (M+H)
+ 362.0392; 
Observed mass:362.0387; 1.33 ppm; Compound has been reported in the literature.123  
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Compounds prepared according to modified procedure D: Amide coupling using 
HOBT and EDCI: 
To a solution of SM (1 equiv) in dichloromethane (2 mL), HOBT (1.5 equiv.), EDCI·HCl 
(1.5 equiv.), amine (1.5 equiv.) and DIPEA (2 equiv.), were added. RM was stirred at 
room temperature overnight. RM was quenched with water and extracted with ethyl 
acetate. Crude product was purified by flash column chromatography or reverse phase 
column chromatography.  
 
tert-butyl 4-[2-[(1'R,2'R,3'R,4'S)-3'-[(6-bromo-3-pyridyl)carbamoyl] spiro 
[cyclopropane-1,7'-norbornane]-2'-carbonyl]oxyethyl]piperidine-1-carboxylate 
(101) 
 
Prepared according to modified procedure D with the 
(1'R,2'R,3'R,4'S)-3'-[(6-Bromo-3-pyridyl)carbamoyl]spiro 
[cyclopropane-1,7'-norbornane]-2'-carboxylic  acid (98) 
(0.14 mmol) and tert-butyl 4-(2-hydroxyethyl)piperidine-1-
carboxylate (2 equiv., 027 mmol). The crude product was 
purified by preparative flash column chromatography (19x100mm (5µm) C-18 Waters 
Xbridge, MeOH, pH=10); Yield: 71 mg, 90%, Appearance: white solid; LCMS: 2.24 min; 
m/z 476.0, 478.0 and 576.0, 578.0 ((M+H)+ 1:1, 79/81Br), method A; 1H NMR (500 MHz, 
CHLOROFORM-d)  ppm 8.40 (br. s., 1 H, ArCH), 8.07 - 8.11 (m, 1 H, ArCH), 7.42 - 
7.46 (m, 1 H, ArCH), 4.19 (m, 2 H, CH2), 3.99 - 4.12 (m, 2 H, CH2), 3.41 - 3.47 (m, 1 H, 
CH), 2.96 (br. d, J=5.73 Hz, 1 H, CH), 2.61 - 2.76 (m, 2 H, CH2), 2.06 (br. d, J=4.58 Hz, 
1 H, CH), 1.84 - 1.92 (m, 2 H, CH2), 1.71 - 1.78 (m, 2 H, CH2), 1.60 - 1.70 (m, 5 H, CH, 
CH2), 1.48 - 1.56 (m, 2 H, CH2), 1.46 (s, 9 H, C(CH3)3), 1.11 - 1.18 (m, 1 H), 0.46 - 0.63 
(m, 4 H, CH2);  Compound has been reported in the literature. 
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(1'R,2'R,3'R,4'S)-N3'-(6-Bromo-3-pyridyl)-N2'-[2-(4-methylpiperazin-1-yl)ethyl] 
spiro[cyclopropane-1,7'-norbornane]-2',3'-dicarboxamide (102) 
 
Prepared according to modified procedure D with the 
(1'R,2'R,3'R,4'S)-3'-[(6-Bromo-3-pyridyl)carbamoyl]spiro 
[cyclopropane-1,7'-norbornane]-2'-carboxylic  acid (98) (0.082 
mmol) and 2-(4-methylpiperazin-1-yl)ethanamine (3 equiv., 
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0.24 mmol). The crude product was purified by preparative flash column chromatography 
(19x100mm (5µm) C-18 Waters Xbridge, MeOH, pH=10); Yield: 14 mg, 35%; 
Appearance: white solid; LCMS: 2.07 min, m/z 490.0, 492.0 ((M+H)+ 1:1, 79/81Br), 
Purity> 95%, method D; 1H NMR (500 MHz, CHLOROFORM-d) δ ppm 10.38 (s, 1 H, 
NH), 8.51 (d, J=2.86 Hz, 1 H, ArCH), 8.06 -8.03(m, 1 H, ArCH),  7.39 (d, J=8.59 Hz, 1 
H, ArCH), 6.62 (br s, 1 H, NH), 3.46 (br s, 1 H, CH2), 3.35 - 3.26 (m, 1 H, CH2), 3.25 - 
3.20 (m, 1 H, CH), 2.65 (d, J=7.45 Hz, 1 H, CH),  2.59- 2.33 (m, 8 H, CH2), 2.29 (s, 3 H, 
CH3),  2.00 – 1.75 (m, 4 H, CH2), 1.76 - 1.73 (m, 1 H, CH), 1.48 - 1.41(m, 1 H, CH), 0.72 
- 0.48 (m, 4 H, CH2); HRMS: Exact mass: 489.1739; (M+H)
+: 490.1818; Observed 
mass:490.1812, 1.15 ppm; a hybrid compound, not described in the patent. 
 
(1'R,2'R,3'R,4'S)-N2'-[2-(4-methylpiperazin-1-yl)ethyl]-N3'-[1-(p-
tolyl)cyclopropyl]spiro[cyclopropane-1,7'-norbornane]-2',3'-dicarboxamide (103) 
 
Prepared according to modified procedure D with the  
intermediate (1'R,2'R,3'R,4'S)-3'-[[1-(p-Tolyl)cyclopropyl] 
carbamoyl] spiro[cyclopropane-1,7'-norbornane]-2'-
carboxylic acid (99) (0.068 mmol) and 2-(4-methylpiperazin-
1-yl)ethanamine (2 equiv., 0.14 mmol). Crude product was 
purified by reverse phase chromatography (ACN pH=1). Methanol solution was passed 
through an Isolute NH2 SPE cartridge (500mg) and filtrate was concentrated under 
reduced pressure to get desired product as a free base. Yield: 16 mg, 51%; Appearance: 
off-white solid; LCMS: 1.94 min, m/z 465.0 (M+H)+, Purity>90%, Method C; 1H NMR 
(500 MHz, CHLOROFORM-d)  7.16 (d, J=7.45 Hz, 2H, ArCH), 7.09 (d, J=8.59 Hz, 
2H, ArCH), 6.92 (s, 1H, NH), 6.54 (br. s., 1H, NH), 3.41-3.23 (m, 2H, CH2), 3.17 (dt, 
J=1.72, 4.30 Hz, 1H, CH2), 2.70 (d, J=6.87 Hz, 1H, CH), 2.50-2.37 (m, 6H, CH2), 2.30 
(s, 3H, CH3), 2.28 (s, 3H, CH3), 1.89-1.79 (m, 2H, CH2), 1.75-1.69 (m, 2H, CH2), 1.66 
(s, 4H, CH2), 1.63-1.56 (m, 1H, CH), 1.47-1.35 (m, 1H, CH), 1.28-1.17 (m, 4H, CH2), 
0.80-0.71 (m, 1H, CH2), 0.62-0.40 (m, 3H, CH2); HRMS: Exact mass: 464.3151; (M+H)
+: 
465.3230; Observed mass: 465.3222; 1.62 ppm; Compound has been reported in the 
literature232. 
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tert-butyl 4-[2-[[(1'R,2'R,3'R,4'S)-3'-[(6-bromo-3-pyridyl) carbamoyl] spiro 
[cyclopropane-1,7'-norbornane]-2'-carbonyl]amino]ethyl]piperidine-1-carboxylate 
(104) 
 
Prepared according to modified procedure D with the 
(1'R,2'R,3'R,4'S)-3'-[(6-Bromo-3-pyridyl)carbamoyl]spiro 
[cyclopropane-1,7'-norbornane]-2'-carboxylic  acid (98) 
(0.271 mmol) and tert-butyl 4-(2-aminoethyl)piperidine-1-
carboxylate (2 equiv., 0.542 mmol). Crude product was 
purified by flash column chromatography (silica gel, PE/EA 2/8)  to obtain desired 
product. Yield: 73 mg, 47%; Appearance: off-white solid; LCMS: 1.94 min, m/z 575.0, 
578.0 ((M+H)+ 1:1, 79/81Br), Purity> 95%, Method A; 1H NMR (500 MHz, 
CHLOROFORM-d)  ppm 9.65 (s, 1 H, NH), 8.46 (d, J=2.29 Hz, 1 H, ArCH), 8.03 (dd, 
J=8.59, 2.86 Hz, 1 H, ArCH), 7.40 (d, J=8.59 Hz, 1 H, ArCH), 5.82 (t, J=5.44 Hz, 1 H, 
NH), 3.97 - 4.22 (m, 2 H, CH2), 3.35 - 3.51 (m, 1 H, CH), 3.20 - 3.35 (m, 2 H, CH2), 2.68 
(d, J=6.87 Hz, 3 H, CH2, CH), 1.84 - 1.97 (m, 4 H, CH2), 1.81 (d, J=13.17 Hz, 1 H, CH), 
1.77 (d, J=4.01 Hz, 1 H, CH), 1.63 - 1.72 (m, 2 H, CH2), 1.45 - 1.57 (m, 5 H, CH2), 1.45 
(s, 9 H, C(CH3)3), 1.39 - 1.43 (m, 1 H, CH2), 1.13 (d, J=8.59 Hz, 1 H, CH), 0.45 - 0.68 
(m, 4 H, CH2); hybrid compound, not described in the patent. 
 
tert-Butyl 4-[[(1'R,2'R,3'R,4'S)-3'-[(6-bromo-3-pyridyl)carbamoyl] spiro 
[cyclopropane-1,7'-norbornane]-2'-carbonyl] amino] piperidine-1-carboxylate 
(105) 
 
Prepared according to modified procedure D with the 
(1'R,2'R,3'R,4'S)-3'-[(6-Bromo-3-pyridyl)carbamoyl]spiro 
[cyclopropane-1,7'-norbornane]-2'-carboxylic  acid (98) (0.1 
mmol) and tert-butyl 4-aminopiperidine-1-carboxylate (2 equiv., 
0.2 mmol). Crude product was purified by reverse phase column 
chromatography (ACN pH=1); Yield: 53 mg, 100%; Appearance: off-white solid; LCMS: 
1.81 min, m/z 547.0, 549.0 ((M+H)+ 1:1, 79/81Br), Purity> 95%, Method A; 1H NMR (500 
MHz, CHLOROFORM-d) δ ppm 9.53 (br s, 1 H, NH), 8.45 (d, J=2.29 Hz, 1 H, ArCH),  
8.04 (dd, J=8.59, 2.86 Hz, 1 H, ArCH), 7.41 (d, J=8.59 Hz, 1 H, ArCH),  5.71 (br d, 
J=8.02 Hz, 1 H, NH), 4.02 - 4.20 (m, 2 H, CH2), 3.91 - 4.01 (m, 1 H, CH), 3.31 (br d, 
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J=2.86 Hz, 1 H, CH),  2.87 (br s, 2 H, CH2),  2.68 (d, J=6.87 Hz, 1 H, CH), 1.86 - 1.97 
(m, 5 H, CH2, CH), 1.82 (br d, J=13.17 Hz, 1 H, CH), 1.76 (d, J=4.01 Hz, 1 H, CH2),  
1.45 (s, 9 H, C(CH3)3 ), 1.24 - 1.40 (m, 3 H, CH2), 0.84 - 0.95 (m, 1 H, CH), 0.47 - 0.67 
(m, 4 H, CH2); hybrid compound, not described in the patent. 
 
tert-Butyl 4-[[(1'R,2'R,3'R,4'S)-3'-[(4-bromo-2-fluoro-phenyl)methylcarbamoyl] 
spiro[cyclopropane-1,7'-norbornane]-2'-carbonyl]amino]piperidine-1-carboxylate 
(106) 
 
Prepared according to modified procedure D with the 
(1'R,2'R,3'R,4'S)-3'-[(4-Bromo-2-fluoro 
phenyl)methylcarbamoyl] spiro[cyclopropane-1,7'-
norbornane]-2'-carboxylic acid (100) (0.2 mmol) and tert-butyl 
4-aminopiperidine-1-carboxylate (2 equiv., 0.3 mmol); Crude 
product was purified by reverse phase column chromatography 
(ACN pH=1); Yield: 64 mg, 70%; Appearance: off-white solid; LCMS: 1.99 min, m/z 
578.1, 580.1 ((M+H)+ 1:1, 79/81Br), Purity> 95%, Method B; 1H NMR (500 MHz, 
CHLOROFORM-d) δ ppm 7.18 - 7.26 (m, 3 H, ArCH), 6.28 (br t, J=5.73 Hz, 2 H, NH),  
4.53 - 4.38 (m, 2 H, NCH2), 3.91 - 3.82 (m, 1 H, NCH), 3.15 (br s, 1 H, CH),  2.87 (br s, 
2 H, CH2),  2.68 (d, J=6.30 Hz, 1 H, CH), 1.91 - 1.79 (m, 4 H, CH2), 1.75 - 1.66 (m, 2 H, 
CH2), 1.54 - 1.47 (m, 1 H, CH), 1.45 (s, 9 H, C(CH3)3), 1.41 - 1.23 (m, 4 H, CH2), 0.90 
(m, 1 H, CH),  0.69 - 0.76 (m, 1 H, CH2), 0.57 - 0.50 (m, 1 H, CH2), 0.49 - 0.42 (m, 2 H, 
CH2); Compound has been reported in the literature.
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(1'S,2'R,3'R,4'R)-N2'-(6-bromo-3-pyridyl)-N3'-(1-methyl-4-piperidyl)spiro 
[cyclopropane-1,7'-norbornane]-2',3'-dicarboxamide (107) 
 
Prepared according to modified procedure D with the 
(1'R,2'R,3'R,4'S)-3'-[(6-Bromo-3-pyridyl)carbamoyl]spiro 
[cyclopropane-1,7'-norbornane]-2'-carboxylic  acid (98) (0.1 
mmol) and 1-methylpiperidin-4-amine (2 equiv., 0.2 mmol). 
Crude product was purified by reverse phase column 
chromatography (ACN pH=1);  Yield: 21 mg, 50%; Appearance: 
off-white solid; LCMS: 1.22 min; m/z  461.1, 463.1 ((M+H)+ 1:1, 79/81Br), Purity> 95%, 
Method A; 1H NMR (500 MHz, CHLOROFORM-d) δ ppm 9.76 (s, 1 H, NH), 8.45 (d, 
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J=2.29 Hz, 1H, ArCH), 8.05 (dd, J=8.59, 2.86 Hz, 1 H, ArCH), 7.40 (d, J=8.59 Hz, 1 H, 
ArCH),   5.77 (br d, J=7.45 Hz, 1 H, NH), 3.89 - 3.78 (m, 1 H, NCH), 3.35 - 3.28 (m, 1 
H, CH), 2.87 (br d, J=10.31 Hz, 2 H, CH2), 2.67 (d, J=6.87 Hz, 1 H, CH),  2.34 (s, 3 H, 
CH3), 2.19 (br t, J=10.88 Hz, 2 H, CH2), 1.94 - 1.98 (m, 2 H, CH2), 1.91 - 1.86 (m, 4 H, 
CH2),  1.76 (d, J=4.01 Hz, 1 H, CH), 1.63 - 1.58 (m, 2H, CH2), 1.48 - 1.40 (m, 1 H, CH2), 
0.66 - 0.59 (m, 1 H, CH2), 0.56 (dappt J=7.45, 4.58 Hz, 2 H, CH2), 0.54 - 0.47 (m, 1 H, 
CH2); HRMS: Exact mass: 460.1474; (M+H)
+: 461.1552; Observed mass: 461.1551; 0.25 
ppm; Hybrid compound, compound not described in the patent. 
 
(1'S,2'R,3'R,4'R)-N2'-[(4-bromo-2-fluoro-phenyl)methyl]-N3'-(1-methyl-4-
piperidyl)spiro[cyclopropane-1,7'-norbornane]-2',3'-dicarboxamide (108) 
 
                                          Prepared according to modified procedure D with the 
(1'R,2'R,3'R,4'S)-3'-[(4-Bromo-2-fluoro phenyl) 
methylcarbamoyl] spiro[cyclopropane-1,7'-norbornane]-2'-
carboxylic acid (100) (0.15 mmol) and 1-methylpiperidin-4-
amine (2equiv., 0.3 mmol). Crude product was purified by 
flash column chromatography (silica gel, PE/EA). Yield: 20 
mg, 30%; Appearance: off-white solid; LCMS: 1.40 min, m/z 
492.1, 494.1 ((M+H)+ 1:1, 79/81Br), Purity> 90%, Method A; 
1H NMR (500 MHz, CHLOROFORM-d)  ppm 7.27 - 7.21 (m, 3 H, ArCH), 6.40 (t, 
J=5.16 Hz, 1 H, NH), 6.16 - 6.29 (m, 1 H, NH), 4.37 - 4.55 (m, 2 H, NCH2), 3.79 (dd, 
J=7.16, 3.72 Hz, 1 H, NCH), 3.18 (dt, J=6.01, 3.29 Hz, 1 H, CH), 2.78 - 2.99 (m, 2 H, 
CH2), 2.70 (d, J=6.30 Hz, 1 H, CH), 2.37 (s, 3 H, CH3), 2.14 - 2.33 (m, 2 H, CH2), 1.85 - 
2.00 (m, 4 H, CH2), 1.70 (s, 1 H, CH), 1.49 - 1.67 (m, 4 H, CH2), 1.35 - 1.43 (m, 1 H, 
CH), 0.66 - 0.75 (m, 1 H, CH2), 0.51 - 0.59 (m, 1 H, CH2), 0.42 - 0.51 (m, 2 H, CH2); 
HRMS: Exact mass: 491.1584; (M+H)+: 492.1662; Observed mass: 492.1657; 1.00 ppm; 
Hybrid compound, compound not described in the patent. 
 
(1R,2R,3R,4S)-N3-(4-Bromophenyl)-N2-[4-(1-piperidyl)butyl] spiro[bicyclo 
[2.2.1]hept-5-ene-7,1'-cyclopropane] -2,3-dicarboxamide (116) 
 
Prepared according to modified procedure D with the (1R,2R,3R,4S)-2-[(4-
Bromophenyl)carbamoyl]spiro[bicyclo[2.2.1]hept-5-ene-7,1'-cyclopropane]-3-
carboxylic acid (115) (0.083 mmol) and 4-(1-piperidyl)butan-1-amine (2 equiv., 0.17 
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mmol); The crude product was purified by preparative flash 
column chromatography (19x100mm (5µm) C-18 Waters 
Xbridge, MeOH, pH=10); Yield: 7 mg, 20% Appearance: white 
solid;  LCMS: 2.24 min, m/z 500.0, 502.0 ((M+H)+ 1:1, 79/81Br), 
method D; 1H NMR (500 MHz, CHLOROFORM-d)  ppm 9.44 
(s, 1 H, NH), 7.43 - 7.49 (m, 2 H, ArCH), 7.35 - 7.43 (m, 2 H, ArCH), 6.49 (dd, J=5.73, 
2.86 Hz, 1 H HC=CH), 6.36 - 6.43 (m, 1 H, NH), 6.32 (dd, J=5.73, 3.44 Hz, 1 H, 
HC=CH), 3.52-3.44 (m, 2 H, CONCH2), 3.27 - 3.35 (m, 1 H, CH), 2.59 (br. s., 1 H, CH), 
2.54 (d, J=5.73 Hz, 1 H, CH), 2.49 (d, J=2.29 Hz, 1 H, CH), 2.28 - 2.46 (m, 6 H, 
NCH2CH2), 1.54 - 1.65 (m, 8 H, CH2), 1.39 - 1.51 (m, 2 H, CH2), 0.48 - 0.62 (m, 4 H, 
CH2) ; HRMS: Exact mass: 499.1834; (M+H)
+ :500.1913; Observed mass: 500.1911; 
0.33 ppm 
 
General procedure G: BOC deprotection 
 
Starting material was dissolved in dichloromethane and hydrochloric acid (4 mol/l) in 
1,4-dioxane (5-10 equiv.) was added. Reaction mixture was stirred at room temperature 
for 2.5h. The solvent was evaporated and crude product was purified by preparative 
HPLC (19x100mm (5µm) C-18 Waters Xbridge, MeOH, pH=10) to obtain final product. 
 
2-(4-piperidyl)ethyl (1R,2R,3R,4S) -2-[(6-bromo-3-pyridyl) carbamoyl] spiro 
[bicyclo[2.2.1] hept-5-ene-7,1'-cyclopropane]-3-carboxylate (27) 
 
Prepared according to procedure G with the  intermediate tert-butyl 
4-[2-[(1'R,2'R,3'R,4'S)-3'-[(6-bromo-3-pyridyl)carbamoyl] spiro 
[cyclopropane-1,7'-norbornane]-2'-carbonyl]oxyethyl] piperidine-
1-carboxylate (101) (0.12 mmol). The crude product was purified 
by preparative flash column chromatography (19x100mm (5µm) 
C-18 Waters Xbridge, MeOH, pH=10). Yield: 17 mg, 30%; Appearance: white solid; 
LCMS: 2.24 min, m/z 476.1, 478.1 ((M+H)+ 1:1, 79/81Br), Purity> 95%, method D; 1H 
NMR (500 MHz, CHLOROFORM-d)  ppm 8.38 (d, J=2.86 Hz, 1 H, ArCH), 8.33 (s, 1 
H, NH), 8.09 (dd, J=8.59, 2.86 Hz, 1 H, ArCH), 7.43 (d, J=8.59 Hz, 1 H, ArCH), 4.13 - 
4.25 (m, 2 H, OCH2), 3.43 - 3.47 (m, 1 H, CH), 3.07 (appt, J=11.46 Hz, 2 H, CH2), 2.95 
(d, J=6.30 Hz, 1 H, CH), 2.58 (td, J=12.17, 2.58 Hz, 2 H, CH2), 2.06 (d, J=4.01 Hz, 1 H, 
240 
 
CH), 1.95 (br. s., 2 H, CH2), 1.84 - 1.92 (m, 2 H, CH2), 1.71 - 1.78 (m, 2 H, CH2), 1.68 
(m, 1 H, CH), 1.60 (q, J=6.87 Hz, 2 H, CH2), 1.43 - 1.54 (m, 2 H, CH2), 1.15 - 1.21 (m, 
1 H, CH), 0.44 - 0.60 (m, 4 H, CH2); HRMS: Exact mass: 475.1471; (M+H)
+: 476.1549; 
Observed mass: 476.1546; 0.59 ppm; Compound was described in the patent.121 
 
(1'S,2'R,3'R,4'R)-N2'-(6-bromo-3-pyridyl)-N3'-(4-piperidyl)spiro[cyclopropane-
1,7'-norbornane]-2',3'-dicarboxamide (109) 
 
Prepared according to procedure G with the  intermediate tert-Butyl 
4-[[(1'R,2'R,3'R,4'S)-3'-[(6-bromo-3-pyridyl)carbamoyl]spiro 
[cyclopropane-1,7'-norbornane]-2'-carbonyl]amino]piperidine-1-
carboxylate (105) (0.089 mmol). The crude product was purified by 
preparative flash column chromatography (19x100mm (5µm) C-18 
Waters Xbridge, MeOH, pH=10). Yield: 35 mg, 87%; Appearance: off-white solid; 
LCMS: 2.003 min, m/z 447, 449 ((M+H)+ 1:1, 79/81Br), Purity> 95%, method D; 1H NMR 
(500 MHz, CHLOROFORM-d)  ppm 9.85 (s, 1 H, NH), 8.48 (d, J=2.29 Hz, 1 H, ArCH), 
8.05 (dd, J=8.59, 2.86 Hz, 1 H, ArCH), 7.41 (d, J=8.59 Hz, 1 H, ArCH), 5.75 (d, J=8.59 
Hz, 1 H, NH), 4.00 – 3.85 (m, 1 H, CH), 3.38 - 3.28 (m, 1 H, CH), 3.17 - 3.07 (m, 2 H 
CH2), 2.83 - 2.70 (m, 2 H, CH2), 2.68 (d, J=6.87 Hz, 1 H, CH), 1.99 - 1.93 (m, 2 H, CH2), 
1.92 - 1.89 (m, 2 H, CH2), 1.85 - 1.80 (m, 1 H, CH), 1.77 (d, J=3.44 Hz, 2 H, CH2), 1.52 
- 1.43 (m, 1 H, CH), 1.43 - 1.31 (m, 2 H, CH2), 0.68 - 0.47 (m, 4 H, CH2); HRMS: Exact 
mass: 446.1317; (M+H)+: 447.1396; Observed mass: 447.1393; 0.59 ppm; Hybrid 
compound, compound not described in the patent. 
 
(1'S,2'R,3'R,4'R)-N2'-[(4-bromo-2-fluoro-phenyl)methyl]-N3'-(4-
piperidyl)spiro[cyclopropane-1,7'-norbornane]-2',3'-dicarboxamide (110) 
 
Prepared according to procedure G with the  intermediate tert-Butyl 
4-[[(1'R,2'R,3'R,4'S)-3'-[(4-bromo-2-fluoro-phenyl) 
methylcarbamoyl]spiro[cyclopropane-1,7'-norbornane]-2'-carbonyl] 
amino]piperidine-1-carboxylate (106) (0.10 mmol). The crude 
product was purified by preparative flash column chromatography 
(19x100mm (5µm) C-18 Waters Xbridge, MeOH, pH=10). Yield: 64 mg, 70%; 
Appearance: off-white solid; LCMS: 2.32 min, m/z 478.1, 481.1 ((M+H)+ 1:1, 79/81Br), 
Purity> 95%, method D; 1H NMR (500 MHz, CHLOROFORM-d)  ppm 7.26 - 7.20 (m, 
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3 H, ArCH), 6.47 (t, J=6.01 Hz, 1 H, NH), 6.15 (d, J=8.02 Hz, 1 H, NH), 4.38 - 4.55 (m, 
2 H, NCH2), 3.76 - 3.90 (m, 1 H, CH), 3.19 (dappt, J=6.59, 3.01 Hz, 1 H, CH), 3.03 - 
3.10 (m, 2 H CH2), 2.65 - 2.74 (m, 3 H CH, CH2), 1.84 - 1.96 (m, 4 H, CH2), 1.68 - 1.72 
(m, 2 H, CH2), 1.52 - 1.59 (m, 1 H, CH), 1.36 - 1.43 (m, 1 H, CH), 1.26 - 1.36 (m, 2 H, 
CH2), 0.72 (dappt, J=9.45, 5.01 Hz, 1 H, CH2), 0.56 (dappt, J=8.88, 5.30 Hz, 1 H, CH2), 
0.44 - 0.50 (m, 2 H, CH2); HRMS: Exact mass: 477.1427; ((M+H)
+:478.1505; Observed 
mass: 478.1504; 0.30 ppm; Compound was described in the patent.233 
 
(1'R,2'R,3'R,4'S)-N3'-(6-bromo-3-pyridyl)-N2'-[2-(4-piperidyl)ethyl] 
spiro[cyclopropane-1,7'-norbornane]-2',3'-dicarboxamide (111) 
 
Prepared according to procedure G with the  intermediate tert-butyl 
4-[2-[[(1'R,2'R,3'R,4'S)-3'-[(6-bromo-3-pyridyl) carbamoyl] spiro 
[cyclopropane-1,7'-norbornane]-2'-carbonyl]amino]ethyl] 
piperidine-1-carboxylate (104) (0.083 mmol). The crude product 
was purified by preparative HPLC (19x100mm (5µm) C-18 
Waters Xbridge, MeOH, pH=1). A product was dissolved in MeOH and filtered through 
ISOLUTE NH2 500mg SPE column (Biotage) to obtain final product as a freebase. Yield: 
39 mg, 98%; Appearance: white solid; LCMS: 1.89 min, m/z 475.1, 477.1 ((M+H)+ 1:1, 
79/81Br), Purity> 95%, method C; 1H NMR (500 MHz, METHANOL-d4)  ppm 8.60 (d, 
J=2.86 Hz, 1 H, ArCH), 7.98 (dd, J=8.88, 2.58 Hz, 1 H, ArCH), 7.54 (d, J=8.59 Hz, 1 H, 
ArCH), 3.73 (td, J=5.01, 2.00 Hz, 1 H CH), 3.33 - 3.39 (m, 2 H, CH2), 3.18 - 3.29 (m, 2 
H, CH), 2.98 (d, J=5.73 Hz, 1 H, CH), 2.93 (td, J=13.03, 3.15 Hz, 2 H, CH2), 1.93 - 2.00 
(m, 3 H CH2, CH), 1.85 - 1.93 (m, 1 H, CH), 1.83 (d, J=4.58 Hz, 1 H, CH), 1.57 - 1.73 
(m, 2 H, CH2), 1.44 - 1.57 (m, 4 H, CH2), 1.31 - 1.44 (m, 2 H, CH2), 0.61 - 0.69 (m, 1 H, 
CH2), 0.57 (dappt, J=9.45, 5.01 Hz, 1 H, CH2), 0.49 (dappt, J=9.45, 5.01 Hz, 1 H, CH2), 
0.38 - 0.46 (m, 1 H, CH2); HRMS: Exact mass: 474.1630; (M+H)
+:475.1709; Observed 
mass: 475.1706; 0.55 ppm; Hybrid compound not described in the patent. 
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(1'R,2'R,3'R,4'S)-N3'-(4-bromophenyl)spiro[cyclopropane-1,7'-norbornane]-2',3'-
dicarboxamide (112) 
 
To a solution of acid (1.0 equiv, 0.16 mmol) in tetrahydrofuran (2 mL) at 
ambient temperature was added 1,1'-carbonyldiimidazole (1.1 equiv., 0.18 
mmol), and the reaction was stirred for two hours. An aqueous solution of 
ammonia 28-30% (1.5 mL) was added, and the reaction was stirred for 12 
hours,  then acidified with 2N HCl. The mixture was extracted with 
EtOAc, dried over Na2SO4, and filtered. The solvent was removed, and the residue was 
purified by preparative HPLC (19x100mm (5µm) C-18 Waters Xbridge, MeOH, pH=1). 
Yield: 7 mg, 10%; Appearance: white solid; LCMS: 2.14 min, m/z 363.1, 365.1 ((M+H)+ 
1:1, 79/81Br), Purity> 95%,  Method D; 1H NMR (500 MHz, CHLOROFORM-d) δ ppm 
8.37 (s, 1 H, NH), 7.45 - 7.40 (m, 4 H, ArCH), 5.95 (br s, 1 H, NH),  5.39 (br s, 1 H, NH), 
3.42 - 3.38 (m, 1 H, CH), 2.81 (d, J=6.87 Hz, 1 H, CH), 1.92 - 1.84 (m, 3 H, CH, CH2), 
1.84 - 1.75 (m, 2 H, CH2), 1.50 - 1.42 (m, 1 H, CH), 0.73 (dappt, J=9.88, 5.08 Hz, 1 H, 
CH2), 0.64 - 0.59 (m, 1 H, CH2), 0.58 - 0.51 (m, 1 H, CH2), 0.51 - 0.43 (m, 1 H, CH2); 
HRMS: Exact mass: 362.0630; (M+H)+ :363.0708; Observed mass: 363.0703; 1.42 ppm. 
 
(1'R,2'R,3'R,4'S)-N3'-(6-bromo-3-pyridyl)-N2'-[2-(1-methyl-4-piperidyl)ethyl] 
spiro[cyclopropane-1,7'-norbornane]-2',3'-dicarboxamide (113) 
 
A solution of formaldehyde (37%) in water (0.18 mmol, 
0.013 mL, 0.014 g) was added to a solution of 
(1'R,2'R,3'R,4'S)-N3'-(6-bromo-3-pyridyl)-N2'-[2-(4-
piperidyl)ethyl]spiro[cyclopropane-1,7'-norbornane]-2',3'-
dicarboxamide (111) (0.044 mmol) in 1,2-dichloroethane 
(2 mL). RM mixture was stirred for 1h. sodium triacetoxyborohydride (3 equiv.) was 
added and RM was stirred at room temperature overnight. Reaction mixture was 
quenched with aq. solution of NaHCO3 and extracted with DCM three times. Organic 
layer was filtered through a phase separator and concentrated under reduced pressure. 
Crude product was purified by prep. HPLC (19x100mm (5µm) C-18 Waters Xbridge, 
MeOH pH=1), product was dissolved in MeOH and filtered through Isolute NH2 SPE 
column (Biotage) to obtain final product as a freebase. Yield: 6.5 mg, 30%; Appearance: 
white solid; LCMS: 1.88 min, m/z 489.1, 491.1 ((M+H)+ 1:1, 79/81Br), Purity>90%; 
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Method C; 1H NMR (500 MHz, CHLOROFORM-d)  ppm 9.79 (s, 1 H, NH), 8.48 (d, 
J=2.86 Hz, 1 H, ArCH), 8.03 (dd, J=8.59, 2.86 Hz, 1 H, ArCH), 7.41 (d, J=8.59 Hz, 1 H. 
ArCH), 5.94 - 5.73 (m, 1 H, NH), 3.36 - 3.45 (m, 1 H, CH2), 3.34 (td, J=4.30, 1.72 Hz, 1 
H, CH), 3.32 - 3.24 (m, 1 H, CH2, CH2), 2.86 (d, J=10.88 Hz, 2 H), 2.69 (d, J=6.87 Hz, 
1 H, CH), 2.27 (s, 2 H), 1.91 (t, J=3.72 Hz, 4 H, CH2), 1.88 - 1.79 (m, 4 H, CH2), 1.75 - 
1.67 (m, 2 H, CH2), 1.53 - 1.40 (m, 3 H, CH, CH2), 1.34 - 1.26 (m, 2 H, CH2), 0.65 - 0.44 
(m, 4 H, CH2); HRMS: Exact mass: 488.1786; (M+H)
+: 489.1865; Observed mass: 
489.1859, 1.25 ppm. 
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12.2.3.3. Oxazole series 
 
Ethyl 5-phenyloxazole-4-carboxylate (119) 
 
Prepared according to the literature procedure.234 A round-bottomed flask 
was charged with a solution of ethyl isocyanoacetate in toluene, then 
sodium hydride (1.15equiv.) was added portion wise. The resulting 
suspension was stirred for approximately 2 hours at room temperature, a solution of 
benzoyl chloride (1.15 equiv.) in 3mL of toluene was added. RM was stirred at room 
temperature overnight. Reaction mixture was quenched with water and extracted with 
ethyl acetate. Organic phase was dried over MgSO4, filtered and concentrated under 
reduced pressure. Crude product was purified by flash column chromatography ( silica 
gel, PE/EA 9/1 to 1/1). Yield: 970 mg, 50.5%; Appearance: yellow oil; LCMS: 1.47 min, 
m/z 218 (M+H)+, Purity>80%; method B; 1H NMR (500 MHz, DMSO-d6)  ppm 8.54 (s, 
1 H, ArCH), 7.92 (dd, J=6.87, 2.86 Hz, 2 H, ArCH), 7.48 - 7.51 (m, 3 H, ArCH), 4.25 (q, 
J=6.87 Hz, 2 H, CH2), 1.23 (t, J=7.16 Hz, 3 H, CH3); Data corresponded to that reported 
in the literature. 
 
5-Phenyloxazole-4-carboxylic acid (120) 
 
Prepared according to the literature procedure.234 To a stirred solution of 
ethyl 5-phenyloxazole-4-carboxylate (119) (900 mg, 4.14 mmol) in 
methanol/water 5/1 was added LiOH (2 equiv. 8.28 mmol). After addition, 
the solution was stirred at 60⁰C overnight. The solution was concentrated under reduced 
pressure, then diluted with water and acidified with 2M HCl. RM was extracted with ethyl 
acetate. Organic layer was dried over MgSO4, filtered and dried under vacuum to give 
crude product as white solid, which was used for next reaction without any further 
purification. Yield: 640 mg, 73.5%; Appearance: white solid; LCMS:  0.29 min, m/z 190 
(M+H)+, Purity>80%; method B; 1H NMR (500 MHz, DMSO-d6)  ppm 13.17 (br. s., 1 
H, COOH), 8.54 (s, 1 H, ArCH), 7.97 - 7.99 (m, 2 H, ArCH), 7.48 - 7.54 (m, 3 H, ArCH); 
Data corresponded to that reported in the literature. 
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Benzyl 2-(tert-butoxycarbonylamino) acetate (122) 
 
Prepared according to the literature procedure 235To a stirred 
solution of 2-(tert-butoxycarbonylamino) acetic acid (3 mmol, 0.5 
g) in dichloromethane, was added phenylmethanol (3 mmol, 0.3 
g) and 4-dimethylaminopyridine (0.3 mmol, 0.03 g) and the 
mixture was cooled to 0⁰C. A 1M solution of N,N'-dicyclohexylcarbodiimide (3 mmol, 
0.5 mL) in dichloromethane was then added. After addition, the reaction mixture was left 
stirring at room temperature for 12 hr. The precipitated urea was filtered off and the 
filtrate was washed with 5 % NaOH and 5 % HCl. The organic phase was then passed 
through the phase separator. The removal of the solvent under reduced pressure afforded 
the crude products without further purification. Yield: 620 mg, 80%; Appearance: white 
solid LCMS: 0.871 min, Purity>90%; Method A; 1H NMR (500 MHz, CHLOROFORM-
d) δ ppm 7.38 - 7.34 (m, 5 H, ArCH), 5.18 (s, 2 H, CH2), 5.00 (br.s, 1 H, CH), 3.96 (d, 
J=5.16 Hz, 2 H, CH2).  1.47 - 1.43 (m, 9 H, C(CH3)3) ; Data corresponded to that reported 
in the literature.236 
 
(2-benzyloxy-2-oxo-ethyl)ammonium chloride (123) 
 
A benzyl 2-(tert-butoxycarbonylamino) acetate (2.3 mmol, 0.62 g) was 
dissolved in ethyl acetate and hydrochloric acid (4 mol/L) in 1,4-
dioxane (12 mmol, 2.9 mL, 3.1 g) was added. The precipitate was 
filtered off and washed with ethyl acetate to afford the HCl-salt of the 
glycine ester. Yield: 440 mg, 93%; Appearance: white solid; LCMS: 0.31 min, m/z 166 
(M+H)+ , Purity>85%; Method A; 1H NMR (500 MHz, DMSO-d6) δ ppm 8.41 (br s, 3 H, 
-NH2
.HCl), 7.30 - 7.43 (m, 5 H, ArCH), 5.21 (s, 2 H,CH2), 3.84 (s, 2 H, CH2)  
 
Benzyl 2-(benzhydrylideneamino)acetate (124) 
 
Prepared according to the literature procedure.158 The round-
bottom flask equipped was charged with (2-benzyloxy-2-oxo-
ethyl)ammonium; chloride (2 mmol, 0.4 g) and dichloromethane 
(8 mL). To this mixture was charged diphenylmethanimine (2 
mmol, 0.4 mL) in one portion. The reaction was stirred at 20°C for 8 h until TLC analysis 
(1:1 ethyl acetate/petroleum ether). The precipitated ammonium salt was removed with a 
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short pad of Celite, and the filter cake was rinsed with CH2Cl2. The filtrates were 
concentrated under reduced pressure. Crude mixture was dissolved in diethyl ether and 
washed three times with water and saturated NaHCO3, Organic phase was filtered through 
a phase separator and concentrated under reduced pressure. Crude product was purified 
via flash column chromatography (PE/EA 8/2, slow gradient) to obtain desired product 
as a transparent oil. Yield: 380 mg, 60%; Appearance: transparent oil LCMS: 1.84 min, 
m/z 330.0 (M+H)+ , Purity>90%, Method A; 1H NMR (500 MHz, DMSO-d6) δ ppm 7.54 
- 7.30 (m, 13 H, ArCH), 7.18 - 7.14 (m, 2 H, ArCH),  5.12 (s, 2 H, CH2), 4.18 (s, 2 H, 
CH2). Data corresponded to that reported in the literature. 
 
Benzyl 2-acetamido-3-(m-tolyl)-3-oxo-propanoate (125) 
 
STEP 1 
 Prepared according to the literature procedure.158 A solution of 
benzyl 2-(benzhydrylideneamino)acetate (124) (0.9 mmol, 0.3 g) 
in anhydrous tetrahydrofuran (5 mL) was cooled to -78 °C under 
nitrogen atmosphere, and a sodium bis(trimethylsilyl)amide (1 
mol/L) in tetrahydrofuran (1 equiv., 0.9 mL) was slowly added while maintaining the 
reaction temperature at -78 °C. After 30 min, the orange solution of the Schiff base anion 
was added via syringe to a stirred solution of the 3-methylbenzoyl chloride (1 equiv., 0.9 
mmol, 0.1 mL) in anhydrous tetrahydrofuran (2mL) at -78 °C, and the mixture was stirred 
for 2 h. The reaction mixture was quenched with hydrochloric acid (4mol/L in dioxane) 
(2 equiv., 2 mmol, 0.5 mL) and concentrated to dryness under reduced pressure. The 
residue was suspended in ether (5 mL) and filtered to remove benzophenone. The 
intermediate β-ketoester hydrochloride salt was obtained as a white solid and used in the 
next reaction without any additional purification. 
STEP 2 
4-methylmorpholine (1.5 equiv., 0.72 mmol) was added to a cooled solution (-20 °C) of 
the intermediate β-ketoester hydrochloride salt (0.48 mmol) in anhydrous tetrahydrofuran 
(2 mL) under inert atmosphere. acetyl chloride (1 equiv., 0.48 mmol) was slowly added 
while maintaining the reaction mixture at -20 °C, and the bath was removed after stirring 
for 15 min. The reaction mixture was stirred for an additional 2 h, and the solvent was 
removed under reduced pressure. The residue was partitioned between ethyl acetate (3 
mL) and water (3 mL). The aqueous layer was extracted with ethyl acetate (3 x 5 mL), 
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and the organic layers were dried over anhydrous sodium sulphate and the solvents 
removed under reduced pressure to yield the crude product, which was then purified by 
flash column chromatography on silica gel (PE/EA 1/1). Yield: 89 mg, 57%; Appearance: 
colourless oil; LCMS: 1.61 min, m/z 326.0 (M+H)+, Purity>90%; Method A; 1H NMR 
(500 MHz, CHLOROFORM-d)  ppm 7.87 (d, J=1.15 Hz, 1 H, ArCH), 7.40 - 7.44 (m, 
1 H, ArCH), 7.32 - 7.37 (m, 1 H, ArCH), 7.23 - 7.30 (m, 4 H, ArCH), 7.08 - 7.12 (m, 2 
H, ArCH), 6.86 (d, J=6.87 Hz, 1 H, NH), 6.24 (d, J=7.45 Hz, 1 H, CH), 5.07 - 5.16 (m, 2 
H, CH2), 2.36 (s, 3 H, CH3), 2.10 (s, 3 H, CH3) 
 
benzyl 2-methyl-5-(m-tolyl)oxazole-4-carboxylate (126) 
 
Prepared according to the literature procedure.158 Triethylamine 
(1.0 mmol, 0.14 ml) was added to a solution of triphenylphosphine 
(2 equiv., 0.51 mmol, 0.12 ml) and iodine (2 equiv., 0.51 mmol) in 
dry dichloromethane (5 ml) and stirred for 5 minutes. then a 
solution of benzyl 2-acetamido-3-(m-tolyl)-3-oxo-propanoate (125) (0.26 mmol) in dry 
dichloromethane was added and the reaction was stirred at room temperature until 
completion Reaction mixture was concentrated under reduced pressure and purified by 
FCC (silica gel, 10g, PE/EA 6/4) to obtain desired product. Yield: 68 mg, 87%; 
Appearance: yellow oil; LCMS: 1.95 min, m/z 308.1 (M+H)+, Purity>90%; Method A; 
1H NMR (500 MHz, CHLOROFORM-d) δ 7.79 (d, J=8.02 Hz, 1H, ArCH), 7.75 (s, 1H, 
ArCH), 7.43-7.40 (m, 2H, ArCH), 7.36-7.28 (m, 4H, ArCH), 7.23 (d, J=7.45 Hz, 1H, 
ArCH), 5.38 (s, 2H, CH2), 2.54 (s,3H, CH3), 2.35 (s, 3H, CH3) 
 
2-methyl-5-(m-tolyl)oxazole-4-carboxylic acid (127) 
 
A benzyl 2-methyl-5-(m-tolyl)oxazole-4-carboxylate (126) 
(0.1920 mmol, 0.059 g)was dissolved in methanol (148 mmol, 6 
mL, 4.75 g) Reaction was run on the H-Cube controlled H2 mode 
at 1 ml/ min, 20 bar at 50 °C, 10% Pd/C CatCart . Solvent was 
evaporated to give desired .Yield: 40 mg, 96%; Appearance: white solid;  LCMS: 1.49 
min, m/z 218.1 (M+H)+, Purity>90%; Method A; 1H NMR (500 MHz, CHLOROFORM-
d)  ppm 8.02 (d, J=7.45 Hz, 1 H, ArCH), 7.99 (s, 1 H, ArCH), 7.38 (t, J=8.59 Hz, 1 H, 
ArCH), 7.29 (br. s, 1 H, ArCH), 2.58 (s, 3 H,CH3), 2.44 (s, 3 H, CH3) 
248 
 
 
methyl 2-(dichloromethyl)-4,5-dihydrooxazole-4-carboxylate (130) 
 
Prepared according to the literature procedure.237 A solution of 
sodium methoxide (0.1 equiv., 1.3 mmol) was diluted with methanol 
(3 mL) and cooled to -10 °C. 2,2-dichloroacetonitrile (1 equiv., 13 
mmol) was added dropwise. The mixture was stirred for 20 min at -5 
°C, and then DL-serine methyl ester hydrochloride (1 equiv., 13 mmol) was added along 
with methanol (5 mL). The mixture was stirred overnight at room temperature. The 
reaction mixture was quenched with water and extracted with dichloromethane twice. The 
combined organic layer was dried over sodium sulphate, filtered and then concentrated 
under vacuum to give crude product.  Yield: 2.34 g, 87%; Appearance: orange oil; LCMS: 
1.88 min, m/z 212.0, 214.0, 216.0 ((M+H)+ 10:6:1, 35/37Cl), Purity>90%; Method A; weak 
UV active; 1H NMR (500 MHz, CHLOROFORM-d)  ppm 6.29 (s, 1 H, CH), 4.91 (dd, 
J=10.60, 8.31 Hz, 1 H, CH2), 4.79 - 4.73 (m, 1 H, CH), 4.67 (dd, J=10.88, 9.17 Hz, 1 H, 
CH2), 3.83 (s, 3 H, CH3); Data corresponded to that reported in the literature.
237 
 
methyl 2-(chloromethyl)oxazole-4-carboxylate (131) 
 
Prepared according to the literature procedure.237 Mixture of methyl 
2-(dichloromethyl)-4,5-dihydrooxazole-4-carboxylate (130) (5.6 g, 
26 mmol) and N,N-diisopropylethylamine (15 mL) were heated at 
50⁰C overnight. RM was diluted with DCM and washed with water 
and brine. Organic layer was passed through a phase separator and concentrated under 
reduced pressure. Crude product was purified by flash column chromatography (silica 
gel, PE/EA 8/2) to obtain desired product. Yield: 3.15 g, 68%; Appearance: white solid; 
LCMS: 0.86 min, m/z 176.0, 178.0 ((M+H)+ 3:1, 35/37Cl), Purity>90%; Method A; 1H 
NMR (500 MHz, CHLOROFORM-d)  ppm 8.25 (s, 1 H, ArCH), 4.64 (s, 2 H, CH2), 
3.93 (s, 3 H, CH3); Data corresponded to that reported in the literature.
237 
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[2-(chloromethyl)oxazol-4-yl]methanol (132) 
 
Prepared according to the literature procedure.128 In a flame dried 
round-bottomed flask equipped with a magnetic stir bar and under 
inert atmosphere methyl 2-(chloromethyl)oxazole-4-carboxylate  
(131) (0.1 g, 0.6 mmol) in tetrahydrofuran (3 mL, 36.9 mmol) at 0⁰C 
was treated with diisobutylaluminum hydride (1 mol/L) in tetrahydrofuran (3.4 equiv., 2 
mmol). RM was stirred at zero degree for 1h. RM was allowed to warm to RT. The 
reaction mixture was carefully poured over a potassium sodium tartrate (20 mL, 40 mmol) 
and ethyl acetate was added. The mixture was stirred for 1.5h. RM was extracted three 
times with EtOAc, then an organic phase was dried over Na2SO4, filtered and 
concentrated under reduced pressure. Crude product was purified by flash column 
chromatography (10g silica) using PE/EtOAc 2/8 to obtain desired product. Yield: 35 mg, 
40%; Appearance: white solid; LCMS: 0.42 min, m/z 148.0, 150.0 ((M+H)+ 3:1, 35/37Cl), 
Purity>90%; Method A; 1H NMR (500 MHz, CHLOROFORM-d) δ ppm 7.61 (s, 1 H, 
ArCH), 4.61 (s, 2 H, CH2), 4.59 (s, 2 H, CH2); Data corresponded to that reported in the 
literature. 
 
2-(chloromethyl)-4-(methoxymethyl)oxazole (133) 
 
Prepared according to the literature procedure.128 In a flame dried 
round-bottomed flask equipped with a magnetic stir bar and under 
inert atmosphere, a solution of [2-(chloromethyl)oxazol-4-
yl]methanol (132) (200 mg, 1.35 mmol)  in dichloromethane (3 mL, 
46.80 mmol) was treated with iodomethane (1.2 equiv., 1.63 mmol) followed by silver 
oxide (1.5 equiv., 2.03 mmol) and the resulting mixture (protected from light) was stirred 
overnight at 40°C. The reaction mixture was filtered, and the solvent was removed under 
reduced pressure. Yield: 55 mg, 25%; Appearance: white solid; LCMS: 0.78 min, m/z 
162.1, 164.0 ((M+H)+ 3:1, 35/37Cl), Purity>90%; Method A; 1H NMR (500 MHz, 
CHLOROFORM-d)  ppm 7.62 (t, J=1.15 Hz, 1 H, ArCH), 4.59 (s, 2 H, CH2), 4.38 (d, 
J=1.15 Hz, 2 H, CH2 ), 3.43 (s, 3 H, CH3); Data corresponded to that reported in the 
literature. 
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2-(chloromethyl)oxazole-4-carbaldehyde (134) 
 
 To a solution of [2-(chloromethyl)oxazol-4-yl]methanol (132) 
(2.8666 mmol, 0.47 g) in dichloromethane  was added Dess-Martin 
periodinane (4.58 mmol, 1.95 g) and the mixture was stirred at room 
temperature overnight. RM was quenched with saturated sodium 
thiosulfate and extracted three times with DCM, organic layer was 
washed with sat.  NaHCO3, filtered through a phase separator and concentrated under 
reduced pressure. Crude product was dry loaded onto silica and purified by flash column 
chromatography ( silica gel, ethyl acetate/petroleum ether 7/3 gradient). Appropriate 
fractions were combined and solvent removed in vacuo to yield 2-(chloromethyl)oxazole-
4-carbaldehyde. Yield: 150 mg, 36%; Appearance: transparent oil; LCMS: weak 
ionization, 0.64 min, m/z 148.0, 150.1 ((M+H)+ 3:1, 35/37Cl) , Purity>90%; Method A; 1H 
NMR (500 MHz, CHLOROFORM-d) δ ppm 9.94 (s, 1 H, CHO), 8.28 (s, 1 H, ArCH), 
4.66 (s, 2 H, CH2); Compound has been reported in the literature.
238  
 
1-[2-(chloromethyl)oxazol-4-yl]ethanol (135) 
 
In a dried round-bottomed flask equipped with magnetic stir bar and 
under inert atmosphere a solution of 2-(chloromethyl)oxazole-4-
carbaldehyde  (134) (0.65 mmol, 95 mg) in dichloromethane (4 mL) was 
treated at 0⁰C with trimethylaluminum (2 mol/L) in heptane (3.26 mmol, 
1.6319 mL). The reaction was stirred at 0⁰C for 60 min. Saturated NH4Cl was then added 
and the aq. layer was extracted twice with DCM and twice with ethyl acetate. Combined 
organic layers were passed through a phase separator and solvent removed in vacuo. 
Crude product was purified via flash column chromatography (silica gel, PE/EA 3/7). 
Yield: 42 mg, 36%; Appearance: transparent oil; LCMS: 0.58 min, 162.1, 164.1 ((M+H)+ 
3:1, 35/37Cl), Purity>90%, Method A; 1H NMR (500 MHz, CHLOROFORM-d) δ ppm 
7.55 (d, J=1.15 Hz, 1 H, ArCH), 4.85 (q, J=5.92 Hz, 1 H, OH), 4.59 (s, 2 H, CH2), 2.38 
(br s, 1 H, CH), 1.53 (d, J=6.87 Hz, 3 H, CH3); Compound has been reported in the 
literature.238 
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1-[2-(chloromethyl)oxazol-4-yl]ethanone (136) 
 
To a solution of 1-[2-(chloromethyl)oxazol-4-yl]ethanol (135) (0.26 
mmol, 42 mg) in dichloromethane was added Dess-Martin periodinane 
(0.42 mmol, 0.18 g) and the mixture was stirred at room temperature 
overnight. RM was quenched with saturated sodium thiosulfate and 
extracted three times with DCM, organic layer was washed with sat.  NaHCO3, passed 
through a phase separator and concentrated under reduced pressure. Crude product was 
dry loaded onto silica and purified by flash column chromatography ( silica gel, ethyl 
acetate/petroleum ether7/3). Yield: 150 mg, 36%; Appearance: white solid; LCMS: 0.86 
min, non-ionizing, Purity>90%; Method A; 1H NMR (500 MHz, CHLOROFORM-d) δ 
ppm 8.21 (s, 1 H, ArCH), 4.64 (s, 2 H, CH2), 2.54 (s, 3 H, CH3); Compound has been 
reported in the literature.238 
  
General procedure H: amination: 
 
A 2-chloromethyloxazole derivative was dissolved in N,N-dimethylformamide (3 mL 
then 3-nitro-1H-pyrazole (1.5 equiv.) and N,N-diisopropylethylamine (3 equiv) were 
added. RM was stirred at room temperature for 30minutes and later heated at 50⁰C. 
Reaction mixture was diluted with ethyl acetate and washed with water and brine. The 
organic layer was passed through the phase separator and concentrated under reduced 
pressure. Crude product was purified by flash column chromatography (PE/EA ) to obtain 
a desired product.  
 
4-(methoxymethyl)-2-[(3-nitropyrazol-1-yl)methyl]oxazole (138) 
 
Prepared according to procedure G with intermediate 2-
(chloromethyl)-4-(methoxymethyl)oxazole (133) (0.34 mmol) 
Crude product was purified by flash column chromatography 
(silica gel, PE/EA 6/4) to obtain a desired product. Yield: 46 mg, 55%; Appearance: 
yellow oil; LCMS: 0.93 min, m/z 239.1 (M+H)+, Purity>90%; Method A; 1H NMR (500 
MHz, CHLOROFORM-d) δ ppm 7.64 - 7.62 (m, 2 H, ArCH); 6.95 (d, J=2.29 Hz, 1 H, 
ArCH)); 5.50 (s, 2 H, CH2); 4.37 (d, J=1.15 Hz, 2 H, CH2); 3.43 (s, 3 H, CH3); Compound 
has been reported in the literature.124 
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1-[2-[(3-nitropyrazol-1-yl)methyl]oxazol-4-yl]ethanone (139) 
 
Prepared according to procedure G with intermediate1-[2-
(chloromethyl)oxazol-4-yl]ethanone (136) (0.23 mmol); Crude 
product was purified by flash column chromatography (silica gel, 
PE/EA 3/7) to obtain a desired product. Yield: 20 mg, 29%; Appearance: yellow oil; 
LCMS: 0.95 min, m/z 237.1 (M+H)+, Purity>80%; Method A; 1H NMR (500 MHz, 
CHLOROFORM-d) δ ppm 8.21 (s, 1 H, ArCH), 7.68 (d, J=2.29 Hz, 1 H, ArCH), 6.96 - 
6.99 (m, 1 H, ArCH), 5.56 (s, 2 H, CH2), 2.52 (s, 3 H, CH3); Compound has been reported 
in the literature124 
 
General procedure I: a reduction of nitro group: 
 
A 4-(methoxymethyl)-2-[(3-nitropyrazol-1-yl)methyl]oxazole (0.180 g, 0.756 mmol) 
was dissolved in methanol (18 mL, 10mg/1mL). A reduction of the nitro group of a 
starting material has been performed using the H-Cube. Conditions: 10% Pd/C CatCart 
at 1mL/min, room temperature, full mode. A solvent was evaporated to give desired 
product. Crude  product was used without further purification. 
 
 
1-[[4-(methoxymethyl)oxazol-2-yl]methyl]pyrazol-3-amine (140) 
 
Prepared according to procedure I with intermediate 4-
(methoxymethyl)-2-[(3-nitropyrazol-1-yl)methyl]oxazole (138) 
(0.76 mmol). Crude product was used without further 
purification. Yield: 131 mg, 83%; Appearance: transparent oil; LCMS: 0.93 min, m/z 
209.1 (M+H)+, Purity>90%; Method A; 1H NMR (500 MHz, DMSO-d6) d ppm 8.00 (d, 
J=1.15 Hz, 1 H, ArCH), 7.44 (d, J=2.29 Hz, 1 H, ArCH), 5.43 (d, J=2.29 Hz, 1 H, ArCH), 
5.16 (s, 2 H, CH2), 4.64 (s, 2 H, NH2), 4.25 (s, 2 H, CH2), 3.25 (s, 3 H, CH3); Compound 
has been reported in the literature.124 
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1-[2-[(3-aminopyrazol-1-yl)methyl]oxazol-4-yl]ethanone (141) 
 
Prepared according to procedure I with intermediate 1-[2-[(3-
nitropyrazol-1-yl)methyl]oxazol-4-yl]ethanone (139) (0.05 mmol); 
Crude  product was used without further purification. Yield: 15 mg, 
100 %; Appearance: transparent oil; LCMS: 0.23 min, m/z 207.1 (M+H)+, Purity>80%; 
Method A; 1H NMR (500 MHz, CHLOROFORM-d) δ ppm 8.15 (s, 1 H, ArCH), 7.28 (d, 
J=2.29 Hz, 1 H, ArCH), 5.67 - 5.65 (m, 1 H, ArCH), 5.22 (s, 2 H, CH2),  2.51 (s, 3 H, 
CH3); Compound has been reported in the literature.
124 
 
Compounds were prepared according to general procedure E for amide coupling 
using T3P: 
 
 
N-[1-[[4-(methoxymethyl)oxazol-2-yl]methyl]pyrazol-3-yl]-5-phenyl-oxazole-4-
carboxamide (142) 
 
Prepared according to procedure E with intermediate 5-
phenyloxazole-4-carboxylic acid (120) (0.3 mmol) and 1-
[[4-(methoxymethyl)oxazol-2-yl]methyl]pyrazol-3-
amine (140) (1 equiv. 0.3 mmol). Crude product was 
purified via flash column chromatography (10g silica, PE/EA 0-->100%); Yield: 71 mg, 
60%; Appearance: cream solid; LCMS: 1.42 min, m/z 380 (M+H)+, Purity>90%; Method 
A; 1H NMR (500 MHz, DMSO-d6)  ppm 10.18 (s, 1 H, NH), 8.64 (s, 1 H, ArCH), 8.13 
- 8.18 (m, 2 H, ArCH), 8.04 - 8.06 (m, 1 H, ArCH), 7.84 (d, J=2.29 Hz, 1 H, ArCH), 7.46 
- 7.57 (m, 3 H, ArCH), 6.66 (d, J=2.29 Hz, 1 H, ArCH), 5.45 (s, 2 H, CH2), 4.27 (s, 2 H, 
CH2), 3.24 - 3.28 (m, 3 H, CH3); 
13C NMR (126 MHz, DMSO-d6)  ppm 159.11 (1 C, 
C=O), 158.62 (1 C, ArC), 151.72 (1 C, ArC), 150.39 (1 C, ArCH), 146.78 (1 C, ArC), 
138.03 (1 C, ArCH), 137.56 (1 C, ArC), 131.99 (1 C, ArC), 130.17 (1 C, ArCquat), 128.65 
(2 C, ArCH), 128.52 (1 C, ArCH), 127.71 (2 C, ArCH), 126.67 (1 C, ArCH), 97.96 (1 C, 
ArCH), 65.24 (1 C, CH2), 57.51 (1 C, CH3), 47.86 (1 C, CH2); HRMS: Exact mass: 
379.1281; (M+H)+: 380.1359; Observed mass: 380.1349; 2.58 ppm. 
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N-[1-[[4-(methoxymethyl)oxazol-2-yl]methyl]pyrazol-3-yl]-2-methyl-5-(m-
tolyl)oxazole-4-carboxamide (143) 
 
Prepared according to procedure E with intermediate 1-
[[4-(methoxymethyl)oxazol-2-yl]methyl]pyrazol-3-
amine (140) (0.19 mmol) and 2-methyl-5-(m-
tolyl)oxazole-4-carboxylic acid (127) Crude product was 
purified via flash column chromatography (10g silica, PE/EA 10-->100%) to give final 
product as a cream solid. Yield: 14 mg, 21%; Appearance: white solid; LCMS: 1.63 min, 
m/z 408.2 (M+H)+, Purity>90%; Method A; 1H NMR (500 MHz, CHLOROFORM-d) δ 
ppm 9.55 (s, 1 H, NH), 8.11 (d, J=8.02 Hz, 1 H, ArCH), 8.01 (s, 1 H, ArCH ), 7.59 (d, 
J=1.15 Hz, 1 H, ArCH), 7.45 (d, J=2.29 Hz, 1 H, ArCH ), 7.35 (t, J=7.73 Hz, 1 H, ArCH 
), 7.22(d, J=7.45 Hz, 1 H, ArCH ), 6.89 (d, J=2.29 Hz, 1 H, ArCH), 5.31 (s, 2 H, CH2), 
4.38 (d, J=1.15 Hz, 2 H, CH2 ), 3.42 (s, 3 H, OCH3), 2.51 (s, 3 H, CH3), 2.42 (s, 3 H, 
CH3) HRMS: Molecular formula: Exact mass: 407.1593;(M+H)
+: 408.1672 Observed 
mass: 408.1662; 2.40 ppm. 
 
N-[1-[(4-acetyloxazol-2-yl)methyl]pyrazol-3-yl]-2-methyl-5-(m-tolyl)oxazole-4-
carboxamide (144) 
 
Prepared according to procedure E with intermediate 1-
[2-[(3-aminopyrazol-1-yl)methyl]oxazol-4-yl]ethanone  
(141) (0.041 mmol) and 2-methyl-5-(m-tolyl)oxazole-4-
carboxylic acid (127) (1.1 equiv., 0.045 mmol). Crude 
product was purified by preparative. HPLC (19x100mm (5µm) C-18 Waters Xbridge, 
MeOH pH=10); Yield: 3.5 mg, 19%; Appearance: white solid; LCMS: 2.15 min, m/z 
406.2 (M+H)+, Purity>90%; Method D; 1H NMR (500 MHz, CHLOROFORM-d) δ ppm 
9.54 (s, 1 H, NH), 8.18 (br.s, 1 H, ArCH), 8.11 (d, J=8.02 Hz, 1 H, ArCH), 8.01 (s, 1 H, 
ArCH), 7.48 (d, J=2.29 Hz, 1 H, ArCH), 7.35 (t, J=7.73 Hz, 1 H, ArCH), 7.22 (d, J=8.02 
Hz, 1 H, ArCH), 6.92 (d, J=2.29 Hz, 1 H, ArCH),  5.36 (s, 2 H, CH2),  2.53 (s, 3 H, CH3), 
2.51 (s, 3 H, CH3), 2.42 (s, 3 H, CH3); HRMS: Exact mass: 405.1437;(M+H)
+:406.151; 
Observed mass: 406.1507; 2.04 ppm 
  
255 
 
12.2.3.4. Kyorin series 
 
ethyl 4-hydroxy-2,5-dihydrofuran-3-carboxylate (149) 
 
Sodium hydride (60 mass%) in mineral oil (6 mmol, 0.2 g) was 
suspended in diethyl ether (10 mL) and cooled in ice-bath. To this 
suspension was added ethyl 2-hydroxyacetate (5 mmol, 0.5 mL) 
dropwise under inert atmosphere. The resulting white slurry was stirred 
at room temperature for 45 min. Ether was removed in vacuo to give white solid. It was 
suspended in dimethyl sulfoxide (4 mL), cooled in ice-bath, and ethyl prop-2-enoate (6 
mmol, 0.7 mL) was added dropwise. The resulting yellow mixture was stirred at RT 
overnight. The reaction solution was poured into 10% aq. HCl slowly. It was extracted 
with ether (3 times). The combined ether extracts were filtered through a phase separator, 
concentrated in vacuo to give product as clear yellow liquid. Crude product was purified 
by flash column chromatography (silica gel, PE/EA 3/1, slow gradient) to give a 
transparent oil. Yield: 650 mg, 90%; Appearance: transparent oil LCMS: 2.15 min, m/z 
406.0 (M+H)+, Purity>90%; Method D; 1H NMR (500 MHz, CHLOROFORM-d) δ ppm 
4.53 - 4.42 (m, 2 H, OCH2CH3), 4.27 - 4.20 (m, 2 H, CH2), 4.07 – 3.93 (m, 2 H, CH2), 
3.50 (t, J=8.31 Hz, 1 H, CH), 1.32 - 1.28 (m, 3 H, CH3); A methyl has been reported in 
the literature.153 
 
ethyl 4-(trifluoromethylsulfonyloxy)-2,5-dihydrofuran-3-carboxylate (150) 
Under an argon atmosphere at 0oC to a solution of N,N-
diisopropylethylamine (2 equiv.,7.85 mmol) and the ethyl 4-hydroxy-
2,5-dihydrofuran-3-carboxylate (3.93 mmol) in dry dichloromethane 
(2 mL) was added trifluoromethanesulfonic anhydride (1.2 
equiv.,4.71 mmol) and the mixture was stirred for 15min in ice bath, and 45min at RT.  
Hydrochloric acid (2 mol/L) in water (11.8 mmol, 5.89 mL) was added and RM was 
stirred for 5 minutes. Diluted with dichloromethane (2 x 10 mL). Organic phase was 
washed with brine and water and extracted with phase separator. Crude product was not 
purified. Yield: 1.05g, 92%; Appearance: reddish oil; LCMS: 1.75 min, no ionization, 
Purity>90%; Method A; 1H NMR (500 MHz, CHLOROFORM-d) δ ppm 4.88 - 4.95 (m, 
2 H, CH2), 4.75 - 4.83 (m, 2 H, CH2), 4.29 (q, J=7.45 Hz, 2 H, CH2), 1.33 (t, J=7.16 Hz, 
3 H, CH3); A methyl has been reported in the literature.
153 
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General procedure J: Suzuki coupling: 
 
Under an inert atmosphere to a solution of ethyl 4-(trifluoromethylsulfonyloxy)-2,5-
dihydrofuran-3-carboxylate (1 equiv.) in N,N-dimethylformamide (2 mL) boronic acid 
(1.3-2 equiv.) and triethylamine (3 equiv.) were added. Reaction mixture was flushed 
with nitrogen for 5 minutes and tetrakis(triphenylphosphine)palladium (0) (10% mmol) 
was added. RM was stirred at 100⁰C for 3h. RM was diluted with ethyl acetate and washed 
with water and brine three times. Organic phase was dried via phase separator and 
concentrated under reduced pressure. Crude product was purified by flash column 
chromatography (PE/EA 40%) to obtain desired product as the yellow oil. 
 
 
ethyl 4-(4-methoxyphenyl)-2,5-dihydrofuran-3-carboxylate (151) 
 
Prepared according to procedure J with intermediate ethyl 4-
(trifluoromethylsulfonyloxy)-2,5-dihydrofuran-3-carboxylate (150) (0.3 
mmol) and (4-methoxyphenyl)boronic acid ( 1.3 equiv. 0.4 mmol); 
Yield: 60 mg, 70%; Appearance: yellow oil ; LCMS: 1.76 min, m/z 249.0 
(M+H)+, Purity>90%; Method A; 1HNMR (500 MHz, CHLOROFORM-
d) δ ppm 7.49 - 7.53 (m, 2 H, ArCH), 6.88 - 6.94 (m, 2 H, ArCH), 5.00 - 5.11 (m, 4 H, 
CH2), 4.19 (q, J=6.89 Hz, 2 H, CH2), 3.84 (s, 3 H, CH3), 1.25 (t, J=6.89 Hz, 3 H, CH3); 
A methyl ester has been reported in the literature.153 
 
ethyl 4-(2,6-difluoro-4-methoxy-phenyl)-2,5-dihydrofuran-3-carboxylate (152) 
 
Prepared according to procedure J with intermediate ethyl 4-
(trifluoromethylsulfonyloxy)-2,5-dihydrofuran-3-carboxylate (150) 
(0.76 mmol) and ((2,6-difluoro-4-methoxy-phenyl)boronic acid ( 
1.8 equiv. 1.36 mmol); Yield: 60 mg, 30%; Appearance: yellow oil 
LCMS: 1.742 min, weak ionization, Method A; Purity>90%; 1H 
NMR (500 MHz, CHLOROFORM-d) δ 6.52-6.44 (m, 2H, ArCH), 5.03-4.93 (m, 4H, 
CH2), 4.14 (q, J=6.87 Hz, 2H, CH2), 3.80 (s, 3H, CH3), 1.17 (t, J=7.16 Hz, 3H, CH3); A 
methyl ester has been reported in the literature.153 
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4-(4-methoxyphenyl)-2,5-dihydrofuran-3-carboxylic acid (153) 
 
To a solution of ethyl 4-(4-methoxyphenyl)-2,5-dihydrofuran-3-
carboxylate (0.23 mmol, 0.058 g) in methanol (49.4 mmol, 2 mL, 1.58 
g) was added potassium hydroxide (2 mol/L) in water (0.47 mmol, 
0.23 mL, 0.27 g). Reaction mixture was stirred at 50⁰C for 4 hours. 2 
mol/L hydrochloric acid was added to make the reaction solution 
acidic. A solution was diluted with water and extracted three times with ethyl acetate. 
Organic layer was filtered through a phase separator and concentrated under reduced 
pressure to obtain desired product. Yield: 60 mg, 30%; Appearance: yellowish solid 
LCMS: 0.49 min, m/z 221.1 (M+H)+, Method B; Purity>90%; 1H NMR (500 MHz, 
CHLOROFORM-d) δ ppm 7.48 - 7.51 (m, 2 H, ArCH), 6.88 - 6.92 (m, 2 H, ArCH), 5.00 
- 5.12 (m, 4 H, CH2) ,3.83 (s, 3 H, CH3)  A compound has been reported in the literature.
153 
 
4-(4-methoxyphenyl)-2,5-dihydrofuran-3-carboxylic acid (155) 
 
A 4-(4-methoxyphenyl)-2,5-dihydrofuran-3-carboxylic acid (153) (0.24 mmol, 0.052 g)  
was dissolved in methanol (5.5 mL). A reduction of the double bond of a starting material 
has been performed using the H-Cube in three cycles: 
• 10% Pd/C CatCart at 1mL/min, room temperature. 50% of product 
• 10% Pd/C CatCart at 1mL/min, room temperature 60-70% of 
product 
• 10% Pd/C CatCart at 1mL/min, 30⁰C, 20bar 90-95%, still some 
traces of SM 
Solvent was evaporated to obtain 4-(4-methoxyphenyl)tetrahydrofuran-3-carboxylic acid 
as a transparent film. Yield: 40 mg, 80%; Appearance: yellowish solid ; LCMS: 0.39  min, 
m/z 223.1 (M+H)+ weak ionization, Method B; Purity>90%; 1H NMR (500 MHz, 
CHLOROFORM-d) δ 7.19-7.15 (m, 2H, ArCH), 6.83-6.79 (m, 2H, ArCH), 4.23 (dd, 
J=6.87, 8.59 Hz, 1H, CH), 4.18-4.13 (m, 1H, CH), 4.13-4.08 (m, 2H, CH2), 3.78 (s, 2H, 
CH2), 3.79-3.76 (m, 1H, CH), 3.48-3.44 (m, 1H, CH); A compound has been reported in 
the literature.153 
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ethyl 4-(2,6-difluoro-4-methoxy-phenyl)tetrahydrofuran-3-carboxylate (154) 
 
The ethyl 4-(2,6-difluoro-4-methoxy-phenyl)-2,5-dihydrofuran-3-
carboxylate (0.18 mmol, 0.051 g) was dissolved in methanol (140 
mmol, 5.5 ml, 4.4 g). a reduction of the double bond of a starting 
material has been performed using the H-cube. conditions:  10% Pd/C 
CatCart® at 1ml/min, 35⁰C, 20bar. solvent was evaporated to obtain 
ethyl 4-(2,6-difluoro-4-methoxy-phenyl)tetrahydrofuran-3-carboxylate as a transparent 
film. Yield: 50 mg, 90%; Appearance: transparent film; LCMS: 1.74 min, low ionization; 
Method A; 1H NMR (500 MHz, CHLOROFORM-d) δ ppm 0.97 (t, J=6.87 Hz, 3 H, CH3) 
3.43 (br s, 1 H, CH) 3.42 - 3.52 (m, 1 H, CH) 3.76 (s, 3 H, CH3) 3.81 - 3.91 (m, 2 H, CH2) 
3.91 - 4.00 (m, 1 H, CH2) 4.12 - 4.25 (m, 4 H, CH2) 6.39 - 6.44 (m, 2 H,) 
 
4-(2,6-difluoro-4-methoxy-phenyl)tetrahydrofuran-3-carboxylic acid (156) 
 
To a solution of ethyl 4-(2,6-difluoro-4-methoxy-
phenyl)tetrahydrofuran-3-carboxylate (0.14 mmol) in methanol (2 
mL) was added potassium hydroxide (2 mol/L) in water (2 equiv., 
0.28 mmol). Reaction mixture was stirred at 50⁰C for 4 hours. The 2 
mol/L solution of hydrochloric acid was added to make the reaction 
solution acidic. A solution was diluted with water and extracted three times with ethyl 
acetate. Organic layer was filtered through a phase separator and concentrated under 
reduced pressure to obtain desired product as the yellowish oil. Yield: 34 mg, 94%; 
Appearance: yellowish oil; LCMS: 1.32 min, weak ionization, Method A; Purity>90% 
1H NMR (500 MHz, CHLOROFORM-d) δ ppm 6.49 - 6.42 (m, 2 H, ArCH), 4.25 - 4.17 
(m, 3 H, CH2), 4.08-3.97 (m, 1 H, CH2), 3.80 - 3.74 (m, 4 H, CH, CH3), 3.46 - 3.40 (m, 1 
H, CH) A compound has been reported in the literature.153 
 
General procedure K:  urea formation using DPPA: 
 
Under an inert atmosphere to a solution of tetrahydrofuran-3-carboxylic acid (1 Equiv.) 
was added triethylamine (2 equiv) and diphenylphosphoryl azide (1 equiv., 0.2 mmol) to 
produce a reaction solution. the reaction solution was stirred at room temperature for 2h 
and then at 100⁰C for 30 minutes. The reaction solution was allowed to cool to room 
temperature, then 4-chloroaniline (1 equiv., 0.2 mmol) was added thereto, and the reaction 
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mixture was heated to reflux for 1 hour. RM was concentrated and purified by FCC 
(PE/EA 80%) to obtain crude product. Crude product was washed with diethyl ether to 
give a final compound as a white solid.  
 
1-(4-chlorophenyl)-3-[4-(4-methoxyphenyl)tetrahydrofuran-3-yl]urea (157) 
 
Prepared according to procedure J with intermediate ethyl 4-
(2,6-difluoro-4-methoxy-phenyl)tetrahydrofuran-3-carboxylate 
(154) (0.2 mmol) and 4-chloroaniline (1 equiv., 0.2 mmol). 
Crude product was purified by preparative. HPLC (19x100mm 
(5µm) C-18 Waters Xbridge, MeOH pH=10): Yield: 60 mg, 
30%; Appearance: white solid; LCMS: 1.677 min, m/z 347.0, 
349.0 ((M+H)+ 3:1, 35/37Cl), Method A; 1H NMR (500 MHz, DMSO-d6) δ 8.44 (s, 1H, 
NH), 7.31-7.24 (m, 2H, ArCH), 7.23-7.17 (m, 2H, ArCH), 7.13 (br d, J=8.59 Hz, 2H, 
ArCH), 6.85 (br d, J=8.59 Hz, 2H, ArCH), 5.90 (br d, J=8.59 Hz, 1H, CH), 4.58-4.48 (m, 
1H, CH2), 4.13 (t, J=8.02 Hz, 1H, CH2), 3.98 (dd, J=6.30, 8.59 Hz, 1H, CH), 3.87 (t, 
J=8.02 Hz, 1H, CH2), 3.68 (s, 3H, CH3), 3.57-3.48 (m, 2H, CH2); HRMS: Exact mass: 
346.1084; ((M+H)+ 347.116; Observed mass: 347.1159; 0.99 ppm; Compound has been 
described in the literature153 
 
1-(4-chlorophenyl)-3-[4-(2,6-difluoro-4-methoxy-phenyl)tetrahydrofuran-3-yl]urea 
(158) 
 
Prepared according to procedure J with intermediate ethyl 44-
(2,6-difluoro-4-methoxy-phenyl)tetrahydrofuran-3-
carboxylic acid (156) (0.13 mmol) and 4-chloroaniline (1 
equiv., 0.13 mmol). Crude product was purified by 
preparative. HPLC (19x100mm (5µm) C-18 Waters Xbridge, 
MeOH pH=10): Yield: 10 mg, 20%; Appearance: white solid.  
LCMS: 1.677 min, m/z 383.0, 385.0 ((M+H)+ 3:1, 35/37Cl), Method A; 1H NMR (500 
MHz, DMSO-d6)  ppm 8.46 (s, 1 H, NH), 7.13 - 7.34 (m, 6 H, CH2), 6.87 (d, J=8.02 Hz, 
2 H, CH2), 5.93 (d, J=8.59 Hz, 1 H, NH), 4.51 - 4.59 (m, 1 H, CH), 4.16 (t, J=8.02 Hz, 1 
H, CH2), 4.01 (dd, J=8.59, 6.30 Hz, 1 H, CH), 3.90 (t, J=8.02 Hz, 1 H, CH2), 3.70 (s, 3 
H, CH3), 3.55 - 3.61 (m, 1 H, CH2), 3.49 - 3.55 (m, 1 H, CH2); HRMS: Exact mass: 
382.0896; (M+H)+: 383.0974; Observed mass:383.0967; 1.83 ppm. 
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12.2.3.5. Pyridinone series 
 
General Chan-Lam coupling procedure L: 
 
The 3-nitro-1H-pyridin-2-one (0.7 mmol), boronic acid (1 mmol, 1.4 equiv.), 
triethylamine (1.4 equiv., 1 mmol), pyridine (1.4 equiv., 1 mmol) and copper(II) acetate 
(0.3 equiv., 0.3 mmol) were added to tetrahydrofuran (5 mL) followed by stirring at room 
temperature overnight. The reaction was poured into aq. ammonia and extracted with 
ethyl acetate. Aq. layer was washed three times with ethyl acetate. Organic phase was 
filtered through a phase separator and concentrated under reduced pressure. Crude 
product was washed with diethyl ether and a precipitate was filtered.  
 
3-nitro-1-phenyl-pyridin-2-one (163) 
 
Prepared according to procedure L with intermediate 3-nitro-1H-
pyridin-2-one (0.7 mmol) and phenylboronic acid (1.7 equiv., 1 
mmol). Crude product was washed with diethyl ether and a precipitate 
was filtered. Yield: 72 mg, 50%; Appearance: orange solid; LCMS: 0.86 min, m/z 217.0 
(M+H)+, Method A; 1H NMR (500 MHz, CHLOROFORM-d)  ppm 8.40 (dd, J=5.73, 
2.90 Hz, 1 H, ArCH), 7.74 (dd, J=4.58, 2.29 Hz, 1 H, ArCH), 7.49 - 7.57 (m, 3 H, ArCH), 
7.38 - 7.42 (m, 2 H, ArCH), 6.35 - 6.44 (m, 1H, ArCH); Compound was described in the 
literature.239 
 
4-(3-nitro-2-oxo-1-pyridyl)benzonitrile (164) 
 
Prepared according to procedure L with intermediate 3-nitro-1H-
pyridin-2-one (2.14 mmol) and 4-cyanophenylboronic acid (2 
equiv., 4.28 mmol).Yield: 160 mg, 31%; Appearance: orange solid 
LCMS: 1.14 min, m/z 242.1 (M+H)+, Method D; Purity<80% 1H NMR (500 MHz, 
DMSO-d6) δ ppm 8.51 (dd, J=5.73, 2.86 Hz, 1 H, ArCH), 8.15 - 8.20 (m, 1 H, ArCH), 
8.02 - 8.07 (m, 2 H, ArCH), 7.71 - 7.75 (m, 2 H, ArCH),  6.54 (dd, J=6.87, 1.15 Hz, 1 H, 
ArCH) Data corresponded to that reported in the literature.240 
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1-(4-chlorophenyl)-3-nitro-pyridin-2-one (165) 
 
Prepared according to procedure J with intermediate 3-nitro-1H-
pyridin-2-one (2.14 mmol) and 4-chlorophenylboronic acid (2 
equiv., 4.28 mmol).Yield: 160 mg, 31%; Appearance: orange 
solid; LCMS: 1.14 min, m/z 251.0, 253.0 ((M+H)+ 3:1, 35/37Cl), Purity > 95%, Method D; 
1H NMR (500 MHz, DMSO-d6) δ ppm 8.49 (dd, J=7.73, 2.00 Hz, 1 H), 8.15 (dd, J=6.59, 
2.00 Hz, 1 H, ArCH), 7.57 - 7.66 (m, 2 H, ArCH), 7.48 - 7.55 (m, 2 H, ArCH), 6.50 (dd, 
J=7.73, 6.59 Hz, 1 H, ArCH)  
 
1-(4-methoxyphenyl)-3-nitro-pyridin-2-one (166) 
 
Prepared according to procedure J with intermediate 3-nitro-1H-
pyridin-2-one (2.14 mmol) and 4-methoxyphenylboronic acid (2 
equiv., 4.28 mmol) Yield: 310 mg, 58%; Appearance: orange solid; 
LCMS: 1.44 min, m/z 247.0 (M+H)+, Method D; Purity >95%; 1H NMR (500 MHz, 
DMSO-d6) δ ppm 8.46 (dd, J=5.16, 3.44 Hz, 1 H, ArCH), 8.11 (dd, J=4.58, 1.72 Hz, 1 
H, ArCH), 7.34 - 7.41 (m, 2 H, ArCH), 7.02 - 7.12 (m, 2 H, ArCH), 6.46 (dd, J=6.30, 
1.15 Hz, 1 H, ArCH), 3.79 (s, 3 H, CH3)  
 
Compounds were prepared according to general procedure I: Reduction of nitro 
group for pyridinone compounds: 
 
 
3-amino-1-phenyl-pyridin-2-one (167) 
 
Prepared according to procedure I with intermediate 3-nitro-1-phenyl-
pyridin-2-one (163); Yield: 92 mg, 76%; Appearance: orange solid; 
LCMS: 0.69 min, m/z 187.2 (M+H)+, Method A; 1H NMR (500 MHz, 
CHLOROFORM-d) δ ppm 7.50 - 7.46 (m, 2 H, ArCH), 7.43- 7.38 (m, 3 H, ArCH), 6.80 
(dd, J=6.87, 1.72 Hz, 1 H, ArCH),  6.59 (dd, J=6.87, 1.72 Hz, 1 H, ArCH), 6.14 (t, J=6.87 
Hz, 1 H, ArCH), 4.29 (br. s, 2 H, NH); Data corresponded to that reported in the 
literature.241 
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3-amino-1-(4-chlorophenyl)pyridin-2-one (169) 
 
Prepared according to procedure I with intermediate 1-(4-
chlorophenyl)-3-nitro-pyridin-2-one (165) (0.75 mmol). Yield: 133 
mg, 79%; Appearance: orange solid; LCMS: 1.81 min, m/z 221.1, 
223.1 ((M+H)+, Cl35/37 3:1), Method C; Purity> 75% (10% dehalogenated SM), 1H NMR 
(500 MHz, DMSO-d6) δ ppm 7.51- 7.56 (m, 2 H, ArCH), 7.40 - 7.44 (m, 2 H, ArCH), 
6.80 - 6.83 (m, 1 H, ArCH),  6.48 (dd, J=4.58, 2.29 Hz, 1 H, ArCH), 6.13 (t, J=7.45 Hz, 
1 H, ArCH),  5.23 (br s, 2 H, NH)  
 
3-amino-1-(4-methoxyphenyl)pyridin-2-one (170) 
 
Prepared according to procedure I with intermediate 1-(4-
methoxyphenyl)-3-nitro-pyridin-2-one (166) (1.01 mmol).Yield: 135 
mg, 62%; Appearance: orange solid; LCMS: 1.26 min,  m/z 217.2 
(M+H)+, Purity >90%, Method C; 1H NMR (500 MHz, DMSO-d6) δ ppm 7.24 - 7.29 (m, 
2 H, ArCH), 6.97 - 7.02 (m, 2 H, ArCH), 6.77 (dd, J=6.87, 1.72 Hz, 1 H, ArCH),  6.45 - 
6.49 (m, 1 H, ArCH), 6.09 (t, J=7.16 Hz, 1 H, ArCH), 5.17 (s, 2 H, NH), 3.77 (s, 3 H, 
CH3)  
 
General procedure A for urea formation (modified): 
 
A 3-amino-pyridin-2-one (1 equiv.), isocyanate (1 equiv.) and triethylamine (1.5- 3.0 
equiv.) was dissolved in dichloromethane/ DMF (4/1). RM was stirred at room 
temperature overnight. Solvent was evaporated, crude product was dissolved in DMSO 
and purified by preparative HPLC (19x100mm (5µm) C-18 Waters Xbridge, MeOH 
pH=10) to yield final urea product as a white solid. 
 
 
1-(4-chlorophenyl)-3-(2-oxo-1-phenyl-3-pyridyl)urea (171) 
 
Prepared according to modified procedure A with intermediate 3-amino-1-phenyl-
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pyridin-2-one (167) (0.15 mmol) and 4-chlorophenyl 
isocyanate (0.15 mmol) Yield: 2.5 mg, 5%; 
Appearance: white solid; LCMS: 1.851 min,  m/z 340.4, 
342.5 ((M+H)+ Cl35/37 3:1), Purity >95%, Method A; 1H NMR (500 MHz, DMSO-d6) δ 
ppm 9.73 (br s, 1 H, NH), 8.64 (s, 1 H, NH), 8.14 (dd, J=7.45, 1.72 Hz, 1 H, ArCH), 7.57 
- 7.49 (m, 2 H, ArCH), 7.49 - 7.41 (m, 5 H, ArCH), 7.34 - 7.28 (m, 2 H, ArCH), 7.24 (dd, 
J=6.87, 1.72 Hz, 1 H, ArCH), 6.35 (t, J=7.16 Hz, 1 H, ArCH); HRMS: Exact Mass: 
339.0774; (M+H)+: 340.0853; Observed Mass: 340.0847; 1.70 ppm. 
  
1-(4-bromophenyl)-3-(2-oxo-1-phenyl-3-pyridyl)urea (172) 
 
Prepared according to modified procedure A with 
intermediate 3-amino-1-phenyl-pyridin-2-one (167) 
(0.15 mmol) and  4-bromophenyl isocyanate (1equiv., 
0.15 mmol); Yield: 5 mg, 8.5%; Appearance: white solid; LCMS: 2.29 min, m/z 384.1, 
386.1 ((M+H)+ 1:1, 79/81Br), Purity>95%, Method D; 1H NMR (500 MHz, DMSO-d6) 
δ ppm 9.73 (br s, 1 H, NH), 8.65 (s, 1 H, NH), 8.14 (dd, J=7.45, 1.72 Hz, 1 H, ArCH), 
7.55 - 7.49 (m, 2 H, ArCH), 7.47 - 7.39 (m, 6 H, ArCH), 7.24 (dd, J=6.87, 1.72 Hz, 1 H, 
ArCH), 6.35 (t, J=7.16 Hz, 1 H, ArCH); HRMS: Exact Mass: 383.0269; MH+: 384.0348; 
Observed Mass: 384.0343; 1.21 ppm. 
 
1-(4-methoxyphenyl)-3-(2-oxo-1-phenyl-3-pyridyl)urea (173) 
Prepared according to modified procedure A with 
intermediate 3-amino-1-phenyl-pyridin-2-one (167) 
(0.15 mmol) and 4-methoxyphenyl isocyanate (1 equiv., 
0.15 mmol); Yield: 5 mg, 15.3%; Appearance: white 
solid; LCMS: 1.99 min, m/z 336.2 (M+H)+, Purity >95%, Method C; 1H NMR (500 MHz, 
DMSO-d6) δ ppm 9.40 (s, 1 H, NH), 8.53 (s, 1 H, NH), 8.13 (dd, J=7.45, 1.72 Hz, 1 H), 
7.49 - 7.54 (m, 2 H, ArCH), 7.42 - 7.47 (m, 3 H, ArCH), 7.31 - 7.35 (m, 2 H, ArCH), 7.21 
(dd, J=6.87, 1.72 Hz, 1 H, ArCH), 6.80 - 6.89 (m, 2 H, ArCH), 6.33 (t, J=7.16 Hz, 1 H, 
ArCH), 3.68 (s, 3 H, OCH3); HRMS: Exact Mass: 335.1270; MH
+: 336.1348; Observed 
Mass: 336.1339; 2.73 ppm 
 
1-(4-bromophenyl)-3-[1-(4-methoxyphenyl)-2-oxo-3-pyridyl]urea (174) 
264 
 
 
Prepared according to modified procedure A with 
intermediate 3-amino-1-(4-methoxyphenyl)pyridin-2-
one (170) (0.18 equiv.) and 4-bromophenyl isocyanate 
(1.1 equiv., 0.20 mmol); Yield: 24 mg, 31%; 
Appearance: white solid ; LCMS: 2.28min, m/z 414.0, 416.1 ((M+H)+ 1:1, 79/81Br), Purity 
>85%, Method D; 1H NMR (500 MHz, DMSO-d6) δ ppm 9.74 (s, 1 H, NH), 8.65 (s, 1 
H), 8.15 (dd, J=7.16, 2.00 Hz, 1 H, NH), 7.48 - 7.41 (m, 5 H, ArCH), 7.39 - 7.35 (m, 2 
H, ArCH), 7.09 - 7.04 (m, 2 H, ArCH), 6.35 (t, J=7.16 Hz, 1 H, ArCH), 3.82 (s, 3 H, 
OCH3); HRMS: Exact Mass: 413.0375; (M+H)
+: 414.0453; Observed Mass: 414.0450; 
0.79 ppm. 
 
1-(4-methoxyphenyl)-3-[1-(4-methoxyphenyl)-2-oxo-3-pyridyl]urea (175) 
 
Prepared according to modified procedure A with 
intermediate 3-amino-1-(4-methoxyphenyl)pyridin-2-
one (170) (0.18 equiv.) and 4-methoxyphenyl 
isocyanate; Yield: (1.1 equiv., 0.20 mmol)  16 mg, 24%; 
Appearance: white solid; LCMS: 1.54 min,  m/z 366.2 (M+H)+, Purity >93%, Method B; 
1H NMR (500 MHz, DMSO-d6) δ ppm 9.42 (s, 1 H, NH), 8.54 (s, 1 H, NH), 8.14 (dd, 
J=7.45, 1.72 Hz, 1 H, ArCH), 7.30 - 7.43 (m, 4 H, ArCH), 7.20 (dd, J=6.87, 1.72 Hz, 1 
H, ArCH), 7.11 - 7.02 (m, 2 H, ArCH), 6.87 (d, J=8.59 Hz, 2 H, ArCH), 6.33 (t, J=7.16 
Hz, 1 H, ArCH), 3.89 - 3.79 (m, 3 H, OCH3), 3.71 (s, 3 H, OCH3); HRMS: Exact Mass: 
365.1376; (M+H)+: 366.1454; Observed Mass: 366.1448; 1.59 ppm. 
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12.2.3.6. Non-natural amino acids series 
 
Procedure for synthesis of  methyl 2-amino-2-tetrahydropyran-4-yl-acetate 
 
Methyl 2-(benzyloxycarbonylamino)-2-tetrahydropyran-4-ylidene-acetate (176) 
 
To acetonitrile (10 ml) solution of methyl 2-(benzyloxycarbonylamino)-2-
dimethoxyphosphoryl-acetate (1 eq., 2 g), 1,8-diazabicyclo[5.4.0]undec-7-ene 
(1 eq., 0.92 g) was added at room temperature and stirred for 30 minutes. 
Acetonitrile (5 ml) solution of tetrahydropyran-4-one (1 eq., 0.60 g) was added 
and stirred overnight at room temperature. Water and ethyl acetate were added to the 
reaction mixture, and the organic layer was separated. The organic layer was washed with 
2M HCl solution, saturated brine, water. Then the organic phase was filtered through the 
phase separator and concentrated under reduced pressure. Crude product was purified via 
flash column silica (50g silica, PE:EtOAc  100:0, 70:30, 30:70) to obtain desired product 
as a white solid. Yield: 800 mg, 40% Appearance: white solid; LCMS: 1.42 min, m/z 
306.2 (M+H)+, Purity >95%, Method B 1H NMR (500 MHz, CHLOROFORM-d) δ ppm 
7.45-7.29 (m, 5 H, ArCH), 6.02 (br s, 1 H, NH), 5.15 (s, 2 H, CH2), 3.97-3.51 (m, 7 H, 
OCH2, CH3), 2.94 (br s, 2 H, CH2), 2.43 (t, J=5.44 Hz, 2 H, CH2); Data corresponded to 
that reported in the literature.242-243 
 
Methyl 2-amino-2-tetrahydropyran-4-yl-acetate (177) 
 
The benzyl deprotection reaction was performed in the H‐Cube reactor (10% 
Pd/C CatCart®, full hydrogen mode, 50 °C, 1.0 mL/min, one cycle). The 
reaction mixture was concentrated under reduced pressure. It was used in the 
next step without purification. methyl 2-amino-2-tetrahydropyran-4-yl-
acetate was obtained with high yield as a colourless oil. Yield: 440 mg, 98% Appearance: 
colourless oil; LCMS: non-UV active; 1H NMR (500 MHz, CHLOROFORM-d) δ ppm  
4.03 - 3.96 (m, 2 H, OCH2), 3.73 (s, 3 H, CH3), 3.37 (td, J=11.74, 1.72 Hz, 2 H, OCH2), 
3.29 (d, J=6.30 Hz, 1 H, NCH), 1.85 (tdt, J=2x11.89, 6.01, 2x3.72 Hz, 1 H, CH), 1.63 - 
1.40 (m, 6 H, NH, CH2); Data corresponded to that reported in the literature.
242-243 
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Compounds were prepared according to general procedure for urea formation 
 
Tert-butyl 2-[(4-bromophenyl)carbamoylamino]acetate (178) 
 
Prepared according to procedure A with intermediate 4-
bromophenyl isocyanate (1 equiv., 3 mmol) and glycine 
tert-butyl ester hydrochloride (1.1 equiv, 3.3 mmol). 
Crude product purified by flash column 
chromatography (silica gel) using PE/EtOAc 1/1. Yield: 460 mg, 90% Appearance: white 
solid; LCMS: 1.614 min, m/z 330, 332 ((M+H)+ 1:1, 79/81Br), Purity >95%, Method B 1H 
NMR (500 MHz, CHLOROFORM-d) δ ppm 7.37 - 7.32 (m, 2 H, ArCH), 7.13 - 7.21 (m, 
2 H, , ArCH), 5.66 (t, J=5.16 Hz, 1 H, NH), 3.96 (d, J=5.16 Hz, 2 H, CH2), 1.47 (s, 9 H, 
C(CH3)3); 
13C NMR (126 MHz, DMSO-d6)  ppm 169.91 (1 C, C=O), 155.03 (1 C, C=O), 
139.74 (1 C, ArC) , 131.42 (2 C, ArCH), 119.63 (2 C, ArCH), 112.55 (1 C, ArC ), 80.57 
(1 C, C(CH3)3), 41.96 (1 C, CH2), 27.77 (3 C, CH3). 
 
Methyl 2-[(4-bromophenyl)carbamoylamino]-2-cyclopentyl-acetate (179) 
 
Prepared according to procedure A with intermediate 1-
bromo-4-isocyanato-benzene(3 mmol) and methyl 2-
amino-2-cyclopentyl-acetate HCL (1 equiv., 3 mmol); 
Yield: 640 mg, 70%; Appearance: white solid; LCMS: 
1.77 min, m/z 356.0, 358.0 ((M+H)+ 1:1, 79/81Br), Method B; 1H NMR (500 MHz, DMSO-
d6)  ppm 8.70 (s, 1 H, NH), 7.29 - 7.47 (m, 4 H, ArCH), 6.62 (d, J=8.02 Hz, 1 H, NH), 
4.13 (t, J=7.73 Hz, 1 H, CH), 3.64 (s, 3 H, CH3), 2.10 - 2.21 (m, 1 H, CH), 1.46 - 1.69 
(m, 6 H, CH2), 1.23 - 1.36 (m, 2 H, CH2); 
13C NMR (126 MHz, DMSO-d6)  ppm 173.18 
(1 C, C=O), 154.75 (1 C, C=O), 139.47 (1 C, ArC), 131.52 (2 C, ArCH), 119.54 (1 C, 
ArCH), 112.69 (1 C, ArC), 55.60 (1 C, CH), 51.82 (1 C, CH3), 41.59 (1 C, CH), 28.63 (1 
C, CH2), 28.22 (1 C, CH2), 24.89 (1 C, CH2), 24.67 (1 C, CH2) 
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Methyl 2-[(4-bromophenyl)carbamoylamino]-2-cyclohexyl-acetate (180) 
 
Prepared according to procedure A with intermediate 1-
bromo-4-isocyanato-benzene(3 mmol) and methyl 2-
amino-2-cyclohexyl-acetate (1.1 equiv., 3.3 mmol). Crude 
product was dry loaded on silica and purified by flash 
column chromatography (silica gel, PE/EA 10-->60%, gradient). The beige solid was 
washed with diethyl ether (15mL), filtered and dried under high vacuum. Yield: 682mg, 
70%; Appearance: white solid; LCMS: 1.87 min, m/z 369.1, 371.1 ((M+H)+ 1:1, 79/81Br), 
Method B; 1H NMR (500 MHz, DMSO-d6) δ ppm 8.67 (s, 1 H, NH), 7.40 - 7.28  (m, 4 
H, ArCH), 6.57 (d, J=8.59 Hz, 1 H, NH), 4.12 (dd, J=8.59, 5.73 Hz, 1 H, CH), 3.62 (s, 3 
H, CH3), 1.63 - 1.73 (m, 3 H, CH, CH2), 1.58 - 1.52 (m, 2 H, CH2), 1.25 – 0.96 (m, 6 H, 
CH2); 
13C NMR (126 MHz, DMSO-d6)  ppm 172.67 (1 C, C=O), 154.68 (1 C, C=O), 
139.49 (1 C, ArC ), 131.48 (2 C, ArCH), 119.44 (2 C, ArCH), 112.60 (1 C, ArC), 57.10 
(1 C, NCH), 51.79 (1 C, CH3), 29.16 (1 C, CH), 28.57 (1 C, CH2), 27.95 (1 C, CH2), 
25.64 (1 C, CH2), 25.49 (2 C, CH2). 
 
methyl 2-[(4-bromophenyl)carbamoylamino]-3-cyclohexyl-propanoate (181) 
Prepared according to procedure A with intermediate 1-
bromo-4-isocyanato-benzene(3 mmol) and methyl 2-
amino-3-cyclohexyl-propanoate HCl (1 equiv. 3.3 mmol). 
Crude product was dry loaded on silica and purified by 
flash column chromatography (silica gel, PE/EA 10-->60%, gradient). The beige solid 
was washed with diethyl ether (15mL), filtered and dried under high vacuum to afford 
desired product as a white solid. Yield: 410 mg, 40%; Appearance: white solid; LCMS: 
1.97 min, m/z 383.2, 385.1 ((M+H)+ 1:1, 79/81Br), Purity 90%, Method B; 1H NMR (500 
MHz, DMSO-d6) δ ppm 8.68 (s, 1 H, NH), 7.39 - 7.30  (m, 4 H, ArCH), 6.57 (d, J=8.02 
Hz, 1 H, NH), 4.22 (td, J=8.31, 5.73 Hz, 1 H, CH), 3.61 (s, 3 H, CH3), 1.70 (br. d, J=12.60 
Hz, 1 H, CH), 1.66 -1.54 (m, 5 H, CH2), 1.50 (ddd, J=8.74, 5.58, 3.44 Hz, 2 H, CH2), 1.22 
- 1.03 (m, 4 H, CH2), 0.96 - 0.79 (m, 2 H, CH2); 
13C NMR (126 MHz, DMSO-d6)  ppm 
173.86 (1 C, C=O), 154.66 (1 C, C=O), 139.50 (1 C, ArC), 131.43 (2 C, ArCH), 119.57 
(2 C, ArCH), 112.63 (1 C, ArC), 51.88 (1 C, CH3), 50.14 (1 C, CH), 33.53 (1 C, CH2), 
33.07 (1 C, CH2), 31.70 (1 C, CH), 25.96 (1 C, CH2), 25.76 (1 C, CH2), 25.57 (1 C, CH2). 
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methyl 2-[(4-bromophenyl)carbamoylamino]-2-tetrahydropyran-4-yl-acetate (182) 
 
Prepared according to procedure A with intermediate 
1-bromo-4-isocyanato-benzene(3 mmol)Crude 
product was purified via FCC (PE/EA 0-->70%). 
Product after column was additionally washed with 
diethyl ether to remove impurities from aliphatic 
region. Yield: 510 mg, 70%; Appearance: white solid; LCMS: 1.93 min, m/z 371.1, 373.0 
((M+H)+ 1:1, 79/81Br), Method B; 1H NMR (500 MHz, CHLOROFORM-d) δ ppm 7.43 - 
7.37 (m, 2 H, ArCH) 7.25 - 7.19 (m, 2 H, ArCH) 6.92 (s, 1 H, NH) 5.61 (d, J=8.59 Hz, 1 
H, NH) 4.57 (dd, J=8.59, 5.16 Hz, 1 H, CH) 3.78 (s, 3 H, CH3) 4.04 - 3.95 (m, 2 H, CH2) 
3.44 - 3.32 (m, 2 H, CH2) 2.13 - 2.03 (m, 1 H, CH) 1.61 - 1.42 (m, 4 H, CH2); 
13C NMR 
(126 MHz, DMSO-d6)  ppm 172.29 (1 C, C=O), 154.68 (1 C, C=O), 139.42 (1 C, ArC), 
131.48 (2 C, ArCH), 119.52 (2 C, ArCH), 112.70 (1 C, ArC), 66.62 (2 C, CH2), 56.57 (1 
C, CH3), 51.91 (1 C, CH), 37.22 (1 C, CH), 29.03 (1 C, CH2), 27.99 (1 C, CH2). 
 
Compound were prepared according to general procedure B: Cleavage of ester: 
 
2-[(4-bromophenyl)carbamoylamino]acetic acid (183) 
 
Prepared according to procedure B with 
intermediate tert-butyl 2-[(4-bromophenyl) 
carbamoylamino]acetate (178). Crude product was 
dry loaded onto silica and purified by flash column 
chromatography (silica gel, PE/EtOAc 6/4). Yield: 460 mg, 80%; Appearance: white 
solid; LCMS: 1.09 min, m/z 273.1, 275.1 ((M+H)+ 1:1, 79/81Br), Purity >95%, Method B; 
1H NMR (500 MHz, DMSO-d6) δ ppm 12.56 (br. s, 1 H, COOH), 8.90 (s, 1 H, NH), 7.39 
- 7.27  (m, 4 H, ArCH), 6.37 (t, J=5.73 Hz, 1 H, NH), 3.75 (d, J=5.73 Hz, 2 H, CH2); 
13C 
NMR (126 MHz, DMSO-d6)  ppm 172.13 (1 C, C=O), 155.01 (1 C, C=O), 139.78 (1 C, 
ArC), 131.43 (2 C, ArCH), 119.57 (2 C, ArCH), 112.51 (1 C, ArC), 41.33 (1 C, CH2). 
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Representative procedure M: ester hydrolysis 
 
Methyl 2-[(4-bromophenyl)carbamoylamino]-2-tetrahydropyran-4-yl-acetate (1 eq.) was 
suspended in the mixture methanol (3 mL)/water (2 mL) and 2M solution of sodium 
hydroxide (1 mL) was added. RM was stirred for 2h at room temperature. Methanol was 
evaporated, the remaining solution was acidified with 1M HCl (pH=2-3). The 
precipitation was filtered washed with water and dried to give final product as a white 
powder.   
 
2-[(4-bromophenyl)carbamoylamino]-2-cyclopentyl-acetic acid (184) 
 
Prepared according to procedure M with intermediate 
Methyl 2-[(4-bromophenyl)carbamoylamino]-2-
cyclopentyl-acetate (179). Yield: 479 mg, 79% 
Appearance: white solid; LCMS: 1.55 min, m/z 341.1, 
343.1 ((M+H)+ 1:1, 79/81Br), Purity=90%, Method D; 
1H NMR (500 MHz, DMSO-d6) δ ppm 9.03 (s,1 H, NH), 7.37 (m, 4 H, ArCH), 6.65 (d, 
J=8.02 Hz, 1 H, NH), 4.06 (dd, J=8.02, 6.30 Hz, 1 H, CH), 2.26 - 2.16 (m, 1 H, CH), 1.68 
- 1.27 (m, 8 H, CH2); 
13C NMR (126 MHz, DMSO-d6) δ ppm 174.40 (1 C, C=O), 154.98 
(1 C, C=O), 140.15 (1 C, ArC), 131.30 (2 C, ArCH), 119.34 (2 C, ArCH), 112.02 (1 C, 
ArC), 55.74 (1 C, CH), 42.20 (1 C, CH), 28.76 (s, 1 C, CH2), 27.72 (1 C, CH2), 24.80 (2 
C, CH2). 
 
2-[(4-bromophenyl)carbamoylamino]-2-cyclohexyl-acetic acid (185) 
 
Prepared according to procedure M with intermediate 
methyl 2-[(4-bromophenyl)carbamoylamino]-2-
cyclohexyl-acetate (180). The crude product was not 
purified further and was taken for next step. Yield: 480 
mg, 97% Appearance: white solid; LCMS: 1.043 min, 
m/z 355, 357 ((M+H)+ 1:1, 79/81Br), Purity>90%, Method B; 1H NMR (500 MHz, DMSO-
d6) δ ppm 12.69 (br. s, 1 H, COOH) 8.72 (s, 1 H, NH) 7.40 - 7.30 (m, 4 H, ArCH) 6.43 
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(d, J=8.59 Hz, 1 H, NH) 4.07 (dd, J=8.59, 4.58 Hz, 1 H, CH) 1.75 - 1.48 (m, 6 H, CH, 
CH2) 1.27 - 1.13 (m, 2 H, CH2) 1.13 - 0.96 (m, 3 H, CH2); 
13C NMR (126 MHz, DMSO-
d6)  ppm 173.60 (1 C, C=O), 154.76 (1 C, C=O), 139.65 (1 C, ArC), 131.55 (2 C, ArCH), 
119.42 (2 C, ArCH), 112.46 (1 C, ArC), 56.91 (1 C, NCH), 29.31 (1 C, CH), 27.67 (2 C, 
CH2), 25.64 (3 C, CH2).
 
 
2-[(4-bromophenyl)carbamoylamino]-3-cyclohexyl-propanoic acid (186) 
 
Prepared according to procedure M with intermediate 
methyl 2-[(4-bromophenyl)carbamoylamino]-3-
cyclohexyl-propanoate (181). The crude product was 
not purified further and was taken for next step. Yield: 
200mg, 60% Appearance: white solid; LCMS: 1.16 
min, m/z 369.1, 371.1 ((M+H)+ 1:1, 79/81Br), Purity>95%, Method B; 1H NMR (500 MHz, 
DMSO-d6) δ ppm 8.93 (s, 1 H, NH), 7.34 (m, 4 H, ArCH), 6.57 (br d, J=8.02 Hz, 1 H, 
NH), 4.11 (td, J=8.59, 5.16 Hz, 1 H, CH), 1.73 (br d, J=12.03 Hz, 1 H, CH), 1.61 (m, 3 
H, CH2), 1.59 -1.41 (m, 3 H, CH2), 1.34 (br d, J=2.86 Hz, 1 H, CH2), 1.20 - 1.04 (m, 3 H, 
CH2), 0.96 - 0.77  (m, 2 H, CH2); 
13C NMR (126 MHz, DMSO-d6)  ppm 174.96 (1 C, 
C=O), 154.72 (1 C, C=O), 139.79 (1 C, ArC), 131.41 (2 C, ArCH), 119.41 (2 C, ArCH), 
112.34 (1 C, ArC), 50.35 ( 1 C, CH), 39.51 (1 C, CHCH2), 33.63 (1 C, CH2), 33.19 (1 C, 
CH2), 31.91 (1 C, CH), 26.02 (1 C, CH2), 25.80 (1 C, CH2), 25.65 (1 C, CH2); once carbon 
(CHCH2) hidden under DMSO peak. 
 
2-[(4-bromophenyl)carbamoylamino]-2-tetrahydropyran-4-yl-acetic acid (187) 
 
Prepared according to procedure M with intermediate 
methyl 2-[(4-bromophenyl)carbamoylamino]-2-
tetrahydropyran-4-yl-acetate (182). The crude product 
was used for next reaction without further purification. 
Yield: 286 mg, 90% Appearance: white solid; LCMS: 
1.36 min, m/z 357.1, 359.1 ((M+H)+ 1:1, 79/81Br), Purity>95%, Method D; 1H NMR (500 
MHz, DMSO-d6) δ ppm 12.83 (br. s, 1 H, COOH), 7.40 - 7.34 (m, 4 H, ArCH), 6.62 (d, 
J=8.59 Hz, 1 H, NH), 4.13 (dd, J=8.59, 5.16 Hz, 1 H, CH), 3.89 - 3.83 (m, 2 H, CH2), 
271 
 
3.27 (qd, J=11.74, 2.00 Hz, 2 H, CH2), 2.01 -1.93 (m, 1 H, CH), 1.51 -1.29 (m, 4 H, CH2); 
13C NMR (126 MHz, DMSO-d6)  ppm 173.19 (1 C, C=O), 154.80 (1 C, C=O), 139.65 
(1 C, ArC), 131.70 (2 C, ArCH), 119.45 (2 C, ArCH), 112.48 (1 C, ArC), 66.78 (2 C, 
CH2), 56.40 (1 C, CH), 37.30 (1 C, CH), 29.21 (1 C, CH2), 27.83 (1 C, CH2). 
 
1-[(4-bromophenyl)carbamoylamino]cyclopentanecarboxylic acid (217) 
 
1-bromo-4-isocyanato-benzene (0.76 mmol) was dissolved in 
dichloromethane (10 mL) at room temperature and methyl 1-
aminocyclopentanecarboxylate HCl (0.76 mmol, 1.0 equiv.) 
was added in one portion. Then triethylamine (1.15 mmol, 1.5 equiv.) was added to the 
solution and  RM was stirred at room temperature overnight.  The RM was diluted with 
DCM and washed twice with water. Organic layer was passed through the phase separator 
and concentrated under reduced pressure. The intermediate was used directly in the next 
step. A 2-(4-bromoanilino)-3-oxa-1-azaspiro[4.4]non-1-en-4-one (0.42 mmol) was 
suspended in the mixture methanol (2 mL)/water (3 mL) and 2M solution of sodium 
hydroxide (0.847 mmol, 0.424 mL) was added. RM was stirred for 4h at room 
temperature. Methanol was evaporated, the remaining solution was acidified with 1M 
HCl (pH=2-3). The precipitation was filtered washed with water and dried to give final 
product as a white powder. Yield: 119 mg, 85%; LCMS:1.35 min, m/z 327.1, 329.1 
((M+H)+ 1:1, 79/81Br), Purity> 95%, Method C; 1H NMR (500 MHz, DMSO-d6)  ppm 
8.56 (s, 1 H, NH), 7.31 - 7.39 (m, 4 H, ArCH), 6.59 (s, 1 H, NH), 2.03 - 2.11 (m, 2 H, 
CH2), 1.82 - 1.89 (m, 2 H, CH2), 1.66 - 1.70 (m, 4 H, CH2); 
13C NMR (126 MHz, DMSO-
d6)  ppm 176.52 (1 C, C=O), 155.05 (1 C, C=O), 140.26 (1 C, ArC.), 131.88 (2 C, 
ArCH), 119.87 (2 C, ArCH), 112.82 (1 C, ArCquat.), 65.30 (1 C, Cspiro.), 37.35 (2 C, 
CH2), 24.61 (2 C, CH2). 
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Compounds were prepared according to general procedure E for amide coupling 
using T3P: 
 
2-[(4-bromophenyl)carbamoylamino]-N-(3-pyridyl)acetamide (188) 
 
Prepared according to procedure E with intermediate 
2-[(4-bromophenyl) carbamoyl amino]acetic acid 
(183) (1 equiv., 0.15 mmol) and 3-aminopyridine (1.1 
equiv., 0.17 mmol). Yield: 40 mg, 80%; Appearance: white solid; LCMS:1.21 min, m/z 
349.2, 351.1 ((M+H)+ 1:1, 79/81Br), Purity> 95%, Method B; 1H NMR (500 MHz, DMSO-
d6)  ppm 10.28 (br. s., 1 H, NH), 9.02 (s, 1 H, NH), 8.74 (d, J=2.86 Hz, 1 H, ArCH), 
8.26 (dd, J=4.87, 1.43 Hz, 1 H, ArCH), 8.03 (dq, J=8.16, 1.48 Hz, 1 H, ArCH), 7.41 - 
7.38 (m, 4 H, ArCH), 7.38 -7.34 (m, 1 H, ArCH), 6.52 (t, J=5.44 Hz, 1 H, NH), 3.96 (d, 
J=5.73 Hz, 2 H, CH2); 
13C NMR (126 MHz, DMSO-d6)  ppm 169.13 (1 C, C=O), 155.09 
(1 C, C=O), 144.26 (1 C, ArCH), 140.77 ( 1 C, ArCH), 139.77 (1 C, ArC), 135.54 (1 C, 
ArC), 131.42 (2 C, ArCH), 126.06 (1 C, ArCH), 123.68 (1 C, ArCH), 119.50 (2 C, ArCH), 
112.49 (1 C, ArC), 43.20 (1 C, CH2); HRMS: Exact Mass: 348.0222; (M+H)
+: 349.0300; 
Mass Observed: 349.0292; 2.33 ppm. 
 
(2S)-2-[(4-bromophenyl)carbamoylamino]-4-methyl-N-(3-pyridyl)pentanamide 
(189) 
Prepared according to procedure E with intermediate tert-butyl 
(2S)-2-[(4-bromophenyl)carbamoylamino]-4-methyl-pentanoic 
acid (66) (0.14 mmol) and 3-aminopyridine (1.3 equiv., 0.18 
mmol). Yield: 34 mg, 61%; Appearance: white solid; LCMS: 1.54 
min, m/z 405.2, 407.1 ((M+H)+ 1:1, 79/81Br), Purity>95%, method 
B; 1H NMR (500 MHz, DMSO-d6) δ ppm 10.38 (s, 1 H, NH), 
8.77 - 8.69 (m, 2 H, ArCH), 8.24 (dd, J=4.87, 1.43 Hz, 1 H, 
ArCH), 8.02 (dq, J=8.16, 1.48 Hz, 1 H, ArCH), 7.40 -7.27 (m, 5 H, ArCH), 6.52 (d, 
J=8.02 Hz, 1 H, NH), 4.49 - 4.33 (m, 1 H, CH), 1.73 - 1.59 (m, 1 H, CH), 1.56 - 1.44 (m, 
2 H, CH2), 0.91 (d, J=6.30 Hz, 6 H, CH3); 
13C NMR (126 MHz, DMSO-d6)  ppm 172.46 
(1 C, C=O), 154.64 (1 C, C=O), 144.41 (1 C, ArCH), 140.94 (1 C, ArCH), 139.60 (1 C 
ArC), 135.56 (1 C, ArC), 131.47 (2 C, ArCH), 126.30 (1 C, ArCH), 123.69 (1 C, ArCH), 
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119.48 (2 C, ArCH), 112.55 (1 C, ArC), 52.09 (1 C, CH), 41.76 (1 C, CH2), 24.43 (1 C, 
CH), 23.05 (1 C, CH3), 21.82 (1 C, CH3); HRMS: Exact Mass: 404.0848; (M+H)
+: 
405.0926; Observed Mass: 405.0921; 1.27 ppm. 
 
2-[(4-bromophenyl)carbamoylamino]-2-cyclopentyl-N-(3-pyridyl)acetamide  (190) 
 
Prepared according to procedure E with intermediate 2-
[(4-bromophenyl)carbamoylamino]-2-cyclopentyl-acetic 
acid (184) (0.11 mmol) and 3-aminopyridine (1.1 equiv., 
0.122 mmol). Crude product was purified by reverse 
phase column chromatography (C18 12g, Water pH-
10/MeOH 90/10→100) to give final product. Yield: 22 
mg, 47% Appearance: white solid; LCMS: 1.57 min m/z 417.2, 419.1 ((M+H)+ 1:1, 
79/81Br), Purity>95% method B; 1H NMR (500 MHz, DMSO-d6)  ppm 10.44 (s, 1 H, 
NH), 8.80 (s, 1 H, NH), 8.77 (d, J=1.72 Hz, 1 H, ArCH), 8.27 (dd, J=4.58, 1.15 Hz, 1 H, 
ArCH), 8.07 - 8.03 (m, 1 H, ArCH), 7.41 - 7.31 (m, 5 H, ArCH), 6.61 (d, J=8.59 Hz, 1 
H, NH), 4.33 (t, J=8.02 Hz, 1 H, CH), 2.20 (sxt, J=7.90 Hz, 1 H, CH), 1.55 - 1.72 (m, 4 
H, CH2), 1.45 - 1.54 (m, 2 H, CH2), 1.31 - 1.43 (m, 2 H, CH2); 
13C NMR (126 MHz, 
DMSO-d6)  ppm 171.80 (1 C, C=O), 154.76 (1 C, C=O), 144.39 (1 C, ArCH), 140.92 
(1 C, ArCH), 139.62 (1 C, ArC), 135.50 (1 C, ArC), 131.53 (2 C, ArCH), 126.24 (1 C, 
ArCH), 123.77 (1 C, ArCH), 119.46 (2 C, ArCH), 112.53 (1 C, ArC ), 56.57 (1C, CH), 
42.73 (1 C, CH), 28.65 (1 C, CH2), 28.22 (1 C, CH2), 24.85 (1 C, CH2), 24.67 (1 C, CH2); 
HRMS: Exact Mass: 416.0848; (M+H)+: 417.0926; Observed Mass: 417.0922; 0.99 ppm. 
 
2-[(4-bromophenyl)carbamoylamino]-N-(3-pyridyl)-2-tetrahydropyran-4-yl-
acetamide (191) 
 
Prepared according to procedure E with intermediate 2-[(4-
bromophenyl)carbamoylamino]-2-tetrahydropyran-4-yl-acetic 
acid (187) (0.14 mmol) and 3-aminopyridine (1.1 equiv., 0.16 
mmol). Crude product was purified by reverse phase column 
chromatography (C18 12g, Water pH-10/MeOH 90/10-->100) 
to give final product. Yield: 25 mg, 41% Appearance: white solid; LCMS: 1.99 min, m/z 
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433.1, 435.1 ((M+H)+ 1:1, 79/81Br),Purity>95%, Method D; 1H NMR (500 MHz, DMSO-
d6) δ ppm 10.51 (s, 1 H, NH), 8.87 (s, 1 H, NH), 8.77 (d, J=3.44 Hz, 1 H, ArCH), 8.28 
(dd, J=4.58, 1.72 Hz, 1 H, ArCH), 8.10 - 8.02 (m, 1 H, ArCH), 7.41 - 7.34 (m, 5 H, 
ArCH), 6.69 (br d, J=8.59 Hz, 1 H, NH), 4.35 (dd, J=8.59, 6.87 Hz, 1 H, CH), 3.91 - 3.82 
(m, 2 H, CH2), 3.31 - 3.22 (m, 2 H, CH2), 1.98 - 1.88 (m, 1 H, CH), 1.57 (br d, J=11.46 
Hz, 1 H, CH2), 1.48 - 1.40 (m, 2 H, CH2), 1.30 (qd, J=12.51, 4.30 Hz, 1 H, CH2); 
13C 
NMR (126 MHz, DMSO-d6)  ppm 170.77 (1 C, C=O), 154.76 (1 C, C=O), 144.26 (1 C, 
ArCH), 140.89 (1 C, ArCH), 139.60 (1 C. ArC), 135.30 (1 C, ArC), 131.43 (2 C, ArCH), 
126.35 (1 C, ArCH), 123.86 (1 C, ArCH), 119.41 (2 C, ArCH), 112.54 (1 C, ArC), 66.59 
(2 C, CH2), 57.48 (1 C, CH), 38.14 (1 C, CH), 29.21 (1 C, CH2), 28.30 (1 C, CH2); HRMS: 
Exact Mass: 432.0797; (M+H)+: 433.0877; Observed Mass: 433.0879; 0.46 ppm. 
 
2-[(4-bromophenyl)carbamoylamino]-3-cyclohexyl-N-(3-pyridyl)propenamide 
(192) 
 
Prepared according to procedure E with intermediate 
2-[(4-bromophenyl)carbamoylamino]-3-cyclohexyl-
propanoic acid (186) (0.087 mmol) and 3-
aminopyridine (1.1 equiv., 0.1 mmol). Crude product 
was purified by reverse phase column chromatography (C18 12g, Water pH-10/MeOH 
90/10-->100) to give final product . Yield: 8 mg, 21% Appearance: white solid; LCMS: 
2.31min, m/z 445.2, 457.2 ((M+H)+ 1:1, 79/81Br), Purity>95%, Method D; 1H NMR (500 
MHz, CHLOROFORM-d) δ ppm 9.91 (br. s, 1 H, NH), 8.72 (d, J=2.29 Hz, 1 H, NH), 
8.31 (dd, J=4.58, 1.15 Hz, 1 H, ArCH), 7.88 - 7.82 (m, 1 H, ArCH), 7.80 (br s, 1 H, 
ArCH), 7.19 (d, J=9.17 Hz, 2 H, ArCH), 7.11 (dd, J=8.31, 4.87 Hz, 1 H, ArCH), 6.94 (d, 
J=9.17 Hz, 2 H, ArCH), 6.77 (br d, J=7.45 Hz, 1 H, NH), 4.84 - 4.74 (m, 1 H, CH), 1.81 
- 1.51 (m, 8 H, CH2), 1.43 (br s, 1 H, CH), 1.21 - 0.84 (m, 4 H, CH2); HRMS: Exact Mass: 
444.1161; (M+H)+: 445.1239; Observed Mass: 445.1234; 1.15 ppm. 
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2-[(4-bromophenyl)carbamoylamino]-N-tetrahydropyran-4-yl-acetamide (193) 
Prepared according to procedure E with 
intermediate 2-[(4-bromophenyl) carbamoyl 
amino]acetic acid (183) (1 equiv., 0.15 mmol) 
and 4-aminotetrahydropyran (1.1 equiv., 0.17 
mmol). The crude product was purified by reverse phase column chromatography (C18 
12g, water pH 10/MeOH gradient 90/10 to 0/100%) to give final product. Yield: 42 mg, 
80%; Appearance: white solid; LCMS: 1.15 min, m/z 356.2, 358.2 ((M+H)+ 1:1, 79/81Br), 
Purity>95%, Method B; 1H NMR (500 MHz, DMSO-d6)  ppm 8.94 (s, 1 H, NH), 7.98 
(d, J=7.45 Hz, 1 H, NH), 7.40 - 7.34 (m, 4 H, ArCH), 6.35 (t, J=5.16 Hz, 1 H, NH), 3.85 
-3.79 (m, 2 H, CH2), 3.79 -3.73 (m, 1 H, CH), 3.71 (d, J=5.16 Hz, 2 H, CH2), 3.38 -3.34  
(m, 1 H, CH2), 3.32 (d, J=2.29 Hz, 1 H, CH2), 1.69 (dd, J=12.32, 2.58 Hz, 2 H, CH2), 
1.45 - 1.33 (m, 2 H, CH2); 
13C NMR (126 MHz, DMSO-d6)  ppm 168.40 (1 C, C=O), 
154.90 (1 C, C=O), 139.87 (1 C, ArC), 131.42 (2 C, ArCH), 119.42 (2 C, ArCH), 112.35 
(1 C, ArC), 65.87 (2 C, OCH2), 44.98 (1 C, CH2), 42.42 (1 C, CH2), 32.49 (2 C, CH2); 
HRMS: Exact Mass: 355.0531; (M+H)+: 356.0610; Mass Observed: 356.0602; 2.19 ppm. 
 
2-[(4-bromophenyl)carbamoylamino]-N-(2-pyridyl)acetamide (194) 
Prepared according to procedure E with 
intermediate 2-[(4-bromophenyl) carbamoyl 
amino]acetic acid (183) (1 equiv., 0.15 mmol) 
and 2-aminopyridine (1.1 equiv., 0.17 mmol). 
The crude product was purified by reverse phase column chromatography (C18 12g, 
water pH 10/MeOH gradient 90/10 to 0/100%) to give final product. Yield: 30 mg, 60%; 
Appearance: white solid; LCMS: 1.33 min, m/z 349.1, 351.1 ((M+H)+ 1:1, 79/81Br), 
Purity>90%, Method B; 1H NMR (500 MHz, DMSO-d6)  ppm 10.53 (s, 1 H, NH), 9.02 
(s, 1 H, NH), 8.31 (dt, J=5.59, 1.22 Hz, 1 H, ArCH), 8.06 (d, J=8.02 Hz, 1 H, ArCH), 
7.81 - 7.76  (m, 1 H, ArCH), 7.42 - 7.35 (m, 4 H, ArCH), 7.12 - 7.08 (m, 1 H, ArCH), 
6.49 (t, J=5.44 Hz, 1 H, NH), 3.99 (d, J=5.73 Hz, 2 H, CH2);
 13C NMR (126 MHz, DMSO-
d6)  ppm 169.35 (1 C, C=O), 155.11 (1 C, C=O), 151.77 (1 C, ArC), 148.03 (1 C, ArCH), 
139.79 (1 C, ArC), 138.26 (1 C, ArCH), 131.44 (2 C, ArCH), 119.56 (2 C, ArCH), 119.41 
(1 C, ArCH), 113.38 (1 C, ArCH), 112.47 (1 C, ArC), 43.33 (1 C, CH2); HRMS: Exact 
Mass: 348.0222; (M+H)+: 349.0300; Mass Observed: 349.0293; 2.04  ppm. 
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tert-butyl 3-[[2-[(4-bromophenyl)carbamoylamino]acetyl]amino]azetidine-1-
carboxylate (195) 
 
Prepared according to procedure E with 
intermediate 2-[(4-bromophenyl) carbamoyl 
amino]acetic acid (183) (1 equiv., 0.15 mmol) 
and tert-butyl 3-aminoazetidine-1-carboxylate 
(1.1 equiv., 0.17 mmol). The crude product was purified by reverse phase column 
chromatography (C18 12g, water pH 10/MeOH gradient 90/10 to 0/100%) to give final 
product. Yield: 43 mg, 73%; Appearance: white solid; LCMS: 1.43 min, m/z 427.1, 429.1 
((M+H)+ 1:1, 79/81Br), Purity>95%, Method B; 1H NMR (500 MHz, DMSO-d6)  ppm 
8.91 (s, 1 H, NH), 8.56 (d, J=7.45 Hz, 1 H, NH), 7.37 - 7.32 (m, 4 H, ArCH), 6.34 (t, 
J=5.44 Hz, 1 H, NH), 4.44 - 4.36 (m, 1 H, CH), 4.02 (br. s, 2 H, CH2), 3.70 (m, 4 H, CH2), 
1.34 (s, 9 H, C(CH3)3). 
 
(2S)-2-[(4-bromophenyl)carbamoylamino]-4-methyl-N-(2-pyridyl)pentanamide 
(197) 
 
Prepared according to procedure E with intermediate tert-butyl 
(2S)-2-[(4-bromophenyl)carbamoylamino]-4-methyl-
pentanoic acid (66) (0.14 mmol) and 2-aminopyridine (1.3 
equiv., 0.18 mmol). Crude products were purified via reverse 
phase column chromatography (C18, water pH=10/ACN, 10-
90%) to give product. Yield: 22 mg, 40%; Appearance: white 
solid; LCMS: 1.70 min, ACN pH=10, m/z 405.2, 407.1 
((M+H)+ 1:1, 79/81Br), Purity>95%; 1H NMR (500 MHz, DMSO-d6) δ ppm 10.64 (s, 1 H, 
NH), 8.76 (s, 1 H, NH), 8.30 - 8.28 (m, 1 H, ArCH), 8.04 (d, J=8.02 Hz, 1 H, ArCH), 
7.78 - 7.71 (m, 1 H, ArCH), 7.39 - 7.30 (m, 4 H, ArCH), 7.10 -7.06 (m, 1 H, ArCH), 6.48 
(d, J=8.59 Hz, 1 H, NH), 4.53 - 4.44 (m, 1 H, CH), 1.71 - 1.60 (m, 1 H, CH), 1.55 - 1.47 
(m, 2 H, CH2), 0.89 (d, J=6.87 Hz, 6 H, CH3); HRMS: Exact Mass: 404.0848; (M+H)
+: 
405.0926; Observed Mass: 405.0922; 1.02 ppm. 
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(2S)-2-[(4-bromophenyl)carbamoylamino]-4-methyl-N-(4-pyridyl)pentanamide 
(198)  
 
Prepared according to procedure E with intermediate tert-butyl 
(2S)-2-[(4-bromophenyl)carbamoylamino]-4-methyl-
pentanoic acid (66) (0.14 mmol) and 4-aminopyridine (1.3 
equiv., 0.18 mmol). Crude product was purified via reverse 
phase column chromatography (C18, water pH=10/ACN, 10-
90%) to give product. Yield: 12 mg, 21%; Appearance: white 
solid; LCMS: 1.54  min, m/z 405.1, 407.2 ((M+H)+ 1:1, 79/81Br), 
Purity>80%, Method B; 1H NMR (500 MHz, DMSO-d6) δ ppm 10.57 (s, 1 H, NH), 8.77 
(s, 1 H, NH), 8.46 - 8.40  (m, 2 H, ArCH), 7.63 - 7.55 (m, 2 H, ArCH), 7.43 - 7.29 (m, 4 
H, ArCH), 6.62 - 6.54 (m, 1 H, NH), 4.40 (q, J=7.83 Hz, 1 H, CH), 1.71 - 1.64 (m, 1 H, 
CH), 1.54 - 1.50 (m, 2 H, CH2), 0.95 - 0.92 (m, 6 H, HC(CH3)2); HRMS: Exact Mass: 
404.0848; (M+H)+: 405.0926; Observed Mass: 405.0923; 0.77 ppm. 
 
(2S)-2-[(4-bromophenyl)carbamoylamino]-4-methyl-N-tetrahydropyran-4-yl-
pentanamide (199) 
 
Prepared according to procedure E with intermediate tert-butyl 
(2S)-2-[(4-bromophenyl)carbamoylamino]-4-methyl-pentanoic 
acid (66) (0.14 mmol) and 4-aminotetrahydropyran (1.3 equiv., 
0.18 mmol). Crude product was purified via reverse phase 
column chromatography (C18, water pH=10/ACN, 10-90%) to 
give product. Yield: 29 mg, 52%; Appearance: white solid; 
LCMS: 1.47 min, m/z 412.2, 414.2 ((M+H)+ 1:1, 79/81Br), 
Purity>95%, Method B; 1H NMR (500 MHz, DMSO-d6)  ppm 8.74 (s, 1 H, NH), 8.13 
(d, J=7.45 Hz, 1 H, NH), 7.41 - 7.30 (m, 4 H, ArCH), 6.34 (d, J=8.59 Hz, 1 H, NH), 4.30 
- 4.16 (m, 1 H, CH), 3.86 - 3.70 (m, 3 H, CH, CH2), 3.34 - 3.29 (m, 2 H, CH2), 1.71 - 1.62 
(m, 2 H, CH2), 1.62 - 1.54 (m, 1 H, CH), 1.47 - 1.32 (m, 4 H, CH2), 0.91 - 0.87 (m, 6 H, 
C(CH3)2); 
13C NMR (126 MHz, DMSO-d6)  ppm 171.66 (1 C, C=O), 154.39 (1 C, C=O), 
139.79 (1 C, ArC), 131.43 (2 C, ArCH), 119.35 (2 C, ArCH), 112.32 (1 C, ArC), 65.89 
(2 C, CH2), 51.10 (1 C, CH), 44.92 (1 C, CH), 42.70 (1 C, CH2), 32.43 (1 C, CH2), 32.32 
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(1 C, CH2), 24.33 (1 C, CH), 23.01 (1 C, CH3), 22.11 (1 C, CH3); HRMS: Exact Mass: 
411.1158; (M+H)+: 412.1236; Observed Mass: 412.1231; 1.16 ppm. 
 
tert-butyl 3-[[(2S)-2-[(4-bromophenyl)carbamoylamino]-4-methyl-pentanoyl] 
amino] azetidine-1-carboxylate (200) 
 
Prepared according to procedure E with intermediate tert-
butyl (2S)-2-[(4-bromophenyl)carbamoylamino]-4-methyl-
pentanoic acid (66) (0.14 mmol) and tert-butyl 3-
aminoazetidine-1-carboxylate (1.3 equiv., 0.18 mmol). 
Crude product was purified via reverse phase column 
chromatography (C18, water pH=10/ACN, 10-90%) to give 
product. Yield: 33 mg, 50%; Appearance: white solid; LCMS: 1.74 min, m/z 483.2, 485.1 
((M+H)+ 1:1, 79/81Br), Purity>95%, Method B; 1H NMR (500 MHz, DMSO-d6)  ppm 
8.74 (d, J=7.45 Hz, 1 H, NH), 8.71 (s, 1 H, NH), 7.41 - 7.32 (m, 4 H, ArCH), 6.36 (d, 
J=8.59 Hz, 1 H, NH), 4.43 - 4.34 (m, 1 H, CH), 4.19 (td, J=8.59, 5.73 Hz, 1 H, CH), 4.10 
- 4.00 (m, 2 H, CH2), 3.68 (m, J=5.70 Hz, 2 H, CH2), 1.64 - 1.55 (m, 1 H CH), 1.46 - 1.38 
(m, 2 H, CH2), 1.37 (s, 9 H, C(CH3)3), 0.90 (dd, J=4.01, 2.86 Hz, 6 H, HC(CH3)2). 
 
tert-butyl 3-[[2-[(4-bromophenyl)carbamoylamino]-2-cyclohexyl-
acetyl]amino]azetidine-1-carboxylate (202) 
 
Prepared according to procedure E with intermediate 2-[(4-
bromophenyl)carbamoylamino]-2-cyclohexyl-acetic acid 
(185) (0.11 mmol) and tert-butyl 3-aminoazetidine-1-
carboxylate (1.1 equiv., 0.12 mmol). Yield: 20 mg, 30%; 
Appearance: white solid; LCMS: 2.36 min, m/z 509.2, 511.2 
((M+H)+ 1:1, 79/81Br), Purity>90%, Method D; 1H NMR (500 
MHz, DMSO-d6) δ  ppm 8.79 (s, 1 H, NH), 8.76 (d, J=6.87 Hz, 1 H, NH), 7.43-7.30 (m, 
4 H, ArCH), 6.39 (d, J=8.59 Hz, 1H, NH), 4.43 - 4.34 (m, 1 H, CH), 4.11 - 4.00 (m, 3 H, 
CH, CH2), 3.67 (d, J=5.73 Hz, 2 H, CH2), 1.74-1.49 (m, 6 H, CH, CH2), 1.37 (s, 9 H, 
C(CH3)3), 1.20 - 0.90 (m, 5 H, CH2); 
13C NMR (126 MHz, DMSO-d6)  ppm 171.35 (1 
C, C=O), 155.48 (1 C, C=O), 154.60 (1 C, C=O), 139.75 (1 C, ArC), 131.41 (2 C, ArCH), 
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119.27 (2 C, ArCH), 112.35 (1 C, ArC), 78.71 (1 C, C(CH3)3), 57.08 (1 C, CH), 40.81 (1 
C, Cquat.), 38.59 (2 C, CH2), 29.27 (2 C, CH2), 28.07 (3 C, C(CH3)3), 25.80 (2 C, CH2), 
25.53 (1 C, CH2), one carbon hidden under DMSO peak. 
 
tert-butyl 3-[[2-[(4-bromophenyl)carbamoylamino]-2-tetrahydropyran-4-yl-
acetyl]amino]azetidine-1-carboxylate (204) 
Prepared according to procedure E with intermediate 2-[(4-
bromophenyl)carbamoylamino]-2-tetrahydropyran-4-yl-acetic 
acid (187) (0.14 mmol) and tert-butyl 3-aminoazetidine-1-
carboxylate (1.1 equiv., 0.16 mmol). Crude product was 
purified by reverse phase column chromatography (C18 12g, 
Water pH-10/MeOH 90/10-->100) to give final product. Yield: 20 mg, 30%; Appearance: 
white solid; LCMS: 2.29 min, m/z 411.1, 413.1 and 511.1, 513.1 ((M+H)+ 1:1, 79/81Br), 
Purity>90%Method D; 1H NMR (500 MHz, DMSO-d6)  ppm 8.82 (d, J=6.87 Hz, 1 H, 
NH), 8.78 (s, 1 H, NH), 7.31 - 7.41 (m, 4 H, ArCH), 6.45 (d, J=9.17 Hz, 1 H, NH), 4.34 
- 4.45 (m, 1 H, CH), 4.01 - 4.15 (m, 3 H, CH, CH2), 3.81 - 3.91 (m, 2 H, CH2), 3.67 (br. 
s., 2 H, CH2), 3.19 - 3.28 (m, 2 H, CH2), 1.75 - 1.88 (m, 1 H, CH), 1.48 (d, J=14.89 Hz, 
1 H, CH2), 1.30 - 1.42 (m, 12 H, C(CH3)3, CH2), 1.16 - 1.31 (m, 1 H, CH2). 
 
 2-[(4-bromophenyl)carbamoylamino]-3-cyclohexyl-N-tetrahydropyran-4-yl-
propanamide (206) 
Prepared according to procedure E with intermediate 2-
[(4-bromophenyl)carbamoylamino]-3-cyclohexyl-
propanoic acid (186) (0.087 mmol) and 4-
aminotetrahydropyran (1.1 equiv., 0.1 mmol). Yield: 12 
mg, 31%; Appearance: white solid; LCMS: 2.307 min, m/z 452.2, 454.2 ((M+H)+ 1:1, 
79/81Br), Purity>95%, Method D; 1H NMR (500 MHz, DMSO-d6)  ppm 8.75 (s, 1 H, 
NH), 8.11 (d, J=8.02 Hz, 1 H, NH), 7.42 - 7.30 (m, 4 H, ArCH), 6.34 (d, J=8.59 Hz, 1 H, 
NH), 4.23 (td, J=8.45, 6.01 Hz, 1 H, CH), 3.86 - 3.77 (m, 2 H, CH2), 3.77 - 3.70 (m, 1 H, 
CH), 3.34 - 3.29 (m, 2 H, CH2), 1.80 - 1.55 (m, 7 H, CH, CH2), 1.47 - 1.33 (m, 4 H, CH2), 
1.32 - 1.21 (m, 1 H, CH), 1.21 - 1.05 (m, 3 H, CH2), 0.94 - 0.81 (m, 2 H, CH2); HRMS: 
Exact Mass: 451.1471; (M+H)+: 452.1549; Observed Mass: 452.1543; 1.28 ppm. 
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 tert-butyl 3-[[2-[(4-bromophenyl)carbamoylamino]-3-cyclohexyl-
propanoyl]amino] azetidine-1-carboxylate (207) 
 
Prepared according to procedure E with intermediate 2-[(4-
bromophenyl)carbamoylamino]-3-cyclohexyl-propanoic 
acid (186) (0.087 mmol) and tert-butyl 3-aminoazetidine-1-
carboxylate (1.1 equiv., 0.1 mmol). Yield: 20 mg, 44% 
Appearance: white solid; LCMS: 2.42 min, m/z 523.2, 525.2 
((M+H)+ 1:1, 79/81Br), Purity>95%, Method D; 1H NMR (500 MHz, DMSO-d6) δ ppm 
8.73-8.64 (m, 2 H, NH), 7.39-7.27 (m, 4 H, ArCH), 6.33 (d, J=8.02 Hz, 1 H, NH), 4.42-
4.29 (m, 1 H, CH), 4.22-4.12 (m, 1 H, CH), 4.01 (br. s., 2 H,CH2 ), 3.71-3.57 (m, 2 H, 
CH2), 1.72 (d, J=12.60 Hz, 1 H, CH), 1.68-1.53 (m, 4 H, CH2), 1.48-1.35 (m, 2 H, CH2), 
1.34 (s, 9 H, C(CH3)3), 1.31-1.22 (m, 1 H, CH2), 1.20-1.04 (m, 3 H, CH2), 0.94-0.79 (m, 
2 H, CH2). 
 
2-[(4-bromophenyl)carbamoylamino]-2-cyclopentyl-N-pyrimidin-5-yl-acetamide 
(210) 
 
Prepared according to procedure E with intermediate 2-[(4-
bromophenyl)carbamoylamino]-2-cyclopentyl-acetic acid 
(184) (0.15 mmol) and pyrimidin-5-amine (1.2 equiv., 0.18 
mmol). The crude product was purified by flash column 
chromatography (silica gel, PE/EA 10-->100%, then 
EA/MeOH 2% gradient). Yield: 29 mg, 65%; Appearance: white solid; LCMS: 2.15 min, 
m/z 418.1, 420.1 ((M+H)+ 1:1, 79/81Br),Purity>95%, Method D; 1H NMR (500 MHz, 
DMSO-d6)  ppm 10.66 (s, 1 H, NH), 9.02 (s, 2 H, ArCH), 8.90 (s, 1 H, NH), 8.79 (s, 1 
H, ArCH), 7.40 - 7.34 (m, 4 H, ArCH), 6.64 (d, J=8.59 Hz, 1 H, NH), 4.33 (t, J=8.02 Hz, 
1 H, CH), 2.21 (sxt, J=8.60 Hz, 1 H, CH), 1.75 - 1.57 (m, 4 H, CH2), 1.57 - 1.47 (m, 2 H, 
CH2), 1.46 - 1.28 (m, 2 H, CH2); 
13C NMR (126 MHz, DMSO-d6)  ppm 172.22 (1 C, 
C=O), 154.76 (1 C, C=O), 153.28 (1 C, ArCH), 147.21 (2 C, ArCH), 139.54 (1 C, ArC), 
134.17 (1 C, ArC), 131.61 (2 C, ArCH), 119.47 (2 C, ArCH) 112.59 (1 C, ArC.), 56.57 
(1 C, CH), 42.48 (1 C, CH), 28.69 (1 C, CH2), 28.19 (1 C, CH2), 24.65 (2 C, CH2) HRMS: 
Exact mass: 417.0800; (M+H)+: 418.0880; Observed mass: 418.0877; 0.81 ppm. 
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 tert-butyl 3-[[2-[(4-bromophenyl)carbamoylamino]-2-cyclopentyl-acetyl]amino] 
azetidine-1-carboxylate (211) 
Prepared according to procedure E with intermediate 2-[(4-
bromophenyl)carbamoylamino]-2-cyclopentyl-acetic acid 
(184) (0.11 mmol) and tert-butyl 3-aminoazetidine-1-
carboxylate (1.1 equiv., 0.122 mmol). Crude product was 
purified by reverse phase column chromatography (C18 12g, 
Water pH-10/MeOH 90/10→100) to give final product. 
Yield: 27 mg, 49%; Appearance: white solid; LCMS: 1.76 min, m/z 495.1, 497.1 ((M+H)+ 
1:1, 79/81Br), Purity>90%, Method B; 1H NMR (500 MHz, DMSO-d6) δ  ppm 8.74 (s, 1 
H, NH), 8.73 (s, 1 H, NH), 7.40-7.27 (m, 4 H, ArCH), 6.41 (d, J=8.59 Hz, 1 H, NH), 4.33 
- 4.41 (m, 1 H, CH), 3.95-4.09 (m, 2 H, CH2), 3.57-3.72 (m, 2 H, CH2), 1.99-2.12 (m, 1 
H, CH), 1.41-1.63 (m, 6 H, CH2), 1.35 (s, 9 H, C(CH3)3), 1.32-1.23 (m, 2 H, CH2); 
13C 
NMR (126 MHz, DMSO-d6)  ppm 172.40 (s, 1 C, C=O), 156.00 (1 C, C=O), 155.13 (s, 
1 C, C=O), 140.25 (1 C, ArC.), 132.01 (2 C, ArCH), 119.91 (2 C, ArCH), 112.91 (1 C, 
ArC.), 79.22 (1 C, C(CH3)3), 56.21 ( 1 C, CH.), 43.36 (1 C,CH), 39.13 (2 C, CH2), 29.17 
(1 C, CH), 28.59 (3 C, C(CH3)3), 28.55 (2 C, CH2), 25.26 (2 C, CH2). 
 
 2-[(4-bromophenyl)carbamoylamino]-2-cyclopentyl-N-(1-methyl-4-piperidyl) 
acetamide (213) 
Prepared according to procedure E with intermediate 2-[(4-
bromophenyl)carbamoylamino]-2-cyclopentyl-acetic acid (184) 
(0.11 mmol) and 4-amino-1-methylpiperidine (1.1 equiv., 0.122 
mmol). The crude product was purified by preparative flash 
column chromatography (19x100mm (5µm) C-18 Waters 
Xbridge, MeOH, pH=10). Yield: 5 mg, 10%; Appearance: white solid; LCMS: 2.17  min, 
m/z 437.1, 439.1 ((M+H)+ 1:1, 79/81Br), Purity>95%, Method D; 1H NMR (500 MHz, 
DMSO-d6)  ppm 8.78 (s, 1 H, NH), 8.24 (br d, J=7.45 Hz, 1 H, NH), 7.31 - 7.41 (m, 4 
H, ArCH), 6.44 (d, J=9.17 Hz, 1 H, NH), 4.10 (br t, J=8.02 Hz, 1 H, CH), 2.89 (br s, 2 H, 
CH2), 3.75 (br. s, 1 H, CH2), 2.12 - 2.01 (m, 2 H, CH2), 2.73 - 2.55 (m, 3 H, CH3), 1.95 - 
1.82 (m, 2 H, CH2), 1.46 (s, 1 H, CH), 1.64 - 1.43 (m, 8 H, CH2), 1.38 - 1.22 (m, 2 H, 
CH2); two protons are hidden under DMSO peak; HRMS: Exact Mass: 436.1474; 
(M+H)+: 437.1552; Observed Mass: 437.1549; 0.72 ppm. 
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 2-[(4-bromophenyl)carbamoylamino]-2-cyclopentyl-N-(oxetan-3-yl)acetamide 
(214) 
Prepared according to procedure E with intermediate 2-[(4-
bromophenyl)carbamoylamino]-2-cyclopentyl-acetic acid 
(184) (0.11 mmol) and 3-oxetanamine (1.1 equiv., 0.122 
mmol). The crude product was purified by preparative flash 
column chromatography (19x100mm (5µm) C-18 Waters 
Xbridge, MeOH, pH=10); Yield: 2.6 mg, 6%; Appearance: white solid; LCMS: 1.41 min, 
m/z 396.1, 398.1 ((M+H)+ 1:1, 79/81Br), Purity>95%, Method B; 1H NMR (500 MHz, 
DMSO-d6)  ppm 8.90 (d, J=6.30 Hz, 1 H, NH), 8.77 (s, 1 H, NH), 7.44 - 7.29 (m, 4 H, 
ArCH), 6.43 (d, J=8.59 Hz, 1 H, NH), 4.82 - 4.73 (m, 1 H, CH), 4.70 (td, J=6.73, 2.00 
Hz, 2 H, CH2), 4.47 - 4.34 (m, 2 H, CH2), 4.15 - 4.15 (m, 1 H, CH), 2.07 (sxt, J=7.90 Hz, 
1 H, CH), 1.64 - 1.42 (m, 6 H, CH2), 1.39 - 1.24 (m, 2 H, CH2); HRMS: Exact Mass: 
395.0845; (M+H)+: 396.0923; Observed Mass: 396.0918; 1.21 ppm. 
  
2-[(4-bromophenyl)carbamoylamino]-2-cyclopentyl-N-tetrahydropyran-4-yl-
acetamide (215) 
Prepared according to procedure E with intermediate 2-[(4-
bromophenyl)carbamoylamino]-2-cyclopentyl-acetic acid 
(184) (0.11 mmol) and 4-aminotetrahydropyran (1.1 equiv., 
0.122 mmol). Crude product was purified by reverse phase 
column chromatography (C18 12g, Water pH-10/MeOH 
90/10→100) to give final product. Yield: 22 mg, 47%; Appearance: white solid; LCMS: 
2.13 min m/z 424.2, 426.2 ((M+H)+ 1:1, 79/81Br),  Purity>95% method D;1H NMR (500 
MHz, DMSO-d6)  8.76 (s, 1 H, NH), 8.11 (d, J=8.02 Hz, 1 H, NH), 7.40-7.27 (m, 4H, 
ArCH), 6.38 (d, J=9.17 Hz, 1 H, NH), 4.13 - 4.05 (m, 1 H, CH), 3.83-3.68 (m, 3 H, CH, 
CH2), 2.02 (sxt, J=8.02 Hz, 1 H, CH), 1.63 (d, J=12.60 Hz, 2 H, CH2), 1.59-1.47 (m, 4 
H, CH2), 1.46-1.23 (m, 6 H, CH2) 2 protons from tetrahydro-2H-pyran hidden under water 
peak; 13C NMR (126 MHz, DMSO-d6)  ppm 170.95 (1 C. C=O), 154.56 (1 C, C=O), 
139.81 (1 C, ArC), 131.49 (1 C, ArCH), 119.41 (1 C, ArCH), 112.32 (1 C, ArC), 65.86 
(2 C, CH2), 55.46 (1 C, CH), 44.77 (1 C, CH), 43.41 (1 C, CH), 32.52 (2 C, CH2), 28.58 
(2 C, CH2), 24.87 (1 C, CH2), 24.64 (1 C, CH2) HRMS: Exact Mass: 423.1158; (M+H)
+: 
424.1236; Observed Mass: 424.1231; 1.13 ppm. 
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2-[(4-bromophenyl)carbamoylamino]-2-cyclopentyl-N-(tetrahydrofuran-2-
ylmethyl)acetamide (216) 
Prepared according to procedure E with intermediate 2-[(4-
bromophenyl)carbamoylamino]-2-cyclopentyl-acetic acid 
(184) (0.11 mmol) and 3-oxetanamine (1.1 equiv., 0.122 
mmol). Crude product was purified by reverse phase column 
chromatography (C18 12g, Water pH-10/MeOH 
90/10→100) to give final product. Yield: 31 mg, 62%; Appearance: white solid; LCMS: 
2.26 min, m/z 424.2, 426.2 ((M+H)+ 1:1, 79/81Br),Purity>95%, Method D; 1H NMR (500 
MHz, DMSO-d6)  ppm 8.79 (s, 1 H, NH), 8.22 - 8.14 (m, 1 H, NH), 7.42 - 7.30 (m, 4 
H, ArCH), 6.41 (d, J=9.17 Hz, 1 H, NH), 4.16 (ddd, J=8.74, 7.30, 2.86 Hz, 1 H, CH), 
3.85 - 3.78 (m, 1 H, CH), 3.77 - 3.69 (m, 1 H, CH2), 3.63 - 3.56 (m, 1 H, CH2), 3.25 - 
3.14 (m, 1 H, CH2), 3.11 - 3.03 (m, 1 H, CH2), 2.08 (sxt, J=7.79 Hz, 1 H, CH), 1.89 - 1.71 
(m, 3 H, CH2), 1.62 - 1.40 (m, 7 H, CH2), 1.39 - 1.24 (m, 2 H, CH2);
 13C NMR (126 MHz, 
DMSO-d6)  ppm 172.01 (1 C, C=O), 154.58 (1 C, C=O), 139.82 (1 C, ArC.), 131.43 (2 
C, ArCH), 119.30 (2 C, ArCH), 112.30 (1 C, ArC), 76.96 (1 C, CH), 67.19 (1 C, CH2), 
55.48 (1 C, CH), 43.09 ( 1 C, CH ), 42.58 (1 C, CH2), 28.57 (1 C, CH2), 28.43 (1 C, CH2), 
27.99 (1 C, CH2), 25.14 (1 C, CH2), 24.86 (1 C, CH2), 24.69 (1 C, CH2); HRMS: Exact 
Mass: 423.1158; (M+H)+: 424.1236; Observed Mass: 424.1234; 0.42 ppm. 
 
1-[(4-bromophenyl)carbamoylamino]-N-(3-pyridyl)cyclopentanecarboxamide (218) 
 
Prepared according to procedure E with intermediate 1-[(4-
bromophenyl)carbamoylamino]cyclopentanecarboxylic acid 
(217) (0.21 mmol) and 3-aminopyridine (1.1 equiv., 0.23 
mmol). Crude product was dry loaded on silica and purified by 
flash column chromatography (silica gel, PE/EA 10-->100%, 
EA/MeOH 2% gradient).; Yield: 45 mg, 50%; Appearance: white solid; LCMS: 1.99 min, 
m/z 403.1, 405.1 (M+H)+ (1:1, 79/81Br), Purity>95%, Method D; 1H NMR (500 MHz, 
DMSO-d6)  ppm  9.75 (s, 1 H, NH), 8.75 (d, J=2.29 Hz, 1 H, ArCH), 8.74 - 8.71 (m, 1 
H, NH), 8.23 (dd, J=4.58, 1.72 Hz, 1 H, ArCH ), 8.06 - 7.99 (m, 1 H, ArCH), 7.40 - 7.29 
(m, 5 H, ArCH), 6.54 (s, 1 H, NH), 2.23 - 2.13 (m, 2 H, CH2), 1.91 - 1.82 (m, 2 H, CH2), 
1.75 - 1.67(m, 4 H, CH2); 
13C NMR (126 MHz, DMSO-d6) d ppm 173.40 (1 C, C=O), 
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154.20 (1 C, C=O), 143.99 (1 C, ArCH), 141.77 (1 C, ArCH), 139.52 (1 C, ArC), 136.00 
(1 C, ArC, 131.61 (2 C, ArCH), 126.99 (1 C, ArCH), 123.51 (1 C, ArCH), 119.54 (2 C, 
ArCH), 112.53 (1 C, ArC), 66.49 (1 C, Cspiro), 36.38 (1 C, CH2), 36.29 (1 C, CH2), 23.69 
(2 C, CH2); HRMS: Exact mass: 402.0691; (M+H)
+: 403.0771; Observed mass: 403.076; 
2.83 ppm. 
 
1-[(4-bromophenyl)carbamoylamino]-N-pyrimidin-5-yl-cyclopentanecarboxamide 
(219) 
 
Prepared according to procedure E with intermediate 1-[(4-
bromophenyl)carbamoylamino]cyclopentanecarboxylic acid 
(217) (0.21 mmol) and 5-aminopyrimidine (1.1 equiv., 0.23 
mmol). Crude product was dry loaded on silica and purified by 
flash column chromatography (silica gel, PE/EA 10-->100%, 
EA/MeOH 2% gradient).; Yield: 37 mg, 43%; Appearance: white solid; LCMS: 2.03 min, 
m/z 404.1, 406.1 ((M+H)+ 1:1, 79/81Br), Purity>95%, Method D; 1H NMR (500 MHz, 
DMSO-d6)  ppm 9.97 (s, 1 H, NH), 9.03 (s, 2 H, ArCH), 8.85 (s, 1 H, ArCH), 8.70 (s, 
1 H, NH), 7.40 - 7.31 (m, 4 H, ArCH), 6.60 (s, 1 H, NH), 2.24 - 2.14 (m, 2 H, CH2), 1.90 
- 1.80 (m, 2 H, CH2), 1.76 - 1.68 (m, 4 H, CH2); 
13C NMR (126 MHz, DMSO-d6)  ppm 
173.85 (1 C, C=O), 154.20 (1 C, C=O), 152.91 (1 C, ArCH), 147.83 (1 C, ArCH), 139.43 
(1 C, ArC), 134.72 (1 C, ArCquat), 131.64 (2 C, ArCH), 119.58 (2 C, ArCH), 112.61 (1 
C, ArC), 66.39 (1 C, Cspiro), 36.41 (2 C, CH2), 23.70 (2 C, CH2); HRMS: Exact mass: 
403.0644; ((M+H)+: 404.0724; Observed mass: 404.0723; 0.22 ppm. 
 
1-[(4-bromophenyl)carbamoylamino]-N-(1,3-dimethylpyrazol-4-yl) cyclopentane 
carboxamide (220) 
 
Prepared according to procedure E with intermediate 1-
[(4-bromophenyl)carbamoylamino] cyclopentane 
carboxylic acid (217) (0.14 mmol) and 1,3-dimethyl-1h-
pyrazol-4-amine (1.1 equiv., 0.16 mmol). Crude product 
was purified by reverse phase column chromatography (C18 12g, Water pH-10/MeOH 
90/10→100) to give final product. Yield: 20 mg, 43%; Appearance: white solid; LCMS: 
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1.92 min, m/z 420.1, 422.1 (M+H+ 1:1, 79/81Br), Purity>95%, Method D; 1H NMR (500 
MHz, DMSO-d6) δ ppm 8.96 (s, 1 H, NH), 8.70 (s, 1 H, NH), 7.41- 7.33 (m, 4 H, ArCH), 
7.24 (s, 1 H, ArCH), 6.52 (s, 1 H, NH), 3.66 (s, 3 H, CH3), 2.18 - 2.09 (m, 2 H, CH2),  
2.06 (s, 3 H, CH3), 1.90 - 1.82 (m, 2 H, CH2), 1.71 - 1.65 (m, 4 H, CH2); 
13C NMR (126 
MHz, DMSO-d6)  ppm 172.91 (1 C, C=O), 154.28 (1 C, C=O), 139.73 (1 C, ArC), 
133.32 (1 C, ArC), 131.89 (1 C, ArCH), 131.45 (2 C, ArCH), 119.35 (2 C, ArCH), 117.82 
(1 C, ArC), 112.38 (1 C, ArC), 66.13 (1 C, Cspiro), 36.49 (2 C, CH2), 36.37 (1 C, CH3), 
23.72 (2 C, CH2), 8.82 (1 C, CH3); HRMS: Exact Mass: 419.0957; (M+H)
+: 420.1037; 
Observed Mass: 420.103; 1.67 ppm. 
 
1-[(4-bromophenyl)carbamoylamino]-N-(2H-tetrazol-5-ylmethyl) 
cyclopentanecarboxamide (221) 
 
Prepared according to procedure E with intermediate 1-
[(4-bromophenyl)carbamoylamino] cyclopentane 
carboxylic acid (217) (0.14 mmol) and c-(2h-tetrazol-5-
yl)-methylamine (1.1 equiv., 0.16 mmol). Crude product was purified by reverse phase 
column chromatography (C18 12g, Water pH-10/MeOH 90/10→100) to give final 
product. Yield: 20 mg, 40% ;Appearance: white solid; LCMS: 1.55 min, m/z 408.1, 410.1 
((M+H)+ 1:1, 79/81Br), Purity>90%, Method D; 1H NMR (500 MHz, DMSO-d6)   ppm 
8.78 (br s, 1 H, NH), 8.54 (br s, 1 H, NH), 7.49 - 7.28 (m, 4 H, ArCH), 6.74 (br s, 1 H, 
NH), 4.54 (br d, J=5.16 Hz, 2 H, CH2), 2.08 (br d, J=13.17 Hz, 2 H, CH2), 1.66 (br s, 4 
H, CH2) 1.81 (br d, J=12.60 Hz, 2 H, CH2); 
13C NMR (126 MHz, DMSO-d6)  ppm 
174.74 (1 C, C=O), 154.99 (1 C, C=O), 154.84 (1 C, ArC), 139.40 (1 C, ArC), 131.46 (2 
C, ArCH), 119.62 (2 C, ArCH), 112.73 (1 C, ArC), 65.86 (1 C, Cspiro), 36.52 (2 C, CH2), 
33.18 (1 C, CH2), 23.79 (2 C, CH2); HRMS: Exact Mass: 407.0705; (M+H)
+: 408.0785; 
Observed Mass: 408.0777; 1.97 ppm. 
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1-[(4-bromophenyl)carbamoylamino]-N-(1-methyl-4-piperidyl) cyclopentane 
carboxamide (222) 
Prepared according to procedure E with intermediate 1-
[(4-bromophenyl)carbamoylamino] cyclopentane 
carboxylic acid (217) (0.12 mmol) and 4-amino-1-
methylpiperidine (1.1 equiv., 0.13 mmol). The crude 
product was purified by preparative flash column chromatography (19x100mm (5µm) C-
18 Waters Xbridge, MeOH, pH=10); Yield: 10 mg, 19.5%; Appearance: white solid; 
LCMS: 2.00 min, m/z 423.1, 425.1 ((M+H)+ 1:1, 79/81Br), Purity>90%, Method D; 1H 
NMR (500 MHz, DMSO-d6)  8.68 (s, 1H, NH), 7.40-7.31 (m, 4H, ArCH), 6.41 (s, 1 H, 
NH), 3.59-3.48 (m, 1H, CH), 2.75 (d, J=9.16 Hz, 2 H, CH2), 2.21 (s, 3 H, CH3), 2.14 (d, 
J=12.03 Hz, 2 H, CH2), 2.07-1.97 (m, 2H, CH2), 1.83-1.74 (m, 2 H, CH2), 1.64 (m, 6 H, 
CH2), 1.40-1.51 (m, 2 H, CH2); 
13C NMR (126 MHz, DMSO-d6)  ppm 173.33 (1 C, 
C=O) 154.20 (1 C, C=O) 139.78 (1 C, ArC) 131.40 (2 C, ArCH) 119.37 (2 C, ArCH) 
112.29 (1 C, ArC) 65.98 (1 C, Cspiro) 53.81 (2 C, CH2) 48.61 (1 C, CH) 45.29 (1 C, CH3) 
36.39 ( 2 C, CH2) 30.72 (2 C, CH2) 23.75 (2 C, CH2); HRMS: Exact Mass: 422.1317; 
(M+H)+ 423.1397; Observed Mass: 423.139; 1.66 ppm. 
 
1-[(4-bromophenyl)carbamoylamino]-N-(1-isopropylpyrazol-4-yl) cyclopentane 
carboxamide (223) 
Prepared according to procedure E with intermediate 1-[(4-
bromophenyl)carbamoylamino] cyclopentanecarboxylic 
acid (217) (0.12 mmol) and 1-isopropyl-1h-pyrazol-4-
amine (1.1 equiv., 0.13 mmol). Crude product was washed 
with diethyl ether to obtain desired product.; Yield: 36 mg, 68%; Appearance: white solid; 
LCMS: 2.01 min, m/z 434.1, 436.1 (M+H+ 1:1, 79/81Br), Purity>95%, Method D; 1H NMR 
(500 MHz, DMSO-d6) δ ppm 9.61 (s, 1 H, NH) 8.62 (s, 1 H, NH), 7.86 (s, 1 H, ArCH), 
7.42 (d, J=1.15 Hz, 1 H, ArCH), 7.36 - 7.28 (m, 4 H, ArCH), 6.43 (s, 1 H, NH), 4.38 
(quin, J=6.73 Hz, 1 H, CH), 2.13 - 2.04 (m, 2 H, CH2), 1.82 - 1.76 (m, 2 H, CH2), 1.69 - 
1.62 (m, 4 H, CH2), 1.33 (d, J=6.87 Hz, 6 H, CH3); 
13C NMR (126 MHz, DMSO-d6)  
ppm 171.30 (1 C, C=O), 154.08 (1 C, C=O), 139.66 (1 C, ArC), 131.45 (2 C, ArCH), 
129.39 (1 C, ArCH), 121.71 (1 C, ArC), 119.29 (2 C, ArCH), 117.90 (1 C, ArCH), 112.38 
(1 C, ArC), 66.04 (1 C, Cspiro), 52.84 (1 C, CH), 36.56 (2 C, CH2), 23.74 (2 C, CH2), 
22.67 (2 C, CH3) ; HRMS: Exact Mass: 433.1113; Observed Mass: 434.1187; 1.39 ppm. 
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1-[(4-bromophenyl)carbamoylamino]-N-(2-pyridyl)cyclopentanecarboxamide (224) 
 
Prepared according to procedure E with intermediate 1-
[(4-bromophenyl)carbamoylamino] cyclopentane 
carboxylic acid (217) (0.12 mmol) and 2-aminopyridine 
(1.1 equiv., 0.13 mmol). The crude product was purified 
by preparative flash column chromatography (19x100mm (5µm) C-18 Waters Xbridge, 
MeOH, pH=10); Yield: 3.8 mg, 7.7%; Appearance: white solid; LCMS: 2.08 min, m/z 
403.1, 405.1 ((M+H)+ 1:1, 79/81Br), Purity>95%, Method D; 1H NMR (500 MHz, DMSO-
d6)  9.85 (s, 1H, NH), 8.91 (s, 1H, NH), 8.22 (d, J=4.81 Hz, 1H, ArCH), 8.06 (d, J=8.17 
Hz, 1H, ArCH), 7.77-7.72 (m, 1H, ArCH), 7.39-7.27 (m, 4H, ArCH), 7.09-6.98 (m, 1H, 
ArCH), 6.65 (s, 1H, NH), 2.19-2.10 (m, 2H, CH2), 1.93-1.85 (m, 2H, CH2), 1.69-1.63 (m, 
4H, CH2); HRMS: Exact Mass: 402.0691; (M+H)
+ 403.0771; Observed Mass: 403.0769; 
0.5 ppm. 
 
1-[(4-bromophenyl)carbamoylamino]-N-(6-methyl-3-pyridyl) cyclopentane 
carboxamide (225) 
 
Prepared according to procedure E with intermediate 1-
[(4-bromophenyl)carbamoylamino] cyclopentane 
carboxylic acid (217) (0.12 mmol) and 5-amino-2-
methylpyridine (1.1 equiv., 0.13 mmol). The crude 
product was purified by preparative flash column chromatography (19x100mm (5µm) C-
18 Waters Xbridge, MeOH, pH=10). Yield: 15 mg, 29 %; Appearance: white solid; 
LCMS: 2.05 min, m/z 417.1, 419.1 ((M+H)+ 1:1, 79/81Br), Purity>95%, Method D; 1H 
NMR (500 MHz, DMSO-d6)  9.67 (s, 1H, NH), 8.78 (s, 1H, NH), 8.60 (d, J=2.86 Hz, 
1H), 7.89 (dd, J=2.58, 8.31 Hz, 1H, ArCH), 7.40-7.31 (m, 4H, ArCH), 7.16 (d, J=8.02 
Hz, 1H, ArCH), 6.59 (s, 1H, NH), 2.39 (s, 3H, CH3), 2.20-2.12 (m, 2H, CH2), 1.89-1.82 
(m, 2H, CH2), 1.70 (t, J=6.87 Hz, 4H, CH2); 
13C NMR (126 MHz, DMSO-d6)  ppm 
173.24 (1 C, C=O), 154.22 (1 C, C=O), 152.09 (1 C, ArC.), 140.94 (1 C, ArCH), 139.59 
(1 C, ArC), 133.50 (1 C, ArC), 131.46 (2 C, ArCH), 127.66 (1 C, ArCH), 122.50 (1 C, 
ArCH), 119.39 (2 C, ArCH), 112.46 (1 C, ArC), 66.47 (1 C, Cspiro), 36.35 (2 C, CH2), 
23.70 (2 C, CH2), 23.33 (1 C, CH3); HRMS: Exact Mass: 416.0848; (M+H)
+ :417.0928; 
Observed Mass: 417.0924; 0.96 ppm. 
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1-[(4-bromophenyl)carbamoylamino]-N-(5-methyl-3-pyridyl) cyclopentane 
carboxamide (226) 
 
Prepared according to procedure E with intermediate 1-
[(4-bromophenyl)carbamoylamino] cyclopentane 
carboxylic acid (217) (0.12 mmol) and 3-amino-5-
methylpyridine (1.1 equiv., 0.13 mmol). The crude 
product was purified by preparative flash column chromatography (19x100mm (5µm) C-
18 Waters Xbridge, MeOH, pH=10); Yield: 10 mg, 20 %; Appearance: white solid; 
LCMS: 2.10 min, m/z 417.1, 419.1 ((M+H)+ 1:1, 79/81Br), Purity=88%, Method D; 1H 
NMR (500 MHz, DMSO-d6) δ ppm 9.66 (s, 1 H, NH), 8.73 (s, 1 H, NH), 8.55 (d, J=2.29 
Hz, 1 H, ArCH), 8.05 (d, J=1.15 Hz, 1 H, ArCH), 7.84 (t, J=2.00 Hz, 1 H, ArCH), 7.39 - 
7.26 (m, 4 H, ArCH), 6.54 (s, 1 H, NH), 2.23 (s, 3 H, CH3), 2.19 - 2.09 (m, 2 H, CH2), 
1.87 - 1.78 (m, 2 H, CH2), 1.72 - 1.63 (m, 4 H, CH2); 
13C NMR (126 MHz, DMSO-d6) 
 ppm 173.37 (1 C, C=O) 154.20 (1 C, C=O) 144.22 (1 C, ArCH) 139.56 (1 C, ArC) 
138.75 (1 C., ArCH) 135.65 (1 C, ArCquat) 132.65 (1 C, ArCH) 131.47 (2 C, ArCH) 
127.34 (1 C, ArC) 119.37 (2 C, ArCH) 112.49 (1 C, ArC) 66.49 (1 C, Cspiro.) 36.33 (2 
C, CH2) 23.69 (2 C, CH2) 17.87 (1 C, CH3); HRMS: Exact Mass: 416.0848; (M+H)
+: 
417.0928; Observed Mass: 417.0925; 0.72 ppm. 
 
1-[(4-bromophenyl)carbamoylamino]-N-(6-chloro-3-pyridyl) cyclopentane 
carboxamide (227) 
 
Prepared according to procedure E with intermediate 1-
[(4-bromophenyl)carbamoylamino] cyclopentane 
carboxylic acid (217) (0.12 mmol) and 5-amino-2-
chloropyridine (1.1 equiv., 0.13 mmol). Crude product 
was washed with diethyl ether to obtain desired product. Yield: 40 mg, 74.5 %; 
Appearance: white solid; LCMS: 2.15 min, m/z 437.0, 439.0, 441.0 ((M+H)+ 3:4:2, 79/81Br 
and 35/37Cl), Purity>95%, Method D; 1H NMR (500 MHz, DMSO-d6) δ ppm 9.87 (s, 1 H, 
NH), 8.69 (s, 1 H, NH), 8.60 (d, J=2.29 Hz, 1 H, ArCH), 8.07 (dd, J=8.59, 2.86 Hz, 1 H, 
ArCH), 7.41 (d, J=8.59 Hz, 1 H, ArCH), 7.36 -7.33 (m, 2 H, ArCH), 7.31 - 7.28 (m, 2 H, 
ArCH), 6.53 (s, 1 H, NH), 2.19 - 2.10 (m, 2 H, CH2), 1.86 - 1.77 (m, 2 H, CH2), 1.71 - 
1.64 (m, 4 H, CH2); 
13C NMR (126 MHz, DMSO-d6)  ppm 174.05 (1 C, C=O) 154.70 
(1 C, C=O) 143.91 (1 C, ArC) 141.62 (1 C, ArCH) 139.98 (1 C, ArC) 136.20 (1 C, ArC) 
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131.94 (2 C, ArCH) 131.06 (1 C, ArCH) 124.50 (s, 1 C, ArCH) 120.02 (2 C, ArCH) 
113.09 (1 C, ArC) 66.99 (1 C, Cspiro) 36.86 (2 C, CH2) 24.20 (2 C, CH2); HRMS: Exact 
Mass: 436.0302; (M+H)+ : 437.0382 Observed Mass: 437.0374; 1.83 ppm. 
 
2-[(4-bromophenyl)carbamoylamino]-2-cyclopentyl-N-(1,3-dimethylpyrazol-4-
yl)acetamide (228) 
 
Prepared according to procedure E with intermediate 2-[(4-
bromophenyl)carbamoylamino]-2-cyclopentyl-acetic acid (184) 
 (0.11 mmol) and 1,3-dimethyl-1h-pyrazol-4-amine (1.1 equiv., 
0.122 mmol). Crude product was washed with diethyl ether to 
give products. Yield: 48 mg, 99 %; Appearance: beige solid; LCMS: 2.14 min, m/z 434.1, 
436.1 ((M+H)+ 1:1, 79/81Br), Purity>95%, Method D; 1H NMR (500 MHz, DMSO-d6) δ 
ppm 9.51 (s, 1 H, NH), 8.81 (s, 1 H, NH), 7.45 - 7.43 (m, 1 H, ArCH), 7.41 - 7.33 (m, 4 
H, ArCH), 6.52 - 6.48 (m, 1 H, NH), 4.35 (t, J=8.31 Hz, 1 H, CH), 3.68 (s, 3 H, CH3), 
2.19 - 2.11 (m, 4 H, CH , CH3), 1.65 - 1.53 (m, 4 H, CH2), 1.53 - 1.32 (m, 4 H, CH2); 
13C 
NMR (126 MHz, DMSO-d6)  ppm 171.11 (1 C, C=O), 155.20 (1 C, C=O), 140.29 (1 C, 
ArC.), 132.89 (1 C, ArC), 132.06 (1C, ArC), 130.63 (2 C, ArCH), 119.95 (2 C, ArCH), 
118.21 (1 C, ArCH), 112.90 (1 C, ArC), 56.03 (1 C, CH), 43.71 (1 C, CH), 36.92 (1 C, 
CH3), 29.17 (1 C, CH2), 28.70 (1 C, CH2), 25.23 (2 C, CH2), 9.32 (1 C, CH3); HRMS: 
Exact Mass: 433.1113; (M+H)+: 434.1193; Observed Mass: 434.1187; 1.39 ppm. 
 
2-[(4-bromophenyl)carbamoylamino]-2-cyclopentyl-N-(1-isopropylpyrazol-4-
yl)acetamide (229) 
 
Prepared according to procedure E with intermediate 2-[(4-
bromophenyl)carbamoylamino]-2-cyclopentyl-acetic acid (184) 
(0.11 mmol) and 1-isopropyl-1h-pyrazol-4-amine (1.1 equiv., 
0.122 mmol). Crude product was washed with diethyl ether to give 
products. Yield: 50 mg, 100 %; Appearance: white solid; LCMS: 
2.23 min, m/z 448.1, 450.1 ((M+H)+ 1:1, 79/81Br ), Purity>95%, Method D; 1H NMR (500 
MHz, DMSO-d6) δ ppm 10.18 (s, 1 H, NH) 8.78 (s, 1 H, NH), 7.88 (s, 1 H, ArCH), 7.42 
(s, 1 H, ArCH), 7.40 - 7.33 (m, 4 H, ArCH), 6.50 (d, J=8.59 Hz, 1 H, NH), 4.43 (dt, 
J=13.32, 6.80 Hz, 1 H, CH), 4.19 (t, J=8.02 Hz, 1 H, CH), 2.14 (sxt, J=7.90 Hz, 1 H, 
CH), 1.69- 1.53 (m, 4 H, CH2), 1.53 - 1.43 (m, 2 H, CH2), 1.37 (d, J=6.87 Hz, 6 H, CH3), 
290 
 
1.35 - 1.29 (m, 2 H, CH2); 
13C NMR (126 MHz, DMSO-d6)  ppm 169.31 (1 C, C=O), 
154.69 (1 C, C=O), 139.68 (1 C, ArC), 131.54 (2 C, ArCH), 129.36 (1 C, ArCH), 120.77 
(1 C, ArC), 119.43 (2 C, ArCH), 118.12 (1 C, ArCH), 112.42 (1 C, ArC), 56.10 (1 C, 
CH), 52.94 (1 C, CH), 42.73 (1 C, CH), 28.66 (1 C, CH2), 28.30 (1 C, CH2), 24.66 (2 C, 
CH2), 22.63 (1 C, CH3); HRMS: Exact Mass: 447.127; (M+H)
+:448.135; Observed Mass: 
448.1345; 1.12 ppm. 
 
2-[(4-bromophenyl)carbamoylamino]-2-cyclopentyl-N-pyridazin-3-yl-acetamide 
(230) 
 
Prepared according to procedure E with intermediate 2-[(4-
bromophenyl)carbamoylamino]-2-cyclopentyl-acetic acid 
(184) (0.11 mmol) and 3-aminopyridazine (1.1 equiv., 0.122 
mmol). Crude product was washed with diethyl ether to give 
products. Yield: 14.3 mg, 31% Appearance: white solid; 
LCMS: 2.07 min, m/z 418.1, 420.1 ((M+H)+ 1:1, 79/81Br ), Purity>95%, Method D; 1H 
NMR (500 MHz, DMSO-d6) δ ppm 11.20 - 11.31 (br.s, 1 H, NH), 8.94 (dd, J=4.58, 1.72 
Hz, 1 H, ArCH), 8.79 (s, 1 H, NH), 8.27 (dd, J=9.17, 1.72 Hz, 1 H, ArCH), 7.65 (dd, 
J=9.17, 4.58 Hz, 1 H, ArCH), 7.33 (q, J=9.17 Hz, 4 H, ArCH), 6.56 (d, J=8.02 Hz, 1 H, 
NH), 4.46 (t, J=7.73 Hz, 1 H, CH), 2.19 (sxt, J=7.79 Hz, 1 H, CH), 1.73 - 1.53 (m, 4 H, 
CH2), 1.52 - 1.38 (m, 3 H, CH2), 1.35 - 1.25 (m, 1 H, CH2); 
13C NMR (126 MHz, DMSO-
d6)  ppm 173.17 (1 C, C=O), 155.39 (1 C, ArC), 154.77 (1 C, C=O), 148.62 (1 C, ArCH), 
139.60 (1 C, ArC), 131.50 (2 C, ArCH), 128.56 (1 C, ArCH), 119.51 (2 C, ArCH), 118.38 
(1 C, ArCH), 112.53 (1 C, ArC), 56.49 (1 C, CH), 42.33 (1 C, CH), 28.55 (1 C, CH2), 
28.13 (1 C, CH2), 24.68 (2 C, CH2); HRMS: Exact Mass: 417.0800; (M+H)
+ 418.088; 
Observed Mass: 418.0876; 0.96 ppm. 
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Compounds were prepared according to general procedure G: BOC deprotection 
 
N-(azetidin-3-yl)-2-[(4-bromophenyl)carbamoylamino]acetamide (196) 
 
Prepared according to procedure G with 
intermediate tert-butyl 3-[[2-[(4-
bromophenyl)carbamoylamino]acetyl] amino] 
azetidine-1-carboxylate (195) (0.11 mmol). The crude product was purified by 
preparative flash column chromatography (19x100mm (5µm) C-18 Waters Xbridge, 
MeOH, pH=10); Yield: 6.7 mg, 19%; Appearance: white solid; LCMS: 1.06 min, m/z 
327.1, 329.1 ((M+H)+ 1:1, 79/81Br), Purity>95%, Method B; 1H NMR (500 MHz, 
METHANOL-d4) δ ppm 7.38 - 7.28 (m, 4 H, ArCH), 4.69 (quin, J=7.73 Hz, 1 H, CH), 
3.89 - 3.79 (m, 4 H, CH2), 3.77 - 3.70 (m, 2 H, CH2) HRMS: Exact Mass: 326.0378; 
(M+H)+: 327.0456; Observed Mass: 327.0449; 2.33 ppm. 
 
(2S)-N-(azetidin-3-yl)-2-[(4-bromophenyl)carbamoylamino]-4-methyl-pentanamide 
(201) 
 
Prepared according to procedure G with intermediate tert-
butyl 3-[[(2S)-2-[(4-bromophenyl)carbamoylamino]-4-
methyl-pentanoyl] amino] azetidine-1-carboxylate (200) 
(0.068 mmol). The crude product was purified by 
preparative flash column chromatography (19x100mm 
(5µm) C-18 Waters Xbridge, MeOH, pH=10); Yield: 5.8 
mg, 20%; Appearance: white solid; LCMS: 1.37 min, m/z 383.1, 385.1 ((M+H)+ 1:1, 
79/81Br), Purity>90%, method B; 1H NMR (500 MHz, METHANOL-d4) δ ppm 7.41 - 
7.24 (m, 4 H, ArCH), 4.66 (quin, J=7.73 Hz, 1 H, CH), 4.28- 4.21 (m, 1 H, CH), 3.82 - 
3.77 (m, 2 H, CH2), 3.71 - 3.61 (m, 2 H, CH2), 1.77 - 1.63 (m, 1 H, CH), 1.55 - 1.49 (m, 
2 H, CH2), 0.96 (t, J=6.30 Hz, 6 H, CH3) HRMS: Exact Mass: 382.1004; (M+H)
+: 
383.1083; Observed Mass: 383.1077; 1.47 ppm. 
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N-(azetidin-3-yl)-2-[(4-bromophenyl)carbamoylamino]-2-cyclohexyl-acetamide) 
(203) 
Prepared according to procedure G with intermediate tert-butyl 
3-[[2-[(4-bromophenyl)carbamoylamino]-2-cyclohexyl-
acetyl]amino]azetidine-1-carboxylate (202).The crude product 
was purified by preparative flash column chromatography 
(19x100mm (5µm) C-18 Waters Xbridge, MeOH, pH=10); 
Yield: 5.2 mg, 32%; Appearance: white solid; LCMS: 2.158 min, m/z 409, 411 ((M+H)+ 
1:1, 79/81Br), Purity>95%, Method D; 1H NMR (500 MHz, METHANOL-d4)  ppm 7.43-
7.25 (m, 4 H, ArCH), 4.68 (quin, J=7.59 Hz, 1 H, CH), 4.08 (d, J=6.30 Hz, 1 H, CH), 
3.77 (t, J=8.59 Hz, 2 H, CH2), 3.69-3.56 (m, 2 H, CH2), 1.83-1.62 (m, 5 H, CH, CH2), 
1.36-1.03 (m, 6 H, CH2); HRMS: Exact Mass: 409.1239; (M+H)
+: 410.1317; Observed 
Mass: 409.1235; 1.01 ppm.  
 
N-(azetidin-3-yl)-2-[(4-bromophenyl)carbamoylamino]-2-tetrahydropyran-4-yl-
acetamide (205) 
 
Prepared according to procedure G with intermediate tert-butyl 
3-[[2-[(4-bromophenyl)carbamoylamino]-2-tetrahydropyran-
4-yl-acetyl]amino]azetidine-1-carboxylate (204). The crude 
product was purified by preparative flash column 
chromatography (19x100mm (5µm) C-18 Waters Xbridge, 
MeOH, pH=10); Yield: 9 mg, 65%; Appearance: white solid; LCMS: 2.05 min, m/z 411, 
413.1 ((M+H)+ 1:1, 79/81Br),Purity>95%, Method D; 1H NMR (500 MHz, METHANOL-
d4)  ppm 7.29 - 7.41 (m, 4 H, ArCH), 4.66 (quin, J=7.73 Hz, 1 H, CH), 4.26 - 4.31 (m, 
2 H, CH2), 4.15 - 4.22 (m, 2 H, CH2), 4.12 (d, J=6.87 Hz, 1 H, CH), 3.93 - 4.01 (m, 2 H, 
CH2), 3.36 - 3.44 (m, 2 H, CH2), 1.95 - 2.06 (m, 1 H, CH), 1.62 - 1.68 (m, 1 H, CH2), 
1.37 - 1.59 (m, 3 H, CH2); HRMS: Exact Mass: 410.0953; (M+H)
+: 411.1034; Observed 
Mass:411.1029; 1.11 ppm. 
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N-(azetidin-3-yl)-2-[(4-bromophenyl)carbamoylamino]-3-cyclohexyl-propanamide 
(208) 
 
Prepared according to procedure G with intermediate tert-butyl 
3-[[2-[(4-bromophenyl)carbamoylamino]-3-cyclohexyl-
propanoyl]amino] azetidine-1-carboxylate (207). The crude 
product was purified by preparative HPLC (19x100mm (5µm) 
C-18 Waters Xbridge, MeOH, pH=10); Yield: 2.5 mg, 19%; 
Appearance: white solid; LCMS: 2.26 min, m/z 423, 425 
((M+H)+ 1:1, 79/81Br), Purity>95%, Method D; 1H NMR (500 MHz, METHANOL-d4) 
 ppm 7.40-7.27 (m, 4 H, ArCH), 4.68 (quin, J=7.59 Hz, 1 H, CH), 4.28 (dd, J=5.16, 9.74 
Hz, 1 H, CH), 3.78-3.72 (m, 2 H, CH2), 3.67-3.56 (m, 2 H, CH2), 1.84 (d, J=12.60 Hz, 1 
H, CH2), 1.77-1.64 (m, 2 H, CH2), 1.62-1.47 (m, 1 H, CH2), 1.42-1.36 (m, 1 H, CH), 1.33-
1.15 (m, 4 H, CH2), 1.05-0.91 (m, 2 H, CH2); HRMS: Exact Mass: 422.1317; (M+H)
+: 
424.1474; Observed Mass: 423.1393; 0.62 ppm. 
 
N-(azetidin-3-yl)-2-[(4-bromophenyl)carbamoylamino]-2-cyclopentyl-acetamide 
(212) 
 
Prepared according to procedure G with intermediate tert-butyl 
3-[[2-[(4-bromophenyl)carbamoylamino]-2-cyclopentyl-
acetyl]amino] azetidine-1-carboxylate (211). The crude 
product was purified by preparative HPLC (19x100mm (5µm) 
C-18 Waters Xbridge, MeOH, pH=10); Yield: 10 mg, 27%; 
Appearance: white solid; LCMS: 2.05 min, m/z 395.1, 397.1 ((M+H)+ 1:1, 79/81Br), 
Purity>90%, Method D;1H NMR (500 MHz, DMSO-d6)  ppm 8.82 (s, 1 H, NH), 8.62 
(d, J=6.87 Hz, 1 H, NH), 7.40-7.31 (m, 4 H, ArCH), 6.45 (d, J=9.17 Hz, 1 H, NH), 4.44 
(sxt, J=7.33 Hz, 1 H, CH), 4.10 (t, J=8.31 Hz, 1 H, CH), 3.51 (t, J=7.45 Hz, 2 H, CH2), 
3.39 (t, J=7.73 Hz, 2 H, CH2), 2.05 (qd, J=7.80, 15.54 Hz, 1 H, CH), 1.61-1.43 (m, 6 H, 
CH2), 1.37-1.24 (m, 2 H, CH2); HRMS: Exact Mass: 394.10044; (M+H)
+: 395.1083; 
Observed Mass: 395.1078; 1.17 ppm. 
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(2S)-2-(tert-butoxycarbonylamino)-3-cyclopropyl-propanoic acid (232) 
 
The cyclohexylamine (CHA) salts need to be converted to the free acid 
before they can be utilized in carbodiimide coupling. Commercially 
available (2S)-2-(tert-butoxycarbonylamino)-3-cyclopropyl-propanoic 
acid CHA salt was dissolved in dichloromethane (5 mL).  The DCM 
solution was washed with ice-cold aqueous KHSO4 solution 3 times. 
The organic layer filtered through a phase separator. The solvent was evaporated under 
reduced pressure to obtain the free acid.  Yield: 50 mg 80%; Appearance: colourless 
liquid; LCMS: UV inactive 1HNMR (500 MHz, CHLOROFORM-d) δ ppm 11.10 (br s, 
1 H, COOH), 5.18 (br d, J=8.02 Hz, 1 H, NH), 4.58 - 4.30 (m,1 H, N CH), 1.80 - 1.60 
(m, 2 H, CH2), 1.44 (s, 9 H, C(CH3)3), 0.89 - 0.67 (m, 1 H, CH), 0.55 - 0.42 (m, 2 H, 
CH2), 0.21 - 0.04 (m, 2 H, CH2). 
 
Compounds were prepared according to general procedure E for amide coupling 
using T3P: 
 
tert-butyl N-[(1S)-1-(cyclopropylmethyl)-2-oxo-2-(2-pyridylamino)ethyl]carbamate 
(234) 
Prepared according to procedure E with intermediate (2S)-2-(tert-
butoxycarbonylamino)-3-cyclopropyl-propanoic acid (232) (0.2 
mmol) and 2-aminopyridine (1.2 equiv., 0.24 mmol). The resulting 
product was purified by reverse phase column chromatography (C-
18, MeOH/ water pH-10 10→100%) to give desired product.; Yield: 9 mg, 20%; 
Appearance: white solid; LCMS: 1.51 min, m/z 306.1 (M+H)+, Method B; 1H NMR (500 
MHz, CHLOROFORM-d) δ ppm 8.59 (br. s, 1 H, NH) 8.29 (dd, J=5.16, 1.15 Hz, 1 H, 
ArCH) 8.21 (d, J=8.59 Hz, 1 H, ArCH) 7.74 - 7.68 (m, 1 H, ArCH) 7.05 (dd, J=6.87, 5.16 
Hz, 1 H, ArCH) 5.18 (br. s, 1 H, NH) 4.36 (br. s, 1 H, CH) 1.80 - 1.71 (m, 2 H, CH2) 1.46 
(s, 9 H, C(CH3)3) 0.80 - 0.71 (m, 1 H, CH) 0.51 (br. d, J=7.45 Hz, 2 H, CH2) 0.14 (d, 
J=4.58 Hz, 2 H, CH2). 
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tert-butyl N-[(1S)-1-(cyclopropylmethyl)-2-oxo-2-(3-pyridylamino)ethyl]carbamate 
(235) 
 
Prepared according to procedure E with intermediate (2S)-2-(tert-
butoxycarbonylamino)-3-cyclopropyl-propanoic acid CHA salt 
(0.19 mmol) and 3-aminopyridine (1.3 equiv.) The resulting product 
was purified by reverse phase column chromatography (C-18, ACN/ 
water pH-10 10:90→80:20) to give desired product Yield: 30 mg, 35%; Appearance: 
white solid; LCMS: 1.30  min, m/z 306.3 (M+H)+ Purity >90%, Method B; 1H NMR (500 
MHz, CHLOROFORM-d)  ppm 8.81 - 9.03 (m, 1 H, NH), 8.59 (d, J=2.29 Hz, 1 H, 
ArCH), 8.31 (br. s., 1 H, ArCH), 8.06 (br. s., 1 H, ArCH), 7.21 (br. s., 1 H, ArCH), 5.38 
(d, J=7.45 Hz, 1 H, NH), 4.39 (br. s., 1 H, CH), 1.65 - 1.83 (m, 2 H, CH2), 1.45 - 1.47 (m, 
9 H, C(CH3)3), 0.75 - 0.85 (m, 1 H, CH), 0.46 - 0.56 (m, 2 H, CH2), 0.10 - 0.18 (m, 2 H, 
CH2).
  
 
tert-butyl N-[(1S)-2-(1,3-benzodioxol-5-ylamino)-1-(cyclopropylmethyl)-2-oxo-
ethyl] carbamate (236) 
 
Prepared according to procedure E with intermediate (2S)-2-(tert-
butoxycarbonylamino)-3-cyclopropyl-propanoic acid (232) (0.4 
mmol) and 1,3-benzodioxol-5-amine (1.1 equiv., 0.44 mmol). The 
resulting product was purified by reverse phase column 
chromatography (C-18, MeOH/ water pH-10 10→100%) to give desired product. Yield: 
25 mg, 22%; Appearance: white solid; LCMS: RT=2.03 min, m/z 249.1 (M+H)+ without 
BOC,  Purity >90%, Method C; 1H NMR (500 MHz, DMSO-d6) δ ppm 9.88 (s, 1 H, NH), 
7.29 (d, J=1.72 Hz, 1 H, ArCH), 7.02 (d, J=8.02 Hz, 1 H, ArCH), 6.97 (dd, J=8.31, 2.00 
Hz, 1 H, ArCH), 6.86 - 6.82 (m, 1 H, NH), 5.97 (d, J=1.72 Hz, 2 H, CH2), 4.15 - 4.02 (m, 
1 H, CH), 1.72 - 1.57 (m, 1 H, CH2), 1.45 - 1.28 (m, 10 H, CH2, C(CH3)3), 0.86 - 0.67 (m, 
1 H, CH), 0.48 - 0.27 (m, 2 H, CH2), 0.17 - 0.01 (m, 2 H, CH2). 
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tert-butyl N-[1-cyclopropyl-2-oxo-2-(2-pyridylamino)ethyl]carbamate (237) 
 
Prepared according to procedure E with intermediate 2-(tert-
butoxycarbonylamino)-2-cyclopropyl-acetic acid (0.37 mmol)  
and 2-aminopyridine (1.3 equiv., 0.48 mmol). Crude products 
were purified via reverse phase column chromatography (C18,10-90% water 
pH=10/ACN) to give products. Yield: 45 mg, 30%; Appearance: off-white solid; LCMS: 
1.34 min, m/z 292.1, (M+H)+ Purity 100%, Method B 1H NMR (500 MHz, 
CHLOROFORM-d) δ ppm 8.73 - 8.54 (m, 1 H, ArCH) 8.31 - 8.27 (m, 1 H, NH) 8.23 (d, 
J=8.02 Hz, 1 H, ArCH) 7.77 - 7.66 (m, 1 H, ArCH) 7.09 - 7.01 (m, 1 H, ArCH) 5.38 - 
5.26 (m, 1 H, NH) 3.75 - 3.61 (m, 1 H, CH) 1.47 - 1.41 (m, 9 H, C(CH3)3) 0.95 - 0.80 (m, 
1 H, CH) 0.75 - 0.64 (m, 1 H, CH2) 0.58 (br d, J=6.30 Hz, 2 H, CH2) 0.53 - 0.44 (m, 1 H, 
CH2). 
 
tert-butyl N-[1-cyclopropyl-2-oxo-2-(3-pyridylamino)ethyl]carbamate (238) 
 
Prepared according to procedure E with intermediate 2-(tert-
butoxycarbonylamino)-2-cyclopropyl-acetic acid (0.37 mmol) 
and 3-aminopyridine (1.3 equiv., 0.48 mmol). Crude products 
were purified via reverse phase column chromatography (C18,10-90% water 
pH=10/ACN) to give products. Yield: 115 mg, 80% ;Appearance: off-white solid; LCMS: 
1.15 min, m/z 292.1, (M+H)+ Purity 95%, Method B 1H NMR (500 MHz, 
CHLOROFORM-d)  ppm 8.57 (d, J=2.86 Hz, 1 H, ArCH), 8.52 (br. s., 1 H, NH), 8.33 
(d, J=3.44 Hz, 1 H, ArCH), 8.12 (d, J=8.02 Hz, 1 H, ArCH), 7.20 - 7.25 (m, 1 H, ArCH), 
5.25 (br. s., 1 H, NH), 3.45 - 3.60 (m, 1 H, CH), 1.46 (s, 9 H, C(CH3)3), 1.22 - 1.29 (m, 1 
H, CH), 0.69 - 0.78 (m, 1 H, CH2), 0.60 - 0.67 (m, 1 H, CH2), 0.54 (br. s., 1 H, CH2), 0.42 
- 0.49 (m, 1 H, CH2). 
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tert-butyl N-[2-(1,3-benzodioxol-5-ylamino)-1-cyclopropyl-2-oxo-ethyl]carbamate 
(239) 
 
Prepared according to procedure E with intermediate 2-(tert-
butoxycarbonylamino)-2-cyclopropyl-acetic acid (0.37 mmol) 
and 3,4-(methylenedioxy)aniline (1.3 equiv., 0.48 mmol). 
Crude products were purified via reverse phase column 
chromatography (C18,10-90% water pH=10/ACN) to give products . Yield: 39 mg, 50%; 
Appearance: beige solid; LCMS: 1.89 min, m/z 335.1 (M+H)+ Purity > 95%, method D; 
1H NMR (500 MHz, CHLOROFORM-d)  ppm 7.98 (br. s., 1 H, NH), 7.26 (d, J=1.72 
Hz, 1 H, ArCH), 6.79 - 6.83 (m, 1 H, ArCH), 6.73 - 6.76 (m, 1 H, ArCH), 5.95 (s, 2 H, 
OCH2), 5.22 (br. s., 1 H, NH), 3.44 - 3.57 (m, 1 H, CH), 1.46 (s, 9 H, C(CH3)3), 1.17 - 
1.28 (m, 1 H, CH), 0.68 - 0.76 (m, 1 H, CH2), 0.57 - 0.66 (m, 1 H, CH2), 0.44 - 0.54 (m, 
2 H, CH2). 
 
Compounds were prepared according to general procedure G: BOC deprotection 
 
(2S)-2-amino-3-cyclopropyl-N-(3-pyridyl)propenamide HCl (240) 
 
Prepared according to general procedure G with the 
intermediate tert-butyl N-[(1S)-1-(cyclopropylmethyl)-2-
oxo-2-(3-pyridylamino)ethyl]carbamate (235) (0.13 mmol). 
The crude product was used in the next step without further 
purification. Yield: 30mg, 95%; Appearance: white solid; LCMS: 0.26 min, m/z 206.2, 
(M+H)+ Purity >90%, Method B 1H NMR (500 MHz, DMSO-d6) δ ppm 9.07 (d, J=2.29 
Hz, 1 H, NH), 8.53 (dd, J=5.16, 1.15 Hz, 1 H, ArCH), 8.50 - 8.45 (m, 3 H, NH), 8.45-
8.42 (m, 1H, ArCH), 7.79 (dd, J=8.59, 5.16 Hz, 1 H, ArCH,), 4.24 - 4.10 (m,1 H, CH), 
1.93 - 1.85 (m, 1 H, CH2), 1.71 - 1.61 (m, 1 H, CH2), 0.87 - 0.76 (m, 1 H, CH), 0.47 - 
0.34 (m, 2 H, CH2), 0.18 - 0.05 (m, 2 H, CH2). 
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[(1S)-2-(1,3-benzodioxol-5-ylamino)-1-(cyclopropylmethyl)-2-oxoethyl]ammonium 
chloride (241) 
 
Prepared according to general procedure G with the 
intermediate tert-butyl N-[(1S)-2-(1,3-benzodioxol-5-
ylamino)-1-(cyclopropylmethyl)-2-oxo-ethyl] carbamate 
(236) (0.072 mmol). The crude product was used in the 
next step without further purification. Yield: 70 mg, 80%; Appearance: brown solid; 
LCMS: 1.68 min, m/z 249.2 (M+H)+ Purity 85-90%, Method D 1H NMR (500 MHz, 
CHLOROFORM-d) δ ppm 10.19 (br. s, 1 H, NH), 8.26 (br. s, 3 H, NH), 7.26 (br. s, 1 H, 
ArCH), 7.03 -6.91 (m, 1 H, ArCH), 6.60 (br. d, J=7.45 Hz, 1 H, ArCH), 5.88 (br. s, 2 H, 
CH2), 4.70 (br. s, 1 H, CH2), 1.73 (br s, 1 H, CH2), 0.75 (br s, 1 H, CH), 0.40 - 0.26 (m, 2 
H, CH2), 0.17-0.0 (br. s, 2 H, CH2). 
 
2-amino-2-cyclopropyl-N-(3-pyridyl)acetamide HCl (242) 
 
Prepared according to general procedure G with the intermediate tert-
butyl N-[1-cyclopropyl-2-oxo-2-(3-pyridylamino)ethyl]carbamate 
(238) (0.395 mmol). The crude product was used in the next step 
without further purification. Yield: 85 mg, 95%; Appearance: off-
white solid; LCMS: 0.54 min, m/z 192.2 (M+H)+ Purity 90%, Method 
B; 1H NMR (500 MHz, DMSO-d6) δ ppm 12.09 (br s, 1 H, NH), 9.16 (d, J=2.29 Hz, 1 
H, ArCH), 8.59 - 8.54 (m, 4 H, NH, ArCH), 7.86 (dd, J=8.31, 5.44 Hz, 1 H, ArCH), 3.51 
(dq, J=9.88, 5.11 Hz, 1H, CH), 1.19 -1.09 (m, 1H, CH), 1.08 -1.00 (m, 1H, CH2), 0.71 -
0.60 (m, 1H, CH2), 0.59 -0.51 (m, 2H, CH2). 
 
2-amino-2-cyclopropyl-N-(2-pyridyl)acetamide  HCl (243) 
 
Prepared according to general procedure G with the intermediate tert-
butyl N-[1-cyclopropyl-2-oxo-2-(2-pyridylamino)ethyl]carbamate (237) 
(0.15 mmol). The crude product was used in the next step without further 
purification. Yield: 30 mg, 90%; Appearance: off-white solid; LCMS: 
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0.77 min, m/z 192.1 (M+H)+ Purity 85-90%, Method B 1H NMR (500 MHz, DMSO-d6) 
δ ppm 10.91 (s, 1 H, NH), 8.48 (br d, J=3.44 Hz, 3 H, NH), 8.38 - 8.32 (m, 1 H, ArCH), 
8.06 (d, J=8.02 Hz, 1 H, ArCH), 7.84 (td, J=7.88, 2.00 Hz, 1 H, ArCH), 7.24 - 7.09 (m, 
1 H, ArCH), 3.48- 3.36 (m, 1 H, CH), 1.16 - 1.07 (m, 1 H, CH), 0.83 (dq, J=9.74, 4.77 
Hz, 1 H, CH2), 0.67 - 0.61 (m, 1 H, CH2), 0.59 - 0.52 (m, 1 H, CH2), 0.52 - 0.46 (m, 1 H, 
CH2). 
 
2-amino-N-(1,3-benzodioxol-5-yl)-2-cyclopropyl-acetamide HCl (244) 
 
Prepared according to general procedure G with the 
intermediate tert-butyl N-[2-(1,3-benzodioxol-5-ylamino)-
1-cyclopropyl-2-oxo-ethyl]carbamate (239) (0.11 mmol). 
The crude product was used in the next step without further purification. Yield: 23 mg, 
90%; Appearance: beige solid; LCMS: 1.43 min, m/z 235.0 (M+H)+ Purity 95%, method 
D 1H NMR (500 MHz, DMSO-d6)  ppm 10.60 (s, 1 H, NH), 8.40 (br. s., 3 H, NH), 7.34 
(d, J=2.29 Hz, 1 H, ArCH), 7.06 (dd, J=8.59, 2.29 Hz, 1 H, ArCH), 6.90 (d, J=8.59 Hz, 
1 H, ArCH), 5.98 - 6.03 (m, 2 H, CH2), 3.29 - 3.34 (m, 1 H, CH), 1.10 - 1.20 (m, 1 H, 
CH), 0.81 - 0.92 (m, 1 H, CH2), 0.62 - 0.70 (m, 1 H, CH2), 0.54 - 0.61 (m, 1 H, CH2), 
0.43 - 0.54 (m, 1 H, CH2).
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Compounds were prepared according to general  procedure  A for urea formation 
 
(2S)-2-[(4-bromophenyl) carbamoyl amino]-3-cyclopropyl-N-(3 pyridyl) 
propenamide (246) 
 
Compound was prepared according to procedure A with 1-
bromo-4-isocyanato-benzene (0.1 mmol) and the intermediate 
(2S)-2-amino-3-cyclopropyl-N-(3-pyridyl) propenamide HCl 
(240) (1 equiv., 0.1 mmol). Crude product was purified by 
reverse phase column chromatography (C18, acetonitrile/ water 
pH=10 10/90→ 80/20). Yield: 27 mg, 66%; Appearance: white solid; LCMS: 1.45 min, 
m/z 403.1, 405.1 ((M+H)+ 1:1, 79/81Br), Purity >95%, Method B 1H NMR (500 MHz, 
DMSO-d6)  ppm 10.40 (s, 1 H, NH), 8.86 (s, 1 H, NH), 8.76 (d, J=1.72 Hz, 1 H, ArCH), 
8.27 (dd, J=4.87, 1.43 Hz, 1 H, ArCH), 8.04 (ddd, J=8.31, 2.58, 1.15 Hz, 1 H, ArCH), 
7.43 - 7.31 (m, 5 H, ArCH), 6.64 (d, J=8.02 Hz, 1 H, NH), 4.46 (q, J=7.45 Hz, 1 H, CH), 
1.70 (dt, J=13.75, 6.87 Hz, 1 H, CH2), 1.52 (ddd, J=13.75, 7.45, 6.30 Hz, 1 H, CH2), 0.85 
- 0.65 (m, 1 H, CH), 0.46 - 0.36 (m, 2 H, CH2), 0.15 - 0.03 (m, 2 H, CH2);
 13C NMR (126 
MHz, DMSO-d6)  ppm 171.85 (1 C, C=O), 154.56 (1 C, C=O), 144.37 (1 C, ArCH), 
140.93 (1 C, ArCH), 139.66 (1 C, ArC), 135.55 (1 C, ArC), 131.45 (2 C, ArCH), 126.25 
(1 C, ArCH), 123.70 (1 C, ArCH), 119.47 (2 C, ArCH), 112.50 (1 C, ArC), 54.05 (1 C, 
CH), 37.70 (1 C, CH2), 7.36 (1 C, CH), 4.41 (1 C, CH2), 4.13 (1 C, CH2); HRMS: Exact 
Mass: 402.0691; (M+H)+: 403.0770; Observed Mass: 403.0763; 1.65 ppm.  
 
2-[(4-bromophenyl)carbamoylamino]-2-cyclopropyl-N-(3-pyridyl)acetamide  
(247) 
 
Compound was prepared according to procedure A with 
1-bromo-4-isocyanato-benzene (0.32 mmol) and the 
intermediate 2-amino-2-cyclopropyl-N-(3-
pyridyl)acetamide HCl (242) (1.1 equiv. 0.35 mmol). 
Crude product was purified by reverse phase column 
chromatography (C18, acetonitrile/ water pH=10 10/90→ 
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80/20). Yield: 85 mg, 69%; Appearance: white solid; LCMS: 1.37 min, m/z  389.1, 391.1 
((M+H)+ 1:1, 79/81Br), Purity >95%, Method B; 1H NMR (500 MHz, DMSO-d6)  ppm 
10.35 (s, 1 H, NH), 8.84 (s, 1 H, NH), 8.78 (d, J=1.72 Hz, 1 H, ArCH), 8.28 (dd, J=4.58, 
1.15 Hz, 1 H, ArCH), 8.06 (ddd, J=8.31, 2.58, 1.15 Hz, 1 H, ArCH), 7.40 - 7.33 (m, 5 H, 
ArCH), 6.70 (d, J=8.02 Hz, 1 H, NH), 3.89 (t, J=7.73 Hz, 1 H, CH), 1.16 - 1.09 (m, 1 H, 
CH), 0.59 - 0.46 (m, 3 H, CH2), 0.38 - 0.34 (m, 1 H, CH2); 
13C NMR (126 MHz, DMSO-
d6)  ppm 171.29 (1 C, C=O), 154.51 (1 C, C=O), 144.43 (1 C, ArC), 140.80 (1 C, ArC), 
139.57 (1 C, ArC), 135.57 (1 C, ArC.), 131.47 (2 C, ArCH), 126.14 (1 C, ArCH), 123.74 
(1 C, ArCH), 119.47 (2 C, ArCH), 112.56 (1 C, ArC), 56.59 ( 1 C, CH), 14.34 (1 C, CH), 
2.98 (1 C, CH2), 2.30 (1 C, CH2); HRMS: Exact Mass: 388.0535; (M+H)
+: 389.0613; 
Observed Mass: 389.0608; 1.32 ppm. 
 
2-[(4-bromophenyl)carbamoylamino]-2-cyclopropyl-N-(2-pyridyl)acetamide  
(248) 
Compound was prepared according to procedure A with 1-
bromo-4-isocyanato-benzene (0.1 mmol) and the 
intermediate 2-amino-2-cyclopropyl-N-(2-pyridyl) 
acetamide  HCl (243). Crude product was purified by 
preparative. HPLC (19x100mm (5µm) C-18 Waters 
Xbridge, MeOH pH=10). Yield: 9 mg, 20%; Appearance: 
white solid; LCMS: 1.52 min, m/z 389.1, 391.1 ((M+H)+ 1:1, 79/81Br), Purity >95%, 
Method B 1H NMR (500 MHz, DMSO-d6)  ppm 8.85 (s, 1 H, NH), 8.35 - 8.31 (m, 1 H, 
ArCH), 8.10 (d, J=8.59 Hz, 1 H, NH), 7.86 - 7.74 (m, 1 H, ArCH), 7.68 (d, J=8.59 Hz, 1 
H, ArCH), 7.40 - 7.32 (m, 4 H, ArCH), 7.14 - 7.10 (m, 1 H, ArCH), 6.64 (d, J=7.45 Hz, 
1 H, NH), 4.03 - 3.97 (m, 1 H, CH), 1.14 - 1.05 (m, 1 H, CH), 0.67 - 0.60 (m, 1 H, CH2), 
0.53 - 0.43 (m, 3 H, CH2); 
13C NMR (126 MHz, DMSO-d6)  ppm 172.22 (1 C, C=O) 
155.01 (1 C, C=O) 152.37 (1 C, ArC) 148.61 (1 C, ArCH) 140.16 (1 C, ArCH) 138.80 (1 
C, ArC) 132.05 (2 C, ArCH) 120.21 (1 C, ArCH) 120.06 (2 C, ArCH) 114.13 (1 C, ArCH) 
113.02 (1 C, ArC) 56.96 (1 C, CH) 14.79 (1 C, CH) 3.50 (1 C, CH2) 2.83 (1 C, CH2); 
HRMS: Exact Mass: 388.0535; (M+H)+: 389.0613; Observed Mass: 389.0605; 2.09 ppm. 
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(2S)-N-(1,3-benzodioxol-5-yl)-2-[(4-bromophenyl)carbamoylamino]-2-cyclopropyl-
acetamide (249) 
 
Compound was prepared according to procedure A with 1-
bromo-4-isocyanato-benzene (0.076 mmol) and the 
intermediate 2-amino-N-(1,3-benzodioxol-5-yl)-2-
cyclopropyl-acetamide HCl (244) (0.076 mmol). Crude product 
was purified by reverse phase column chromatography (C18, 
acetonitrile/ water pH=10 10/90→ 80/20). Yield: 18 mg, 55%; Appearance: white solid; 
LCMS: 1.63 min, m/z  432.1, 434.1 ((M+H)+ 1:1, 79/81Br), Purity >95%, Method D; 1H 
NMR (500 MHz, DMSO-d6)  ppm 10.04 (s, 1 H, NH), 8.83 - 8.84 (m, 1 H, NH), 7.34 - 
7.40 (m, 4 H, ArCH), 7.32 - 7.33 (m, 1 H, ArCH), 6.97 - 7.01 (m, 1 H, ArCH), 6.85 - 6.88 
(m, 1 H, ArCH), 6.63 (d, J=7.45 Hz, 1 H, NH), 5.98 (s, 2 H, CH2), 3.87 (t, J=8.02 Hz, 1 
H, CH), 1.04 - 1.12 (m, 1 H, CH2), 0.44 - 0.55 (m, 3 H, CH2), 0.31 - 0.40 (m, 1 H, CH2); 
HRMS: Exact Mass 431.0480; (M+H)+ :432.0559; Mass Observed: 432.0556; 0.68 ppm. 
 
(2S)-N-(1,3-benzodioxol-5-yl)-2-[(4-bromophenyl) carbamoylamino]-3-cyclopropyl- 
(250) 
Compound was prepared according to procedure A with 1-
bromo-4-isocyanato-benzene (0.061 mmol) and the 
intermediate [(1S)-2-(1,3-benzodioxol-5-ylamino)-1-
(cyclopropylmethyl)-2-oxoethyl]ammonium chloride (241) 
(1 equiv., 0.061 mmol). Crude product was purified by 
preparative. HPLC (19x100mm (5µm) C-18 Waters Xbridge, 
MeOH pH=10). Yield: 8 mg, 30%; Appearance: beige solid; LCMS: 2.22 min, m/z  446.1, 
448.1 ((M+H)+ 1:1, 79/81Br), Method D; 1H NMR (500 MHz, DMSO-d6)  ppm 10.08 (s, 
1 H, NH), 8.88 - 8.80 (m, 1 H, NH), 7.42 - 7.33 (m, 4 H, ArCH), 7.30 (d, J=1.72 Hz, 1 
H, ArCH), 6.98 (dd, J=8.31, 2.00 Hz, 1 H, ArCH), 6.85 (d, J=8.59 Hz, 1 H, ArCH), 6.56 
(d, J=8.59 Hz, 1 H, NH), 5.98 (q, J=1.15 Hz, 2 H, CH2), 4.41 (q, J=8.02 Hz, 1 H, CH), 
1.65 (dt, J=13.75, 6.87 Hz, 1 H, CH2), 1.48 (dt, J=15.47, 6.87 Hz, 1 H, CH2), 0.77 - 0.68 
(m, 1 H, CH), 0.44 - 0.34 (m, 2 H, CH2), 0.12 - 0.03 (m, 2 H, CH2); HRMS: Exact Mass: 
445.0637; (M+H)+: 446.0715; Observed Mass: 446.0707; 1.89 ppm.  
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12.2.3.7. Pyrrolidinone series 
 
General procedure N for amide formation from acyl chloride and cyclization of 
pyrrolidinone 
 
STEP I 
To a solution of amine (1eq.) in anhydrous diethyl ether (12 mL) was added, under inert 
atmosphere, triethylamine (2eq.) followed by a 2,4-dibromobutanoyl chloride (1.1 eq). 
After 16 hours at room temperature, the solution was filtered, and the filtrate concentrated 
under reduced pressure. The solvent was evaporated, and the crude product was used in 
the next step without further purification.  
 
STEP II 
A sodium hydride (60 mass%) in mineral oil (1.2-1.5 eq) was added to a stirred solution 
of intermediate (1 eq.) in tetrahydrofuran at 0⁰C. The reaction mixture was allowed to 
warm up to room temperature and stir for an additional 2h. The reaction was carefully 
quenched with ice and diluted with water. The resulting mixture was extracted with 
EtOAc. The combined organic layers were washed with brine and water. The organic 
phase was filtered through a phase separator and concentrated under reduced pressure. 
Crude product was dry loaded on silica and purified by flash column chromatography to 
obtain desired product. 
 
1-benzyl-3-bromo-pyrrolidin-2-one (265) 
 
Prepared according to general procedure N with phenylmethanamine 
(0.93 mmol). and 2,4-dibromobutanoyl chloride (1.2 equiv., 1.12 
mmol). Crude product was dry loaded on silica and purified by flash 
column chromatography (25g silica gel, PE/EA 0-->70% 15CV 
gradient) to obtain desired product. Yield: 200 mg, 75%; Appearance: yellow oil; LCMS: 
1.78 min, m/z 254.0, 256.1 ((M+H)+ 1:1, 79/81Br), prep.HPLC method: AN_MEOH-
PH10-10100_3_POS.M; 1H NMR (500 MHz, CHLOROFORM-d)  ppm 7.38 - 7.26 (m, 
4 H, ArCH), 7.25 - 7.23 (m, 1 H, ArCH), 4.57 - 4.52 (m, 1 H, CH2), 4.47 (dd, J=7.45, 
2.29 Hz, 1 H, CH), 4.46 - 4.41 (m, 1 H, CH2), 3.46 - 3.38 (m, 1 H, CH2), 3.20 (ddd, 
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J=9.88, 7.88, 2.29 Hz, 1 H, CH2), 2.60 - 2.51 (m, 1 H, CH2), 2.29 (ddt, J=14.54, 6.66, 
2.58, 2.58 Hz, 1 H, CH2); 
13C NMR (126 MHz, CHLOROFORM-d)  ppm 170.74 (1 C, 
C=O), 135.58 (1 C, ArCquat.), 128.81 (2 C, ArCH), 128.07 ( 2 C, ArCH), 127.86 (1 C, 
ArCH), 47.13 (1 C, CH), 44.56 (1 C, CH), 44.22 (1 C, CH), 30.14 (1 C, CH); Data 
corresponded to that reported in the literature.244 
 
tert-butyl 4-(3-bromo-2-oxo-pyrrolidin-1-yl)piperidine-1-carboxylate (266) 
 
Prepared according to general procedure N with tert-butyl 4-
aminopiperidine-1-carboxylate (2.5 mmol) and 2,4-
dibromobutanoyl chloride (1.2 equiv., 3 mmol); Crude product 
was dry loaded on silica and purified by flash column chromatography (50g silica gel, 
PE/EA 1/1 1, gradient) to obtain desired product. Yield: 600 mg, 70%; Appearance: 
yellow oil; LCMS: 1.86 min, m/z 247.1, 249.1 ((M+H)+ 1:1, 79/81Br),  Purity>95%, 
Method D; 1H NMR (500 MHz, CHLOROFORM-d)  ppm 4.43 (dd, J=7.16, 2.58 Hz, 1 
H, CH), 4.22 (br. s, 2 H, CH2), 4.15 - 4.07 (m, 1 H, CH), 3.47 (ddd, J=9.74, 8.02, 6.87 
Hz, 1 H, CH2), 3.31 (ddd, J=9.88, 7.88, 2.29 Hz, 1 H, CH2), 2.79 (br. s, 2 H, CH2), 2.60 
- 2.49 (m, 1 H, CH2), 2.33 (ddt, J=14.54, 6.52, 2.36, 2.36 Hz, 1 H, CH2), 1.79 - 1.71 (m, 
1 H, CH2), 1.71 - 1.63 (m, 1 H, CH2), 1.62 - 1.50 (m, 2 H, CH2), 1.46 (s, 9 H, C(CH3)3); 
13C NMR (126 MHz, CHLOROFORM-d)  ppm 170.54 (1 C, C=O), 154.69 (1 C, C=O), 
79.95 (1 C, C(CH3)3.), 49.86 (1 C, NCH), 44.83 (1 C, CH2), 43.04 (2 C, NCH2), 41.18 (1 
C, CH), 30.48 (1 C, CH2), 29.28 (1 C, CH2), 28.67 (1 C, CH2), 28.50 (3 C, C(CH3)3). 
 
tert-butyl 4-[(3-bromo-2-oxo-pyrrolidin-1-yl)methyl]piperidine-1-carboxylate (267) 
 
Prepared according to general procedure N with tert-butyl 4-
(aminomethyl)piperidine-1-carboxylate (2.332 mmol) and 2,4-
dibromobutanoyl chloride (1.2 equiv., 2.8 mmol); Crude product was dry 
loaded on silica and purified by flash column chromatography (50g silica 
gel, PE/EA 1/9, gradient) to obtain desired product. Yield: 440 mg, 40%; 
Appearance: yellow oil; LCMS: 1.92  min, m/z 361.1, 363.1 ((M+H)+ 1:1, 79/81Br), method 
C; 1H NMR (500 MHz, CHLOROFORM-d)  ppm 4.42 (dd, J=6.87, 2.29 Hz, 1 H, CH), 
4.02 - 4.19 (m, 2 H, CH2), 3.59 - 3.66 (m, 1 H, CH2), 3.24 - 3.44 (m, 2 H, CH2), 3.00 - 
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3.22 (m, 1 H, CH2), 2.69 (br. s., 2 H, CH2), 2.55 - 2.64 (m, 1 H, CH2), 2.34 (ddt, 1 H, 
CH2), 1.85 (ttd, 1 H, CH), 1.52 - 1.71 (m, 2 H, CH2), 1.45 (s, 9 H, C(CH3)3), 1.14 - 1.24 
(m, 2 H, CH2); 
13C NMR (126 MHz, CHLOROFORM-d)  ppm 171.08 (1 C, C=O), 
154.70 (1 C, C=O), 79.43 (1 C, C(CH3)3), 48.76 (1 C, CH2 ), 46.24 (1 C, CH2), 44.29 (1 
C, CH), 43.44 (2 C, NCH2), 34.66 (1 C, CH), 30.46 (1 C, CH2), 29.72 (1 C, CH2), 29.52 
(1 C, CH2), 28.41 (3 C, C(CH3)3). 
 
3-bromo-1-(5-phenyl-1,3,4-oxadiazol-2-yl)pyrrolidin-2-one (268) 
 
Prepared according to general procedure N with 5-phenyl-1,3,4-
oxadiazol-2-amine (1.24 mmol). and 2,4-dibromobutanoyl 
chloride (1.2 equiv., 1.48 mmol). Crude product was dry loaded 
on silica and purified by flash column chromatography (25g 
silica, PE/EA 0-->70%, gradient) to obtain desired product. Yield: 70 mg, 16%; 
Appearance: yellow oil; LCMS: 1.72 min, m/z 308.0, 310.0 ((M+H)+ 1:1, 79/81Br), 
Purity=80%, Method C; 1H NMR (500 MHz, CHLOROFORM-d)  ppm 8.11 - 8.05 (m, 
2 H, ArCH), 7.57 - 7.47 (m, 3 H, ArCH), 4.60 (dd, J=6.87, 2.86 Hz, 1 H, CH), 4.29 - 4.18 
(m, 2 H, CH2), 2.90 - 2.81 (m, 1 H, CH2), 2.60 - 2.53 (m, 1 H, CH2); 
13C NMR (126 MHz, 
CHLOROFORM-d)  ppm 167.78 (1 C, C=O), 162.46 (1 C, ArC), 156.94 (1 C, ArC), 
131.75 (1 C, ArCH), 129.02 (2 C, ArCH), 126.74 (2 C, ArCH), 123.33 (1 C, ArCquat.), 
45.55 (1 C, CH2), 42.20 (1 C, CH), 30.32 (1 C, CH2). 
 
3-bromo-1-(5-phenyloxazol-2-yl)pyrrolidin-2-one (269) 
 
Prepared according to general procedure N with 5-
phenyloxazol-2-amine (1.24 mmol). and 2,4-dibromobutanoyl 
chloride (1.2 equiv., 1.48 mmol). Crude product was dry loaded 
on silica and purified by flash column chromatography (25g 
silica, PE/EA 0-->100% 20CV gradient) to obtain desired product. Yield: 75 mg, 18%; 
Appearance: yellow oil which solidified after few hours; LCMS: 1.89 min m/z 307.0, 
309.0, ((M+H)+ 1:1, 79/81Br), Purity=91%, Method C; 1H NMR (500 MHz, 
CHLOROFORM-d)  ppm 7.66 - 7.63 (m, 2 H, ArCH), 7.44 - 7.39 (m, 2 H, ArCH), 7.32 
(tt, J=7.45, 1.70 Hz, 1 H, ArCH), 7.25 (s, 1 H, ArCH), 4.60 (dd, J=6.87, 2.29 Hz, 1 H, 
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CH), 4.23 - 4.16 (m, 1 H), 4.16 - 4.10 (m, 1 H, CH2), 2.80 (dtd, J=14.61, 8.16, 8.16, 6.87 
Hz, 1 H, CH2), 2.54 - 2.47 (m, 1 H, CH2); 
13C NMR (126 MHz, CHLOROFORM-d)  
ppm 167.41 (1 C, C=O), 151.97 (1 C, ArC), 148.37 (1 C, ArC), 128.60 (2 C, ArCH), 
128.08 ( 1 C, ArCH), 127.08 ( 1 C, ArCH), 123.59 (2 C, ArCquat), 120.95 (1 C, ArCH), 
45.19 (1 C, CH2), 42.95 ( 1 C, CH), 29.89 (1 C, CH2). 
 
3-bromo-1-(3,5-dimethyl-1-phenyl-pyrazol-4-yl)pyrrolidin-2-one (270) 
 
Prepared according to general procedure N with 5-
phenyloxazol-2-amine (1.24 mmol). and 2,4-dibromobutanoyl 
chloride (1.2 equiv., 1.48 mmol). Crude product was dry 
loaded on silica and purified by flash column chromatography 
(silica gel, PE/EA 0-->100% 20CV gradient) to obtain desired product. Yield: 200 mg, 
50%; Appearance: brown oil which solidified after few hours LCMS: 1.75 min m/z 334.1, 
336.0 ((M+H)+ 1:1, 79/81Br), Purity=95%, Method D; 1H NMR (500 MHz, 
CHLOROFORM-d)  ppm 7.49 - 7.41 (m, 4 H, ArCH), 7.41 - 7.35 (m, 1 H, ArCH), 4.56 
(dd, J=6.87, 1.72 Hz, 1 H, CH), 3.89 (ddd, J=10.17, 8.74, 6.30 Hz, 1 H, CH2), 3.66 - 3.61 
(m, 1 H, CH2), 2.82 - 2.75 (m, 1 H, CH2), 2.47 (ddt, J=14.39, 6.23, 1.72, 1.72 Hz, 1 H, 
CH2), 2.25 (s, 3 H, CH3), 2.23 (s, 3 H, CH3); 
13C NMR (126 MHz, CHLOROFORM-d)  
ppm 171.04 (1 C, C=O), 145.28 (1 C, ArC), 139.59 (1 C, ArC), 135.97 (1 C, ArC), 129.25 
(2 C, ArCH), 127.81 (1 C, ArCH), 124.79 (2 C, ArCH), 117.49 (1 C, ArC), 48.63 (1 C, 
CH2), 44.19 (1 C, CH), 31.02 (1 C, CH2), 11.72 (1 C, CH3), 10.85 (1 C, CH3). 
 
tert-butyl 3-(3-bromo-2-oxo-pyrrolidin-1-yl)azetidine-1-carboxylate (271) 
 
Prepared according to general procedure N with tert-butyl 3-
aminoazetidine-1-carboxylate (1.74 mmol) and 2,4-
dibromobutanoyl chloride (1.1 equiv., 1.9 mmol). Crude 
product was dry loaded on silica and purified by flash column chromatography (silica gel, 
PE/EA 0-->80% , gradient) to obtain desired product. Yield:  368 mg, 60%; Appearance: 
yellow oil which solidified after few hours; LCMS: 1.73  min m/z 319.1, 321.1 ((M+H)+ 
1:1, 79/81Br), Purity=95%, Method D; 1H NMR (500 MHz, CHLOROFORM-d)  ppm 
4.94 (tt, J=8.09, 5.37 Hz, 1 H, CH), 4.43 (dd, J=7.16, 2.58 Hz, 1 H, CH), 4.19 (td, J=8.88, 
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4.01 Hz, 2 H, CH2), 4.01 (dd, J=9.45, 5.44 Hz, 1 H, CH2), 3.95 (dd, J=9.74, 5.16 Hz, 1 
H, CH2), 3.71 (ddd, J=9.74, 7.73, 6.59 Hz, 1 H, CH2), 3.58 (ddd, J=10.02, 7.73, 2.86 Hz, 
1 H, CH2), 2.68 - 2.59 (m, 1 H, CH2), 2.40 (ddt, J=14.32, 6.59, 2.72, 2.72 Hz, 1 H, CH2), 
1.45 (s, 9 H, C(CH3)3); 
13C NMR (126 MHz, CHLOROFORM-d)  ppm 170.89 (1 C), 
155.95 (1 C), 80.15 (1 C, C(CH3)3), 52.62 (2 C, CH2), 43.79 (1 C, CH2), 41.65 (1 C, CH), 
41.26 (1 C, CH2), 30.24 (1 C, CH2), 28.28 (3 C, C(CH3)3). 
 
tert-butyl (3S)-3-(3-bromo-2-oxo-pyrrolidin-1-yl)piperidine-1-carboxylate (272) 
 
Prepared according to general procedure N with tert-butyl (3S)-
3-aminopiperidine-1-carboxylate (1.99 mmol) and 2,4-
dibromobutanoyl chloride (1.2 equiv., 2.4  mmol). Crude product 
was dry loaded on silica and purified by flash column 
chromatography (silica gel, PE/EA 0→100%, gradient) to obtain desired product (first 
fraction). Yield:  300 mg, 90%; Appearance: yellow oil; LCMS: 1.87 min m/z 347.1, 
349.1 ((M+H)+ 1:1, 79/81Br), Purity=90%, Method D; 1H NMR (500 MHz, 
CHLOROFORM-d)  ppm 4.41 (dd, J=6.87, 2.29 Hz, 1 H, CH), 3.95 (br. s., 3 H, CH2, 
CH), 3.58 - 3.46 (m, 1 H, CH2), 3.43 - 3.30 (m, 1 H, CH2), 2.87 (d, J=10.88 Hz, 1 H, 
CH2), 2.71 (t, J=11.74 Hz, 1 H, CH2), 2.60 - 2.50 (m, 1 H, CH2), 2.38 - 2.26 (m, 1 H, 
CH2), 1.94 - 1.74 (m, 1 H, CH2), 1.74 (d, J=10.31 Hz, 1 H, CH2), 1.68 - 1.52 (m, 2 H, 
CH2), 1.45 (d, J=3.44 Hz, 9 H, C(CH3)3); 
13C NMR (126 MHz, CHLOROFORM-d)  
ppm 170.64 (1 C, C=O), 154.58 (1 C, C=O), 80.00 (1 C, C(CH3)3.), 48.92 (1 C, CH2), 
48.75 (1 C, CH), 44.49 (1 C, CH2), 44.38 (1 C, CH2), 42.18 (1 C, CH), 30.58 (1 C, CH2), 
28.31 (1 C, C(CH3)3), 27.91 (1 C, CH2), 23.95 (1 C, CH2). 
 
tert-butyl (3S)-3-(3-bromo-2-oxo-pyrrolidin-1-yl)piperidine-1-carboxylate (273) 
 
Prepared according to general procedure N with tert-butyl (3S)-
3-aminopiperidine-1-carboxylate (1.99 mmol) and 2,4-
dibromobutanoyl chloride (1.2 equiv., 2.4  mmol). Crude product 
was dry loaded on silica and purified by flash column 
chromatography (silica gel, PE/EA 0→100%, gradient) to obtain desired product (second 
fraction). Yield:  250 mg, 80%; Appearance: yellow oil; LCMS: 1.75 min m/z 334.1, 
308 
 
336.1 ((M+H)+ 1:1, 79/81Br), Purity=90%, Method D; 1H NMR (500 MHz, 
CHLOROFORM-d)  ppm 4.41 (dd, J=6.87, 2.29 Hz, 1 H, CH), 3.95 (br. s., 3 H, CH2, 
CH), 3.58 - 3.46 (m, 1 H, CH2), 3.43 - 3.30 (m, 1 H, CH2), 2.87 (d, J=10.88 Hz, 1 H, 
CH2), 2.71 (t, J=11.74 Hz, 1 H, CH2), 2.60 - 2.50 (m, 1 H, CH2), 2.38 - 2.26 (m, 1 H, 
CH2), 1.94 - 1.79 (m, 1 H, CH2), 1.74 (d, J=10.31 Hz, 1 H, CH2), 1.68 - 1.52 (m, 2 H, 
CH2), 1.45 (d, J=3.44 Hz, 9 H, C(CH3)3); 
13C NMR (126 MHz, CHLOROFORM-d)  
ppm 170.59 (1 C, C=O), 154.54 (1 C, C=O), 80.00 (1 C, C(CH3)3.), 48.90 (1 C, CH2), 
48.71 (1 C, CH), 44.45 (1 C, CH2), 44.37 (1 C, CH2), 42.14 (1 C, CH), 30.54 (1 C, CH2), 
28.29 (3 C, C(CH3)3), 27.88 (1 C, CH2), 23.91 (1 C, CH2). 
 
tert-butyl 3-(3-bromo-2-oxo-pyrrolidin-1-yl)pyrrolidine-1-carboxylate (274) 
 
Prepared according to general procedure N with tert-butyl 3-
aminopyrrolidine-1-carboxylate (1.6 mmol) and 2,4-
dibromobutanoyl chloride (1.2 equiv., 1.92  mmol). Crude 
product was dry loaded on silica and purified by flash column 
chromatography (silica gel, PE/EA 0→100%, gradient) to obtain desired product (first 
fraction).Yield:  166 mg, 66%; Appearance: yellow oil; LCMS: 1.76 min m/z 332.1, 334.1 
((M+H)+ 1:1, 79/81Br), Purity=80-85%, Method D; 1H NMR (500 MHz, CHLOROFORM-
d) δ ppm 4.70 (td, J=6.87, 13.75 Hz, 1 H, CH), 4.41 (dd, J=2.29, 6.87 Hz, 1 H, CH), 4.03-
4.03 (m, 1H, CH2), 3.63-3.43 (m, 4H, CH2), 3.36 (ddd, J=2.00, 7.73, 9.74 Hz, 2 H, CH2), 
2.56 (dd, J=7.16, 14.61 Hz, 1 H, CH2), 2.34 (ddd, J=2.86, 5.73, 11.46 Hz, 1 H, CH2), 
2.22-2.07 (m, 1 H, CH2), 2.05 - 1.94 (m, 1 H, CH2), 1.47 (s, 9 H, C(CH3)3); 
13C NMR 
(126 MHz, CHLOROFORM-d)  ppm 170.94 (1 C, C=O), 154.39 (1 C, C=O), 79.95 (1 
C, C(CH3)3), 51.60 (1 C, CH), 50.72 (1 C, CH2), 48.26 (1 C, CH2), 47.78 (1 C, CH2), 
44.38 (1 C, CH2), 41.89 (1 C, CH), 30.48 (1 C, CH2), 28.56 (3 C, C(CH3)3), 28.01 (1 C, 
CH2); mixture of stereoisomers. 
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tert-butyl 3-(3-bromo-2-oxo-pyrrolidin-1-yl)pyrrolidine-1-carboxylate (275) 
 
Prepared according to general procedure N with tert-butyl 3-
aminopyrrolidine-1-carboxylate (1.6 mmol) and 2,4-
dibromobutanoyl chloride (1.2 equiv., 1.92  mmol). Crude 
product was dry loaded on silica and purified by flash column 
chromatography (silica gel, PE/EA 0→100%, 15CV gradient) to obtain desired product 
(second fraction).Yield:  193 mg, 66%; Appearance: yellow oil; LCMS: 1.792 min m/z 
332.1, 334.1 ((M+H)+ 1:1, 79/81Br), Purity=80-85%, Method D; 1H NMR (500 MHz, 
CHLOROFORM-d)  ppm 4.76-4.66 (m, 1 H, CH), 4.42 (dd, J=2.29, 6.87 Hz, 1 H, CH), 
3.65-3.44 (m, 4 H, CH2), 3.43-3.32 (m, 2 H, CH2), 2.58 (qt, J=7.35, 14.46 Hz, 1 H, CH2), 
2.39-2.31 (m, 1 H, CH2), 2.19-2.10 (m, 1 H, CH2), 2.04 - 1.93 (m, 1 H, CH2), 1.47 (s, 9 
H, C(CH3)3); 
13C NMR (126 MHz, CHLOROFORM-d)  ppm 171.00 (1 C, C=O), 154.40 
(1 C, C=O), 79.95 (1 C, C(CH3)3), 51.59 (1 C, CH), 50.94 (1 C, CH2), 47.63 (1 C, CH), 
44.19 (1 C, CH2), 41.89 (1 C, CH2), 30.48 (1 C, CH2), 28.56 (1 C, C(CH3)3), 28.40 (1 C, 
CH2); mixture of stereoisomers. 
 
3-bromo-1-(1,3-dimethylpyrazol-4-yl)pyrrolidin-2-one (276) 
 
Prepared according to general procedure N with 1,3-
dimethylpyrazol-4-amine (1.8 mmol) and 2,4-dibromobutanoyl 
chloride (1.2 equiv., 2.16  mmol). Crude product was dry loaded 
on silica and purified by flash column chromatography (silica gel, 
PE/EA 0→100%, and then EA/MeOH 9/1) to obtain desired product Yield:  230 mg, 
60%; Appearance: yellow oil; LCMS: 0.93 min, m/z 258.1, 260.1 ((M+H)+ 1:1, 79/81Br), 
Purity>85%, Method D; 1H NMR (500 MHz, CHLOROFORM-d)  ppm 7.38 (s, 1 H, 
ArCH), 4.52 (dd, J=6.87, 2.29 Hz, 1 H, CH), 3.87 (ddd, J=10.02, 8.31, 6.30 Hz, 1 H, CH), 
3.77 (s, 3 H, CH3), 3.64 (ddd, J=10.17, 7.88, 2.00 Hz, 1 H, CH2), 2.81 - 2.70 (m, 1 H, 
CH2), 2.45 - 2.38 (m, 1 H, CH2), 2.21 (s, 3 H, CH3); 
13C NMR (126 MHz, 
CHLOROFORM-d)  ppm 169.93 (1 C, C=O), 134.14 (1 C, ArC), 133.43 (1 C, ArC), 
117.88 (1 C, ArCH), 49.06 (1 C, CH2), 44.10 (1 C, CH), 36.77 (1 C, CH3), 30.59 (1 C, 
CH2), 9.79 (1 C, CH3). 
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3-bromo-1-(1-isopropylpyrazol-4-yl)pyrrolidin-2-one (277) 
 
Prepared according to general procedure N with 1-
isopropylpyrazol-4-amine (2.0 mmol) and 2,4-
dibromobutanoyl chloride (1.2 equiv., 2.4 mmol). Crude 
product was dry loaded on silica and purified by flash column 
chromatography (silica gel, PE/EA 0→100%, and then EA/MeOH 9/1) to obtain desired 
product. Yield:  384 mg, 67%; Appearance: yellow oil; LCMS: 1.44 min, m/z 272.1, 274.1 
((M+H)+ 1:1, 79/81Br), Purity>90%, Method D; 1H NMR (500 MHz, DMSO-d6)  ppm 
8.07 (s, 1 H, ArCH), 7.68 (s, 1 H, ArCH), 4.83 (dd, J=7.16, 3.15 Hz, 1 H, CH), 4.49 (quin, 
J=6.59 Hz, 1 H, CH), 3.70 - 3.80 (m, 2 H, CH2), 2.79 (dq, J=14.89, 7.45 Hz, 1 H, CH2), 
2.35 (ddt, J=14.46, 6.44, 3.29, 3.29 Hz, 1 H, CH2), 1.39 (d, J=6.87 Hz, 6 H, CH3);
  13C 
NMR (126 MHz, DMSO-d6)  ppm 167.33 (1 C, C=O), 128.54 (1 C, ArCH), 122.07 (1 
C, ArC), 117.76 (1 C, ArCH), 53.31 (1 C, C(CH3)2), 45.68 (1 C, CH2), 43.53 (1 C, CH), 
29.85 (1 C, CH2), 22.60 (2 C, CH3). 
 
3-bromo-1-(1-phenylpyrazol-4-yl)pyrrolidin-2-one (278) 
 
Prepared according to general procedure N with 1-phenylpyrazol-4-
amine (0.95  mmol) and 2,4-dibromobutanoyl chloride (1.2 equiv., 
1.13  mmol). Crude product was dry loaded on silica and purified by 
flash column chromatography (silica gel, PE/EA 0→100%, and then EA/MeOH 9/1) to 
obtain desired product .Yield: 177 mg, 66%; Appearance: white solid; LCMS: 1.84 min, 
m/z 306.1, 308.1 ((M+H)+ 1:1, 79/81Br), Purity>95%, Method D; 1H NMR (500 MHz, 
DMSO-d6) δ ppm 8.67 (s, 1 H, ArCH) 8.08 (s, 1 H, ArCH) 7.81 (d, J=7.45 Hz, 2 H, 
ArCH) 7.47 (t, J=8.02 Hz, 2 H, ArCH) 7.29 (t, J=7.34 Hz, 1 H, ArCH) 4.86 (dd, J=7.45, 
3.44 Hz, 1 H, CH) 3.76 - 3.87 (m, 2 H, CH2) 2.82 (dq, J=14.46, 7.40 Hz, 1 H, CH2) 2.34 
- 2.41 (m, 1 H, CH2);
 13C NMR (126 MHz, DMSO-d6)  ppm 167.95 (1 C, C=O), 139.48 
(1 C, ArC), 131.92 (2 C, ArCH), 129.62 (1 C, ArCH), 126.40 (1 C, ArC), 125.30 (1 C, 
ArCH), 118.17 (2 C, ArCH), 117.16 (1 C, ArCH), 45.93 (1 C, CH), 43.69 ( 1 C, CH2), 
29.87 (1 C, CH2). 
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3-bromo-1-[1-(4-pyridyl)pyrazol-4-yl]pyrrolidin-2-one (279) 
 
Prepared according to general procedure N with 1-(4-
pyridyl)pyrazol-4-amine (0.65 mmol) and 2,4-dibromobutanoyl 
chloride (1.2 equiv., 0.8 mmol). Crude product was dry loaded on 
silica and purified by flash column chromatography (silica gel, PE/EA 0→100%, and 
then EA/MeOH 9/1) to obtain desired product Yield: 60 mg, 31%; Appearance: white 
solid; LCMS: 1.56 min,  m/z 307.0, 309.1 ((M+H)+ 1:1, 79/81Br), Purity>95%, Method D; 
1H NMR (500 MHz, DMSO-d6)   ppm 8.86 (s, 1 H, ArCH) 8.61 (dd, J=6.30, 1.72 Hz, 2 
H, ArCH) 8.21 (s, 1 H, ArCH) 7.85 (dd, J=6.30, 1.72 Hz, 2 H, ArCH) 4.87 (dd, J=7.45, 
3.44 Hz, 1H, CH) 3.88 - 3.77 (m, 2 H, CH2) 2.88 - 2.78 (m, 1 H, CH2) 2.42 - 2.34 (m, 1 
H, CH2);
 13C NMR (126 MHz, DMSO-d6)  ppm 168.35 (1 C, C=O), 149.41 (2 C, ArCH), 
134.67 (1 C, ArC), 125.99 (1 C, ArC), 117.60 (2C, ArCH), 112.42 (2 C, ArCH), 45.84 ( 
1 C, CH2), 45.61 (1 C, CH), 29.84 (1 C, CH2).  
 
3-bromo-1-(1-pyrimidin-2-yl-4-piperidyl)pyrrolidin-2-one (280) 
 
Prepared according to general procedure N with 1-
pyrimidin-2-ylpiperidin-4-amine;dihydrochloride (0.88 
mmol) and 2,4-dibromobutanoyl chloride (1.2 equiv., 1.05  
mmol). Crude product was dry loaded on silica and purified by flash column 
chromatography (silica gel, PE/EA 0→100%, and then EA/MeOH 9/1) to obtain desired 
product Yield: 80 mg, 44%; Appearance: white solid; LCMS: 1.60 min, m/z 325.1, 327.1 
((M+H)+ 1:1, 79/81Br), Purity>85%, Method D; 1H NMR (500 MHz, DMSO-d6)  ppm 
8.35 (d, J=4.58 Hz, 2 H, ArCH), 6.60 (t, J=5.16 Hz, 1 H, ArCH), 4.74 - 4.81 (m, 2 H, 
CH2), 4.66 (dd, J=10.31, 3.44 Hz, 1 H, CH), 4.03 (tt, J=11.74, 4.30 Hz, 1 H, CH), 3.29 - 
3.33 (m, 2 H, CH2), 2.87 - 2.95 (m, 2 H, CH2), 2.51 - 2.58 (m, 1 H, CH2), 2.12 - 2.19 (m, 
1 H, CH2), 1.52 - 1.67 (m, 4 H, CH2)
 ; 13C NMR (126 MHz, DMSO-d6)  ppm 169.40 (1 
C, C=O), 160.98 (1 C, ArC), 158.02 (2 C, ArCH), 109.92 (1 C, ArCH), 49.78 (1 C, CH), 
46.77 (2 C, CH2), 42.42 (1 C, CH), 40.88 (1 C, CH2), 29.89 (1 C, CH2), 27.95 (2 C, CH2). 
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General procedure O: synthesis of amine 
 
3-bromopyrrolidin-2-one derivative (1 eq.) was dissolved in acetonitrile (4 mL). Under 
nitrogen atmosphere ammonia (32 mass%) in water (2 mL) was added to the reaction 
mixture. The RM was stirred overnight at 40 degree. LCMS showed only partially formed 
product. Acetonitrile was evaporated and remaining aq. phase was extracted with DCM. 
Organic phase was filtered through a phase separator and concentrated under reduced 
pressure to obtain desired 3-aminopyrrolidin-2-one derivative. The crude product was 
used in the next step without any purification step. 
 
3-amino-1-benzyl-pyrrolidin-2-one (281) 
Product was synthesized according to general procedure O with 1-
benzyl-3-bromo-pyrrolidin-2-one (265) (0.4 mmol). Crude product 
was used in the next step without any purification step. Yield: 39 mg, 
60%; Appearance: yellow oil; LCMS: 1.25 min m/z 191.1, (M+H)+ 
Purity>80%, Method D; 1H NMR (500 MHz, CHLOROFORM-d) δ ppm 7.35 - 7.26 (m, 
3 H, ArCH), 7.24 - 7.20 (m, 2 H, ArCH), 4.45 (d, J=1.72 Hz, 2 H, PhCH2), 3.56 (dd, 
J=9.74, 8.59 Hz, 1 H, CH), 3.21 - 3.12 (m, 2 H, CH2), 2.43 - 2.35 (m, 1 H, CH2), 1.77 - 
1.64 (m, 3 H, NH, CH2); Compound has been reported in the literature.
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tert-butyl 4-(3-amino-2-oxo-pyrrolidin-1-yl)piperidine-1-carboxylate (282) 
Product was synthesized according to general procedure O with 
tert-butyl 4-(3-bromo-2-oxo-pyrrolidin-1-yl)piperidine-1-
carboxylate (266) (0.79 mmol). Yield: 440 mg, 72%; 
Appearance: yellow oil; LCMS: 1.57 min m/z 284.0, (M+H)+ Purity>90%, weak UV 
active, Method D; 1H NMR (500 MHz, CHLOROFORM-d)  ppm 4.21 (br. s., 2 H, CH2), 
4.14 - 4.05 (m, 1 H, CH), 3.54 (dd, J=9.74, 8.59 Hz, 1 H, CH), 3.30 (td, J=9.17, 1.72 Hz, 
1 H, CH2), 3.20 (td, J=9.45, 6.87 Hz, 1 H, CH2), 2.79 (br. s., 2 H, CH2), 2.44 (dddd, 
J=12.67, 8.23, 6.59, 1.72 Hz, 1 H, CH2), 1.80 - 1.73 (m, 2 H, CH2), 1.73 - 1.68 (m, 1 H, 
CH2), 1.68 - 1.53 (m, 4 H, CH2), 1.46 (s, 9 H, C(CH3)3); 
13C NMR (126 MHz, 
CHLOROFORM-d)  ppm 175.32 (1 C, C=O), 154.60 (1 C, C=O), 79.75 (1 C, C(CH3)3), 
53.42 (1 C, CH), 49.30 (1 C, CH), 42.80 (2 C, CH2), 39.60 (1 C, CH2), 29.11 (1 C, CH2), 
28.90 (1 C, CH2), 28.39 (3 C, C(CH3)3). 
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tert-butyl 4-[(3-amino-2-oxo-pyrrolidin-1-yl)methyl]piperidine-1-carboxylate (283) 
 
Product was synthesized according to general procedure O with tert-
butyl 4-[(3-bromo-2-oxo-pyrrolidin-1-yl)methyl]piperidine-1-
carboxylate (267) Yield: 128 mg, 70%; Appearance: yellow oil; 
LCMS: 1.67 min m/z 298.2, (M+H)+ Purity>90%, weak UV active, 
Method D; 1H NMR (500 MHz, CHLOROFORM-d)   ppm 4.20-4.05 (m, 2H, CH2), 
3.58 (dd, J=8.59, 9.74 Hz, 1H, CH), 3.35-3.29 (m, 2H, CH2), 3.17 (br. s., 2H, CH2), 2.73-
2.63 (m, 2H, CH2), 2.49-2.41 (m, 1H, CH), 2.27-2.07 (m, 2H, CH2), 1.85-1.73 (m, 2H, 
CH2), 1.64-1.54 (m, 2H, CH2), 1.45 (s, 9H, C(CH3)3), 1.21-1.12 (m, 2H, CH2); 
13C NMR 
(126 MHz, CHLOROFORM-d)  ppm 175.88 (1 C, C=O), 154.71 (1 C, C=O), 79.41 (1 
C, C(CH3)3), 52.91 (1 C, CH), 48.73 (1 C, CH2), 44.93 (1 C, CH2), 42.95 (2 C, CH2), 
34.58 (1 C, CH), 29.69 (1 C, CH2), 28.82 (2 C, CH2), 28.41 (3 C, C(CH3)3). 
 
tert-butyl 3-(3-amino-2-oxo-pyrrolidin-1-yl)pyrrolidine-1-carboxylate (284) 
 
Product was synthesized according to general procedure O with 
tert-butyl 3-(3-bromo-2-oxo-pyrrolidin-1-yl)pyrrolidine-1-
carboxylate (274) (0.45 mmol); Yield: 86 mg, 71%; Appearance: 
light orange oil; LCMS: 1.26 min, m/z 170.2 (M+H)+ , mass without BOC group 
Purity>90%, weak UV active, Method D; 1H NMR (500 MHz, CHLOROFORM-d) 
 ppm 4.75-4.64 (m, 1H, CH), 3.66-3.42 (m, 3H, CH2, CH), 3.41-3.18 (m, 4H, CH2), 
2.51-2.35 (m, 3H, CH2), 2.08 (d, J=5.73 Hz, 1H, CH2), 2.03-1.89 (m, 1H, CH2), 1.87-
1.70 (m, 1H, CH2), 1.45 (s, 9H, C(CH3)3); 
13C NMR (126 MHz, CHLOROFORM-d)  
ppm 175.58 (1 C, C=O), 154.30 (1 C, C=O), 79.68 (1 C, C(CH3)3), 53.40 (1 C, CH), 53.06 
(1 C, CH), 50.92 (1 C, CH2), 47.75 (1 C, CH2), 44.68 (1 C, CH2), 28.99 (1 C, CH2), 28.41 
(3 C, C(CH3)3), 28.00 (1 C, CH2). 
 
tert-butyl 3-(3-amino-2-oxo-pyrrolidin-1-yl)pyrrolidine-1-carboxylate (285) 
 
Product was synthesized according to general procedure O with 
tert-butyl 3-(3-bromo-2-oxo-pyrrolidin-1-yl)pyrrolidine-1-
carboxylate (275) (0.54 mmol); Yield: 100 mg, 70% 
Appearance: orange oil; LCMS: 1.47 min, m/z 170.2 (M+H)+ , mass without BOC group 
314 
 
Purity>90%, weak UV active, Method D; 1H NMR (500 MHz, CHLOROFORM-d) 
 4.76-4.65 (m, 1 H , CH), 3.63-3.44 (m, 3 H, CH, CH2), 3.42-3.18 (m, 4 H, CH2), 2.52-
2.41 (m, 1 H, CH2), 2.16-2.04 (m, 1 H, CH2), 2.01 -1.91 (m, 1H, CH2), 1.88 (br. s, 2 H, 
CH2), 1.79-1.66 (m, 1 H), 1.46 (s, 9 H, C(CH3)3); 
13C NMR (126 MHz, CHLOROFORM-
d)  ppm 175.87 (1 C, C=O), 154.31 (1 C, C=O), 79.68 (1 C, C(CH3)3), 53.41 (1 C, CH), 
53.12 (1 C, CH), 50.29 (1 C, CH2), 47.06 (1 C, CH2), 44.16 (1 C, CH2), 28.81 (1 C, CH2), 
28.43 (1 C, C(CH3)3), 28.00 (s, 1 C, CH2). 
 
tert-butyl (3S)-3-(3-amino-2-oxo-pyrrolidin-1-yl)piperidine-1-carboxylate (286) 
 
Product was synthesized according to general procedure O with 
tert-butyl (3S)-3-(3-bromo-2-oxo-pyrrolidin-1-yl)piperidine-1-
carboxylate (272) (0.75 mmol). Yield: 200 mg, 94%; 
Appearance: orange oil; LCMS: 1.60 min, m/z 184.2 (M+H)+ 
mass without BOC group, Purity>80%, weak UV active, Method D; 1H NMR (500 MHz, 
CHLOROFORM-d)  ppm 4.05 - 3.88 (br. m, 2 H, CH), 3.43 - 3.25 (br. m, 2 H, CH2), 
3.16 (br. s, 2 H, CH2), 2.88 - 2.76 (m, 1 H, CH2), 2.66 (br. s, 1 H, CH2), 2.52 - 2.42 (m, 1 
H, CH2), 1.84 (br. s, 2 H, CH2), 1.72 (dd, J=6.30, 2.86 Hz, 1 H, CH2), 1.64 - 1.51 (m, 2 
H, CH2), 1.44 (s, 9 H, C(CH3)3); a mixture of regioisomers. 
 
tert-butyl (3S)-3-(3-amino-2-oxo-pyrrolidin-1-yl)piperidine-1-carboxylate (287) 
 
Product was synthesized according to general procedure O with 
tert-butyl (3S)-3-(3-bromo-2-oxo-pyrrolidin-1-yl)piperidine-1-
carboxylate (273) (0.6 mmol). Yield: 107 mg, 70%; Appearance: 
orange oil; LCMS: 1.63 min, m/z 184.2  (M+H)+ , mass without 
BOC group, Purity>80%, weak UV active, Method D; 1H NMR (500 MHz, 
CHLOROFORM-d)  ppm 4.11 - 3.75 (m, 3 H, CH, CH2,), 3.58 - 3.46 (m, 1 H, CH), 
3.42 - 3.32 (m, 1 H, CH2), 3.31 - 3. 18 (m, 1 H, CH2), 2.86 - 2.77 (m, 1 H, CH2), 2.67 (br. 
s, 1 H, CH2), 2.47 - 2.38 (m, 1 H, CH2), 1.93 (br. s, 2 H, CH2), 1.86 - 1.78 (m, 1 H, CH2), 
1.77 - 1.66 (m, 2 H, CH2), 1.65 - 1.50 (m, 2 H, CH2), 1.43 (s, 9 H, C(CH3)3); a mixture of 
regioisomers. 
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tert-butyl 3-(3-amino-2-oxo-pyrrolidin-1-yl)azetidine-1-carboxylate (288) 
 
Product was synthesized according to general procedure O tert-
butyl 3-(3-bromo-2-oxo-pyrrolidin-1-yl)azetidine-1-
carboxylate (271) (1.1 mmol). Yield: 220 mg, 79%; 
Appearance: yellow oil; LCMS: 1.37 min, m/z 156.2 (M+H)+  mass without BOC group, 
Purity>90%, weak UV active, Method D; 1H NMR (500 MHz, CHLOROFORM-d)  
ppm 4.99 - 4.91 (m, 1 H, CH), 4.19 - 4.09 (m, 2 H, CH, CH2), 3.97 (dd, J=6.87, 5.73 Hz, 
2 H, CH2), 3.56 (dd, J=9.74, 8.02 Hz, 2 H, CH2), 3.42 (td, J=9.74, 6.87 Hz, 1 H, CH2), 
2.51 (dddd, J=12.67, 8.09, 6.73, 1.72 Hz, 1 H, CH2), 1.84 (br. s, 2 H, CH2), 1.81 - 1.72 
(m, 1 H, CH2), 1.44 (s, 9 H, C(CH3)3); 
13C NMR (126 MHz, CHLOROFORM-d)  ppm 
175.97 (1 C, C=O), 155.95 (1 C, C=O), 80.01 (1 C, C(CH3)3), 53.19 (1 C, CH), 52.58 (2 
C, CH2), 41.14 (1 C, CH2), 39.70 (1 C, CH), 28.65 (1 C, CH2), 28.25 (3 C, C(CH3)3). 
 
3-amino-1-(5-phenyl-1,3,4-oxadiazol-2-yl)pyrrolidin-2-one (289) 
 
Product was synthesized according to general procedure O 
with 3-bromo-1-(1-phenylpyrazol-4-yl)pyrrolidin-2-one 
(278). Yield: 12 mg, 20%; Appearance: white solid; LCMS: 
1.336 min, m/z 245 (M+H)+ Purity>80%, Method D; 1H NMR 
(500 MHz, METHANOL-d4)  ppm 7.91 - 7.85 (m, 2 H, ArCH), 7.58 - 7.49 (m, 3 H, 
ArCH), 4.69 (d, J=4.58 Hz, 1 H, CH), 3.58 - 3.50 (m, 1 H, CH2), 3.42 - 3.34 (m, 1 H, 
CH2), 2.25 - 2.19 (m, 1 H, CH2), 2.10 - 2.01 (m, 1 H, CH2). 
 
3-amino-1-(3,5-dimethyl-1-phenyl-pyrazol-4-yl)pyrrolidin-2-one (290) 
 
Product was synthesized according to general procedure O with 
3-bromo-1-(3,5-dimethyl-1-phenyl-pyrazol-4-yl)pyrrolidin-2-
one (270) (0.39 mmol). Yield: 40 mg, 38%; Appearance: 
yellowish oil; LCMS: 1.39  min m/z 271.2, (M+H)+ 
Purity>90%, Method D; 1H NMR (500 MHz, CHLOROFORM-d)  ppm 7.50 - 7.41(m, 
4 H, ArCH), 7.40 - 7.34 (m, 1 H, ArCH), 3.74 (dd, J=10.31, 8.02 Hz, 1 H, CH), 3.65 (td, 
J=9.74, 6.87 Hz, 1 H, CH2), 3.56 (td, J=9.45, 1.72 Hz, 1 H, CH2), 2.63 - 2.55 (m, 1 H, 
CH2), 2.23 - 2.22 (s, 3 H, CH3), 2.21 - 2.19 (s, 3 H, CH3), 1.97 (dq, J=12.60, 9.36 Hz, 1 
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H, CH2), 1.82 - 1.65 (m, 2 H, NH2); 
13C NMR (126 MHz, CHLOROFORM-d)  ppm 
176.01 (1 C, C=O), 145.05 (1 C, ArC), 139.55 (1 C, ArC), 135.49 (1 C, ArC), 129.07 (1 
C, ArCH), 127.57 (2 C, ArCH), 124.63 (2 C, ArCH), 118.32 (1 C, ArC), 52.80 (1 C, CH), 
47.06 (1 C, CH2), 29.64 (1 C, CH2), 11.67 (1 C, CH3), 10.86 (1 C, CH3). 
 
3-amino-1-(1,3-dimethylpyrazol-4-yl)pyrrolidin-2-one (291) 
 
Product was synthesized according to general procedure O with 3-
bromo-1-(1,3-dimethylpyrazol-4-yl)pyrrolidin-2-one (266), (0.73 
mmol). Yield: 150 mg, 84%; Appearance: yellowish oil; LCMS: 
0.29 min m/z 195.2, (M+H)+ Purity>90%, Method C; 1H NMR (500 MHz, DMSO-d6) 
 7.32-7.34 (m, 1H, ArCH), 3.68-3.71 (s, 3H, CH3), 3.51-3.57 (m, 1H, CH), 3.46-3.48 
(m, 1H, CH2), 3.43-3.46 (m, 1H, CH2), 2.31 (dddd, J=2.00, 6.59, 8.31, 12.32 Hz, 1H, 
CH2), 2.11 (s, 3H, CH3), 1.69-1.82 (m, 1H, CH2); 
13C NMR (126 MHz, DMSO-d6)  ppm 
175.18 (1 C, C=O), 133.20 (1 C, ArC), 133.01 (1 C, ArC), 119.19 (1 C, ArCH), 52.45 (1 
C, CH), 46.90 (1 C, CH2), 36.55 (1 C, CH3), 28.93 (1 C, CH2), 9.49 (1 C, CH3),  The 
NMR analysis showed rotamers. 
 
3-amino-1-(1-isopropylpyrazol-4-yl)pyrrolidin-2-one (292) 
 
Product was synthesized according to general procedure O 3-
bromo-1-(1-isopropylpyrazol-4-yl)pyrrolidin-2-one (277) (0.57 
mmol). Yield: 125 mg, 94%; Appearance: off-white solid; LCMS: 
0.98 min, m/z 209.2 (M+H)+ Purity>90%, Method D; 1H NMR (500 MHz, DMSO-d6) δ 
ppm 7.97 (s, 1 H, ArCH), 7.61 (s, 1 H, ArCH), 4.45 (quin, J=6.73 Hz, 1 H, CH), 3.65 - 
3.57 (m, 2 H, CH2) 3.56 - 3.48 (m, 1 H, CH2) 2.41 - 2.33 (m, 1 H, CH2) 1.85 - 1.75 (m, 1 
H, CH2) 1.35 (d, J=6.30 Hz, 6 H, C(CH3)2); 
13C NMR (126 MHz, DMSO-d6)  ppm 
171.85 (1 C, C=O), 128.30 (1 C, ArC.), 122.52 (1 C, ArCH), 117.24 (1 C, ArCH), 53.21 
(1 C, CH), 52.15 (1 C, CH), 44.20 (1 C, CH2), 27.35 (1 C, CH2), 22.65 (2 C, CH3). 
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3-amino-1-(1-phenylpyrazol-4-yl)pyrrolidin-2-one (293) 
 
Product was synthesized according to general procedure O with 3-
bromo-1-(1-phenylpyrazol-4-yl)pyrrolidin-2-one (278) (0.2 mmol). 
Yield: 50 mg, 95%; Appearance: orange oil; LCMS: 1.46 min, m/z 
243.2 (M+H)+ Purity>95%, Method D; 1H NMR (500 MHz, DMSO-d6) δ ppm 8.61 (s, 1 
H, ArCH), 8.09 (s, 1 H, ArCH), 7.86 - 7.80 (m, 2 H, ArCH), 7.54 - 7.47 (m, 2 H, ArCH), 
7.34 - 7.27 (m, 1 H, ArCH ), 3.70 (td, J=9.45, 2.29 Hz, 1 H, CH), 3.65 - 3.57 (m, 1 H, 
CH2), 3.53 (dd, J=9.45, 8.31 Hz, 1 H, CH2), 2.45 - 2.38 (m, 1 H, CH2), 1.81 (dq, J=12.32, 
9.26 Hz, 1 H, CH2);
 13C NMR (126 MHz, DMSO-d6)  ppm 174.76 (1 C, C=O), 140.10 
(1 C, ArC), 132.42 (1 C, ArC), 130.18 ( 2 C, ArCH), 126.85 (1 C, ArCH), 126.00 (1 C, 
ArCH), 118.52 (2 C, ArCH), 116.87 (1 C, ArCH), 53.38 (1 C, CH2), 44.70 (1 C, CH2), 
29.01 (1 C, CH2). 
 
3-amino-1-[1-(4-pyridyl)pyrazol-4-yl]pyrrolidin-2-one (294) 
 
Product was synthesized according to general procedure O with 
3-bromo-1-[1-(4-pyridyl)pyrazol-4-yl]pyrrolidin-2-one (279) 
(0.16 mmol). Yield: 50 mg, 95% Appearance: orange oil; LCMS: 
1.46 min, m/z 243.2 (M+H)+ Purity>95%, Method D; 1H NMR 
(500 MHz, DMSO-d6) δ ppm 8.90 (s, 1 H, ArCH), 8.67 - 8.63 (m, 2 H, ArCH), 8.28 (s, 1 
H, ArCH), 7.94 - 7.84 (m, 2 H, ArCH), 4.25 (t, J=9.45 Hz, 1 H, CH), 3.91 - 3.82 (m, 1 H, 
CH2), 3.81 -3.72 (m, 1 H, CH2), 2.64 - 2.55 (m, 1 H, CH2), 2.21 - 2.08 (m, 1 H, CH2); 
13C 
NMR (126 MHz, DMSO-d6)  ppm 167.79 (1 C, C=O), 151.28 (2 C, ArCH), 145.23 (1 
C, ArC), 133.79 (1 C, ArC), 125.34 (1 C, ArCH), 117.27 ( 2 C, ArCH), 111.93 (1 C, 
ArC), 50.21 (1 C, NCH), 44.78 (1 C, NCH2), 24.05 (1 C, CH2) 
 
3-amino-1-(1-pyrimidin-2-yl-4-piperidyl)pyrrolidin-2-one (295) 
 
Product was synthesized according to general procedure O with 
3-bromo-1-(1-pyrimidin-2-yl-4-piperidyl)pyrrolidin-2-one 
(280) (0.2 mmol).Yield: 60 mg, 90% Appearance: off-white 
solid; LCMS: 1.18 min, m/z 262.2 (M+H)+ Purity>90%, Method D; 1H NMR (500 MHz, 
DMSO-d6) δ ppm 8.31 (d, J=4.58 Hz, 2 H, ArCH) 6.56 (t, J=4.58 Hz, 1 H, ArCH) 4.77 - 
4.70 (m, 2 H, CH2) 4.03 – 3.93 (m, 1 H, CH) 3.27 (dd, J=9.74, 8.02 Hz, 1 H, CH) 3.18 
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(td, J=9.17, 2.29 Hz, 1 H, CH2) 3.05 (td, J=9.45, 6.87 Hz, 1 H, CH2) 2.92 - 2.81 (m, 2 H, 
CH2) 2.16 (dddd, J=12.17, 8.16, 6.59, 1.72 Hz, 1 H, CH2) 1.79 (br s, 1 H, CH2) 1.61 -1.43 
(m, 4 H, CH2);
13C NMR (126 MHz, DMSO-d6)  ppm 175.05 (1 C, C=O), 160.97 (1 C, 
ArC.), 158.01 (2 C, ArCH), 109.86 (1 C, ArCH), 53.03 (1 C, CH), 49.16 (1 C, CH), 42.50 
(2 C, CH2), 42.52 (1 C, CH2), 28.60 (1 C, CH2), 28.49 (2 C, CH2). 
 
 
The urea formations with 3-aminopyrrolidin-2-one derivatives were performed 
according to modified procedure A 
 
1-(1-benzyl-2-oxo-pyrrolidin-3-yl)-3-(4-bromophenyl)urea (297) 
 
Prepared according to modified procedure A with 
intermediate 3-amino-1-benzyl-pyrrolidin-2-one 
(281) (0.18 mmol) and 4-bromophenyl isocyanate; 
(1.1 equiv., 0.20 mmol) Crude product was purified 
by reverse phase column chromatography (C18, acetonitrile/ water pH=10).Yield: 42 mg, 
62%; Appearance: white solid; LCMS: 2.06 min m/z 388.1, 390.1 ((M+H)+ 1:1, 79/81Br), 
Method D; 1H NMR (500 MHz, DMSO-d6)   ppm 8.81 (s, 1H, NH), 7.42-7.33 (m, 6H, 
ArCH), 7.31-7.21 (m, 4H, ArCH), 6.60 (d, J=6.87 Hz, 1H, NH), 4.47-4.36 (m, 2H, CH2), 
4.36-4.27 (m, 1H, CH), 3.26-3.14 (m, 2H, CH2), 2.41-2.33 (m, 1H, CH2), 1.88-1.78 (m, 
1H, CH2); 
13C NMR (126 MHz, DMSO-d6)  ppm 172.26 (1 C, C=O), 154.79 (1 C, C=O), 
139.71 (1 C, ArC), 136.65 (1 C, ArCquat.), 131.41 (2 C, ArCH), 128.59 (2 C, ArCH), 
127.63 (2 C, ArCH), 119.64 (2 C, ArCH), 119.55 (1 C, ArCH), 112.54 (1 C, ArC.), 51.06 
(1 C, CH), 46.06 ( 1 C, CH2), 43.02 (1 C, CH2), 26.89 (1 C, CH2); HRMS: Exact Mass: 
387.0582; (M+H)+: 388.0662; Observed mass: 388.0668; 1.45 ppm. 
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tert-butyl 4-[3-[(4-bromophenyl) carbamoylamino] -2-oxo-pyrrolidin-1-yl] 
piperidine-1-carboxylate (298) 
 
Prepared according to modified procedure A with 
intermediate tert-butyl 4-(3-amino-2-oxo-pyrrolidin-
1-yl)piperidine-1-carboxylate (282) (0.25 mmol) and 
4-bromophenyl isocyanate (1.1 equiv., 0.27 mmol); 
Crude compound was dry loaded on silica and purified 
by flash column chromatography (silica gel, PE/EtOAc 0-100%). Yield: 65 mg, 49%; 
Appearance: white solid; LCMS: 2.15 min m/z 481.1, 483.1 ((M+H)+ 1:1, 79/81Br), 
Purity=90%, Method D; 1H NMR (500 MHz, CHLOROFORM-d)   ppm 7.96 (br. s, 1 
H, NH), 7.28 -7.26 (m, 2 H, ArCH), 7.14 (d, J=8.59 Hz, 2 H, ArCH), 6.33 (br. s, 1 H, 
NH), 4.39 - 4.27 (m, 1 H, CH), 4.27 - 4.13 (m, 2 H, CH2), 4.12 - 4.04 (m, 1 H, CH), 3.46 
- 3.38 (m, 1 H, CH2), 3.34 - 3.27 (m, 1 H, CH2), 2.74 (br. s, 2 H, CH2), 2.68 - 2.60 (m, 1 
H, CH2), 2.07 -1.96 (m, 1 H, CH2), 1.69 - 1.56 (m, 4 H, CH2), 1.47 (s, 9 H, C(CH3)3); 
13C 
NMR (126 MHz, CHLOROFORM-d)  ppm 173.61 (1 C, C=O), 155.65 (1 C, C=O), 
154.50 (1 C, C=O), 138.20 (1 C, ArC), 131.55 (2 C, ArCH), 120.62 (2 C, ArCH), 114.82 
(1 C, ArC.), 79.99 (1 C, C(CH3)3), 53.07 (1 C, CH), 50.13 (1 C, CH), 42.87 ( 2 C, CH2), 
40.53 (1 C, CH2), 29.10 (1 C, CH2), 28.75 ( 2 C, CH2), 28.37 (3 C, C(CH3)3); HRMS: 
Exact mass: 480.1372; (M+H)+:481.1452; Observed mass: 481.1446; 1.29 ppm. 
 
tert-butyl 4-[[3-[(4-bromophenyl)carbamoylamino]-2-oxo-pyrrolidin-1-yl]methyl] 
piperidine-1-carboxylate (299) 
 
Prepared according to modified procedure A 
with intermediate tert-butyl 4-[(3-amino-2-
oxo-pyrrolidin-1-yl)methyl]piperidine-1-
carboxylate (283) (0.37 mmol) and 4-
bromophenyl isocyanate (1.1 equiv., 0.41 mmol); Crude compound was dry loaded on 
silica and purified by flash column chromatography (silica gel, DCM/MeOH 97/3). Yield: 
160 mg, 83%; Appearance: white solid; LCMS: 2.20 min m/z 495.1, 497.1 ((M+H)+ 1:1, 
79/81Br), Purity=95%, Method D; 1H NMR (500 MHz, CHLOROFORM-d)  ppm 7.93 
(br. s, 1 H, NH), 7.23 (d, J=8.59 Hz, 2 H, ArCH), 7.10 (d, J=8.59 Hz, 2 H, ArCH), 6.50 
(br. s., 1 H, NH), 4.39 - 4.23 (m, 1 H, CH), 4.13 (d, J=6.87 Hz, 2 H, CH2), 3.51- 3.39 (m, 
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2 H, CH2), 3.32 - 3.13 (m, 2 H, CH2), 2.69 (br. s., 2 H, CH2), 2.61 (br. s, 1 H CH2), 2.22 
- 2.05 (m, 1 H, CH2), 1.81 (dtt, J=11.17, 7.45, 7.45, 3.87, 3.87 Hz, 1 H, CH), 1.68 - 1.56 
(m, 2 H, CH2), 1.45 (s, 9 H, C(CH3)3), 1.20 - 1.08 (m, 2 H, CH2); 
13C NMR (126 MHz, 
CHLOROFORM-d)  ppm 174.64 (s, 1 C, C=O), 155.71 (1 C, C=O), 154.79 (s, 1 C, 
C=O), 138.26 (s, 1 C, ArC), 131.59 (2 C, ArCH), 120.77 (2 C, ArCH), 114.89 (s, 1 C, 
ArC), 79.73 (1 C, C(CH3)3), 52.74 (1 C, CH), 49.16 (1 C, CH2), 45.57 (2 C, CH2), 43.19 
( C, CH2), 34.52 (1 C, CH2), 29.82 (1 C, CH2), 28.56 (1 C, CH2), 28.52 (3 C, C(CH3)3); 
HRMS: Exact Mass: 494.1529; (M+H)+: 495.1609; Observed mass: 495.1599; 2.02 ppm. 
 
tert-butyl 3-[3-[(4-bromophenyl)carbamoylamino]-2-oxo-pyrrolidin-1-yl]azetidine-
1-carboxylate (300) 
 
Prepared according to modified procedure A with 
intermediate tert-butyl 3-(3-amino-2-oxo-pyrrolidin-1-
yl)azetidine-1-carboxylate (288) (0.29 mmol) and 4-
bromophenyl isocyanate (1.1 equiv., 0.32 mmol); Crude 
compound was dry loaded on silica and purified by flash 
column chromatography (silica gel, DCM/MeOH 97/3). Yield: 62 mg, 44%; Appearance: 
beige solid; LCMS: 2.090 min m/z 453, 455 ((M+H)+ 1:1, 79/81Br), Purity=95%, Method 
D; 1H NMR (500 MHz, CHLOROFORM-d)  ppm 7.79 (br. s., 1 H, NH), 7.28 - 7.27 (m, 
1 H, ArCH), 7.27 - 7.25 (m, 1 H, ArCH), 7.13 - 7.09 (m, 2 H, ArCH), 6.27 (d, J=5.73 Hz, 
1 H, NH), 4.89 (tt, J=8.16, 5.59 Hz, 1 H, CH), 4.31 (dd, J=7.45, 5.16 Hz, 1 H, CH), 4.17 
(td, J=8.88, 5.16 Hz, 2 H, CH2), 4.03 (dt, J=9.88, 5.08 Hz, 2 H, CH2), 3.67 (td, J=8.02, 
2.86 Hz, 1 H, CH2), 3.51 (td, J=9.59, 7.16 Hz, 1 H, CH2), 2.72 - 2.63 (m, 1 H, CH2), 2.16 
- 2.05 (m, 1 H, CH2), 1.45 (s, 9 H, C(CH3)3); 
13C NMR (126 MHz, CHLOROFORM-d) 
 ppm 174.33 (1 C, C=O), 156.02 (1 C, C=O), 155.53 (1 C, C=O), 137.94 (1 C, ArC), 
131.63 (2 C, ArCH), 120.80 (2 C, ArCH), 115.13 (1 C, ArC), 80.31 (1 C, C(CH3)3), 52.91 
(1 C, CH), 52.43 (2 C, CH2), 41.83 (1 C, CH2), 40.85 (1 C, CH), 28.30 (1 C, CH2), 27.23 
(1 C, C(CH3)3); HRMS: Exact mass: 452.1059; 453.1139; (M+H)
+ Observed mass: 
453.1127; 2.65 ppm. 
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tert-butyl (3S)-3-[3-[(4-bromophenyl)carbamoylamino]-2-oxo-pyrrolidin-1-yl] 
piperidine-1-carboxylate (301) 
 
Prepared according to modified procedure A with 
intermediate tert-butyl (3S)-3-(3-amino-2-oxo-pyrrolidin-
1-yl)piperidine-1-carboxylate (286) (0.6 mmol) and 4-
bromophenyl isocyanate (1.1 equiv., 0.66 mmol); Crude 
compound was dry loaded on silica and purified by flash 
column chromatography (silica gel, DCM/MeOH 97/3). Yield: 150 mg, 49% 
Appearance: beige solid; LCMS: 2.129 min m/z 481, 483 ((M+H)+ 1:1, 79/81Br), 
Purity=85%, Method D; 1H NMR (500 MHz, DMSO-d6)  ppm 8.83 - 8.72 (m, 1 H, NH), 
7.41 - 7.34 (m, 4 H, ArCH), 6.56 - 6.48 (m, 1 H, NH), 4.30 - 4.22 (m, 1 H, CH), 3.83 (d, 
J=9.74 Hz, 2 H, CH2), 3.76 - 3.65 (m, 1 H, CH), 3.39 - 3.34 (m, 1 H, CH2), 3.33 - 3.30 
(m, 1 H, CH2), 3.30 - 3.19 (m, 1 H, CH2), 2.95 - 2.74 (m, 1 H, CH2), 2.41 - 2.32 (m, 1 H, 
CH2), 1.80 - 1.65 (m, 3 H, CH2), 1.59 (qd, J=12.03, 3.44 Hz, 1 H, CH2), 1.41 - 1.38 (m, 
9 H, C(CH3)3), 1.37 (br. s, 1 H, CH2); broad peaks, possible rotamers; 
13C NMR (126 
MHz, DMSO-d6)  ppm 172.03 (1 C, C=O), 154.80 (1 C, C=O), 153.93 (1 C, C=O), 
139.69 (1 C, ArC), 131.41 (2 C, ArCH), 119.63 (2 C, ArCH), 112.52 (1 C, ArC), 78.90 
(1 C, C(CH3)3), 54.94 (1 C, CH), 51.28 (1 C, CH), 48.61 (1 C, CH2), 48.17 (1 C, CH2), 
28.06 (3 C, C(CH3)3), 27.38 (1 C,CH2), 27.28 (1 C, CH2), 24.01 (1 C, CH2), 1 carbon 
hidden under DMSO peak; HRMS: Exact Mass: 480.1372; (M+H)+ 481.1452; Observed 
mass: 481.1443; 1.87 ppm. 
 
tert-butyl (3S)-3-[3-[(4-bromophenyl)carbamoylamino]-2-oxo-pyrrolidin-1-yl] 
piperidine-1-carboxylate (302) 
 
Prepared according to modified procedure A with 
intermediate tert-butyl (3S)-3-(3-amino-2-oxo-pyrrolidin-
1-yl)piperidine-1-carboxylate (287) (0.3 mmol) and 4-
bromophenyl isocyanate (1.1 equiv., 0.33 mmol); Crude 
compound was dry loaded on silica and purified by flash 
column chromatography (silica gel, DCM/MeOH 97/3). Yield: 125 mg, 54%; 
Appearance: beige solid; LCMS: 2.13 min m/z 481.1, 483.1 ((M+H)+ 1:1, 79/81Br), 
Purity=85%, Method D; 1H NMR (500 MHz, DMSO-d6)  ppm 8.78 (s, 1 H, NH), 7.41 
- 7.35 (m, 4 H, ArCH), 6.55 - 6.49 (m, 1 H, NH), 4.32 - 4.22 (m, 1 H, CH), 3.83 (br.d, 2 
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H, CH2) 3.74 - 3.65 (m, 1 H, CH) 3.39 - 3.34 (m, 1 H, CH2) 3.30 - 3.19 (m, 1 H, CH2) 
2.96 - 2.59 (m, 2 H, CH2) 2.41 - 2.32 (m, 1 H, CH2) 1.81 - 1.64 (m, 4 H, CH2) 1.64 - 1.51 
(m, 1 H, CH2) 1.40 (d, J=2.29 Hz, 9 H, C(CH3)3); 
13C NMR (126 MHz, DMSO-d6)  ppm 
172.04 (1 C, C=O), 154.81 (1 C, C=O), 153.85 (1 C, C=O), 139.70 (1 C, ArC), 131.41 (2 
C, ArCH), 119.63 (2 C, ArCH), 112.52 (1 C, ArC), 78.91 (1 C, C(CH3)3), 51.37 (1C, 
CH), 51.28 (1 C, CH), 48.17 (1 C, CH2), 28.06 (3 C,  C(CH3)3), 27.43 (1 C, CH2), 27.28 
(1 C, CH2), 27.05 (1 C, CH2) 1 carbon hidden under DMSO peak; HRMS: Exact Mass: 
480.1372; (M+H)+ 481.1452; Observed mass:481.145; 0.42 ppm. 
 
tert-butyl 3-[3-[(4-bromophenyl)carbamoylamino]-2-oxo-pyrrolidin-1-yl] 
pyrrolidine-1-carboxylate (303) 
 
Prepared according to modified procedure A with 
intermediate tert-butyl 3-(3-amino-2-oxo-pyrrolidin-1-
yl)pyrrolidine-1-carboxylate (284) (0.3 mmol) and 4-
bromophenyl isocyanate (1.1 equiv., 0.33 mmol); Crude 
compound was dry loaded on silica and purified by flash 
column chromatography (silica gel, DCM/MeOH 97/3). Yield: 90 mg, 60%; Appearance: 
beige solid; LCMS: 2.12 min m/z 467.1, 469.1 ((M+H)+ 1:1, 79/81Br), Purity=85%, 
Method D; 1H NMR (500 MHz, CHLOROFORM-d)  ppm 7.98 (br. s., 1 H, NH), 7.25 
(br. s, 2 H, ArCH), 7.13 (br. s., 2 H, ArCH), 6.51 - 6.32 (m, 1 H, NH), 4.72 - 4.63 (m, 1 
H, CH), 4.32 - 4.21 (m, 1 H, CH), 3.61 - 3.51 (m, 2 H, CH2), 3.50 - 3.43 (m, 2 H, CH2), 
3.43 - 3.28 (m, 3 H, CH2), 2.68 - 2.58 (m, 1 H, CH2), 2.11 (br. s, 1 H, CH2), 2.08 - 1.93 
(m, 2 H, CH2), 1.47 (s, 9 H, C(CH3)3), broad peaks, possible rotamers; 
13C NMR (126 
MHz, CHLOROFORM-d)  ppm 174.19 (1 C, C=O), 155.61 (1 C, C=O), 154.26 (1 C, 
C=O), 138.09 (1 C, ArC), 131.56 (2 C, ArCH), 120.64 (2 C, ArCH), 114.93 (1 C, ArC), 
79.97 (1 C, C(CH3)3), 52.89 (1 C, CH), 51.57 (1 C, CH), 51.01 (1 C, CH2), 47.69 (1 C, 
CH2), 44.56 (1 C, CH2), 29.04 (1 C, CH2), 28.44 (3 C, C(CH3)3), 27.93 (1 C, CH2) 
 
tert-butyl 3-[3-[(4-bromophenyl)carbamoylamino]-2-oxo-pyrrolidin-1-yl] 
pyrrolidine-1-carboxylate (304) 
 
Prepared according to modified procedure A with intermediate tert-butyl 3-(3-amino-2-
oxo-pyrrolidin-1-yl)pyrrolidine-1-carboxylate (285) (0.24 mmol) and 4-bromophenyl 
isocyanate (1.1 equiv., 0.27 mmol); Crude compound was dry loaded on silica and 
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purified by flash column chromatography (silica gel, 
DCM/MeOH 97/3). Yield: 50 mg, 44%; Appearance: 
beige solid; LCMS: 2.13 min m/z 467.1, 469.1 ((M+H)+ 
1:1, 79/81Br), Purity=85%, Method D; 1H NMR (500 
MHz, METHANOL-d4)  ppm 7.37 - 7.27 (m, 4 H), 
4.65 - 4.55 (m, 1 H), 4.43 - 4.30 (m, 1 H), 3.60 - 3.46 (m, 2 H), 3.45 - 3.40 (m, 1 H), 3.40 
- 3.31 (m, 3 H), 2.54 - 2.44 (m, 1 H), 2.16 - 2.02 (m, 2 H), 2.00 -1.85 (m, 1 H), 1.45 (s, 9 
H), broad peaks,  possible rotamer; 13C NMR (126 MHz, METHANOL-d4)  ppm 173.95 
(1 C, C=O), 156.10 (1 C, C=O), 154.90 (1 C, C=O), 138.85 (1 C, ArC), 131.36 (2 C, 
ArCH), 120.45 (2 C, ArCH), 114.26 (1 C, ArC), 79.87 (1 C, C(CH3)3), 52.04 (1 C, CH), 
51.78 (1 C, CH), 44.50 (1 C, CH2 ), 44.03 (1 C, CH2), 40.46 (1 C, CH2), 28.27 (1 C, CH2), 
27.39 (3 C, C(CH3)3), 26.67 (1 C, CH2). 
 
1-(4-bromophenyl)-3-[1-(3,5-dimethyl-1-phenyl-pyrazol-4-yl)-2-oxo-pyrrolidin-3-
yl]urea (305) 
 
Prepared according to modified procedure A with 
intermediate 3-amino-1-(3,5-dimethyl-1-phenyl-pyrazol-4-
yl)pyrrolidin-2-one (290) (0.11 mmol) and 4-bromophenyl 
isocyanate (1.1 equiv., 0.12 mmol); Crude compound was 
purified by reverse phase column chromatography 
(MeOH/water pH=10). Yield: 47 mg, 90%; Appearance: white solid; LCMS: 2.094 min 
m/z 468, 470 ((M+H)+ 1:1, 79/81Br), Purity=95%, Method D; 1H NMR (500 MHz, DMSO-
d6)  ppm 8.81 (s, 1 H, NH), 7.48 (d, J=4.58 Hz, 4 H, ArCH), 7.42 - 7.34 (m, 5 H, ArCH), 
6.63 (d, J=6.87 Hz, 1 H, NH), 4.46 (ddd, J=10.45, 8.74, 7.16 Hz, 1 H, CH), 3.68 - 3.61 
(m, 1 H, CH2), 3.47 (dt, J=8.59, 1.72 Hz, 1 H, CH2), 2.17 (s, 3 H, CH3), 2.09 (s, 3 H, 
CH3), 2.07 - 2.01 (m, 1 H, CH2); 
13C NMR (126 MHz, DMSO-d6)  ppm 173.02 (1 C, 
C=O), 155.33 (1 C, C=O), 145.34 (1 C, ArC), 140.23 (1 C, ArC), 139.95 (1 C, ArC), 
135.98 (1 C, ArC), 131.95 (2 C, ArCH), 129.76 (2 C, ArCH), 127.79 (1 C, ArCH), 124.40 
(1 C, ArC), 120.20 (2 C, ArCH), 119.50 (2 C, ArCH), 113.09 (1 C, ArC), 51.31 (1 C, 
CH), 47.05 (1 C, CH2), 28.07 (1 C, CH2), 11.89 (1 C, CH3), 11.10 (1 C, CH3); HRMS: 
Exact Mass: 467.0957; (M+H)+ 468.1037; Observed mass:468.103; 1.5 ppm. 
 
324 
 
1-(4-bromophenyl)-3-[1-(1,3-dimethylpyrazol-4-yl)-2-oxo-pyrrolidin-3-yl]urea 
(306) 
 
Prepared according to modified procedure A with 
intermediate 3-amino-1-(1,3-dimethylpyrazol-4-
yl)pyrrolidin-2-one (291) (0.26 mmol) and 4-bromophenyl 
isocyanate (1.1 equiv., 0.28 mmol); Crude compound was 
purified by reverse phase column chromatography (MeOH/water pH=10); Yield: 35mg, 
35%; Appearance: white solid; LCMS: 1.78 min m/z 392.1, 394.1 ((M+H)+ 1:1, 79/81Br), 
Purity>95%, Method D; 1H NMR (500 MHz, DMSO-d6)  ppm 8.92 (s, 1 H, NH), 7.39 
(s, 4 H, ArCH), 7.36 (s, 1 H, ArCH), 6.73 (d, J=6.87 Hz, 1 H, NH), 4.41 (ddd, J=10.45, 
8.74, 7.16 Hz, 1 H, CH), 3.71 (s, 3 H, CH3), 3.65 (td, J=9.59, 6.59 Hz, 1 H, CH2), 3.45 - 
3.55 (m, 1 H, CH2), 2.41 - 2.48 (m, 1 H, CH2), 2.14 (s, 3 H, CH3), 2.00 (dd, J=12.60, 
10.31 Hz, 1 H, CH2);
 13C NMR (126 MHz, DMSO-d6)  ppm 171.64 (1 C, C=O), 154.85 
(1 C, C=O), 139.78 (1 C, ArC), 133.51 (1 C, ArC), 133.06 (1 C, ArCH), 131.43 (2 C, 
ArCH), 119.68 (2 C, ArCH), 119.01 (1 C, ArC), 112.55 (1 C, ArC), 50.91 (1 C, CH), 
46.95 (1 C, CH2), 36.58 (1 C, CH3), 27.29 (1 C, CH2), 9.45 (1 C, CH3); HRMS: Exact 
Mass: 391.0644; (M+H)+:392.0724; Observed Mass: 392.0719; 1.28 ppm. 
   
1-(4-bromophenyl)-3-[1-(1-isopropylpyrazol-4-yl)-2-oxo-pyrrolidin-3-yl]urea (307) 
 
Prepared according to modified procedure A with intermediate 
3-amino-1-(1-isopropylpyrazol-4-yl)pyrrolidin-2-one (292) 
(0.24 mmol) and 4-bromophenyl isocyanate (1.1 equiv., 0.264 
mmol); Crude compound was purified by preparative HPLC 
(19x100mm (5µm) C-18 Waters Xbridge, MeOH pH=10).; Yield: 38 mg, 39%; 
Appearance: white solid; LCMS: 1.92 min m/z 406.1, 408.0 ((M+H)+ 1:1, 79/81Br), 
Purity>95%, Method D; 1H NMR (500 MHz, DMSO-d6)  ppm 8.87 (s, 1 H, NH), 8.01 
(s, 1 H, ArCH), 7.66 (s, 1 H, ArCH), 7.45 - 7.33 (m, 4 H, ArCH), 6.63 (d, J=7.45 Hz, 1 
H, NH), 4.49 (quin, J=6.59 Hz, 1 H, CH), 4.42 (ddd, J=10.17, 8.74, 7.45 Hz, 1 H, CH), 
3.71 - 3.64 (m, 1 H, CH2), 3.63 - 3.55 (m, 1 H, CH2), 2.49 - 2.46 (m, 1 H, CH2), 2.01 (dd, 
J=12.32, 10.02 Hz, 1 H, CH2), 1.39 (d, J=6.30 Hz, 6 H, C(CH3)2); 
13C NMR (126 MHz, 
DMSO-d6) δ ppm 170.50 (1 C, C=O), 155.28 (1 C, C=O), 140.22 (1 C, ArC), 131.92 (2 
C, ArCH), 128.76 (1 C, ArCH), 123.22 ( 1C, ArCH), 120.22 (2 C, ArCH), 117.71 (1 C, 
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ArC), 113.08 (1 C, ArC), 53.72 (1 C, CH), 51.79 (1 C, CH), 44.59 (1 C, CH2), 27.28 (1 
C, CH2), 23.16 (2 C, C(CH3)2); HRMS: Exact Mass: 405.0800; (M+H)
+: 406.088; 
Observed Mass: 406.0872; 1.97 ppm. 
 
1-(4-bromophenyl)-3-[2-oxo-1-[1-(4-pyridyl)pyrazol-4-yl]pyrrolidin-3-yl]urea (308) 
 
Prepared according to modified procedure A with intermediate 
3-amino-1-[1-(4-pyridyl)pyrazol-4-yl]pyrrolidin-2-one (294) 
(0.24 mmol) and 4-bromophenyl isocyanate (1.1 equiv., 0.264 
mmol); Crude compound was purified by preparative HPLC 
(19x100mm (5µm) C-18 Waters Xbridge, MeOH pH=1). the 
compound was dissolved in MeOH and passed through the Isolute SPE column (500mg) 
to obtain desired product as free base.; Yield: 28 mg, 51%; Appearance: white solid; 
LCMS: 1.92 min, m/z 441.0, 443.0 ((M+H)+ 1:1, 79/81Br), Purity>95%, Method D; 1H 
NMR (500 MHz, DMSO-d6) δ ppm 8.88 (s, 1 H, NH) 8.77 (s, 1 H, ArCH) 8.59 - 8.63 (m, 
2 H, ArCH) 8.22 (s, 1 H, ArCH) 7.81 - 7.86 (m, 2 H, ArCH) 7.34 - 7.40 (m, 4 H, ArCH) 
6.66 (d, J=7.45 Hz, 1 H, NH) 4.43 - 4.51 (m, 1 H, CH) 3.70 - 3.79 (m, 1 H, CH2) 3.62 - 
3.70 (m, 1 H, CH2) 2.49 - 2.53 (m, 1 H, CH2) 2.02 - 2.13 (m, 1 H, CH2); 
13C NMR (126 
MHz, DMSO-d6) δ ppm 171.49 (1 C, C=O), 155.24 (1 C, C=O), 151.68 (2 C, ArCH), 
145.84 (1 C), 140.21 (1 C, ArCH), 134.16 (1 C, ArC), 131.93 (2 C, ArCH), 126.82 (1 C, 
ArCH), 120.26 (, ArCH ), 116.98 (ArCH ), 113.14 (1 C, ArC), 112.35 (1 C, ArCH), 51.76 
(1 C, CH), 44.72 (1 C, CH2), 26.99 (1 C, CH2); HRMS: Exact Mass: 440.0596; (M+H)
+: 
441.0676; Observed Mass: 441.0669; 1.59 ppm. 
 
1-(4-bromophenyl)-3-[2-oxo-1-(1-phenylpyrazol-4-yl)pyrrolidin-3-yl]urea (309) 
 
Prepared according to modified procedure A with 
intermediate 3-amino-1-(1-phenylpyrazol-4-yl)pyrrolidin-2-
one (293) (0.16 mmol) and 4-bromophenyl isocyanate (1.1 
equiv., 0.18 mmol); Crude compound was purified by 
preparative HPLC (19x100mm (5µm) C-18 Waters Xbridge, 
MeOH pH=10).; Yield: 12 mg, 16%; Appearance: white solid; LCMS: 2.09 min, m/z 
440.0, 442.0 ((M+H)+ 1:1, 79/81Br), Purity>95%, Method D; 1H NMR (500 MHz, DMSO-
d6)  8.88 (s, 1H, NH), 8.60 (s, 1H, ArCH), 8.08 (s, 1H, ArCH), 7.80 (d, J=8.02 Hz, 2H, 
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ArCH), 7.47 (dd, J=7.45, 8.59 Hz, 2H, ArCH), 7.39-7.33 (m, 4H, ArCH), 7.28 (t, J=7.39 
Hz, 1H, ArCH), 6.65 (d, J=7.45 Hz, 1H, NH), 4.46 (ddd, J=7.45, 8.88, 10.02 Hz, 1H, 
CH), 3.77-3.70 (m, 1H, CH2), 3.69-3.63 (m, 1H, CH2), 2.53-2.49 (m, 1H, CH2), 2.10-2.00 
(m, 1H, CH2); 
13C NMR (126 MHz, DMSO-d6)  ppm 170.66 (1 C, C=O), 154.75 (1 C, 
C=O), 139.69 (1 C, ArC), 139.55 (1 C, ArC), 131.75 (1 C, ArCH), 131.41 (2 C, ArCH), 
129.60 (2 C, ArCH), 126.23 (1 C, ArC), 125.41 (1 C, ArCH), 119.73 ( 2 C, ArCH), 118.03 
(2 C, ArCH), 116.39 (1 C, ArCH), 112.59 (1 C ArC), 51.25 (1 C, CH), 44.21 (1 C, CH2), 
26.59 (1 C, CH2); HRMS: Exact Mass: 439.0644; (M+H)
+:440.0724; Observed Mass: 
440.0715; 2.05 ppm. 
   
1-(4-bromophenyl)-3-[2-oxo-1-(1-pyrimidin-2-yl-4-piperidyl)pyrrolidin-3-yl]urea 
(310) 
 
Prepared according to modified procedure A with 
intermediate 3-amino-1-(1-pyrimidin-2-yl-4-
piperidyl)pyrrolidin-2-one (295) (0.14 mmol) and 4-
bromophenyl isocyanate (1.1 equiv., 0.155 mmol); Crude 
compound was purified by preparative HPLC (19x100mm (5µm) C-18 Waters Xbridge, 
MeOH pH=10).; Yield: 38 mg, 60%; Appearance: white solid; LCMS: 1.99 min , m/z 
459.0, 461.0 ((M+H)+ 1:1, 79/81Br), Purity=95%, Method D; 1H NMR (500 MHz, DMSO-
d6)  8.80 (s, 1H, NH), 8.35 (d, J=4.58 Hz, 2H, ArCH), 7.35-7.41 (m, 4H, ArCH), 6.60 
(t, J=4.58 Hz, 1H, NH), 6.53 (d, J=6.87 Hz, 1H, CH), 4.74-4.82 (m, 2H, CH2), 4.25 (ddd, 
J=6.87, 8.59, 10.31 Hz, 1H, CH), 4.02-4.11 (m, 1H, CH), 3.26-3.32 (m, 1H, CH2), 3.15-
3.22 (m, 1H, CH2), 2.86-2.97 (m, 2H, CH2), 2.32-2.40 (m, 1H, CH2), 1.69-1.77 (m, 1H, 
CH2), 1.48-1.69 (m, 4H, CH2); 
13C NMR (126 MHz, DMSO-d6) δ ppm 171.64 (1 C, C=O) 
161.00 (1 C, C=O)  158.18 (1 C, ArC) 154.82 (2 C, ArCH) 139.71 (1 C, ArC) 131.40 (2 
C, ArCH) 119.35  (2 C, ArCH) 112.51 (1 C, ArC) 109.91 (1 C, ArCH) 51.60 (1 C, CH) 
49.52 (1 C, CH) 42.55 (2 C, CH2) 28.33 (1 C, CH2) 27.33 (2 C, CH2); HRMS: Exact 
Mass: 458.1066; (M+H)+:459.1146; Observed Mass: 459.1142; 0.87 ppm. 
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Compound were synthesized according to general procedure G: BOC deprotection 
 
1-(4-bromophenyl)-3-[2-oxo-1-(4-piperidyl)pyrrolidin-3-yl]urea (311) 
 
Compound was prepared according to general procedure 
G with intermediate: tert-butyl 4-[3-[(4-bromophenyl) 
carbamoylamino] -2-oxo-pyrrolidin-1-yl] piperidine-1-
carboxylate (298) (0.11 mmol). A crude product was 
dissolved in methanol. Methanol solution was passed 
through the Isolute NH2 SPE cartridge (500mg) and filtrate was concentrated under 
reduced pressure to get desired product as a free base. Yield: 40 mg, 92%; Appearance: 
light grey solid: LCMS: 1.72 min m/z 381.1, 383.1 ((M+H)+ 1:1, 79/81Br), Purity>95%, 
Method D; 1H NMR (500 MHz, DMSO-d6)  ppm 8.86 (s, 1 H, NH), 7.39 - 7.30 (m, 4 
H, ArCH), 6.54 (d, J=6.87 Hz, 1 H, NH), 4.20 (ddd, J=10.31, 8.59, 6.87 Hz, 1 H, CH), 
3.84 (ddd, J=16.04, 12.03, 4.01 Hz, 1 H, CH), 3.29 - 3.23 (m, 1 H, CH2), 3.18 (td, J=9.45, 
6.87 Hz, 1 H, CH2), 3.07 - 3.00 (m, 2 H, CH2), 2.66 - 2.56 (m, 2 H, CH2), 2.38 - 2.31 (m, 
1 H, CH2), 1.75 - 1.67 (m, 1 H, CH2), 1.67 - 1.58 (m, 1 H, CH2), 1.57 - 1.46 (m, 3 H, 
CH2); 
13C NMR (126 MHz, METHANOL-d4)  ppm 174.86 (1 C, C=O), 157.79 (1 C, 
C=O), 140.51 (1 C, ArC), 133.02 (2 C, ArCH), 122.11 (2 C, ArCH), 115.91 (1 C, ArC), 
53.98 (1 C, CH), 51.32 (1 C, CH), 46.30 (2 C, CH2), 41.52 (1 C, CH2), 30.08 (2 C, CH2), 
28.48 (1 C, CH2); HRMS: Exact Mass: 380.0848; (M+H)
+: 381.0928; Observed Mass: 
381.0924; 1.05 ppm. 
 
1-(4-bromophenyl)-3-[2-oxo-1-(4-piperidylmethyl)pyrrolidin-3-yl]urea (312) 
 
Compound was prepared according to general 
procedure G with intermediate: tert-butyl 4-[[3-[(4-
bromophenyl)carbamoylamino]-2-oxo-pyrrolidin-
1-yl]methyl] piperidine-1-carboxylate (299) (0.303 
mmol). A crude product was dissolved in methanol. Methanol solution was passed 
through the Isolute NH2 SPE cartridge and filtrate was concentrated under reduced 
pressure to get desired product as a free base. Yield: 120 mg, 100%; Appearance: light 
brown solid; LCMS: 1.75 min m/z 395.1, 397.1 ((M+H)+ 1:1, 79/81Br), Purity>95%, 
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Method D;  1H NMR (500 MHz, METHANOL-d4)   ppm 7.38 - 7.35 (m, 2 H, ArCH). 
7.33 - 7.28 (m, 2 H, ArCH), 4.35 (t, J=9.74 Hz, 1 H, NCH), 3.42 - 3.47 (m, 2 H, CH2), 
3.28 - 3.21 (m, 4 H, CH2), 2.81 (td,J=10.30, 2.86 Hz, 2 H, CH2), 2.52 - 2.44 (m, 1 H, 
CH2), 2.09 - 2.00 (m, 1 H, CH2), 2.00 – 1.90 (m, 1 H, CH), 1.90 - 1.76 (m, 2 H, CH2), 
1.38 - 1.27 (m, 2 H, CH2);
 13C NMR (126 MHz, METHANOL-d4)  ppm 175.62 (1 C, 
C=O), 157.55 (1 C, C=O), 140.31 (1 C, ArC), 132.84 (2 C, ArCH), 121.99 (2 C, ArCH), 
115.76 (1 C, ArC), 53.59 (1 C, CH), 50.15 (1 C, CH2, partially hidden under methanol-
d4 peak), 46.15 ( 2 C, CH2), 45.73 (1 C, CH2), 34.16 (1 C, CH), 29.25 (2C, CH2), 27.91 
(1 C, CH2) HRMS: Exact Mass: 394.1004; (M+H)
+: 395.1084; Observed Mass: 
395.1081; 0.76 ppm. 
 
1-(4-bromophenyl)-3-(2-oxo-1-pyrrolidin-3-yl-pyrrolidin-3-yl)urea (313) 
 
Compound was prepared according to general 
procedure G with intermediate tert-butyl 3-[3-[(4-
bromophenyl)carbamoylamino]-2-oxo-pyrrolidin-1-
yl] pyrrolidine-1-carboxylate (303) (0.16 mmol); A 
crude product was dissolved in methanol. Methanol 
solution was passed through the Isolute NH2 SPE cartridge (500mg) and filtrate was 
concentrated under reduced pressure to get desired product as a free base. Yield: 59 mg, 
100% ;Appearance: light brown solid; LCMS: 1.69 min m/z 367.1, 369.1 ((M+H)+ 1:1, 
79/81Br), Purity=90%, Method D; 1H NMR (500 MHz, METHANOL-d4)  ppm 7.37 - 
7.33 (m, 2 H, ArCH), 7.31 - 7.26 (m, 2 H, ArCH), 4.55 - 4.46 (m, 1 H, CH), 4.34 (t, 
J=9.45 Hz, 1 H, CH), 3.48 - 3.36 (m, 2 H, CH2), 3.14 - 3.03 (m, 2 H, CH2), 2.98 - 2.89 
(m, 2 H, CH2), 2.51 - 2.44 (m, 1 H, CH2), 2.13 - 2.00 (m, 1 H, CH2), 1.98 - 1.86 (m, 2 H, 
CH2); 
13C NMR (126 MHz, METHANOL-d4)  ppm 175.31 (1 C, C=O), 157.60 (1 C, 
C=O), 140.32 (1 C, ArC), 132.84 (2 C, ArCH), 121.94 (2 C, ArCH), 115.75 (1 C, ArC), 
54.71 (1 C, CH), 53.74 (1 C, CH), 49.90 (1 C, CH2), 47.17 (1 C, CH2), 42.66 (1 C, CH2), 
30.31 (1 C, CH2), 28.25 (1 C, CH2). 
  
329 
 
1-(4-bromophenyl)-3-(2-oxo-1-pyrrolidin-3-yl-pyrrolidin-3-yl)urea (314) 
 
Compound was prepared according to general 
procedure G with intermediate tert-butyl 3-[3-[(4-
bromophenyl)carbamoylamino]-2-oxo-pyrrolidin-1-
yl] pyrrolidine-1-carboxylate (304) (0.1 mmol). A 
crude product was dissolved in methanol. Methanol 
solution was passed through the Isolute NH2 SPE cartridge (500mg) and filtrate was 
concentrated under reduced pressure to get desired product as a free base. Yield: 29 mg, 
70%; Appearance: white solid; LCMS: 1.68 min m/z 367.0, 369.0 ((M+H)+ 1:1, 79/81Br), 
Purity=85%, Method D; 1H NMR (500 MHz, METHANOL-d4)  ppm 7.36 - 7.26 (m, 4 
H, ArCH), 4.56 - 4.46 (m, 1 H, CH), 4.35 (dd, J=10.31, 8.59 Hz, 1 H, CH), 3.47 - 3.35 
(m, 2 H, CH2), 3.11 - 2.97 (m, 2 H, CH2), 2.95 - 2.82 (m, 2 H, CH2), 2.51 - 2.43 (m, 1 H, 
CH2), 2.09 - 1.96 (m, 1 H, CH2), 1.95 - 1.83 (m, 2 H, CH2); 
13C NMR (126 MHz, 
METHANOL-d4)  ppm 174.98 (1 C, C=O), 157.42 (1 C, C=O), 140.16 (1 C, ArC), 
132.66 (2 C, ArCH), 121.76 (ArCH), 115.56 (1 C, ArC), 54.32 (1 C, CH), 53.49 (1 C, 
CH), 49.92 (1 C, CH2), 47.06 (1 C, CH2), 42.12 (1 C, CH2), 29.82 (1 C, CH2), 27.99 (1 
C, CH2). 
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General procedure P: N-alkylation 
 
1-(4-bromophenyl)-3-[2-oxo-1-(4-piperidylmethyl)pyrrolidin-3-yl]urea (1 eq.) was 
dissolved in N,N-dimethylformamide (1 mL) To the reaction, N,N-diisopropylethylamine 
(0.1 mmol, 2 eq.) following benzyl bromide (1.1 eq.) were added via syringe. A reaction 
was stirred overnight. A crude product was purified by preparative HPLC under basic 
condition to give final compound. 
 
1-[1-[(1-benzyl-4-piperidyl)methyl]-2-oxo-pyrrolidin-3-yl]-3-(4-bromophenyl)urea 
(315) 
 
Compound was prepared according to general procedure P 
with intermediate 1-(4-bromophenyl)-3-[2-oxo-1-(4-
piperidylmethyl)pyrrolidin-3-yl]urea (312) and benzyl 
bromide (1.2 equiv., 1 mmol). Yield: 10 mg, 30%; 
Appearance: white solid; LCMS: 2.18 min m/z 485.1, 487.1, 
((M+H)+ 1:1, 79/81Br), Purity=95%, Method D; 1H NMR (500 
MHz, DMSO-d6)  ppm 8.74 (s, 1 H, NH), 7.37 - 7.30 (m, 4 
H, ArCH), 7.30 - 7.22 (m, 4 H, ArCH), 7.22 - 7.18 (m, 1 H, ArCH), 6.47 (d, J=6.87 Hz, 
1 H, NH), 4.22 (ddd, J=10.31, 8.59, 6.87 Hz, 1 H, CH), 3.41 (s, 2 H. CH2), 3.28 - 3.21 
(m, 2 H, CH2), 3.05 (qd, J=13.65, 7.16 Hz, 2 H, CH2), 2.73 (d, J=10.88 Hz, 2 H, CH2), 
2.37 - 2.30 (m, 1 H, CH2), 1.90 - 1.81 (m, 2 H, CH2), 1.81 - 1.70 (m, 1 H, CH), 1.59 - 
1.46 (m, 3 H, CH2), 1.15 - 1.03 (m, 2 H, CH2); 
13C NMR (126 MHz, DMSO-d6)  ppm 
172.22 (1 C, C=O), 154.82 (1 C, C=O), 139.70 (1 C, ArC), 138.64 (1 C, ArCquat), 131.42 
(2 C, ArCH), 128.72 (2 C. ArCH), 128.14 (2 C, ArCH), 126.83 (1 C, ArCH), 119.60 (2 
C, ArCH), 112.49 (1 C, ArC), 62.35 (1 C, CH2), 52.72 (1 C, CH), 51.09 (1 C, CH), 48.04 
(2 C, CH2), 43.90 (1 C, CH2), 33.57 (1 C, CH), 29.47 (2 C, CH2), 27.46 (1 C, CH ); 
HRMS: Exact mass: 484.1474; (M+H)+: 485.1554; Observed mass: 485.1545; 1.86 ppm. 
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1-[1-(1-benzyl-4-piperidyl)-2-oxo-pyrrolidin-3-yl]-3-(4-bromophenyl)urea (316) 
 
Compound was prepared according to general 
procedure P with intermediate: 1-(4-bromophenyl)-3-
[2-oxo-1-(4-piperidyl)pyrrolidin-3-yl]urea (311) (0.066 
mmol) and benzyl bromide (1.2 equiv., 0.9 mmol). 
Crude product was purified by prep. HPLC (19x100mm 
(5µm) C-18 Waters Xbridge, MeOH pH=10). Yield: 10 mg, 30% Appearance: white 
solid; LCMS: 2.184 min m/z 471.1, 473.1 ((M+H)+ 1:1, 79/81Br), Purity=95%, Method D; 
1H NMR (500 MHz, DMSO-d6)  ppm 8.75 (s, 1 H, NH), 7.36-7.30 (m, 4H, ArCH), 7.30-
7.23 (m, 4 H, ArCH), 7.23-7.20 (m, 1H, ArCH), 6.48 (d, J=6.87 Hz, 1 H, NH), 4.19 (ddd, 
J=5.16, 6.87, 10.31 Hz, 1 H, CH), 3.70 (tt, J=4.08, 11.96 Hz, 1 H, CH), 3.42 (s, 2 H, 
CH2), 3.29 (d, J=9.16 Hz, 1H, CH2), 3.18 (dt, J=2.86, 6.30 Hz, 1 H, CH2), 3.14-3.13 (m, 
1H, CH2), 2.86-2.78 (m,  2H, CH2), 2.37 - 2.30 (m, 1 H, CH2), 1.96 (dd, J=2.29, 11.46 
Hz, 2 H, CH2), 1.74-1.65 (m, 2 H, CH2), 1.60 (dq, J=3.72, 12.12 Hz, 1 H, CH2), 1.53-
1.42 (m, 2 H, CH2); HRMS: Exact mass: 470.1317; (M+H)
+ : 471.1397; Observed mass: 
471.1395; 0.43 ppm. 
 
1-[1-(1-benzylpyrrolidin-3-yl)-2-oxo-pyrrolidin-3-yl]-3-(4-bromophenyl)urea (317) 
 
Compound was prepared according to general procedure 
P with intermediate 1-(4-bromophenyl)-3-(2-oxo-1-
pyrrolidin-3-yl-pyrrolidin-3-yl)urea (313) (0.08 mmol) 
and benzyl bromide (1.2 equiv., 1 mmol). Crude product 
was purified by prep. HPLC (19x100mm (5µm) C-18 
Waters Xbridge, MeOH pH=10). Yield: 16mg, 40%; 
Appearance: white solid; LCMS: 2.194 min m/z 457, 459 ((M+H)+ 1:1, 79/81Br), 
Purity=95%, Method D; 1H NMR (500 MHz, DMSO-d6)  ppm 8.82 - 8.95 (br.s, 1 H, 
NH), 7.43 - 7.55 (m, 5 H, ArCH), 7.34 - 7.41 (m, 5 H, ArCH), 6.56 - 6.70 (br.s, 1 H, NH), 
4.60 - 4.80 (m, 1 H, CH), 4.36 - 4.52 (m, 1 H, CH), 4.16 - 4.36 (m, 2 H, CH2), 3.39 - 3.53 
(m, 2 H, CH2), 3.16 - 3.30 (m, 2 H, CH2), 2.25 - 2.45 (m, 2 H, CH2), 1.95 - 2.22 (m, 2 H, 
CH2), 1.63 - 1.94 (m, 2 H, CH2); broad peaks due to presence of rotamers. HRMS: Exact 
mass: 456.1161; (M+H)+: 457.1241; Observed mass: 457.1238; 0.66 ppm. 
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1-[1-(1-benzylpyrrolidin-3-yl)-2-oxo-pyrrolidin-3-yl]-3-(4-bromophenyl)urea (318) 
 
Compound was prepared according to general procedure G with 
intermediate 1-(4-bromophenyl)-3-(2-oxo-1-pyrrolidin-3-yl-
pyrrolidin-3-yl)urea (314); Crude product was purified by prep. 
HPLC (19x100mm (5µm) C-18 Waters Xbridge, MeOH 
pH=10); Yield: 12 mg, 30%; Appearance: white solid; LCMS: 
2.198 min, m/z 457, 459( (M+H)+1:1, 79/81Br), Purity=95%, Method D; 1H NMR (500 
MHz, DMSO-d6)  ppm 8.80 - 8.97 (br.s, 1 H, NH), 7.29 - 7.40 (m, 9 H, ArCH), 6.51 - 
6.66 (br.s, 1 H, NH), 4.50 - 4.65 (m, 1 H, CH), 4.30 - 4.49 (m, 1 H, CH), 4.15 - 4.29 (m, 
2 H, CH2), 3.34 - 3.48 (m, 2 H, CH2), 3.12 - 3.27 (m, 2 H, CH2), 2.26 - 2.39 (m, 2 H, 
CH2), 1.94 - 2.14 (m, 2 H, CH2), 1.68 - 1.85 (m, 2 H, CH2); broad peaks due to presence 
of rotamers; HRMS: Exact mass: 456.1161; (M+H)+: 457.1241;  Observed mass: 
457.1238; 0.66 ppm. 
 
12.2.3.8. Ligands from Phase Ligand screening 
 
 
ethyl 2-[3-[(4-bromophenyl)carbamoylamino]-4-chloro-phenyl]acetate (258) 
 
Compound was prepared according to general procedure 
A for urea formation with 1-bromo-4-isocyanato-benzene 
(0.4 mmol) and ethyl 2-(3-amino-4-chloro-phenyl)acetate (1 equiv., 0.4 mmol). Crude 
product was dry loaded on silica and purified by flash column chromatography (silica gel, 
PE/EA 10-->60%, gradient). The beige solid was washed with diethyl ether (15mL), 
filtered and dried under high vacuum to afford desired product. Yield: 53 mg, 30%; 
Appearance: white solid; LCMS: 1.94 min, m/z 412.0, 413.0, 415.0,( (M+H)+ 35/37Cl, 
79/81Br), Purity=95%, Method D;1H NMR (500 MHz, DMSO-d6)  ppm 9.55 (s, 1 H, NH), 
8.32 (s, 1 H, NH), 8.09 (d, J=1.72 Hz, 1 H, ArCH), 7.39 - 7.49 (m, 6 H, ArCH), 6.94 (dd, 
J=8.31, 2.00 Hz, 1 H, ArCH), 4.08 (q, J=7.45 Hz, 2 H, CH2), 3.65 (s, 2 H, CH2), 1.15 - 
1.22 (m, 3 H, CH3); HRMS: Exact mass: 410.0033; (M+H)
+:411.0111; Observed mass: 
411.0104; 1.72 ppm. 
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ethyl 2-[3-[(4-bromophenyl)carbamoylamino]phenyl]acetate (260) 
 
Compound 260 was synthesized according to general 
procedure A for urea formation with 1-bromo-4-
isocyanato-benzene (0.86 mmol) and ethyl 2-(3-
aminophenyl)acetate (1 equiv., 0.86 mmol) Crude product was purified by flash column 
chromatography (PE/EA 4/6, gradient).  The beige solid was washed with diethyl ether 
(15mL), filtered and dried under high vacuum. Yield: 140 mg, 43%; Appearance: white 
solid; LCMS: 1.80 min, m/z 377.0, 379.0 ((M+H)+ 79/81Br), Purity=92%, Method D;1H 
NMR (500 MHz, DMSO-d6)  ppm 8.78 (s, 1 H, NH), 8.70 (s, 1 H, NH), 7.38 - 7.44 (m, 
4 H, ArCH), 7.34 (s, 1 H, ArCH), 7.31(d, J=8.59 Hz, 1 H, ArCH), 7.19 (t, J=7.73 Hz, 1 
H, ArCH), 6.84 (d, J=7.45 Hz, 1 H, ArCH) 4.05 (q, J=6.87 Hz, 2 H, CH2), 3.59 (s, 2 H, 
CH2), 1.16 (t, J=7.16 Hz, 3 H, CH3); HRMS: Exact mass:376.0423; (M+H)
+: 377.0501; 
Observed mass: 377.0492; 2.33 ppm. 
 
2-[3-[(4-bromophenyl)carbamoylamino]-4-chloro-phenyl]acetic acid (259) 
 
2-[3-[(4-bromophenyl)carbamoylamino]-4-chloro-
phenyl]acetic acid (258) (0.047 mmol, 0.018 g) was 
suspended in the mixture methanol (2 mL)/water (1 mL) 
and 2M solution of sodium hydroxide (0.15 mmol, 0.08 mL). RM was stirred for 4h at 
room temperature. Methanol was evaporated, the remaining solution was acidified with 
1M HCl (pH=2-3). The precipitation was filtered washed with water and dried to give  a 
beige powder (80% pure). Compound was purified via reverse phase column 
chromatography (C18, acetonitrile/water pH=10) to obtain final product. Yield: 18 mg, 
61%; Appearance: white solid; LCMS: 0.96 min, m/z 383.0, 385.0, 387.0 ((M+H)+ 35/37Cl, 
79/81Br), Purity=95%, Method D; 1H NMR (500 MHz, DMSO-d6)  ppm 9.85 (s, 1 H, 
NH), 8.60 (s, 1 H, NH), 7.98 (d, J=2.29 Hz, 1 H, ArCH), 7.45 (m, 4 H), 7.34 (m, J=8.02 
Hz, 1 H, ArCH ), 6.88 - 6.95 (m, 1 H, ArCH), 3.46 (s, 2 H, CH2); HRMS: Exact mass: 
381.9720; (M+H)+: 382.9798; Observed mass: 382.9792; 1.59 ppm. 
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2-[3-[(4-bromophenyl)carbamoylamino]phenyl]acetic acid (261) 
 
Compound 261 was synthesized according to procedure 
used for compound 259 using ethyl 2-[3-[(4-
bromophenyl)carbamoylamino]phenyl]acetate (260) (0.1 
mmol). The precipitation was filtered, washed with water and dried to give final product. 
Yield: 38 mg, 80%; Appearance: beige solid; LCMS: 1.50 min, m/z 349.1, 351.1 ((M+H)+ 
79/81Br), Purity=95%, Method A; 1H NMR (500 MHz, DMSO-d6) d ppm 8.82 (s, 1 H, 
NH), 8.74 (s, 1 H, NH), 7.41 - 7.47 (m, 4 H, ArCH), 7.37 (t, J=1.72 Hz, 1 H, ArCH), 7.30 
- 7.34 (m, 1 H, ArCH), 7.21 (t, J=7.73 Hz, 1 H, ArCH), 6.87 (d, J=7.45 Hz, 1 H, ArCH), 
3.52 (s, 2 H, CH2); HRMS: Exact mass: 348.0110; (M+H)
+: 349.0188; Observed mass: 
349.018; 2.23 ppm. 
  
335 
 
12.3. General biological procedures 
 
12.3.1. Cell maintenance procedure 
 
PathHunter® CHO-K1 FPRL1 cells (DISCOVERx) were grown in the F-12 nutrient 
mixture (HAM) (21765-037, Gibco®) supplemented with 10% Fetal Bovine Serum 
(A3840401, Thermo Fisher Sci), Hygromycin B 800 µg/mL (10687-010, Thermo Fisher 
Sci), Geneticin 300 µg/mL (10131-027, Thermo Fisher Sci). The cells were incubated at 
37oC and passaged every 2-3 days, based on the doubling time of the cell line. The 
Accutase ® (AT104-500) was used as the cell detachment solution. 
 
12.3.2. β-arrestin Path Hunter® assay detection protocol 
 
To identify novel FPR2 agonists PathHunter® CHO-K1 FPRL1 cells (DISCOVERx) 
expressing complementing fragments of the β -galactosidase (β-gal) enzyme were used. 
One day before the assay, the cells were diluted to a concentration of 0.5x106/mL in 
DISCOVERx plating media (Assay Complete™ Cell Plating 2 Reagent; 93-0563R2A). 
The cells were plated out 10 μL per well of 384 well plate (5,000 cells per well) and 
incubated 1 hour at room temperature then overnight at 37°C. 10 mM stock solutions of 
compounds were serially diluted in assay buffer (PBS using a half log dilution protocol 
on a Biomek instrument (automated liquid handler). The compound addition to the assay 
plate was performed Biomek instrument. Cells were stimulated with compounds or for 
high controls with W-peptide (a control ligand sequence WKYMVm; concentration = 
100 nM) for 150 minutes at 37 °C. Detection reagent (19 parts Assay buffer, 5 parts 
Emerald II and 1 part Galacton Star; Pathhunter detection kit (93-0001) DISCOVERx) 
was added 12 μL per well and incubated for 60 minutes in the dark at room temperature. 
Receptor activation was determined by chemiluminescence using a BMG Pherastar plate 
reader. Raw data were entered into GraphPad Prism 7.01 analysis software for data 
processing and visualisation. 
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12.3.3. Calcium mobilization assay protocol 
 
The increase in cytosolic Ca2+ was measured by the FLIPR® Tetra® High-Throughput 
Cellular Screening System. In the calcium mobilization assay FLIPR calcium 6 dye 
(Molecular Devices) was used. One day before the assay, the cells were diluted to a 
concentration of 0.5x106/mL in F-12 nutrient mixture (HAM) (21765-037, Gibco®) 
containing 10% Fetal Bovine Serum (A3840401, Thermo Fisher Sci) and plated out 40 
μL per well of 384 well plate (20,000 cells per well) then incubated 1 h at RT and then 
overnight at 37 °C. On the assay day, media was removed from the cell plate and  20 μLs 
of dye per well were added. The cell plate was incubated for 2 h at 37 °C and later for 30 
minutes at RT in the dark. Ten mM stock solutions of compounds were serially diluted in 
assay buffer (HBSS 20 mM HEPES) using a half log dilution protocol on a Biomek 
instrument (automated liquid handler). In both assays W-peptide was used as a control 
compound (100 nM). The 5 µL compound addition was performed by the FLIPR® 
Tetra® High-Throughput Cellular Screening System. The calcium mobilization was 
measured for 240s (Read Mode: Exc. Wavelength 470-495 nm, Em. Wavelength 515-
575 nm, Gain: 2000). Data are processed using ScreenWorks 4.0.0.30. Raw data were 
entered into GraphPad Prism 7.01 analysis software for data processing and visualisation. 
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12.3.4. Isolation of human neutrophils from venous blood 
 
Blood was collected from healthy donors in accordance with a protocol approved by the 
Ludwig Maximilian University of Munich. Neutrophils were isolated from the blood 
using Polymorphprep (Axi-Shield) following the manufacturer’s instructions. Isolated 
neutrophils were washed and resuspended in HBSS buffer containing 20 mM HEPES, 
0.25% BSA, Ca2+ pH 7.4 (0.5x106 cells/mL) and used on the day of the experiment. 
Determination of cells number using a haemocytometer: 
The average cell count was taken from each of the sets of 16 corner squares and multiplied 
by 10,000. The final value was the number of viable cells/mL in the original cell 
suspension.  
 
12.3.5. Human neutrophil static adhesion assay 
 
The static adhesion assay was performed with the aim of examining the small molecule 
agonists and their anti-inflammatory and proresolving properties. Day before the assay, 
96-well flat-bottomed plates were coated with 50 µL of cell adhesion molecules with the 
final concentration 1 μg/mL: P-selectin (13025-H02H-100; SinoBiological) and ICAM-
1 (10346-H03H-100; SinoBiological). The coated plates were kept at 4⁰C overnight. The 
excess of solution was removed with pipette and the surface was blocked with BSA 2% 
for 1h at room temperature. 
Pre-incubation plate: Add of 120 μL of neutrophils (0.5x106 cells/mL) per well with 30 
μL of the agonists (final dilution 1:5). Cells were incubated 30 min 37°C with gentle 
continuous mixing. Assay plate: 125 μL of mix  from pre-incubation plate was transferred 
per well into the assay plate. The reaction was incubated for 20 min at 37°C. Non-adherent 
neutrophils were removed, and the fixation step was performed with PFA 4%. Cells were 
stained with DAPI for 10 minutes and then washed gently with 200 μL PBS. Four picture 
per well were taken with Leica microscope (Leica microscope type DMI8, software: LAS 
X. V.3.4.2.18368, autofocus, exposure 51-57ms, gain: 1.5, DAPI). The image files were 
processed using an ImageJ macro. Raw data were entered into GraphPad Prism 7.01 
analysis software for data processing and visualisation. Each compound was tested in 
technical triplicates. 
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12.3.6. Human neutrophil flow chamber adhesion assay 
 
Day before the assay, the chambers IBIDI (u-slide VI 0.1, non-treated and uncoated, 
Product no.: 80661-IBI) were coated with 50 µL of cell adhesion molecules with the final 
concentration 5 μg/mL: P-selectin (13025-H02H-100; SinoBiological) and ICAM-1 
(10346-H03H-100; SinoBiological). The coated slides were kept at 4⁰C overnight. The 
excess of solution was removed with pipette and the surface was blocked with BSA 2% 
for 1h at room temperature. The pre-incubation step is the same as in the case of the static 
adhesion assay. After pre-incubation time the reaction mixture was transferred into the 
flow chamber slide. Each treatment group (duplicates) had its own reservoir. The 
leukocyte samples were perfused through the channels. Non-adherent neutrophils were 
removed, and the fixation step was performed with PFA 4%. The pictures were taken 
manually with Leica inverted microscope type DMI8 in the bright field (4 pictures per 
chamber). Raw data was entered into the GraphPad Prism 7.01 analysis software for data 
processing and visualisation. 
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12.3.7. Statistical data analysis 
 
GraphPad Prism 7.01 (GraphPad Software, San Diego, CA, USA) was used for statistical 
analysis of the data. For comparison of treatment groups with the control group and P-
value determination, the one-way Anova analysis followed by Dunnett’s multiple 
comparison test was used. All data were shown as means ± SEM. Differences were 
considered statistically significant for a P < 0.05. P value; *** P < 0.001; ** P < 0.01; * 
P< 0.05, ns – nonsignificant 
In the nitrite-reductase assay, the statistical significance between curves was determined 
using 2-way ANOVA followed by Tukey post-tests. Differences were considered 
statistically significant for a P < 0.05. P value : #P<0.05, ##P<0.005, ****P<0.0001 
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12.4. In vitro ADMET studies  
 
12.4.1. Kinetic solubility measurements 
 
Aqueous solubility is a crucial physicochemical parameter in any drug discovery project. 
Compounds with poor solubility have low absorption and can give a false result in 
biological assays and later have an impact on bioavailability. The kinetic solubility was 
measured by diluting a 4 µL of 10 mM DMSO stock solution of the compound into PBS 
buffer pH 7.4 in a filtration plate at a target concentration of 200 μM giving a final 
solution composition of 98:2 PBS:DMSO. For each compound, measurements were 
performed in triplicates with two standard compounds (Verapamil and Ketoconazole) on 
the same plate. The filtration plate was agitated at 500 rpm for 90 minutes and then filtered 
into V-bottom plate. The filtrate was sampled and diluted further with a DMSO:PBS 
mixture in a flat bottomed UV plate resulting with a final solution composition of 
PBS:DMSO 80:20. A serial dilution for each compound was then performed in flat 
bottomed plates in PBS:DMSO 80:20 with concentrations 200 μM, 100 μM, 50 μM, 25 
μM, 12.5 μM and 6.75 μM. The UV absorbance was read across 230-400 nm at 1 nm 
intervals using a TECAN Safire II plate reader and a suitable UV wavelength chosen 
around the UV maximum of each compound. This was used to calculate the concentration 
in the filtrate for each compound, and hence amount remaining in solution after 90 
minutes which is reported as the kinetic solubility. 
 
12.4.2. LogD measurements  
 
Lipophilicity is an important element of the pharmacokinetics The right balance between 
lipophilicity and polarity should be maintained, the lipophilic character of molecule helps 
it cross the fatty membranes, while the polarity increases solubility and also makes the 
molecule less likely to cross the blood-brain barrier. LogD measurements were conducted 
using the shake flask method. Compound was diluted from 10 mM DMSO stock solution 
into an eppendorf containing equal amounts of octanol and phosphate buffered saline 
(PBS) to give a final concentration of 100 μM. The tubes were shaken for 12 hours, 
centrifuged at 10000 rpm for 10 minutes and samples taken from the octanol and PBS 
layers. The samples from both layers were analysed in triplicate by LC-MS/MS (Agilent 
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Technologies G6410 series, triple quadrupole with MM-ESI ion source) using optimised 
multiple reaction monitoring (MRM) scans and a standard column gradient on an Acquity 
UPLC BEH C8 1.7 μm column, running acetonitrile and water with 0.05% Acetic Acid 
as the mobile phase. The ratios of areas of the peaks were used to calculate the LogD in 
accordance with the equation: 
 LogD = Log10(Area-TL/Area BL) 
 
12.4.3. Microsomal stability assay  
 
The human liver is an important site of drug metabolism; using a microsomal stability 
assay, the metabolism of the compounds can be investigated. Molecules with high 
clearance values are undesired since the compound could be rapidly cleared in in vivo 
studies. The human and mouse liver microsomes (MLM) were obtained from BD 
Biosciences. The compounds were pre-incubated at 37 °C for 5 minutes with the 
microsomes and the reaction was initiated by adding an equal volume of NADPH 
generating solution (BD Biosciences). The final compound concentration in the 
incubation is 1 μM, and the microsomal protein concentration is 0.2 mg/mL. A sample 
was taken at t=0 and quenched with two times volume of ice-cold methanol containing 
an internal standard reference compound (Carbamazepine). The reaction was agitated at 
37 °C for 30 minutes, when a further sample was taken and quenched in an identical 
fashion. The samples were centrifuged at 10000 rpm for 10 minutes and the supernatant 
taken for analysis in triplicate by LC-MS/MS (Agilent Technologies G6410 series, triple 
quadrupole with MM-ESI ion source) using optimised multiple reaction monitoring scans 
and a standard column gradient on an Acquity UPLC BEH C8 1.7μm column (mobile 
phase: acetonitrile and water with 0.05% acetic). The % turnover was obtained by 
calculating the percentage difference of the peak areas, normalised to the internal 
standard, at t=0 and t=30. Verapamil was used as the standard compound. 
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12.4.4. Cell Health Assay 
 
In order to measure a variety of parameters which leads to cell viability, cell death, 
cytotoxicity or cell proliferation, the cell health assay was performed. A human 
hepatocyte carcinoma cells (HepG2 cells EACC origin) were cultured a week before 
assay in Eagle’s Minimum Essential Medium (EMEM) inc. NEAA (non-essential amino 
acids) with 10% Fetal Bovine Serum and 2mM GlutaMAX. During cell plating 1% 
Penicillin/Streptomyocin was added to media. 2000 HepG2 cells per well were plated in 
25 μL media of a 384 well plate and incubated at 37⁰C overnight. The compounds were 
added from the serial dilution plates using Biomek robot (automated liquid handler). The 
assay plates were incubated at 37⁰C for 72 hours. Four live staining dyes were added on 
Biomek robot and plates were incubate 1 hour at 37⁰C. Cell measurements were imaged 
on the InCELL Analyzer 2000 using the following four wavelength channels for each of 
the four dyes: Hoechst (nuclei) - DAPI channel; Fluo-4 AM (cellular calcium) - 
Fluorescein isothiocyanate (FITC) channel; Tetramethylrhodamine, methyl ester 
(TMRM) (mitochondria) - Texas Red channel; TOTO-3 (dead nuclei) – Cy® 5 channel. 
Raw data were processed and visualised in Genedata Screener analysis software. The cell 
measurements were normalised as a percentage in contradiction of low control. Any cell 
parameter that deviates from 100% baseline shows a variation in cell phenotype and 
cytotoxicity after drug treatment.  
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Appendix 1. Protein sequence alignment 
 
Segment Sequence 
number 
Generic 
number 
Reference 
receptor 
Backbone 
template 
Rotamer 
template 
TM1 24 1x30 fpr2_human 5C1M 5C1M 
TM1 25 1x31 fpr2_human 5C1M None 
TM1 26 1x32 fpr2_human 5C1M None 
TM1 27 1x33 fpr2_human 5C1M 5C1M 
TM1 28 1x34 fpr2_human 5C1M 5T04 
TM1 29 1x35 fpr2_human 5C1M None 
TM1 30 1x36 fpr2_human 5C1M None 
TM1 31 1x37 fpr2_human 5C1M 5XRA 
TM1 32 1x38 fpr2_human 5C1M 3SN6 
TM1 33 1x39 fpr2_human 5C1M 5TUD 
TM1 34 1x40 fpr2_human 5C1M 4MQT 
TM1 35 1x41 fpr2_human 5C1M None 
TM1 36 1x42 fpr2_human 5C1M None 
TM1 37 1x43 fpr2_human 5C1M 5UNG 
TM1 38 1x44 fpr2_human 5C1M 5C1M 
TM1 39 1x45 fpr2_human 5C1M 5DYS 
TM1 40 1x46 fpr2_human 5C1M 5C1M 
TM1 41 1x47 fpr2_human 5C1M 3SN6 
TM1 42 1x48 fpr2_human 5C1M 5UNG 
TM1 43 1x49 fpr2_human 5C1M 5C1M 
TM1 44 1x50 fpr2_human 5C1M 5C1M 
TM1 45 1x51 fpr2_human 5C1M None 
TM1 46 1x52 fpr2_human 5C1M 5C1M 
TM1 47 1x53 fpr2_human 5C1M 5C1M 
TM1 48 1x54 fpr2_human 5C1M 3SN6 
TM1 49 1x55 fpr2_human 5C1M 5G53 
TM1 50 1x56 fpr2_human 5C1M 5C1M 
TM1 51 1x57 fpr2_human 5C1M None 
TM1 52 1x58 fpr2_human 5C1M None 
TM1 53 1x59 fpr2_human 5C1M None 
TM1 54 1x60 fpr2_human 5C1M None 
ICL1 55 None fpr2_human None None 
ICL1 56 None fpr2_human 4NTJ None 
ICL1 57 None fpr2_human None None 
TM2 58 2x37 fpr2_human 5C1M 5C1M 
TM2 59 2x38 fpr2_human 5C1M 5UNG 
TM2 60 2x39 fpr2_human 5C1M 5C1M 
TM2 61 2x40 fpr2_human 5C1M None 
TM2 62 2x41 fpr2_human 5C1M 5C1M 
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TM2 63 2x42 fpr2_human 5C1M None 
TM2 64 2x43 fpr2_human 5C1M None 
TM2 65 2x44 fpr2_human 5C1M 5DYS 
TM2 66 2x45 fpr2_human 5C1M 5C1M 
TM2 67 2x46 fpr2_human 5C1M 5C1M 
TM2 68 2x47 fpr2_human 5C1M 5C1M 
TM2 69 2x48 fpr2_human 5C1M 5C1M 
TM2 70 2x49 fpr2_human 5C1M 5C1M 
TM2 71 2x50 fpr2_human 5C1M 5C1M 
TM2 72 2x51 fpr2_human 5C1M None 
TM2 73 2x52 fpr2_human 5C1M None 
TM2 74 2x53 fpr2_human 5C1M None 
TM2 75 2x54 fpr2_human 5C1M 5C1M 
TM2 76 2x55 fpr2_human 5C1M 5UNG 
TM2 77 2x56 fpr2_human 5C1M 5C1M 
TM2 78 2x57 fpr2_human 5C1M 5C1M 
TM2 79 2x58 fpr2_human 5C1M 5C1M 
TM2 80 2x59 fpr2_human 5C1M 5C1M 
TM2 81 2x60 fpr2_human 5C1M None 
TM2 82 2x61 fpr2_human 5C1M 5G53 
TM2 83 2x62 fpr2_human 5C1M 5C1M 
TM2 84 2x63 fpr2_human 5C1M None 
TM2 85 2x64 fpr2_human 5C1M None 
TM2 86 2x65 fpr2_human 5C1M None 
TM2 87 2x66 fpr2_human 5C1M 5C1M 
ECL1 88 None fpr2_human None None 
ECL1 89 None fpr2_human None None 
ECL1 90 23x49 fpr2_human 3ODU None 
ECL1 91 23x50 fpr2_human 3ODU 3ODU 
ECL1 92 23x51 fpr2_human 3ODU 5C1M 
ECL1 93 23x52 fpr2_human None None 
TM3 94 3x21 fpr2_human 5C1M 5C1M 
TM3 95 3x22 fpr2_human 5C1M None 
TM3 96 3x23 fpr2_human 5C1M 3SN6 
TM3 97 3x24 fpr2_human 5C1M 5C1M 
TM3 98 3x25 fpr2_human 5C1M 5C1M 
TM3 99 3x26 fpr2_human 5C1M 5C1M 
TM3 100 3x27 fpr2_human 5C1M 5DYS 
TM3 101 3x28 fpr2_human 5C1M 5G53 
TM3 102 3x29 fpr2_human 5C1M None 
TM3 103 3x30 fpr2_human 5C1M None 
TM3 104 3x31 fpr2_human 5C1M None 
TM3 105 3x32 fpr2_human 5C1M 5G53 
TM3 106 3x33 fpr2_human 5C1M 5T04 
TM3 107 3x34 fpr2_human 5C1M None 
TM3 108 3x35 fpr2_human 5C1M 5C1M 
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TM3 109 3x36 fpr2_human 5C1M None 
TM3 110 3x37 fpr2_human 5C1M 5C1M 
TM3 111 3x38 fpr2_human 5C1M None 
TM3 112 3x39 fpr2_human 5C1M 5C1M 
TM3 113 3x40 fpr2_human 5C1M 4MQT 
TM3 114 3x41 fpr2_human 5C1M 5C1M 
TM3 115 3x42 fpr2_human 5C1M None 
TM3 116 3x43 fpr2_human 5C1M 5UNG 
TM3 117 3x44 fpr2_human 5C1M None 
TM3 118 3x45 fpr2_human 5C1M None 
TM3 119 3x46 fpr2_human 5C1M 3SN6 
TM3 120 3x47 fpr2_human 5C1M 3SN6 
TM3 121 3x48 fpr2_human 5C1M None 
TM3 122 3x49 fpr2_human 5C1M 5C1M 
TM3 123 3x50 fpr2_human 5C1M 5C1M 
TM3 124 3x51 fpr2_human 5C1M None 
TM3 125 3x52 fpr2_human 5C1M 5C1M 
TM3 126 3x53 fpr2_human 5C1M 4MQT 
TM3 127 3x54 fpr2_human 5C1M 5C1M 
TM3 128 3x55 fpr2_human 5C1M None 
TM3 129 3x56 fpr2_human 5C1M 5C1M 
ICL2 130 34x50 fpr2_human 5C1M 5C1M 
ICL2 131 34x51 fpr2_human 5C1M 5C1M 
ICL2 132 34x52 fpr2_human 5C1M None 
ICL2 133 34x53 fpr2_human 5C1M 5C1M 
ICL2 134 34x54 fpr2_human 5C1M 3SN6 
ICL2 135 34x55 fpr2_human 5C1M None 
ICL2 136 34x56 fpr2_human 5C1M None 
ICL2 137 34x57 fpr2_human 5C1M 5C1M 
TM4 138 4x38 fpr2_human 5C1M 5C1M 
TM4 139 4x39 fpr2_human 5C1M None 
TM4 140 4x40 fpr2_human 5C1M 5T04 
TM4 141 4x41 fpr2_human 5C1M None 
TM4 142 4x42 fpr2_human 5C1M 5C1M 
TM4 143 4x43 fpr2_human 5C1M None 
TM4 144 4x44 fpr2_human 5C1M 5T04 
TM4 145 4x45 fpr2_human 5C1M 5C1M 
TM4 146 4x46 fpr2_human 5C1M 3SN6 
TM4 147 4x47 fpr2_human 5C1M 5C1M 
TM4 148 4x48 fpr2_human 5C1M None 
TM4 149 4x49 fpr2_human 5C1M None 
TM4 150 4x50 fpr2_human 5C1M 5C1M 
TM4 151 4x51 fpr2_human 5C1M 5C1M 
TM4 152 4x52 fpr2_human 5C1M 5C1M 
TM4 153 4x53 fpr2_human 5C1M 5UNG 
TM4 154 4x54 fpr2_human 5C1M 5DYS 
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TM4 155 4x55 fpr2_human 5C1M 5XRA 
TM4 156 4x56 fpr2_human 5C1M 5T04 
TM4 157 4x57 fpr2_human 3ODU None 
TM4 158 4x59 fpr2_human 3ODU 5UNG 
TM4 159 4x60 fpr2_human 5C1M 5UNG 
TM4 160 4x61 fpr2_human 5C1M 5TUD 
TM4 161 4x62 fpr2_human 5C1M 5C1M 
TM4 162 4x63 fpr2_human 5C1M None 
TM4 163 4x64 fpr2_human 5C1M 5UNG 
TM4 164 4x65 fpr2_human 3ODU None 
ECL2 165 None fpr2_human 5C1M 5C1M 
ECL2 166 None fpr2_human 5C1M 5C1M 
ECL2 167 None fpr2_human 5C1M None 
ECL2 168 None fpr2_human 5C1M None 
ECL2 169 None fpr2_human 5C1M None 
ECL2 170 None fpr2_human 5C1M None 
ECL2 171 None fpr2_human 5C1M None 
ECL2 172 None fpr2_human 5C1M None 
ECL2 173 None fpr2_human 5C1M None 
ECL2 174 None fpr2_human 5C1M None 
ECL2 175 None fpr2_human None None 
ECL2 176 45x50 fpr2_human 5C1M 5C1M 
ECL2 177 45x51 fpr2_human 5C1M 5C1M 
ECL2 178 45x52 fpr2_human 5C1M 4LDE 
ECL2 179 None fpr2_human None None 
ECL2 180 None fpr2_human None None 
ECL2 181 None fpr2_human None None 
ECL2 182 None fpr2_human None None 
ECL2 183 None fpr2_human None None 
ECL2 184 None fpr2_human None None 
ECL2 185 None fpr2_human None None 
ECL2 186 None fpr2_human None None 
ECL2 187 None fpr2_human None None 
ECL2 188 None fpr2_human None None 
ECL2 189 None fpr2_human None None 
ECL2 190 None fpr2_human None None 
ECL2 191 None fpr2_human None None 
ECL2 192 None fpr2_human None None 
ECL2 193 None fpr2_human None None 
ECL2 194 None fpr2_human None None 
ECL2 195 None fpr2_human None None 
ECL2 196 None fpr2_human None None 
TM5 197 5x35 fpr2_human 5C1M None 
TM5 198 5x36 fpr2_human 5C1M None 
TM5 199 5x37 fpr2_human 5C1M None 
TM5 200 5x38 fpr2_human 5C1M 3SN6 
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TM5 201 5x39 fpr2_human 5C1M None 
TM5 202 5x40 fpr2_human 5C1M None 
TM5 203 5x41 fpr2_human 5C1M 5C1M 
TM5 204 5x42 fpr2_human 5C1M None 
TM5 205 5x43 fpr2_human 5C1M None 
TM5 206 5x44 fpr2_human 5C1M 5C1M 
TM5 207 5x45 fpr2_human 5C1M 5DYS 
TM5 208 5x46 fpr2_human 5C1M None 
TM5 209 5x461 fpr2_human 5C1M 5UNG 
TM5 210 5x47 fpr2_human 5C1M 5C1M 
TM5 211 5x48 fpr2_human 5C1M 5XRA 
TM5 212 5x49 fpr2_human 5C1M 4MQT 
TM5 213 5x50 fpr2_human 5C1M 5C1M 
TM5 214 5x51 fpr2_human 5C1M 5T04 
TM5 215 5x52 fpr2_human 5C1M None 
TM5 216 5x53 fpr2_human 5C1M 5C1M 
TM5 217 5x54 fpr2_human 5C1M None 
TM5 218 5x55 fpr2_human 5C1M 5UNG 
TM5 219 5x56 fpr2_human 5C1M 5T04 
TM5 220 5x57 fpr2_human 5C1M 5C1M 
TM5 221 5x58 fpr2_human 5C1M 5C1M 
TM5 222 5x59 fpr2_human 5C1M 5C1M 
TM5 223 5x60 fpr2_human 5C1M 5C1M 
TM5 224 5x61 fpr2_human 5C1M 5UNG 
TM5 225 5x62 fpr2_human 5C1M 5T04 
TM5 226 5x63 fpr2_human 5C1M None 
TM5 227 5x64 fpr2_human 5C1M 5T04 
TM5 228 5x65 fpr2_human 5C1M None 
TM5 229 5x66 fpr2_human 5C1M 5XRA 
TM5 230 5x67 fpr2_human 5C1M 5UNG 
TM5 231 5x68 fpr2_human 5C1M 5TUD 
ICL3 232 None fpr2_human None None 
ICL3 233 None fpr2_human None None 
ICL3 234 None fpr2_human None None 
ICL3 235 None fpr2_human None None 
TM6 236 6x30 fpr2_human 5C1M None 
TM6 237 6x31 fpr2_human 5C1M None 
TM6 238 6x32 fpr2_human 5C1M 5C1M 
TM6 239 6x33 fpr2_human 5C1M None 
TM6 240 6x34 fpr2_human 5C1M 5UNG 
TM6 241 6x35 fpr2_human 5C1M 5C1M 
TM6 242 6x36 fpr2_human 5C1M 5T04 
TM6 243 6x37 fpr2_human 5C1M 3SN6 
TM6 244 6x38 fpr2_human 5C1M None 
TM6 245 6x39 fpr2_human 5C1M 5UNG 
TM6 246 6x40 fpr2_human 5C1M 5C1M 
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TM6 247 6x41 fpr2_human 5C1M 5C1M 
TM6 248 6x42 fpr2_human 5C1M 5C1M 
TM6 249 6x43 fpr2_human 5C1M None 
TM6 250 6x44 fpr2_human 5C1M 5C1M 
TM6 251 6x45 fpr2_human 5C1M None 
TM6 252 6x46 fpr2_human 5C1M 5UNG 
TM6 253 6x47 fpr2_human 5C1M 5C1M 
TM6 254 6x48 fpr2_human 5C1M 5C1M 
TM6 255 6x49 fpr2_human 5C1M None 
TM6 256 6x50 fpr2_human 5C1M 5C1M 
TM6 257 6x51 fpr2_human 5C1M 5UNG 
TM6 258 6x52 fpr2_human 5C1M None 
TM6 259 6x53 fpr2_human 5C1M None 
TM6 260 6x54 fpr2_human 5C1M 3SN6 
TM6 261 6x55 fpr2_human 5C1M 5DYS 
TM6 262 6x56 fpr2_human 5C1M 5T04 
TM6 263 6x57 fpr2_human 5C1M 5UNG 
TM6 264 6x58 fpr2_human 5C1M None 
TM6 265 6x59 fpr2_human 5C1M 4MQT 
TM6 266 6x60 fpr2_human 5C1M None 
TM6 267 6x61 fpr2_human 5C1M None 
ECL3 268 None fpr2_human None None 
ECL3 269 None fpr2_human 4XES None 
ECL3 270 None fpr2_human 4XES 4XES 
ECL3 271 None fpr2_human 4XES None 
ECL3 272 None fpr2_human None None 
TM7 273 7x23 fpr2_human 3ODU None 
TM7 274 7x24 fpr2_human 3ODU None 
TM7 275 7x25 fpr2_human 3ODU None 
TM7 276 7x26 fpr2_human 3ODU None 
TM7 277 7x27 fpr2_human 5C1M None 
TM7 278 7x28 fpr2_human 5C1M 5XRA 
TM7 279 7x29 fpr2_human 5C1M None 
TM7 280 7x30 fpr2_human 5C1M 5UNG 
TM7 281 7x31 fpr2_human 5C1M 5UNG 
TM7 282 7x32 fpr2_human 5C1M 5DYS 
TM7 283 7x33 fpr2_human 5C1M 5TUD 
TM7 284 7x34 fpr2_human 5C1M None 
TM7 285 7x35 fpr2_human 5C1M None 
TM7 286 7x36 fpr2_human 5C1M None 
TM7 287 7x37 fpr2_human 5C1M 5T04 
TM7 288 7x38 fpr2_human 5C1M 5XRA 
TM7 289 7x39 fpr2_human 5C1M None 
TM7 290 7x40 fpr2_human 5C1M 5C1M 
TM7 291 7x41 fpr2_human 5C1M 5T04 
TM7 292 7x42 fpr2_human 5C1M 5UNG 
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TM7 293 7x43 fpr2_human 5C1M None 
TM7 294 7x45 fpr2_human 5C1M 5C1M 
TM7 295 7x46 fpr2_human 5C1M 5C1M 
TM7 296 7x47 fpr2_human 5C1M 5C1M 
TM7 297 7x48 fpr2_human 5C1M 5C1M 
TM7 298 7x49 fpr2_human 5C1M 5C1M 
TM7 299 7x50 fpr2_human 5C1M 5C1M 
TM7 300 7x51 fpr2_human 5LWE None 
TM7 301 7x52 fpr2_human 5LWE 5LWE 
TM7 302 7x53 fpr2_human 5LWE 5LWE 
TM7 303 7x54 fpr2_human 5LWE 5LWE 
TM7 304 7x55 fpr2_human 5LWE 5LWE 
TM7 305 7x56 fpr2_human 5LWE 5LWE 
H8 306 8x47 fpr2_human 5LWE 5UNG 
H8 307 8x48 fpr2_human 5LWE None 
H8 308 8x49 fpr2_human 5LWE 5LWE 
H8 309 8x50 fpr2_human 5LWE 5UNG 
H8 310 8x51 fpr2_human 5LWE 5LWE 
H8 311 8x52 fpr2_human 5LWE None 
H8 312 8x53 fpr2_human 5LWE None 
H8 313 8x54 fpr2_human 5LWE 5UNG 
H8 314 8x55 fpr2_human 5LWE None 
H8 315 8x56 fpr2_human 5LWE 4MQT 
H8 316 8x57 fpr2_human 5LWE None 
H8 317 8x58 fpr2_human 5LWE 3SN6 
H8 318 8x59 fpr2_human 5LWE 5LWE 
H8 319 8x60 fpr2_human 5LWE None 
H8 320 8x61 fpr2_human 5LWE None 
 
 
